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Abstract 
The renin angiotensin system (RAS), a homeostatic system involved in blood pressure and 
volume control, is implicated in the pathology of several risk factors for ischaemic stroke. 
Mounting evidence now suggests that the RAS may play a role in the pathophysiology of 
ischaemic stroke. This is thought to be due to an imbalance between the classical RAS 
axis, Angiotensin converting enzyme/Angiotensin II/Angiotensin II receptor type I 
(ACE/Ang II/AT1R), and the counter-regulatory RAS axis, Angiotensin converting 
enzyme 2/Angiotensin-(1-7)/Mas receptor [ACE2/Ang-(1-7)/MasR]. The counter-
regulatory axis has been shown to provide neuroprotection in ischaemic stroke animal 
models. Therefore, the studies conducted in this thesis aimed to test the neuroprotective 
potential of Ang-(1-7) as a post-stroke therapy following transient focal cerebral 
ischaemia. Furthermore, experiments were conducted to test a potential synergistic effect 
between MasR and alternative Ang II receptor, Angiotensin II receptor type II (AT2R), 
agonism following stroke.   
Aim 1: To optimise the experimental model of stroke and carry out exploratory 
therapeutic studies with an ACE2 activator following stroke. 
The intraluminal filament model of transient middle cerebral artery occlusion (MCAO) 
allows for investigation of reperfusion following stroke; however, the model leads to 
considerable variability in lesion size thereby limiting data interpretation particularly in 
therapeutic studies. Therefore, there is a need to address confounding variables and 
determine methods to predict final infarct outcome. Additionally, counter-regulatory RAS 
targeting therapies have been primarily studied in ischaemic stroke through 
intracerebroventricular (ICV) administration, which is not a recommended route of 
administration for clinical use. Consequently, we aimed to optimise the animal model used 
and RAS targeting therapies. We show that following permanent MCAO, Wistar rats 
display significantly larger lesion volumes with less variability than Sprague Dawley 
animals. Importantly, the use of Laser Doppler Flowmetry did not successfully predict 
final infarct volume. Finally, systemic administration of diminazene aceturate (DIZE; 
ACE2 activator) did not reduce final infarct volume following transient MCAO. For future 
studies, we decided to use Wistar rats, ICV route of administration and acute magnetic 
resonance imaging (MRI) to confirm successful occlusion of the MCA. 
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Aim 2: To determine the effects of Ang-(1-7) and/or Compound 21 (C21) on the 
extent of tissue salvage following transient focal cerebral ischaemia.    
We investigated the impact of Ang-(1-7) and/or C21 (AT2R agonist) on the extent of tissue 
salvage following reperfusion. Acute MRI angiography was carried out during MCAO to 
confirm successful MCAO and to assess baseline lesion volume. At day 7 following 
reperfusion, MRI-T2 was carried out to determine final infarct volume thereby allowing us 
to longitudinally assess the change in lesion volume. We demonstrate that prior to therapy 
there was substantial variability in baseline lesion volume across the treatment groups. 
When normalising the data to initial lesion for each animal, Ang-(1-7) along with 
reperfusion significantly increased tissue salvage compared to vehicle animals with no 
effect on blood pressure. C21 and combination group [Ang-(1-7) +C21] however, did not 
induce a therapeutic effect. Additionally, neurological score was comparable amongst 
groups. Gene expression experiments confirmed that there is an imbalance of the RAS 
following stroke as AT2R was upregulated and MasR downregulated at day 7 following 
MCAO. Ang-(1-7) did not influence inflammatory gene expression markers; however, it 
significantly attenuated the increase of NADPH oxidase type 1 (NOX1) seen in the control 
animals, possibly promoting a neurogenesis effect at the time point assessed. 
Aim 3: To determine the impact of Ang-(1-7) on blood brain barrier (BBB) 
breakdown and microglia activation following transient focal cerebral ischaemia. 
Evidence from the literature suggests that Ang-(1-7) induces an anti-inflammatory effect 
particularly at acute stages of injury (24 hrs and 72 hrs) following transient MCAO. 
Accordingly, we hypothesised that post-stroke Ang-(1-7) therapy exerts a therapeutic 
effect by attenuating BBB breakdown and microglia activation and inflammatory profile at 
24 hrs following MCAO. Using T1 contrast enhanced MRI we demonstrated that Ang-(1-7) 
did not alter BBB breakdown at 24 hrs and that BBB disruption was highly variable 
amongst animals. Ang-(1-7) treatment did not alter infarct volume at 24 hrs post MCAO 
compared to control and there were no differences in neurological outcome. There was no 
influence of Ang-(1-7) treatment on microglia number and activation within the peri-
infarct and homotopic contralateral regions. Moreover, gene expression showed that pro-
inflammatory markers were upregulated following MCAO with no effect of Ang-(1-7) on 
these markers. Interestingly, RAS receptor components were comparable to Sham animals, 
indicating that the RAS follows a biphasic pattern and does not promote injury at 24 hrs 
following transient MCAO in the filament model. 
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Aim 4: To determine whether Ang-(1-7) acts on the cerebrovasculature to improve 
CBF following transient focal cerebral ischaemia. 
Results from the previous studies raised the question whether Ang-(1-7) post stroke 
therapy enhances cerebral blood flow (CBF) at hyper-acute stages of injury after 90 min 
MCAO. The effects of Ang-(1-7) intravenous infusion at start of reperfusion and for a 
period of 90 min on cortical CBF were studied with Laser Speckle Contrast Imaging 
(LSCI). LSCI allowed changes in cortical perfusion to be assessed with a high temporal 
resolution across the entire cortical surface of the brain. Regions of interest were 
determined based on perfusion thresholds during MCAO and post-reperfusion treatment 
was assessed. Ang-(1-7) significantly attenuated the increase in CBF within the 
contralateral hemisphere compared to control animals. However, therapy did not alter CBF 
within the ischaemic hemisphere. Furthermore, Ang-(1-7) did not alter mean arterial blood 
pressure (MABP), which was maintained within normal ranges for both treatment groups, 
nor did it influence the occurrence of peri-infarct depolarisations. The Ang-(1-7) effect 
observed in this study could be the outcome of “steal phenomena” reversal, therefore, 
preventing CBF shift towards the non-ischaemic side. 
Conclusion     
This thesis conducted novel studies that demonstrate that central administration of Ang-(1-
7) following transient MCAO induces a mild to moderate neuroprotective effect where it 
increases tissue salvage. Conversely, Ang-(1-7) did not prevent BBB breakdown or exert 
an anti-inflammatory effect at the microglia level. These experiments highlight the 
neuroprotective potential of selective MasR agonists in the ischaemic stroke context. 
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Chapter 1  
1.1 Stroke 
Stroke is a complex and devastating neurological disorder characterised by a vascular 
induced injury to the central nervous system arising from more than 150 known aetiologies 
(Chen et al., 2012). The World Health Organisation describes stroke as a vascular 
condition that quickly leads to clinical signs of cerebral dysfunction due to focal or global 
injury and with symptoms lasting for at least 24 hrs or death. Conversely, cerebrovascular 
accidents in which the symptoms are prevalent for less than 24 hrs are deemed as transient 
ischaemic attacks (Saver et al. 2008; Sacco et al. 2013). The exact definition of stroke is 
under extensive debate as it encompasses a wide range of cerebrovascular disorders. For 
this reason, the American Heart Association/American Stroke Association published a 
report on updated stroke definitions where these are categorised depending on stroke type, 
location and duration (Sacco et al., 2013).  
There are two types of stroke, haemorrhagic and ischaemic (Chen et al., 2012). 
Haemorrhagic stroke constitutes up to 15% of all strokes and is subdivided into 
subarachnoid haemorrhage (SAH) and intracranial haemorrhage (ICH) (Chen et al., 2012). 
SAH occurs due to the rupture of a cerebral vessel causing haemorrhage within the 
subarachnoid space whereas ICH is associated with brain parenchyma bleeding (Dupont et 
al., 2010; Elliott and Smith, 2010). Ischaemic stroke accounts for 85% of all strokes and is 
classified as an occlusion of a cerebral blood vessel, resulting in the blockage of cerebral 
blood flow (CBF). The condition occurs suddenly and is characterised by the rapid onset of 
symptoms such as aphasia, hemiparesis, ataxia, visual field deficit, hemisensory 
impairment and facial droop.  
1.1.1 Epidemiology 
Currently, stroke is the second leading cause of death in the world and fourth in the UK 
(Stroke Association, 2017). It is estimated that in the UK alone, more than 152,000 people 
will suffer from the condition and stroke accounts forapproximately 40,000 deaths a year 
(Stroke Association, 2017). Although the mortality rates in the UK have decreased by 46% 
in 20 years (1990-2010), there has been a steep increase in stroke survivor numbers, now 
consisting of a 1.2 million population (Stroke Association 2017). In terms of disability, 
stroke is the leading condition in the UK. Over 50% of survivors are left permanently 
disabled whereas two thirds of all surviving patients display visual and speech, limb 
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movement, swallowing as well as bladder and bowel control complications (Adamson et 
al., 2004; Stroke Association, 2017). Additionally, recent reports indicate that stroke 
survivors are at higher risk of developing dementia in the longer term, particularly the 
younger patient population (Corraini et al., 2017). Consequently, stroke outcome 
management accounts for approximately £8.9 billion of tax payer costs and 5% of total 
NHS expenditure, a concerning health and socio-economic burden (Adamson et al., 2004; 
Saka et al., 2009). 
1.1.2 Risk factors 
Stroke is a multifactorial condition and can arise from several risk factors that are 
classified as non-modifiable, modifiable and potentially modifiable (Khare, 2016). Table 
1-1 provides an overview of the most common risk factors within these categories. 
Table 1-1 Stroke risk factors. Adapted from (Go et al., 2014; Khare, 2016) 
Non-Modifiable Potentially Modifiable/Modifiable 
Age Hypertension Psychological stress 
Sex Cardiac disease Diet 
Race Diabetes Mellitus Physical inactivity 
Family history Obesity Drug abuse 
Genetics Dyslipidaemia Current smoking 
 
Non-modifiable risk factors comprise age, sex, race and family history/genetics. Of all 
these, age is the most well documented factor, with risk for a stroke doubling every 10 
years after the age of 55 (Sacco et al., 1997). Although stroke may be considered a 
condition primarily occurring in elderly individuals, the number of strokes in people aged 
between 20 and 64 has increased by 25% worldwide in a decade (Feigin et al., 2014). In 
terms of sex differences, males have a higher incidence; however, after menopause, the 
incidence in females increases drastically due to a decline in oestrogen levels (Appelros et 
al., 2009). Furthermore, black people are twice as likely to have a stroke at a younger age 
4 
 
and black men over the age of 85 are mostly affected when compared to Mexican and non-
Hispanic whites (Khare 2016). 
A study carried out across 22 countries identified that there are ten crucial risk potentially 
modifiable/modifiable factors associated with 90% of stroke risk (O’Donnell et al., 2010). 
These risk factors include hypertension, current smoking, waist to hip ratio, diet risk score, 
lack of regular physical activity, diabetes mellitus, alcohol intake, psychosocial stress and 
depression, cardiac causes and ratio of apolipoproteins B and A1 (O’Donnell et al., 2010). 
Of all these conditions, hypertension is the single most important risk factor for ischaemic 
stroke, inducing a relative risk of approximately 4-fold when systolic blood pressure is 
over 160 mmHg and/or diastolic blood pressure above 95 mmHg (Khare 2016; Sacco et al. 
1997). In addition, the relationship between high blood pressure and stroke is considered 
linear and independent of other risk factors (Goldstein et al., 2006). Currently, 
hypertension is responsible for 54% of all stroke cases and treating the condition is an 
effective strategy to prevent stroke occurrence (Chalmers et al., 2003; Stroke Association, 
2017).  
1.2 Ischaemic stroke 
Ischaemic stroke results from an occlusion of a cerebral blood vessel, typically arteries, 
due to the presence of a thrombus or embolus, resulting in the blockage of blood flow to 
the brain (Figure 1-1) (Deb et al., 2010). There are several ways in which ischaemic stroke 
may occur; therefore, subclassification methods were developed with Trial of Org10172 in 
Acute Stroke Treatment (TOAST) being the most widely used method. TOAST divides 
strokes into large artery, cardioembolic, small-vessel occlusion, stroke of other determined 
causes and stroke of undetermined aetiology (Adams and Biller, 2015).  
Large artery occlusions are usually characterised by the formation of lipid laden 
atherosclerotic plaques in the inner vessel wall due to pre-existent conditions such as 
hypercholesterolaemia, hypertension or diabetes (Luitse et al., 2012). These co-morbidities 
cause endothelial cell damage and predispose the vessel to the generation of atherosclerotic 
plaques that may diminish or completely obstruct blood flow (Figure 1-1). It often occurs 
in the bifurcations of the common carotid arteries, along the middle cerebral artery (MCA) 
and at the origin of the vertebral arteries (Derdeyn, 2007; Rovira et al., 2005) and 
represents approximately 50% of all ischaemic strokes (Staals et al., 2014). This type of 
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stroke may also occur due to the rupture of the atherosclerotic plaques, forming a thrombus 
that may travel through the circulation reaching a cerebral vessel (Rapp et al., 2003).  
Cardioembolic stroke is characterised by cerebral vessel occlusion due to blood clots. The 
blood clots, or emboli, are typically formed in the heart as a result of atrial fibrillation. In 
turn, these will travel in the circulation leading to cerebral vessel occlusion, accounting for 
18-25% of all stroke cases (Olsson and Halperin, 2005). This type of stroke usually occurs 
in multiple arteries and has the worst clinical prognosis (Arboix, 2015). In addition, small 
vessel or lacunar strokes account for one quarter of all ischaemic strokes. These take place 
in the microcirculation due to lipohyalinotic alterations in the vessel wall or 
microatheromas (Arboix and Martí-Vilalta, 2009). Lacunar occlusions are typically located 
deeply in cerebral vessels such as the corona radiata, internal capsule and MCA supplied 
branches. Patients with this type of stroke are identified by the classical lacunar syndrome, 
which consists of motor symptoms, sensory, sensorimotor, ataxic hemiparesis or 
dysarthria-clumsy hand and display lower functional disability when compared to the other 
types (Arboix et al., 2005). Other less common causes of stroke include vasospasms due to 
SAH, cerebral vasculitis and coagulopathies (Ferro, Massaro and Mas, 2010). 
 
Figure 1-1 Ischaemic stroke illustration. Coronal brain section displaying the cerebral 
vasculature. The left middle cerebral artery is occluded due to the presence of an atherosclerotic 
plaque and blood clot obstructing blood flow. Grey area illustrates ischaemic damage due to 
cessation of blood supply and subsequent cell death. Figure adapted from strokecenter.org. 
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1.2.1 Cerebral blood flow and ischaemic stroke 
Although the brain represents 2% of overall body weight, it is estimated that it receives 15-
20% of total cardiac output (Heiss et al., 2011). As a result of an intense metabolic 
demand, the brain relies on CBF being maintained at critical levels despite variations in 
mean arterial blood pressures (MABP). Normal CBF in humans is approximately 50-60 
mL/100g/min (Ellenbogen et al., 2012; Hossmann and Traystman, 2008). The effective 
cerebral perfusion pressure (CPP) is the difference between the systemic MABP and 
intracranial pressure (ICP) and is regulated by a number of factors. The arterial blood 
partial pressure of carbon dioxide (PaCO2) is a critical regulator of cerebral vessels where 
it is a potent vasodilator (Shardlow and Jackson, 2008). Cerebral blood vessels possess a 
unique property where they have the ability to autoregulate (passively dilate or constrict) in 
response to fluctuations in systemic blood pressure and CPP thereby maintaining CBF 
within normal levels. If CPP fluctuates within a range of 60-150 mmHg, the brain has the 
capacity to maintain a relatively constant CBF. However, if CPP drops below this critical 
threshold then autoregulatory capacity is lost and CBF will then become linearly dependent 
on changes in MABP (Figure 1-2). Consequently, when CPP is below the autoregulation 
limit, cerebral ischaemia occurs (Hossmann and Traystman, 2008). In addition, following 
cerebral ischaemia the cerebral vessels lose their ability to autoregulate and therefore CBF 
follows a linear relationship with CPP (Figure 1-2) (Dirnagl and Pulsinelli, 1990). 
 
Figure 1-2 Relationship between CBF and CPP. When CPP fluctuates between 60-150 mmHg, 
CBF is maintaned at normal levels through autoregulation. If CPP is below or above that limit, it will 
become linearly dependent on mean arterial blood pressure. During ischaemia, autoregulation is 
lost and therefore CBF is linearly dependent on CPP. 
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During ischaemic stroke, CBF reduces across the vascular territory of the occluded vessel 
at differing levels. In the early 70s, Symon and colleagues identified that following 
cerebral ischaemia in baboons, CBF progressively decreased among three separate brain 
compartments that were later defined as irreversibly damaged (ischaemic core), tissue at 
risk of infarction (ischaemic penumbra) and hypoperfused tissue not at risk (benign 
oligaemia) (Symon et al., 1974). 
1.2.1.1 The ischaemic penumbra: the therapeutic target 
Critical CBF thresholds were first identified in non-human primates where it was observed 
that the area directly affected by the occluded vessels comprises the ischaemic core of 
irreversibly damaged tissue. In the ischaemic core, CBF is less than 6 mL/100g/min 
(Astrup et al., 1981); therefore, this area undergoes energy failure and irreversible cellular 
necrosis within minutes of stroke onset. In humans, position emission tomography studies 
identify the ischaemic core as tissue with a flow less than 12 mL/100g/min (Heiss, 2000).  
Surrounding the ischaemic core is an area of brain tissue referred to as the ischaemic 
penumbra. The ischaemic penumbra was first identified in 1981 by Astrup and colleagues 
and described as: 
“areas with less severe ischaemia with electrical failure but sustained energy metabolism 
(…) with the possible potential for recovery”, (Astrup et al., 1981). 
Therefore, the ischaemic penumbra is a region of non-functioning but viable tissue. This 
concept was then expanded with the aid of imaging techniques where it was seen that the 
penumbral tissue consists of metabolically active tissue with reduced CBF yet increased 
oxygen extraction fraction (OEF, the fraction of oxygen extracted from arterial blood) and 
maintained oxygen consumption (CMRO2) (Baron et al., 2008). CBF within the ischaemic 
penumbra ranges between 8-22 mL/100g/min in non-human primates and 12-22 
mL/100g/min in humans (Astrup et al., 1977; Ford et al., 2012; Heiss, 1983, 2000). There 
are varying functional thresholds within the penumbra region, which means that there are 
different levels of possible neuronal recovery. For instance, in non-human primates, mild 
paresis is observed at 22 mL/100g/min whereas complete paralysis is seen at 8 
mL/100g/min (Jones et al., 1981). Plus, spontaneous neuronal activity is abolished at 18 
mL/100g/min and evoked potentials are prevented between 15-20 mL/100g/min CBF 
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(Branston et al., 1974; Heiss and Rosner, 1983). Therefore, at certain levels of CBF deficit, 
neurons are functionally inactive; however, structurally viable and possibly salvageable. 
Perfusion within the penumbra is maintained by collateral blood supply. These include 
primary collaterals that form the arterial segments of the circle of Willis and secondary 
collaterals that include the ophthalmic artery and leptomeningeal vessels (Liebeskind 
2003). Still, these cells have limited energy supply and if adequate blood supply is not 
provided, in time, the tissue becomes part of the core (Dirnagl et al., 1999). The 
characteristics of the penumbra led to the conclusion that this area provides a potential 
therapeutic opportunity to limit infarct size and progression (Figure 1-3). Consequently, 
the scientific community has been committed to the development of adjuvant 
neuroprotective drugs that could prevent penumbral cell death prior to and following 
reperfusion. 
Benign oligaemia is characterised by CBF thresholds of above 22 mL/100g/min in both 
non-human primates and humans (Heiss, 2000). Here, tissue is characterised by reduced 
CBF but increased OEF and normal CMRO2, therefore, CPP is fairly maintained due to 
autoregulatory compensation mechanisms (Lee et al., 2005). Oligaemic tissue is not 
usually at risk of infarction; however, if hypoxia persists and secondary events such as 
hypotension or hyperglycaemia take place, it may force this area to become at risk (Lee et 
al., 2005). 
 
Figure 1-3 Cerebral blood flow compartments following cerebral ischaemia. A) CBF 
compartments after stroke onset. Irreversibly damaged (ischaemic core; black), tissue at risk of 
infarction (ischaemic penumbra; red) and hypoperfused tissue not at risk (benign oligaemia; blue). 
B) Ischaemic core evolution. If reperfusion is not established or a neuroprotective agent 
administered, penumbral tissue eventually becomes part of the infarct, increasing neuronal 
damage. 
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1.2.2 Pathobiology overview: from hypoxia to infarct 
Ischaemic stroke is characterised by a substantial loss of glucose and oxygen delivery to 
the highly metabolic brain. Lack of adequate CBF delivery quickly triggers a 
pathophysiological cascade involving multiple mechanisms: bioenergetic failure, 
excitotoxicity, peri-infarct depolarisations, oxidative stress, blood brain barrier (BBB) 
breakdown, inflammatory responses and apoptosis (Brouns and De Deyn, 2009). 
Collectively these events are known as the “ischaemic cascade”, a process that starts 
minutes after stroke onset and that lasts for several days, even when reperfusion is 
established. In fact, reperfusion alone results in secondary damages characterised by 
enhanced oxidative stress, inflammation and BBB disruption (Brouns and De Deyn, 2009). 
The components of the ischaemic cascade occur at different time points following the 
initiation of ischaemia with the collective end point resulting in cell death (Figure 1-4). 
 
Figure 1-4 The ischaemic cascade. Injury starts with bioenergetic failure followed by 
excitotoxicity, oxidative stress and peri-infarct depolarisations. At later stages, inflammation and 
apoptosis take places with subsequent BBB breakdown. Figure adapted from Brouns & De Deyn 
2009. 
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1.2.2.1 Energy failure and excitotoxicity 
A normally functional brain is dependent on energy in the form of adenine triphosphate 
(ATP) primarily produced in the mitochondria (Sanderson et al., 2013). During ischaemia, 
glucose and oxygen cessation results in mitochondria failure and ATP production 
depletion, impairing ion transport pump maintenance. This results in depolarisation and 
excitatory amino acid release into the pre-synaptic space, particularly glutamate (Dirnagl et 
al. 1999). Glutamate extracellular accumulation is then further exacerbated by loss of 
energy dependent reuptake within astrocytes, triggering excitotoxicity (Dirnagl et al. 
1999). Excessive glutamate overwhelmingly activates N-methyl-D-aspartate (NMDA) and 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. In turn, 
intracellular Ca2+ and Na+ disproportionately accumulate in brain cells, triggering oxidative 
stress, cytotoxic oedema and necrosis (Dirnagl et al., 1999; Lipton, 1999).  
1.2.2.2 Peri-infarct depolarisations 
In healthy brain tissue, slowly propagating depolarisations take place across the cerebral 
cortex, a phenomena termed cortical spreading depolarisations (CSD) (Leão, 1944). These 
are triggered when a strong stimulus depolarises a certain volume of brain tissue, 
approximately 1 mm3 in rats (Ayata and Lauritzen, 2015; Matsuura and Bureš, 1971). CSD 
are characterised by an intense depolarisation of both neurons and glial cells and 
subsequent rise in metabolic demand to restore ionic gradients (Ayata and Lauritzen, 
2015). In a healthy brain, CSDs do not induce cell death and are well tolerated (Matsuura 
and Bureš, 1971; Nedergaard and Hansen, 1988). However, during cerebral ischaemia, 
CSD like depolarisations occur in the penumbral cells and are termed peri-infarct 
depolarisations (PIDs) (Hossmann, 1996).  
PIDs are characterised by repetitive propagating depolarisations across the whole 
hemisphere, typically travelling at 3 mm/min and are associated with accelerated cerebral 
infarction (Hossmann, 1996). PIDs arise spontaneously within the ischaemic penumbra and 
are triggered by cells within the ischaemic core (Ayata and Lauritzen, 2015). In the latter, 
neuronal cells are undergoing permanent anoxic depolarisation, resulting in exacerbated 
extracellular release of glutamate and K+. This ionic imbalance propagates to surrounding 
penumbral cells inducing depolarisation (Ayata and Lauritzen, 2015). On the contrary to 
cells within the ischaemic core, penumbral cells can repolarise; however, the mismatch 
between metabolic demands to support repolarisation and CBF delivery, further exhausts 
the limited ATP supply and potentiates cell death (Back et al., 1996). PIDs are crucial 
11 
 
elements of ischaemic stroke pathology as these exacerbate hypoperfusion. Plus, the PID 
number and duration correlate with infarct progression in several animal models and in 
humans (Dohmen et al., 2007; Fabricius et al., 2006; Mies et al., 1993; Shin et al., 2006). 
1.2.2.3 Oxidative and nitrosative stress 
Oxidative and nitrosative stress is characterised by the overwhelming generation of free 
radicals that surpass endogenous scavenger actions, resulting in cellular damage. There are 
several sources of free radical formation including Ca2+ overload, inflammation and 
reperfusion injury (Lakhan et al., 2009). Intracellular Ca2+ overload, triggers the activation 
of endonucleases, proteases and lipases (Crack and Taylor, 2005), which degrade cellular 
integrity components such as actin and laminin (Ankarcrona et al., 1995; Furukawa et al., 
1997). In addition, Ca2+ overload activates phospholipase A2 (PLA2) and cyclooxygenase 
(COX), which generate reactive oxygen species (ROS) leading to lipid peroxidation and 
cellular damage (Jovin et al., 2008; Mattson et al., 2000). As a result of ROS formation, 
mitochondria become disrupted and leaky resulting in free radical burst, accentuating 
oxidative stress (Kristián and Siesjö, 1998). ROS are a main source of tissue damage by 
directly inducing cell death and their main source are NADPH oxidases (NOX), 
membrane-bound enzyme complex composed of membrane and cytosolic subunits 
(Girouard et al., 2009). In the brain, there are 3 main types: NOX1, NOX2 and NOX4. 
NOX1 is expressed in human brain tissue and in microglia (Cheret et al., 2008; Infanger et 
al., 2006), NOX2, or phagocytic NOX, is an inducible isoform localised in intracellular 
phagosomes and microglia (Cheret et al., 2008) whereas NOX4 is expressed in cortical 
neurons and capillaries after ischaemia (Vallet et al., 2005). NOX2 is the most crucial ROS 
generator during cerebral ischaemic injury (Girouard et al., 2009).  
Another crucial player in free radical generation is nitric oxide (NO), a water soluble 
radical produced by nitric oxide synthase (NOS) on L-arginine (Iadecola, 1997). There are 
three types of NOS: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS 
(eNOS) (Iadecola, 1997). During ischaemia, Ca2+ overload activates NOS generating NO 
which then reacts with superoxide to form a potent reactive nitrogen species, peroxynitrite 
(Iadecola, 1997). During ischaemia, nNOS and eNOS become quickly upregulated 
whereas the increased iNOS expression is delayed by 6-12 hrs after stroke onset and 
primarily associated with reperfusion injury (Iadecola, 1997; Lakhan et al., 2009).  
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1.2.2.4 Post-ischaemic inflammatory response  
Inflammatory responses are triggered within hours of ischaemia onset and are part of a 
secondary phase of injury. During hypoxia, intracellular Ca2+ and free radicals activate a 
series of pro-inflammatory transcription factors such as nuclear factor kappa beta (NF-B), 
which in turn stimulate the production of cytokines, chemokines and adhesion molecules 
that stimulate leukocyte infiltration (Moskowitz et al., 2010). Following the initiation of 
reperfusion, a robust inflammatory response takes place by permitting inflammatory cells 
to flow into the injury site. In turn, these inflammatory mediators contribute to cell death, 
BBB disruption and leukocyte infiltration in a temporal manner (Figure 1-5) (Benakis et 
al., 2015). Microglia and infiltrating leukocytes play a crucial role in exacerbating cell 
damage by releasing ROS, pro-inflammatory cytokines [i.e interleukin 1 beta (IL-1& 
interleukin 6 (IL-6)], iNOS and matrix metalloproteinase 9 (MMP9) as well as enhancing 
cyclooxygenase 2 (COX-2) expression and NF-B activation (Lakhan et al., 2009; Liu et 
al., 1994; Schilling et al., 2009; Suzuki et al., 1999).  
Resident microglial cells are the first cells to respond to ischaemic insult by changing from 
a ramified (resting) phenotype to an active amoeboid shape (Kettenmann et al., 2011). 
Activated microglia in the brain can be identified by ionised calcium binding adapter 
molecules (IBA1) and it has been shown that they are present within the peri-infarct region 
from as early as 3.5 hrs post-stroke whereas in the ischaemic core they typically appear 
from around 24 hrs post injury (Ito et al., 2001). In addition to microglia activation, 
inflammatory cells such as neutrophils, macrophages and lymphocytes accumulate within 
the injured site. Several chemokines and receptors are involved in leukocyte recruitment 
with interleukin 8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and regulated on 
activation normal T cell expressed and secreted (RANTES) receiving particular focus (Deb 
et al., 2010). IL-8 activates C-X-C motif chemokine receptor 2 (CXCR2) stimulating 
neutrophil chemotaxis (Jickling et al., 2015; Kostulas et al., 1999). MCP-1 activates C-C 
motif chemokine receptor 2 (CCR2) leading to macrophage infiltration (Dimitrijevic et al., 
2007) whereas RANTES mediates its effects through C-C motif chemokine receptor 5 
(CCR5) acting as a powerful leukocyte activator, particularly T cells (Deb et al., 2010; 
Terao et al., 2008).  
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Figure 1-5 Spatio-temporal profile of microglia and leukocytes in infarct and peri infarct 
regions following transient middle cerebral artery occlusion (MCAO). In the infarct area 
(outlined in red), neutrophils are the first leukocytes to arrive to injury site with subsequent 
infiltration of M2 microglia/macrophages. In peri-infarct regions (outlined in pink), microglia are the 
first cells to become activated followed by neutrophil and macrophage infiltration. M2 type 
microglia/macrophage are concentrated within the infarct from 1-5 days post MCAO and then shift 
towards a M1 phenotype from 5-14 days post injury. In the peri-infarct, M1 phenotype is primarily 
present at 3-7 days and then becoming M2 type at 7-14 days. Figure adapted from Benakis et al., 
2015. 
 
Neutrophils are the first leukocytes to reach the ischaemic area and are detected from 1 to 7 
days post stroke (Figure 1-5) (Huang et al., 2006). These are followed by macrophage 
infiltration, which are highly present across injured areas between 3-7 days after insult. As 
dying neurons activate macrophages, these become morphologically undistinguishable 
from microglia, and are referred to as microglia/macrophage. Microglia/macrophages are 
suggested to exert a dual role in ischaemic stroke (Benakis et al., 2015). Initially these cells 
induce neurotoxic effects through the production of ROS, IL-1 and IL-6 cytokine release 
(Rothwell et al., 1997) whereas at later stages microglia/macrophages are neuroprotective 
by phagocytosing excitotoxins and releasing neurotropic factors including transforming 
growth factor 1 (TGF-1) and interleukin 10 (IL-10) (Iadecola and Anrather, 2011). 
These two alternating states are defined as M1 profile for pro-inflammatory and M2 for an 
anti-inflammatory and exhibit a specific gene expression profile (Table 1-2) (Hu et al., 
2012). M1 phenotype is first observed in the peri-infarct region from day 3 whereas from 
day 5 onwards it is widely expressed in the infarct core. On the other hand, M2 type is 
highly expressed within the core between 1-5 days (Figure 1-5) (Benakis et al., 2015). 
Finally, lymphocytes can enter the infarcted brain in the later phases of cerebral ischaemia 
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between 3 to 7 days post strokeand peak no earlier than 5 days post stroke (Grønberg et al., 
2013). 
Table 1-2 Simplified list of microglia/macrophage M1 and M2 type specific genes 
M1 type genes M2 type genes References 
 Cluster 
differentiation 86 
(CD86) 
 Cluster 
differentiation 32 
(CD32) 
 Cluster 
differentiation 11b 
(CD11b) 
 C-C chemokine 
receptor 7 (CCR7) 
 IL-1 
 IL-6 
 iNOS 
 Ym1/2 
 TGF-1 
 C-C motif 
chemokine 22 
(CCL22) 
 IL-10 
 Arginase 1 
(Arg1) 
 Cluster 
differentiation 
163 (CD163) 
 Cluster 
differentiation 
206 (CD206) 
Hu et al. 
2012;  
Cherry et al. 
2014;  
Durafourt et 
al. 2012. 
 
 
1.2.2.5 Blood brain barrier disruption 
The BBB is a continuous and impermeable membrane that prevents the entry of potential 
harmful substances into the brain. The basic structure of the BBB consists of a capillary 
network where endothelial cells lack fenestrations and contain tight junction proteins 
(TJPs) (Lo et al., 2003). TJPs along with adherens junctions form a circumferential zipper-
like structure between endothelial cells, limiting hydrophilic molecule passage. The 
preservation of the TJ is governed by three essential transmembrane proteins: claudins, 
occludin and junction adhesion molecules which are linked to the actin cytoskeleton 
through cytoplasmic zona occludens (ZO) proteins: ZO-1, ZO-2 and ZO-3 (Yang and 
Rosenberg, 2011). At present, it is widely recognised that the BBB is also formed by 
surrounding pericytes, perivascular astrocytes, neurons, extracellular matrix, microglia and 
oligodendrocytes and together, these components form the neurovascular unit (NVU) (del 
Zoppo, 2010).  
Following stroke, the NVU becomes disrupted and TJP disassemble, allowing leakage of 
blood components into the brain parenchyma, a process named vasogenic oedema (Lo et 
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al., 2003). The effects of vasogenic oedema are overwhelming as it increases ICP, raising 
the risk of vascular compression, herniation and hemisphere displacement (Dirnagl et al., 
1999). One of the initial events that results in damage to the BBB is the marked rise in 
oxidative stress that occurs resulting in the release of proteases and lipases that damage 
extracellular matrix and cytoskeletal components (Brouns and De Deyn, 2009). Following 
reperfusion, BBB breakdown is thought to occur in a biphasic pattern and to be the 
outcome of inflammation, oxidative stress and angiogenesis (Sandoval and Witt, 2008). 
Early BBB opening is suggested to occur between 3 to 6 hrs reperfusion and followed by 
BBB closing at approximately 15 to 24 hrs post reperfusion. After, the secondary phase of 
BBB breakdown takes place at around 48 to 72 hrs post stroke onset (Belayev et al., 1996; 
Pillai et al., 2009; Rosenberg et al., 1998; Veltkamp et al., 2005). The final phase of BBB 
disruption correlates with increased vasogenic oedema and greater tissue damage by 
allowing free leukocyte flow into the brain parenchyma and extravasation of red blood 
cells, resulting in haemorrhagic transformation (HT) (Mergenthaler et al., 2004).  
1.2.2.6 Cell death after ischaemia 
In the ischaemic brain, cell death occurs in a heterogeneous fashion. In the core, cell death 
occurs through necrosis, a rapid event that takes place within few minutes of stroke onset 
(Dirnagl et al., 1999). In these cells, the overwhelming Ca2+ and H2O influx induces 
cytotoxic oedema and nuclear chromatin condensation takes place. Subsequently, nuclear, 
organelle and plasma membrane become disrupted, releasing intracellular content (Dirnagl 
et al., 1999). In the penumbra, cell death tends to occur through apoptosis, an organised 
energy dependent form of cell death that starts hours after injury, lasts for several days and 
contributes towards infarct expansion (Love, 2003; Mergenthaler et al., 2004). Apoptosis is 
associated with the upregulation of aspartate-specific cysteine proteases named caspases, 
particularly through the release of cytochrome C from the mitochondria (Love, 2003). 
These will cleave structural proteins leading to cytoplasm shrinkage, cell fragmentation, 
chromatin condensation and cell fragmentation (Love 2003). The main difference between 
necrosis and apoptosis is that in the former, dying cells will release glutamate and toxins 
that affect the surrounding cells whereas apoptosis leads to marginal inflammation and 
genetic content release. Both cell processes may occur in ischaemic cells and are 
dependent on degree of ischaemia, Ca2+ concentration and cellular microenvironment 
(Brouns and De Deyn, 2009; Unal-Cevik et al., 2004).  
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1.2.3 Current therapies and challenges 
The first goal in ischaemic stroke treatment is to restore blood flow to the ischaemic brain. 
At the moment, intravenous (IV) alteplase stroke therapy or recombinant tissue 
plasminogen activator (rt-PA) is the only non-surgical treatment available and it works by 
lysing the clot obstructing the vessel following IV administration (Roth, 2011). 
Recanalization and consequent reperfusion of ischaemic brain is associated with reduced 
neurological deficit and mortality (Rha and Saver, 2007). Nonetheless, IV rt-PA has 
various limitations, for instance, the efficacy and safety of treatment is restricted to patients 
assessed within 4.5 hours of symptom onset and is mostly effective when administered 
within 90 min of symptom start (Emberson et al., 2014). Unfortunately, IV rt-PA may lead 
to serious complications including symptomatic intracranial haemorrhage, systemic 
bleeding and orolingual oedema (Tawil and Muir, 2017). Thus, this therapy is clinically 
challenging since it depends on a short therapeutic time window and balancing the benefit 
to risk (Figure 1-6). These limitations result in small eligibility numbers, which at the 
moment comprise 20% of patients (Figure 1-6) (Tawil and Muir, 2017). In addition, IV rt-
PA therapy frequently fails to induce successful vessel recanalization, especially in patients 
with proximal large artery occlusion (Bhatia et al., 2010).  
In order to target patients who are not eligible for or did not benefit from IV rt-PA, intra-
arterial therapy and mechanical removal of the obstructing clot are a current line of therapy 
(Tawil and Muir, 2017). In 2015, five separate randomised controlled clinical trials tested 
the efficacy of stent retrievers for recanalization of proximal vessel occlusion compared to 
IV rt-PA or standard care. The results in these trials showed that mechanical endovascular 
thrombectomy significantly improved functional outcome after 90 days follow up 
(Berkhemer et al., 2015; Campbell et al., 2015; Goyal et al., 2015; Jovin et al., 2015; Saver 
et al., 2015). In particular, in the MR CLEAN trial, patients subjected to endovascular 
therapy within 6 hrs of symptom onset displayed improved modified Rankin Scale scores, 
smaller infarct volumes and lower final National Institutes of Health Stroke Scale (NIHSS) 
values (Berkhemer et al., 2015). Still, the efficacy of these options is equally time-
dependent and relies on the expertise and efficiency of clinical centres (Tawil and Muir, 
2017).  
Although reperfusion is the main clinical outcome, reperfusion alone may exacerbate tissue 
salvage through reperfusion injury (Pan et al., 2007). CBF reestablishment leads to 
exacerbated inflammatory response that promotes hypoperfusion, cerebral oedema, HT and 
neuronal cell death (Pan et al., 2007). In fact, many patients treated with both thrombolysis 
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and thrombectomy procedures exhibit a phenomenon termed hyperintense acute 
reperfusion marker (HARM), characterised by blood vessel permeability in the meninges 
over the area of the stroke. This phenomenon is associated with worse clinical outcome as 
well as HT (Kassner et al., 2009; Kidwell et al., 2008; Kohrmann et al., 2012; Renú et al., 
2015). Since alteplase administration is the treatment of choice and endovascular therapy is 
becoming increasingly used (Tawil and Muir, 2017), it is crucial to identify a potential 
adjuvant therapy with the capacity to limit injury following reperfusion.  
 
Figure 1-6 Indications and contraindications for thrombolysis (rt-PA) treatment in clinic 
stroke. BP: blood pressure; CT: computerised tomography; IV: intravenous; NIHSS: National 
Institutes of Health Stroke Scale. Figure adapted from Tawil & Muir, 2017. 
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1.2.4 Imaging the ischaemic brain 
Imaging has become a critical component of stroke diagnosis with computed tomography 
(CT) being the most widely used technique clinically and the use of magnetic resonance 
imaging (MRI) in a research setting being increasingly used. MRI provides a more 
versatile technique that offers better image quality; however, CT remains the standard tool 
for initial diagnostics due to its wider availability and cost. These techniques are 
particularly useful in ruling out IHC and SAH to select patients for thrombolysis therapy 
(Muir and Macrae, 2016). Plus, these imaging techniques are of extreme relevance to 
detect alterations in ischaemic lesions and identify patients that will most likely benefit 
from therapy (Muir and Macrae, 2016). Although CT techniques are still the gold standard 
in clinic, these show lack of sensitivity in detecting early ischaemic lesions particularly 
between 6-12 hrs post stroke (Baird and Warach, 1998). On the other hand, MRI offers 
higher anatomical resolution capable of detecting pathological processes and organ 
function, arterial occlusion or stenosis in the circle of Willis. Consequently, MRI is a 
highly useful technique in the stroke context, being widely used in clinical and pre-clinical 
studies (Muir and Macrae, 2016). 
1.2.4.1 Diffusion weighted imaging  
Diffusion weighted imaging (DWI) is a sensitive MRI technique for detection of acute 
ischaemic lesions. The signal is based on the Brownian motion of protons or H2O in 
biological tissues (Moseley, Cohen, et al., 1990). Under normal conditions extracellular 
water molecules diffuse relatively freely; however, following stroke, ATP depletion 
triggers an influx of extracellular Na+ and Cl- into the cell accompanied by H2O 
accumulation, causing cytotoxic oedema (Liang et al., 2007). Cytotoxic oedema restricts 
extracellular H2O diffusion, increasing the diffusion constant and DWI signal (Moseley, 
Cohen, et al., 1990). The decrease in H2O diffusion can be quantified by calculating the 
apparent diffusion coefficient (ADC), allowing a quantitative measure of diffusion within a 
voxel. Higher ADC values represent areas of high diffusion whereas a decrease in ADC 
values is a result of H2O diffusion restriction (Moseley, Cohen, et al., 1990). The latter is 
translated into a hyperintense signal on DWI scans and a hypointense signal on the ADC 
image. DWI can detect early ischaemic damage within minutes of ischaemic stroke onset 
in both animal models of stroke and in humans (Moseley, Kucharczyk, et al., 1990; Rother 
et al., 1996; Yoneda et al., 1999). Furthermore, it is reported to consist of a reliable 
quantification of immediate irreversible ischaemic damage (Baird and Warach, 1998). 
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DWI is also useful in the context of penumbra volume determination. Along with DWI, 
Perfusion Weighted imaging (PWI) can be carried out to detect the area of hypoperfusion. 
Following stroke, if the hypoperfused tissue region is larger than the DWI lesion then this 
can be used as an approximation of the ischaemic penumbra. Consequently, when 
overlaying the CBF map and DWI, there is a brain region which is hypoperfused but not 
irreversibly damaged, named DWI/PWI mismatch and representing the ischaemic 
penumbra (Schlaug et al., 1999).  
1.2.4.2 MRI-T2 weighted imaging 
T2-weighted imaging can be used to detect vasogenic oedema characterised by 
accumulation of extracellular fluid due to BBB breakdown. In comparison to normal 
tissue, infarcted tissue has a longer T2 relaxation time. As a result, damaged cells will 
present higher signal intensity on T2-weighted scans (Baird and Warach, 1998). T2 fails to 
detect injury 2-3 hrs after stroke; therefore, it cannot be used to assess early ischaemia 
severity (Moseley, Kucharczyk, et al., 1990). However, it has been shown to reliably detect 
infarcted tissue during acute and subacute phases from 7 hrs after stroke (Boisvert et al., 
1990; Loubinoux et al., 1997). At 24 hrs following stroke onset, the water content in the 
parenchyma increases resulting in a hyperintense signal on T2 weighted imaging and 
therefore this increases sensitivity for infarct detection by up to 90% (Yuh et al., 1991). 
During subacute phases, between 24 hrs and 14 days, vasogenic oedema results in better 
definition of the infarct. As brain swelling and therefore vasogenic oedema begins to 
resolve around 7 to 10 days post stroke onset, T2 MRI fogging occurs as a result of 
inflammatory cell infiltration and lesion resolution, yet, T2 weighted imaging has been 
shown to provide adequate infarct detection sensitivity (Ricci et al., 1999).  
1.2.5 Animal models of focal cerebral ischaemia 
Ischaemic stroke is primarily studied in animal models by permanently or transiently 
occluding the MCA. Over the decades, several stroke models have been developed with 
two main purposes: to understand the pathological mechanisms underlying the condition 
and most importantly, to develop new therapies (Macrae, 2011). Human ischaemic stroke 
is incredibly diverse in terms of causes and localisation. Conversely, animal models 
provide a controllable, reproducible and standardised approach to study focal cerebral 
ischaemia, allowing a greater understanding of the molecular, physiological and 
biochemical brain alterations that cannot be detected in humans due to its invasive nature 
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(Fluri et al., 2015; McCabe et al., 2017). In fact, current pharmacological and imaging 
interventions used in clinic are the outcome of animal model studies. For instance, rt-tPA 
was first identified as a treatment option in a rabbit model and the usefulness of DWI 
studied in cats (Moseley, Kucharczyk, et al., 1990; Zivin et al., 1985). Since then, over 
1000 agents have been tested in animals of stroke and reported to be neuroprotective 
(O’Collins et al., 2006); however, the compounds reaching clinical trials failed to show an 
improved outcome when compared to placebo (Henninger et al., 2010). Potential reasons 
for this translation failure have been extensively addressed, leading to the formation of The 
Stroke Therapy Academic Industry Roundtable (STAIR), which provides best practice 
guidelines to improve preclinical study quality (Fisher et al., 2009).  
The majority of stroke studies are performed in rodents, primarily rats, as these are of 
lower cost, are more ethically accepted compared to larger species and allow access to 
transgenic techniques. In addition, rodents have a similar cerebral vasculature to that 
observed in humans and are relatively homogeneous amongst strains (Fluri et al., 2015). In 
human ischaemic stroke, the most commonly affected vessel is the MCA (Bogousslavsky 
et al., 1988), thus, a wide range of middle cerebral artery occlusion (MCAO) models have 
been developed, including the embolic, electrocoagulation, endothelin-1 (ET-1) and 
filament MCAO models (Longa et al., 1989; Macrae et al., 1993; Sharkey, 1993; Tamura 
et al., 1981). The choice of animal model is dependent on the drug being studied and its 
reported mechanism of action, with models of transient focal ischaemia being the most 
suitable models to examine potential anti-inflammatory agents. The most commonly used 
are the ET-1 induced and the filament model (Macrae, 2011).  
1.2.5.1 Endothelin-1 induced MCAO model 
This model was first developed in the rat and is based on the application of the potent 
vasoconstrictor ET-1 within the MCA territory (Macrae et al., 1993). It can be applied on 
the cortical surface of the exposed MCA or applied directly on the MCA through 
intracerebral injection leading to a highly reproducible infarct that covers all cortical layers 
(Fuxe et al., 1997; Macrae et al., 1993; Sharkey, 1993). Once administered, ET-1 will 
induce potent dose-dependent vasoconstriction that results in an initial CBF deficit of up to 
50% (Biernaskie et al., 2001). After this steep reduction, reperfusion gradually occurs over 
a number of hours (Macrae, 2011). This model may be an adequate approach to replicate 
rt-PA administration in the clinic since reperfusion also occurs gradually after therapy 
(Sutherland et al., 2016). Advantages of this model include the possibility to visually 
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confirm ischaemia and adjust ET-1 doses accordingly, low mortality and the fact that it is 
less invasive in terms of surgical preparation (Fluri et al., 2015; Macrae, 2011). 
Disadvantages include variability in ET-1 potency and stability as well as the fact that ET-
1 receptors are present in neurons and astrocytes (Fluri et al., 2015; Macrae, 2011). Once 
ET-1 receptors are activated, astrocytosis and axonal spouting may take place, impairing 
result interpretation (Fluri et al., 2015). In addition, ischaemia is reported to develop 
slowly after ET-1 injection, therefore, this model is considered by some as an unsuitable 
approach to replicate human stroke (Schirrmacher et al., 2016). 
1.2.5.2 Intraluminal filament MCAO model 
The intraluminal filament model is the most widely used model in rodents and is 
characterised by the insertion of a flexible monofilament into the internal carotid artery 
(ICA) until it occludes the MCA (Macrae, 2011). One of its advantages is that it can be 
used to study permanent ischaemia by leaving the filament in place or transient ischaemia 
by removing the filament and allowing reperfusion. In the latter, the most common 
ischaemic duration periods are 60, 90 and 120 min (Fluri et al., 2015; Garcia et al., 1995). 
This model allows you to precisely control ischaemia duration, is relatively non-invasive 
as it does not require craniotomy and it is characterised by large infarcts (Macrae, 2011). 
Disadvantages include reproducibility and mortality issues. For instance, blocking the 
MCA should induce both cortical and striatal injuries; however, it is common for some 
animals to exhibit striatal infarcts only, possibly as a result of inadequate vessel occlusion 
(Macrae, 2011). Plus, the fact that this is a closed skull model, enhanced cerebral oedema 
is present between 24-48 hrs post injury and mortality rates can go up to 42% (Macrae, 
2011).  
Since the majority of thromboembolic strokes occur within the MCA territory, this model 
is considered suitable to directly replicate the condition; however, in humans, vessel 
occlusion is often incomplete and partial spontaneous reperfusion usually occurs due to 
thrombus degradation (Zanette et al., 1995). In the filament model, reperfusion occurs 
suddenly and for this reason, this model may be deemed unsuitable to test future stroke 
therapies (Hossmann, 2012). Nonetheless, the success in thrombectomy therapies within 
the clinic has given new light to the use of this set up. Transient MCAO with the filament 
model and thrombectomy surgery lead to abrupt reperfusion and induce a similar CBF 
post-ischaemic profile (Sutherland et al., 2016). Therefore, the filament model is now 
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considered the most suitable model for studying potential adjunctive therapies that can be 
given alongside thrombectomy (Sutherland et al., 2016). 
1.3 The Renin Angiotensin System: from homeostasis to 
cardiovascular disease 
The Renin Angiotensin System (RAS) is a crucial component of homeostatic control of 
blood pressure, tissue perfusion, extracellular volume and electrolytes in vertebrates 
(Skeggs et al., 1976). However, its pathological activation is implicated in the development 
and progression of cardiovascular disease (CVD) by inducing excessive vasoconstriction, 
inflammation, oxidative stress, cell growth and hypertrophy (Dzau, 2001). RAS 
overactivation mediates injury in multiple ischaemic stroke risk factors such as 
hypertension, myocardial infarction and atherosclerosis (Dzau, 2001). As a result, RAS 
blockers including angiotensin converting enzyme (ACE) inhibitors and angiotensin II 
receptor type 1 (AT1R) blockers (ARBs) have revolutionised the treatment of CVD and 
shown to decrease stroke incidence in hypertensive patients (Griendling et al., 1996; 
Thone-Reineke et al., 2006). The impact of RAS overactivation in ischaemic stroke 
pathology alone is not well understood; however, increasing evidence from animal models 
suggest that the RAS is not only implicated in injury but may also provide a therapeutic 
target (Culman et al., 2002; Walther et al., 2002). 
1.3.1 Brief historical perspective on the RAS 
The RAS was first discovered more than 100 years ago by Tigerstedt & Bergman 
following the observation that renal cortex extracts, which they named renin, promoted 
hypertension in a rabbit model (Tigerstedt and Bergman, 1898). The link between these 
extracts and hypertension was later observed in an ischaemic model of renal injury, in 
which a pressor substrate was shown to be released following injury (Goldblatt et al., 
1934). It was then identified that apart from renin, a short-lived pressor protein, 
angiotensinogen, was released and served as its substrate. The outcome of this enzymatic 
reaction was demonstrated to be angiotensin (Ang), initially named as hypertensin and 
angiotonin by two different research groups (Braun-Menendez et al., 1940; Page and 
Helmer, 1940). Following the discovery of Ang it was then shown to be expressed in the 
blood plasma in two distinct isoforms, angiotensin I (Ang I) and angiotensin II (Ang II) 
(Skeggs et al., 1954). The former was demonstrated to be an inactive decapeptide that is 
converted to the main effector Ang II through the cleavage activity of ACE at the histidyl-
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leucine from the C terminus (Skeggs et al., 1954; Skeggs, Lentz, et al., 1956). Since its 
initial discovery, new RAS components have been identified and this line of research is 
ongoing. 
1.3.2 The Classical RAS 
Under normal physiological conditions, the classical circulating RAS is triggered by 
multiple stimuli. These include alterations in blood pressure detected at the levels of the 
renal afferent arteriole, changes in NaCl delivery to the macula densa of the distal tubule 
and 1 adrenergic receptor nerve stimulation (Reid, 1985). The classical RAS axis is 
initiated with the release of renin, a single chain aspartyl protein and rate-limiting enzyme, 
from the juxtaglomerular apparatus of the kidney (Reid, 1985). Renin cleaves the leucine 
and valine amino acids on angiotensinogen, a -2 glycoprotein constitutively produced and 
released from the liver (Deschepper, 1994). The product of this enzymatic activity is Ang 
I, which is cleaved in plasma and pulmonary circulation by ACE (Corvol et al., 1995; 
Skeggs, Kahn, et al., 1956). ACE is a carboxypeptidase and the main enzyme responsible 
for the conversion of Ang I to the potent vasoconstrictor Ang II (Skeggs, Kahn, et al., 
1956). Apart from its role in generating Ang II, ACE has the ability to hydrolyse 
bradykinin, inhibiting its vasodilatory actions (Yang et al., 1970). There are two forms of 
ACE, somatic and germinal, the former is expressed ubiquitously whereas the latter is 
predominantly found in testes (Turner and Hooper, 2002). Once generated, Ang II binds to 
G coupled protein receptors (GPCRs), AT1R and angiotensin II receptor type II (AT2R); 
however, it predominantly exerts its effects through the AT1R (Mehta and Griendling, 
2007). Together these components form the classical arm of RAS defined as the ACE/Ang 
II/AT1R axis (Figure 1-7).  
 
Figure 1-7 The classical RAS. Under physiological conditions, the circulating RAS is triggered 
and renin released from the juxtaglomerular apparatus. Renin will then cleave angiotensinogen, 
which is released from liver; to from Ang I. Ang I is converted by ACE in the circulation and lungs to 
form Ang II, the main effector. Ang II will exert its effects by primarily binding to AT1R. 
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1.3.3 The Extended RAS 
Advances in the field have demonstrated that the RAS is far more complex than initially 
thought. Distinct Ang II receptors and signal transduction pathways have been 
characterised, new biologically active peptides and enzymes identified as well as new 
pathways for peptide generation (Figure 1-8) (Paul et al., 2006). In addition, it is now 
accepted that the RAS is ubiquitously expressed and produced as a local/tissue system 
independent from circulation recruitment and present in several organs, including the brain 
(Paul et al., 2006).  
The discovery of new components and local tissue RAS has changed the conventional 
conception of the RAS. For instance, it is now understood that renin is released as an 
inactive pre-prohormone, where the pre-segment acts as signal peptide destined to direct 
the prohormone for secretion. The prorenin binds to the pro-renin receptor (PRR) present 
on the cell membrane and the pro-segment is removed to generate active renin (Nguyen et 
al., 2002; Nguyen and Muller, 2010). This step is crucial in tissue RAS as it provides a 
mechanism to locally generate renin (Paul et al., 2006). Once Ang II is formed through the 
classical pathway described above, it will be metabolised by several enzymes such as 
aminopeptidase A, which converts Ang II to Ang III, the latter stimulating vasopressin 
release in the brain (Zini et al., 1996). Subsequently Ang III is metabolised by 
aminopeptidase N to form Ang IV, a ligand for the angiotensin type IV receptor (AT4R), 
involved in memory processing (McKinley et al., 2003; Swanson et al., 1992). Most 
importantly, Ang II can be metabolised by angiotensin converting enzyme 2 (ACE2), a 
novel zinc metalloproteinase discovered in 2000 (Donoghue et al., 2000). ACE2 is an 805 
amino acid sequence type 1 membrane-bound glycoprotein encoded on the X chromosome, 
presents a molecular weight of 120kDa and shares 42% homology with the catalytic 
domain ofsomatic ACE (Donoghue et al., 2000; Tipnis et al., 2000). Initially it was shown 
that ACE2 hydrolysed Ang I to form angiotensin-(1-9) (Ang-(1-9)); however, further 
studies showed that ACE2 has a 400-fold higher catalytic efficiency for Ang II rather than 
Ang I (Donoghue et al., 2000; Vickers et al., 2002).  
Ang II is the main substrate for ACE2 and the most important product is angiotensin-(1-7) 
[Ang-(1-7)], a biological active heptapeptide (Santos et al., 2003; Vickers et al., 2002). 
Ang-(1-7) can be formed through various pathways, for example, Ang (1-9) can be 
converted by ACE and neprilysin (NEP) forming Ang-(1-7) (Donoghue et al., 2000; 
Vickers et al., 2002). Moreover, Ang-(1-7) can be formed by the direct actions of NEP, 
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thimet oligopeptidase (TOP) and prolyl endopeptidases (PEP) on Ang I (Figure 1-8) 
(Gironacci et al., 2014; Welches et al., 1991; Yamamoto et al., 1992). Ang-(1-7) is also 
degraded by ACE to produce Ang-(1-5) (Figure 1-8) (Chappell et al., 1998). Further 
research has identified that Ang-(1-7) specifically activates the Mas receptor (MasR) and 
its biological effects antagonise the classical ACE/Ang II/AT1R (Sampaio et al. 2007; 
Santos et al. 2003). This led to the identification of a new arm of the RAS, the counter-
regulatory RAS axis: ACE2/Ang-(1-7)/MasR axis (Donoghue et al., 2000; Santos et al., 
2003; Vickers et al., 2002).  
 
Figure 1-8 The extended RAS. Ang II is generated by the classical pathway and will bind to two 
receptors, AT1R and AT2R. Ang II is cleaved by aminopeptidase A generating Ang III, which is then 
metabolised by aminopeptidase N forming Ang IV, a ligand for AT4R. In addition, Ang II is 
metabolised by ACE2 producing the heptapeptide Ang-(1-7), a ligand for MasR. Other Ang-(1-7) 
pathways include direct actions of NEP, TOP and PEP on Ang I. Moreover, Ang I can be 
metabolised by ACE2 generating Ang-(1-9), which is then cleaved by ACE and NEP to produce 
Ang-(1-7). Once formed, Ang-(1-7) will be degraded by ACE to form Ang-(1-5). 
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1.3.4 ACE/Ang II/AT1R: the detrimental axis in cardiovascular 
disease 
Studies conducted in stroke risk factors, primarily hypertension, have provided valuable 
information regarding the involvement of the RAS in CVD pathology, setting the premise 
that the RAS may be implicated in ischaemic stroke. As research continues within the 
stroke field in clarifying this hypothesis, it is plausible to assume that some of the effects 
induced in peripheral CVDs may overlap with the stroke setting. Therefore, this section 
will outline findings in peripheral CVDs that support a rationale for RAS targeting in 
cerebral ischaemia. 
Under normal conditions, Ang II is primarily generated by ACE and its plasma levels 
range between 41.8 – 61.7 pg/mL in healthy humans and 53.0 – 141.6 pg/mL in 
anaesthetised male rats (Huang et al., 1989; Vilas-Boas et al., 2009). Once formed, Ang II 
will exhibit a half-life of 30 sec in the circulation and 15 min in tissues (van Kats et al., 
1997). Physiologically, Ang II leads to vasoconstriction; aldosterone release from adrenal 
glands, NaCl reabsorption and K+ excretion, vasopressin secretion from the pituitary gland 
and increased sympathetic activity (Reid, 1985). During CVD; however, the RAS is 
overactive leading to exacerbated formation of Ang II. In turn, Ang II through the AT1R 
will mediate the pathophysiology of several conditions including hypertension, 
atherosclerosis, and myocardial infarction by stimulating vasoconstriction, oxidative stress, 
inflammation, cellular growth, migration and hypertrophy (Mehta and Griendling, 2007; 
Touyz and Schiffrin, 2000). For this reason, ACE inhibitors such as ramipril and ARBs, 
the latter referred to as “sartans” are successfully used to treat hypertension (Menard and 
Patchett, 2001). Conversely, AT2R activation is believed to counteract the detrimental 
effects of the ACE/Ang II/AT1R axis inducing vasodilation, anti-oxidative, anti-
inflammatory and anti-proliferative effects (Schmieder et al., 2007).   
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1.3.4.1 The Angiotensin II receptor type I  
The AT1R is a GPCR composed of a 359 amino acid protein with approximately 40kDa 
molecular weight (Mehta and Griendling, 2007). In humans, the AT1R gene is mapped to 
chromosome 3 whereas in rodents it is present as two isoforms, AT1a and AT1b, which are 
mapped on chromosome 17 and 2, respectively (Mehta and Griendling, 2007). These 
isoforms are not distinguishable pharmacologically; instead, they exhibit different tissue 
distribution. AT1a is mostly expressed in rat cardiovascular tissues and in the cerebrum and 
cerebellum whereas AT1b is predominantly found in the adrenal and pituitary glands 
(Kakar et al., 1992; Kitami et al., 1992). Once activated, AT1Rs are quickly desensitised 
(10 min after activation), a process characterised by ligand-receptor uncoupling, receptor 
endocytosis and total receptor number downregulation (Griendling et al., 1987; Guo et al., 
2001). The mechanisms by which AT1R acts involve multiple G-protein-dependent and G 
protein-independent signalling pathways and are well characterised in the periphery 
(Mehta and Griendling, 2007). 
The classical GPCR signalling, involves Gq/11, Gq12/13 and Gy coupling to AT1R, 
resulting in phospholipase C (PLC), phospholipase A2 (PLA2) and phospholipase D (PLD) 
activation (Ushio-Fukai et al., 1998). PLC quickly triggers the formation of inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to its receptor in the sarcoplasmic 
reticulum increasing intracellular Ca2+ concentration and resulting in vasoconstriction 
(Kanaide et al., 2003), whereas DAG activates protein kinase C (PKC), leading to 
vasoconstriction, cell proliferation and oxidative stress by directly activating NOX 
(Kanaide et al., 2003; Vallega et al., 1988). PLD activation results in the generation of 
choline and phosphatidic acid, the latter is then converted to DAG (Lassègue et al., 1993). 
Activation of PLA2 stimulates the release of arachidonic acid from the phospholipid cell 
membrane in vascular smooth muscle cells. Arachidonic acid is processed by COX-2 and 
lipoxygenases to generate prostaglandins (PG) and leukotrienes (LT), which are implicated 
in vasoconstriction, inflammation and oxidative stress (Figure 1-9) (Griendling et al., 
1996).   
G-protein independent pathways include NOX, mitogen-activated protein kinases 
(MAPKs) such as extracellular-signal-related kinase 1/2 (ERK1/2), p38 MAPK and c-Jun 
NH2-terminal kinase (JNK) as well as non-receptor tyrosine kinases (NRTKs) including 
the Src, the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and 
the focal adhesion kinase (FAK) pathways (Mehta and Griendling, 2007). Furthermore, 
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Ang II can trigger receptor tyrosine kinase (RTK) activation such as endothelial growth 
factor receptor (EGFR) and platelet derived growth factor (PDGF), inducing cellular 
remodelling (Mehta and Griendling, 2007). Ang II activates NOX1 and NOX4 in the 
vascular cell membrane, generating ROS and potentiating oxidative stress (Lassègue et al., 
2001). ROS signalling then activates a series of signalling molecules and transcription 
factors such as NF-B and activator protein 1 (AP-1), promoting apoptosis and the 
expression of inflammatory mediators (Sen and Packer, 1996). Ang II induced activation 
of p38 MAPK, Src and EGFR is ROS-sensitive and once triggered will mediate cell 
proliferation, hypertrophy, migration, fibrosis and inflammation (Mehta and Griendling, 
2007). Moreover, Ang II induced ERK1/2, JNK and p38 MAPK activation leads to cell 
proliferation, inflammation and fibrosis (Figure 1-9) (Mehta and Griendling, 2007).   
 
Figure 1-9 The Angiotensin II receptor type I signalling. AT1R activation through Ang II leads to 
a wide range of effects including vasoconstriction, oxidative stress, inflammation, proliferation, 
migration and fibrosis. AT1R activates PLC, PLA2 and PLD, receptor tyrosine kinases (RTKs), non-
receptor tyrosine kinases (NRTKs) and MAPKs. PLC leads to IP3 and DAG formation. IP3 increases 
intracellular Ca2+ whereas DAG activates PKC. PKC and AT1R activate NOX generating ROS, 
which will trigger NRTKs and MAPKs. PLA2 stimulates the production of PG and LT. 
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1.3.4.2 The Angiotensin II receptor type II  
The AT2R is a GPCR composed of a 363 amino acid peptide with a 41kDa molecular 
weight. AT2R is 34% identical to AT1R and is expressed as one subtype only in both 
humans and rodents, sharing 92% homology (Griendling et al., 1996). The AT2R is 
encoded on the X chromosome and although primarily activated by Ang II, other RAS 
components have shown to have affinity for this receptor and suggested to pose as possible 
ligands. The order of affinity is as follows: Ang II>Ang III>Ang IV>Ang-(1-7) (Bosnyak 
et al., 2011). Moreover, several agonists have been developed such as CGP42112A and 
Compound 21 (C21), a promising selective non-peptide and orally active AT2R 
agonist(Wan et al., 2004). These compounds are currently being tested as possible 
therapeutic CVD strategies whereas receptor antagonists include PD123319 (Matavelli and 
Siragy, 2015; Steckelings et al., 2012). AT2R is predominantly expressed in foetal tissues 
(Millan et al., 1991; Shanmugam et al., 1996; Tsutsumi and Saavedra, 1991a) and unlike 
other GPCRs, it does not undergo desensitisation or internalisation (Turu et al., 2006). 
Instead, receptor activation induces a sustained response whilst possessing constitutive 
activity independent of ligand binding (Miura et al., 2005). 
In CVD, AT2Rs are suggested to be involved in three main pathways: NO-cyclic guanosine 
monophosphate (cGMP) system regulation, PLA2 release stimulation and activation of 
phosphatases (Nouet and Nahmias, 2000). These effects are G-protein-independent and 
dependent (Hansen et al., 2000). In endothelial cells, AT2R activates eNOS stimulating the 
production of NO, which will then act on guanylyl cyclase to produce cGMP and induce 
vasorelaxation (Ritter et al., 2002). Similarly, NO induced vasodilation can be triggered 
through AT2R interaction with bradykinin receptor 2 (B2R) by forming AT2R:B2R 
complexes (Abadir et al., 2006). AT2R activation also leads to PLA2 stimulation inducing 
the generation of epoxyeicosatrienoic acids, promoting vasodilation (Arima et al., 1997). 
Furthermore, AT2R signalling is implicated in SHR2 domain-containing tyrosine 
phosphatase (SHP-1), protein phosphatase 2 (PP2A) and MAP kinase phosphatase (MKP-
1) activation (Nouet and Nahmias, 2000). PP2A and MKP-1 directly inhibit MAPK 
(ERK1/2), stimulating apoptotic mechanisms whereas SHP-1 inhibits NOX and ERK1/2, 
diminishing ROS generation and inflammation (Figure 1-10) (Rompe et al., 2010; Wu et 
al., 2004).  
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Figure 1-10 The proposed signalling at the Angiotensin II receptor type II. The AT2R is 
suggested to counteract the detrimental effects of AT1R by activating SHP-1, PP2A and MKP-1. 
These will then inhibit AT1R induced activation of NOX and ERK1/2. AT2R is thought to trigger NO 
formation through eNOS and by interacting with B2R to enhance NO formation. Additionally, it is 
suggested to activate PLA2, possibly inducing vasodilation. Altogether, AT2R signalling is proposed 
to induce vasodilatory, anti-inflammatory, anti-oxidative and anti-proliferative effects in CVD. Image 
also depicts the site of action for ARBs and ACE inhibitors (ACEi) as well as AT2R agonists, Ang II, 
CGP42112A & C21, and antagonist, PD123319. 
 
1.3.5 ACE2/Ang-(1-7)/MasR: the counter-regulatory axis 
In 1988, Santos and colleagues discovered Ang-(1-7), a biologically active heptapeptide 
(Santos et al., 1988) generated by the actions of ACE2 on Ang II as well as alternative 
pathways as described in section 1.3.3. The biological activity of Ang-(1-7) was observed 
in the rat hypothalamo-neurohypophysial system in vitro as it stimulated vasopressin 
release and in in vivo where it triggered a hypotensive and bradycardic response following 
medulla oblongata stimulation (Campagnole-Santos et al., 1989; Schianove et al., 1988). 
Under physiological conditions, Ang-(1-7) circulating levels range between 17.1–25.5 
pg/mL in humans and are approximately 4 pg/mL in rats (Ocaranza et al., 2006; Vilas-
Boas et al., 2009). Ang-(1-7) has a half-life of approximately 30 min following 
subcutaneous (SC) and IV injections in humans (Kono et al., 1986; Petty et al., 2009). In 
rodents, the half-life of Ang-(1-7) is very short and reported to be 10 sec following IV 
administration (Yamada et al., 1998). It is important to note that Ang-(1-7) measurements 
are often performed using antibody-based immunoassays. As a result, cross-reactivity with 
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other RAS peptides may occur. Additionally, Ang-(1-7) is quickly degraded by ACE and 
the detected concentration in tissue samples may not necessarily be accurate. 
Ang-(1-7) is suggested to act as the main counter-regulatory mediator of the RAS by 
inducing vasodilation, anti-proliferative, anti-inflammatory, anti-oxidative effects (Iusuf et 
al., 2008). For this reason ACE2 activators have been used in preclinical studies such as 
diminazene aceturate (DIZE) and regarded as a potential antihypertensive drug (Gjymishka 
et al., 2010). Ang-(1-7) is suggested to directly act as an antagonist on the AT1R and the 
AT1A and to mediate part of its effects by activating the AT2R (Clark et al., 2001; 
Gironacci et al., 1999; Roks et al., 1999; Walters et al., 2005). Most recently it was 
discovered that Ang-(1-7) is a selective agonist for the orphan Mas proto-oncogene (Kd 
=0.83 nmol/L) (Santos et al., 2003). 
1.3.5.1 The Mas receptor  
The MasR is a GPCR composed of 325 amino acid peptide encoded in the distal half of 
chromosome 6q (Rabin et al., 1987; Young et al., 1986). It was initially characterised as a 
proto-oncogene involved in tumorigenesis and inaccurately suggested to be an Ang II and 
Ang III receptor (Young et al. 1986; Jackson et al. 1988); however, it is now established as 
a selective receptor for Ang-(1-7) (Santos et al., 2003). The MasR gene is present in 
humans, rats and mice, sharing a 97% homology between rodents, and it is ubiquitously 
expressed with highest concentration in the brain (Metzger et al., 1995; Young et al., 
1988). Ang-(1-7) promotes MasR internalisation and endocytosis through a clathrin-
mediated pathway 10 min post stimuli (Gironacci et al., 2011). Currently, Ang-(1-7) is the 
main agonist tested in experimental studies whereas A779 is a potent receptor antagonist 
(Santos et al., 1994). Additionally, specific MasR agonists include AVE 0991 (Santos and 
Ferreira, 2006).   
In CVD, the MasR is suggested to act as an AT1R antagonist by forming heterodimers and 
inhibiting Ang II induced vasoconstriction (Kostenis et al., 2005). Nonetheless, MasR 
activation alone induces vasodilation by stimulating NO production through the protein 
kinase B (PKB) pathway (Sampaio et al., 2007). Plus, MasR-induced NO production is 
exacerbated by B2K interactions, promoting the NO-cGMP signalling pathway (Gironacci 
et al.,2004). MasR also stimulates PLA2 and PG generation, contributing towards 
vasodilation, prevents NOX activation and directly inhibits NF-B activation (Albrecht, 
2007; Meng et al., 2014; Tallant et al., 2005). MasR signalling outcome includes the 
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enhancement of SH2-containing tyrosine phosphatase (SHP-2), which then inhibits 
MAPKs (p38 MAPK, ERK1/2 and JNK), diminishing inflammation, oxidative stress, 
proliferative and cell growth mechanisms (Figure 1-11) (Mercure et al., 2008; Su et al., 
2006).  
 
Figure 1-11 The proposed signalling at the Mas receptor. The MasR is suggested to counteract 
the detrimental effects of AT1R by activating SHP-2, which will inhibit AT1R induced activation of 
ERK1/2, JNK, p38 MAPK. In addition, MasR directly inhibits NOX and AT1R activation. MasR is 
suggested to trigger NO formation through eNOS and by interacting with B2R to enhance NO 
formation. Moreover, MasR is thought to activate PLA2, possibly inducing vasodilation. Altogether, 
MasR signalling is proposed to induce vasodilatory, anti-inflammatory, anti-oxidative and anti-
proliferative effects in CVD. Image also depicts the site of action for ACE2 activator, DIZE, as well 
as MasR agonists, Ang-(1-7) & AVE0991, and antagonist, A779. 
 
1.3.6 Peripheral RAS and stroke incidence 
Given that RAS is highly implicated in CVD pathology and antagonising the RAS is the 
standard care for hypertension, focus has shifted towards its therapeutic effects in 
ischaemic stroke. For this purpose, several clinical trials have been performed where ARBs 
and ACE inhibitors were tested as possible stroke preventive therapies in hypertensive 
patients. The LIFE trial assessed whether losartan reduced cardiovascular disease and 
mortality (Dahlöf et al., 2002). In this study, patients were either administered losartan or 
atenolol-based antihypertensive therapy for a minimum period of 4 years where it was 
33 
 
found that losartan treatment resulted in an approximately 25% decrease in fatal or non-
fatal stroke risk compared to atenolol (Dahlöf et al., 2002). The ACCESS study was then 
conducted to examine the safety of blood pressure (BP) reduction as an early therapy for 
stroke. Although the trial had to be ceased prematurely, the authors identified that 
hypotension induced by candesartan cilexetil lowered mortality and vascular event 
incidence compared to placebo (Schrader et al., 2003). Similarly, in the MOSES trial, 
hypertensive stroke patients treated with eprosartan showed decreased mortality and 
cerebrovascular events when compared to nitrendipine (calcium channel blocker) 
(Schrader et al., 2005) while the TRANSCEND trial reported that telmisartan therapy in 
patients intolerant to ACE inhibitors led to a mild attenuation in stroke incidence compared 
to placebo (Yusuf et al., 2008a). 
Conversely, several studies failed to detect a benefit in preventing stroke incidence with 
ARBs. Stroke patients randomised to either telmisartan or placebo therapy showed no 
differences in terms of stroke incidence after 2.5 years follow up (Yusuf et al., 2008b). 
Moreover, when testing BP lowering in ischaemic or haemorrhagic stroke, candesartan did 
not induce any beneficial effects (Sandset et al., 2011). Similarly, when testing the ACE 
inhibitor captopril in hypertensive patients, it was found that the risk of fatal and non-fatal 
stroke was more common in the captopril-treated group than placebo (Hansson et al., 
1999). To date, clinical trials have focused on BP lowering strategies as a means to prevent 
stroke incidence in hypertensive patients. The clinical trials outlined suggest that the RAS 
may be implicated in stroke injury; however, there is still limited information regarding the 
role of the RAS in ischaemic stroke pathology and independently of risk factors. 
1.4 Brain RAS and ischaemic stroke 
The brain RAS was initially proposed in 1971 upon the discovery that RAS components 
were present within the brain parenchyma in dogs (Ganten et al., 1971). RAS peptides do 
not cross the BBB, therefore, RAS activity depends on local synthesis rather than uptake 
from blood (Schelling et al., 1976). At the same time, the existence of circumventricular 
organs (CVOs), brain regions that lack BBB and are involved in BP, sodium and water 
regulation; provide a crossing point between peripheral and central RAS (McKinley et al., 
2003; Wright and Harding, 2013). In the past decade, emerging in vivo studies have 
hypothesised that the RAS is implicated in ischaemic stroke independent of BP-induced 
effects, providing a possible strategy that not only targets risk factors but stroke pathology 
itself and defining the brain RAS as a therapeutic target. 
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1.4.1 Brain RAS expression 
The existence of a brain RAS depends on locally produced renin and this has been the 
subject of extensive debate. Renin mRNA is poorly expressed in the brain and its site of 
production is not clearly defined however, there is evidence that renin mRNA is expressed 
in astrocytes and neurons (Dzau et al., 1986). On the contrary to the periphery, brain renin 
expression takes place intracellularly as a non-secreted shorter isoform lacking the signal 
peptide in its preprorenin sequence (Morimoto et al., 2002). Nevertheless, recent studies 
postulate that brain renin is actually the outcome of trapped renin and that Ang II is taken 
from the blood instead of being locally synthesised (van Thiel et al., 2017), contradicting 
the existence of a local brain RAS.  
In addition to renin, other RAS components have been described in the brain. Ang I, Ang 
II and Ang-(1-7) were detected in plasma, CSF and brain parenchyma using 
radioimmunoassays (Chappell et al., 1987). Ang-(1-7), in particular, is an endogenous 
constituent of the brain and its presence is separate from circulating plasma Ang-(1-7) 
(Chappell et al., 1989). Angiotensinogen is constitutively secreted by astrocytes and also 
expressed in neurons to a lesser extent (Intebi et al., 1990; Thomas and Sernia, 1988; Yang 
et al., 1999). ACE is expressed across the brain parenchyma, choroid plexus and it is 
maximally concentrated within the CVOs (Saavedra & Chevillard 1982; Turner & Hooper 
2002). Similarly, ACE2 is widely expressed in the brain and present in arterial and 
endothelial cells (Hamming et al., 2004), neuronal cell body cytoplasm (Doobay et al., 
2007) and cerebellar and medullary astrocytes (Gallagher et al., 2006).  
The AT1R is ubiquitously expressed in the brain and predominantly found within the 
CVOs (Allen et al., 1998, 1999; Lenkei et al., 1997; McKinley et al., 2003). Likewise, the 
AT2R is present in various brain regions including the hypothalamus, cerebellum, 
subfornical organ, brainstem and thalamus (Allen et al., 1999; Lenkei et al., 1997). Both 
AT1R and AT2R are expressed in dopaminergic neurons, astrocytes and microglia in 
human, non-human primate, rats and mice as well as in cerebral microvessels and cerebral 
arteries (Garrido-Gil et al. 2013; Rodriguez-Pallares et al. 2008; Speth & Harik 1985; 
Tsutsumi & Saavedra 1991b). Regarding MasR expression, this receptor is highly present 
in the rat’s cortex and hippocampus as well as cardiovascular regulatory centres (Becker et 
al., 2007; Young et al., 1988). It is maximally expressed within neurons and selectively 
present in brain endothelial cells when compared to peripherally derived endothelial cells 
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(Becker et al., 2007; Kumar et al., 1996). Furthermore, MasR is present in astrocytes and 
cultured rat microglia (Guo et al., 2010; Lu et al., 2013; Regenhardt et al., 2013). 
1.4.2 Ang II and ischaemic stroke 
Until recently, it was unclear whether brain RAS expression was changed after ischaemic 
stroke; however, it is now established that following injury, the ACE/AngII/AT1R axis is 
enhanced. In normotensive rats, Ang II protein expression is increased within the ventral 
cortex, hypothalamus and rostral ventrolateral medulla (RVLM) compared to non-stroke 
animals whereas AT1R protein levels are decreased in the ventral cortex but enhanced in 
the RVLM, the latter a central nervous system (CNS) centre known to influence peripheral 
BP (Chang et al., 2014; Kagiyama et al., 2003). In addition, ACE mRNA levels were 
enhanced in the MCA after MCAO, suggesting an exacerbated production of Ang II to 
promote injury (Stenman and Edvinsson, 2004). 
Studies conducted in knockout (KO) mice have helped elucidate the involvement of the 
classical RAS axis in stroke. AT1R KO mice subjected to permanent MCAO have a larger 
penumbra volume and improved CBF within the core and penumbra (Walther et al., 2002). 
Not surprisingly, mice overexpressing angiotensinogen were shown to have a smaller 
volume of penumbra volume, enhanced ATP depletion and decreased perfusion within the 
core and penumbra compared to WT (Walther et al., 2002). Plus, mice carrying human 
renin and angiotensinogen genes display exacerbated infarcts 24 hrs post MCAO with 
aggravated neurological deficit (Inaba et al., 2009). The role of Ang II in isolated cerebral 
vessels following focal cerebral ischaemia has also been investigated. Ang II treatment of 
isolated MCAs obtained 48 hrs post MCAO, enhances AT1R induced contractile response 
when compared to sham animals (Stenman and Edvinsson, 2004). When taken together, 
these studies suggest that the classical brain RAS plays a role in the pathogenesis of 
neuronal injury following stroke. In support of this, serum samples obtained 24 hrs after 
stroke onset in patients indicate that Ang II levels negatively correlates with stroke severity 
as defined by NIHSS (Mogi et al., 2014).   
The AT2R has also shown to be altered after cerebral ischaemia. After focal cerebral 
ischaemia, AT2Rs are upregulated in the rat brain, primarily within the cortical penumbral 
regions and hippocampus (Makino et al., 1996; Zhu et al., 2000). This indicates a possible 
role in ischaemic lesion progression; however, it is necessary to clarify whether it is a 
detrimental or cytoprotective effect. For example, after transient MCAO in normotensive 
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animals, AT1R expression either decreases or remains unaltered whereas Ang II and AT2R 
mRNA and protein levels are enhanced (Kagiyama et al., 2003; Makino et al., 1996; Zhu et 
al., 2000). Therefore, it has been suggested that following reperfusion, the AT2R may 
mimic actions of the AT1R instead of providing cytoprotection(Kagiyama et al., 2003; 
Makino et al., 1996; Zhu et al., 2000). KO studies; however, indicate thatthe AT2R is in 
fact cytoprotective since KO mice exhibit larger ischaemic lesions compared to WT after 
MCAO (Iwai et al., 2004).  
1.4.2.1 AT1R targeting  
The mechanisms by which Ang II exerts its detrimental effects have been widely 
investigated in animal models by testing ARBs (Figure 1-12). The first study conducted in 
normotensive animals was performed by Dai and colleagues (Dai et al., 1999). There, 
irbesartan administered 5 days prior to transient MCAO at a non-hypotensive dose 
improved neurological outcome, an effect associated with a reduction in pro-apoptotic 
proteins expression, c-Fos and c-Jun, in the ipsilateral cortex (Dai et al., 1999). 
Disappointingly, the authors did not assess the effect on final infarct volume; however, the 
results provided a promising line of research with subsequent studies showing that 
candesartan as an IV bolus after transient MCAO decreased infarct volume and oedema 
whilst improving neurological deficit (Fagan et al., 2006; Mecca et al., 2009). The 
underlying neuroprotective effects of ARBs are suggested to be due to an anti-
inflammatory and anti-oxidative effect since ARBs attenuate apoptosis TUNEL marker 
and diminish active microglia/macrophages within the parietal cortex at 3 and 7 days post 
transient MCAO (Lou et al., 2004). Similarly, in mice, valsartan treatment prior to MCAO 
was shown to attenuated superoxide production and mRNA expression of MCP-1 within 
the ipsilateral hemisphere (Li et al., 2008) whereas candesartan pre-treatment diminished 
oxidative damage within the ischaemic penumbra (Liu et al., 2008). The impact of Ang II 
is extended to BBB breakdown exacerbation since olmesartan therapy for a period of 7 
days post MCAO reduces Ang II and MMP9 levels within the ipsilateral hemisphere, 
decreasing cerebral oedema and BBB breakdown (Figure 1-12) (Hosomi et al., 2005).  
Other reported ARB induced effects include vasodilation and angiogenesis. In 
normotensive animals, candesartan IV therapy as a single pre- or post-treatment dose as 
well as chronic dose following transient MCAO significantly attenuated infarct volume in 
all groups, an outcome attributed to enhanced CBF (Engelhorn et al., 2004). Similarly, in 
spontaneously hypertensive rats (SHR), candesartan treatment prior to MCAO decreased 
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brain AT1R levels and attenuated the CBF deficit irrespective of BP alterations (Nishimura 
et al., 2000). The authors proposed that ARBs normalised autoregulation after MCAO, a 
conclusion subsequently confirmed with chronic SC candesartan administration prior to 
permanent MCAO and distal MCAO. The authors demonstrated that chronic treatment 
with candesartan prior to MCAO decreased infarct volume by preventing MCA media 
thickness remodelling and enhancing CBF within the penumbral areas (Ito et al., 2002). 
Other possible underlying mechanisms include enhanced neurogenesis and angiogenesis. 
ARBs increase vascular endothelial growth factor (VEGF), brain derived neurotrophic 
factor (BDNF) levels within the peri-infarct in both normotensive and SHR animals 
(Alhusban et al., 2013; Ishrat et al., 2015; Krikov et al., 2008). 
 
Figure 1-12 The proposed AT1R induced outcome during ischaemic stroke. In the brain, 
angiotensinogen is produced by astrocytes whereas the production of renin is unclear. 
Angiotensinogen will lead to Ang I through renin. Ang I will then be cleaved by ACE possibly in the 
CVOs or choroid plexus. Ang II will then activate ubiquitous receptor AT1R leading to apoptosis, 
neuroinflammation, BBB disruption, oxidative stress, vasoconstriction, impaired autoregulation, 
remodelling and anti-angiogenic effects during cerebral injury. 
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1.4.2.2 AT2R targeting  
It is proposed that the neuroprotective mechanisms induced by ARBs might be due to a 
preferable action of Ang II on the AT2R (Faure et al., 2008). Plus, the fact that these 
receptors are upregulated during cerebral ischaemia particularly in the peri-infarct region 
of the cortex supports this hypothesis (Makino et al., 1996; Zhu et al., 2000).  
Initial studies testing AT2R agonists were conducted in hypertensive animals using the 
specific AT2R agonists, GCP42112 or C21 (Table 1-3). In conscious SHR rats, central 
treatment with CGP42112 before and after ET-1 induced MCAO attenuated lesion volume 
and improved motor function, independent of BP alterations (McCarthy et al., 2009). The 
underlying mechanism was suggested to be the result of increased AT2R expression and 
decrease of superoxide within the infarcted cortex (McCarthy et al., 2009). Similarly, when 
CGP42112 was given centrally following MCAO, there was an improved motor function 
and reduced infarct volume (McCarthy et al., 2012). The improvement in outcome was 
associated to a reduction in caspase-3 positive apoptotic cells and increase in microglia 
activity within the peri-infarct area (McCarthy et al., 2012). The authors then conducted a 
follow up study testing C21 as a pre and post therapy in the same MCAO protocol 
(McCarthy et al., 2014). C21 attenuated infarct growth and enhanced motor function 
without BP induced effects 3 days post ET-1 induced MCAO. The underlying mechanism 
was attributed to increased neuronal survival and microglia activation, reportedly secreting 
anti-inflammatory mediator BDNF (McCarthy et al., 2014). In addition, myography studies 
performed in basilar arteries concluded that C21 induced vasodilatory effects could have 
contributed to enhanced CBF (Table 1-3) (McCarthy et al., 2014). These findings were 
supported by in vitro data where CGP42112 attenuated cell death in primary cortical 
neurons following oxygen deprivation challenge (OGD) (Lee et al., 2012).  
In normotensive rats, C21 was given centrally as both a pre- and post-treatment following 
ET-1 induced MCAO (Joseph et al., 2014). After 3 days of recovery, C21 decreased infarct 
volume and improved neurological score, an effect attributed to a decrease in iNOS and 
CCR2 mRNA expression in the ipsilateral cortex (Joseph et al., 2014). In transient MCAO, 
intraperitoneal (IP) C21 post treatment for a period of 24 hrs or 7 days was equally 
neuroprotective (Alhusban et al., 2015). There, C21 upregulated anti-inflammatory 
cytokine IL-10 whilst decreasing nitrosative markers nitrotyrosine and iNOS within the 
ipsilateral hemisphere. Moreover, eNOS and AT2R levels were upregulated whereas AT1R 
expression was decreased (Alhusban et al., 2015). Similarly, in a recent study, CGP42112 
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treatment  induced a neuroprotective effect due to decreased IL-1 expression and 
enhanced IL-10, providing further evidence for an anti-inflammatory mechanism (Ma and 
Yin, 2016).  
The proposed anti-apoptotic, anti-inflammatory and anti-oxidative theory was also detected 
in mice studies. AT2R agonism after transient MCAO attenuated infarct lesion possibly 
due to an enhancement in cell viability (Lee et al., 2012) whereas in permanent MCAO, 
C21 treatment induced an anti-inflammatory and anti-oxidative effect by diminishing 
MCP-1, TNF- and superoxide expression whilst improving BBB integrity (Min et al., 
2014). Most recently, AT2R agonism was shown to promote neurogenesis and 
angiogenesis by augmenting VEGF and BDNF in peri-infarct regions in both permanent 
and transient MCAO models (Alhusban et al., 2015; Mateos et al., 2016; Schwengel et al., 
2016). Together, these reports place AT2R agonism as a potential therapy in ischaemic 
stroke particularly by preventing oxidative stress and inflammation following reperfusion 
(Table 1-3). Still, there is a lack of understanding of the effects of C21 in infarct volume 
following transient MCAO models in normotensive rats. 
1.4.3 Ang-(1-7) and ischaemic stroke 
Similar to the classical axis, counter-regulatory ACE2/Ang-(1-7)/Mas axis expression is 
altered after cerebral ischaemia. Lu and colleagues demonstrated that following permanent 
MCAO, Ang-(1-7) levels in serum and cerebral cortex protein levels are enhanced as early 
as 6 hrs following injury and remain elevated for at least 48 hrs(Lu et al., 2013). In 
addition, MasR mRNA in the cerebral cortex is upregulated from 6 to 48 hrs reaching a 
peak at 24 hrs post ischaemic insult (Lu et al., 2013). ACE2 protein and mRNA levels 
were also shown to be increased at 6 hrs followinginjury, peaking at 12 hrs MCAO and 
subsequently decreasing to the point where at 48 hrs after MCAO the levels were 
comparable to sham (Lu et al., 2013). In transient MCAO, MasR protein and mRNA levels 
are upregulated after 3 days reperfusion and enhanced for at least 7 days whereas Ang-(1-
7) protein expression initially decreases at day 1 post-reperfusion and then rises over time 
in the RVLM (Chang et al., 2014). Similarly, in their study, Chang and colleagues showed 
that ACE2 levels were equally increased within the RVLM (Chang et al., 2014).  
ACE2 expression seems to be important in the clinical setting. Patients who suffered a 
cardioembolism exhibit higher ACE2 serum levels with its expression correlating with 
diminished injury severity according to the NIHSS (Mogi et al., 2014). Concomitantly, 
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transgenic mice overexpressing ACE2 display smaller infarct sizes compared to human 
renin and angiotensinogen double transgenic mice, an effect that is partially reversed by 
the MasR antagonist, A779 (Chen et al., 2014). In in vitro brain slices obtained from mice 
overexpressing ACE2 and subjected to OGD, there was reduced cell death and swelling, an 
effect also inhibited by A779 (J Zheng et al., 2014). Current evidence indicates that 
similarly to the ACE/Ang II/AT1R and the alternative receptor AT2R, the ACE2/Ang-(1-
7)/Mas axis expression is altered after stroke. For this reason, it has been hypothesised that 
when enhancing the endogenous counter-regulatory axis after stroke injury, particularly 
through Ang-(1-7), neuroprotection may be induced.  
1.4.3.1 MasR targeting 
The effect of Ang-(1-7) and MasR activation has received recent focus and become a 
promising target in ischaemic stroke (Table 1-4). In 2011, Mecca and colleagues 
performed the first experiment examining treatment effects in infarct volume in 
normotensive rats (Mecca et al., 2011). In their study, Ang-(1-7) was administered 
centrally as a pre- and post-treatment in an ET-1 induced MCAO model. After 3 days 
recovery, Ang-(1-7) improved motor function, neurological score and diminished infarct 
volume by over 50% without impacting BP, an effect reversed by A779 (Mecca et al., 
2011). The authors also examined the effect of DIZE, a proposed ACE2 activator, and 
again demonstrated a reduced infarct volume with the effects of DIZE being abolished 
with the MasR antagonist, A779 (Mecca et al., 2011). The authors attributed the 
underlying mechanism to a decrease in iNOS levels within the ipsilateral hemisphere, 
therefore, providing the first line of evidence for a possible anti-inflammatory and anti-
oxidative mechanism (Mecca et al., 2011). Subsequently, other studies confirmed this 
hypothesis. In Sprague-Dawley rats, central administration of Ang-(1-7) starting 7 days 
prior to ET-1 induced MCAO decreased infarct volume and led to a reduction in iNOS in 
ipsilateral cortex at 24 hrs post stroke onset, an effect reversed by A779 (Regenhardt et al., 
2013). In addition, treatment reduced mRNA levels for leukocyte chemokine CXCL12 at 6 
hrs post stroke onset and pro-inflammatory mediators IL-1, IL-6, CD11b at 24 hrs post 
stroke, confirming an anti-inflammatory role (Regenhardt et al., 2013). These findings 
were further reinforced in permanent MCAO studies where central Ang-(1-7) infusion 
through MasR activation, reduced infarct volume and improved neurological function an 
effect associated with reduced malondialdehyde and superoxide dismutase, NF-B activity 
and COX-2 in the peri-infarct as well as TNF- and IL-1able 1-4)Jiang et al., .  
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The anti-inflammatory effect is highly attributed to a direct action on microglia. The MasR 
is expressed in cultured rat microglia and when subjected to Ang-(1-7) treatment in basal 
conditions, the cytokine profile shifts from pro-inflammatory to anti-inflammatory by 
stimulating IL-10 levels and attenuating IL-1, TNF- and CD11b as well as NF-B 
activation (Liu et al., 2016). Similarly, in in vivo studies, Regenhardt and colleagues 
support this hypothesis where they observed reduced levels of M1 type markers iNOS and 
CD11b within the ipsilateral hemisphere following MCAO (Regenhardt et al., 2013). 
Furthermore, in stroke prone spontaneously hypertensive rats (SHRSP), Ang-(1-7) 
administration for 6 weeks increased survival in animals whilst diminishing activated 
microglia number within the striatum (Regenhardt et al., 2014). More recently, it was 
shown that older animals overexpressing ACE2 have reduced infarct volume and tissue 
swelling following MCAO, an outcome prevented by A779. ACE2 led to reduced NOX2 
expression in the brain, an effect again ablated by A779 (Zheng et al. 2014). Equally to 
AT2R agonism, the anti-inflammatory/anti-oxidative effect of Ang-(1-7) is a fairly well-
established mechanism. Yet, these studies have primarily assessed Ang-(1-7)/MasR effects 
in acute stages of injury as a pre and post-therapy and in ET-1 induced MCAO models.  
The vasodilatory effects of Ang-(1-7) in the brain are less well defined; however, there are 
indications that Ang-(1-7) may enhance NO levels within the brain and possibly enhance 
CBF after stroke. For instance, central infusion of Ang-(1-7)  following MCAO improved 
neurological score whilst stimulating the expression of NO, bradykinin and its receptors 
B2R and B1R in the core and penumbra (Lu et al., 2008; Zhang et al., 2008). Although 
infarct volume effects were not assessed in these studies, the outcome observed placed 
Ang-(1-7) and MasR as possible vasodilators. Furthermore, mice overexpressing ACE2 
present enhanced NO within the peri-infarct and diminished NOX, which supports both a 
MasR induced anti-oxidative and vasodilatory effect (Chen et al., 2014). Recently, Ang-(1-
7) infusion for a period of 4 weeks and prior to permanent MCAO was shown to enhance 
brain capillary density and improve penumbral CBF through a MasR dependently derived 
eNOS mechanism, thus, placing Ang-(1-7)/MasR signalling as a possible target to enhance 
CBF following stroke (Jiang et al., 2014). Nonetheless, these effects are controversial since 
Mecca et al. reported that Ang-(1-7) 7 days prior to stroke did not affect blood flow after 
ET-1 transient MCAO (Table 1-4) (Mecca et al., 2011). 
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Table 1-3 Rat studies assessing the therapeutic potential of AT2R agonists in ischaemic stroke models. BP: blood pressure; CBF: cerebral blood flow; ET-1: 
endothelin-1; ICV: intracerebroventricular; IP: intraperitoneal; MCAO: middle cerebral artery occlusion; NO: nitric oxide; NS: neurological score; SHR: spontaneously 
hypertensive rat. Table adapted from Arroja et al., 2016. 
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Table 1-4 Rat studies assessing the therapeutic potential of Ang-(1-7) in ischaemic stroke models. BP: blood pressure; CBF: cerebral blood flow; ET-1: 
endothelin-1; ICV: intracerebroventricular; MCAO: middle cerebral artery occlusion; NO: nitric oxide; NS: neurological score. Table adapted from Arroja et al., 2016. 
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1.4.4 Summary 
Ischaemic stroke is a heterogeneous condition and a major contributor towards mortality 
and morbidity in the UK. Currently, rt-PA and thrombectomy are the only available 
therapies and these work by inducing vessel recanalization with the aim to reperfuse the 
parenchyma. Despite significant efforts from the scientific community, there is a lack of 
adjuvant neuroprotective agents that could aid the prevention of cerebral damage following 
rt-PA and/or thrombectomy treatment.  
The RAS is widely implicated in CVD and is a major therapeutic target for hypertension, a 
major stroke risk factor. Studies in CVD have helped elucidate the mechanisms in which 
RAS induces injury through the ACE/Ang II/AT1R axis. Additionally, it has allowed the 
identification of the AT2R and the counter-regulatory axis ACE2/Ang-(1-7)/MasR, which 
are thought to serve as an endogenous mechanism to counteract injury. Increasing evidence 
place the RAS as a locally synthesised system in the brain and a potential mediator in 
ischaemic stroke injury via the classical axis, independently from risk factors. A few 
studies have assessed the effects of the ACE2/Ang-(1-7)/MasR axis in normotensive 
animals and shown to induce vasodilatory, anti-inflammatory, anti-oxidative and pro-
angiogenic effects. The main proposed mechanism mediated via the MasR is thought to be 
anti-inflammatory effects by direct targeting of the microglia; however, these have been 
mainly assessed by mRNA analysis and in in vitro experiments. Moreover, the experiments 
have been primarily performed in ET-1 MCAO induced models, as a pre- and post-
treatment, assessed at acute stages of injury only and by one research group only. 
Similarly, AT2R agonism is suggested to induce similar effects to those observed in MasR 
activation, yet, a potential synergistic effect between these two receptors has not been 
established. Increasing evidence supports the neuroprotective role of the ACE2/Ang-(1-
7)/MasR axis and AT2R activation following experimental stroke as single therapies. As a 
result, we aim to study the neuroprotective effect of the counter-regulatory axis following 
ischaemic stroke as a potential thrombectomy adjuvant therapy using the transient filament 
MCAO model. In addition, this thesis will examine the underlying mechanisms of the 
counter-regulatory axis and study a possible synergistic effect with AT2R agonism. 
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1.5 Thesis aims 
1. To optimise the experimental model of stroke and carry out exploratory therapeutic 
studies with an ACE2 activator following stroke. 
2. To determine the effects of Ang-(1-7) and/or Compound 21 on the extent of tissue 
salvage following transient focal cerebral ischaemia.  
3. To determine the impact of Ang-(1-7) on BBB breakdown and microglia activation 
following transient focal cerebral ischaemia. 
4. To study the effects of Ang-(1-7) on CBF profile following transient focal cerebral 
ischaemia.
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Chapter 2  
2.1 Legislation 
All studies were carried out under a UK Home Office Project License and in accordance 
with the Animals (Scientific Procedures) Act, 1986: Project License P643E898D8 and 
Personal license number 70/22456. Experiments were performed either under protocol 
number 2 (focal cerebral ischaemia lesions; non-recovery experiments; severity limit: 
unclassified) or protocol number 3 (focal cerebral ischaemic lesions; recovery experiments; 
severity limit: substantial). Experiments were reported in accordance with the ARRIVE 
(Animal Research; Reporting in vivo Experiments; https://www.nc3rs.org.uk/arrive-
guidelines) and National Centre for the Replacement, Refinement and Reduction of 
Animals in Research (NC3R’s) guidelines. Unless otherwise stated, Mariana Arroja 
performed all the experimental procedures. 
2.2 Animals 
Adult male Sprague Dawley or Wistar rats were obtained from Charles River Laboratories 
(Kent, UK) and housed in the Veterinary Research Facility (VRF), University of Glasgow. 
Rats were housed in groups of 3 to 4 in a plexiglassbox containing sawdust, nesting 
material and cardboard tubes. Animals were maintained ina controlled environment with a 
12:12 hour light/dark cycle, room temperature maintained between 15-25°C and rat chow 
food and water were available ad libitum. Upon arrival to VRF, animals were allowed to 
acclimatise to the new animal facility for 7 days prior to any surgical procedures to allow 
animals to overcome transportation induced stress (Capdevila et al., 2007). Prior to 
experimental procedures, all animals were randomly assigned to surgery day and treatment 
group using an online randomisation generator (www.random.org). In addition, the 
surgeon (MA) was blinded to treatment allocation, except in Chapter 6.  
2.3 Aseptic technique 
All surgical procedures were conducted under aseptic techniqueas detailed in our local 
Project License appendix. Surgical surfaces were disinfected with 70% ethanol (Sigma, 
UK) and autoclaved drapes positioned on the work area where the sterilised surgical 
instruments, swabs and cotton buds were placed. During surgery, instruments were further 
disinfected using chlorhexidine gluconate (Hydrex®, Ecolab, UK) and cleaned with sterile 
saline (sodium chloride 0.9% w/v, Baxter, UK). Prior to surgery, all animals were 
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transferred to a separate shaving area within the laboratory where the incision areas were 
quickly shaved using electric clippers (Wella, Germany) and disinfected with 
chlorhexidine gluconate. All surgical material used (swabs, cotton buds; etc.) were 
autoclaved and packaged under sterile conditions and Doccol intraluminal filaments 
(Doccol Corporation, USA) were disinfected with 70% ethanol and cleaned with sterile 
saline for a period of 10 min prior to use. The surgeon (MA) was equipped with autoclaved 
surgical gowns and sterile gloves, which were changed following each surgical procedure. 
2.4 Analgesia 
Local anaesthetic, ropivacaine (10 mg/mL; Naropin, GSK, UK) was administered SC at 
surgical incision sites at a dose of 2 mg/kg. For recovery surgery, rats were administered 
buprenorphine hydrochloride (Vetergesic, Ceva Animal Health Ltd, Amersham, UK) at a 
dose of 0.03 mg/kg SC prior to anaesthetic recovery. In Chapter 3, where osmotic pumps 
were implanted prior to stroke surgery, carprofen (Rimadyl, Pfizer, UK) was administered 
SC at 5 mg/kg at incision site. 
When rats are under anaesthesia, they lack corneal reflex, therefore, this may lead to eye 
damage when performing experiments for long periods of time, particularly during 
stereotaxic surgery were the microscope light is directly placed above the head. To prevent 
discomfort upon recovery, Viscotears® liquid gel (Novartis, UK) containing polyacrylic 
acid as an active ingredient, was applied to the animal’s eyes at start of surgery.  
2.5 Anaesthetic procedures 
2.5.1 Induction 
For all experiments, rats were weighted and then transferred to an anaesthetic gas chamber 
for anaesthesia induction. Induction was carried out with 5% isoflurane (Baxter Healthcare 
Ltd, UK) delivered in a 30:70% oxygen-nitrous oxide mixture, respectively. To ensure that 
animals were adequately anaesthetised, breathing rate was closely monitored and the pedal 
withdrawal reflex assessed by tightly squeezing the hindpaw and observing whether a 
withdrawal reaction was evoked. Animals were then subjected to either surgical 
tracheotomy or oral intubation for anaesthesia maintenance throughout surgical 
experimentation depending on experimental outline.  
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2.5.2 Maintenance 
2.5.2.1 Surgical intubation 
In Chapter 3 in non-recovery experiments, rats underwent surgical tracheotomy. Following 
induction, anaesthesia was maintained with a facemask delivering 2-3% isoflurane in a 
30:70% O2-N2O mixture. A ventral incision was made through the skin and fascia of the 
neck using sharp ended scissors (World Precision Instruments, UK) and the underlying 
sternomastoid and sternohyoid musclessplit by blunt dissection using blunt ended scissors 
(World Precision Instruments, UK). The sternohyoid muscle was separated by blunt 
dissection to expose the trachea and the surrounding connective tissue carefully cleared. 
Two 2-0 sutures (SofsilkTM, Covidien Ltd, UK) were placed under the trachea at the 
proximal and distal ends of the trachea and loosely tied. Tension was applied on both 
threads to maintain the trachea in a straight position andwith the use of microscissors 
(Braun Medical Ltd, UK) a horizontal incision was made between the tracheal cartilage. A 
breathing tube (Linton Instrumentation, UK) was carefully inserted into the trachea and 
advanced towards the bronchi for up to 2 cm, thereby guaranteeing that there was no 
airway obstruction or damage. The ventilation tube was then quickly connected to the 
ventilator (Ugo Basile, Linton Instrumentation, UK) where the stroke volume was set to 
approximately 3 mL at a frequency of 48-50 strokes per minute. To secure the ventilation 
tube in place, the two sutures were tightly tied around the trachea overlying the breathing 
tube. 
2.5.2.2 Recovery experiments 
Endotracheal oral intubation was carried out in all recovery surgeries to ensure better 
control of anaesthesia and to aid post-surgical recovery. Following induction, a 2-0 silk 
thread (SofsilkTM, Covidien Ltd, UK) was placed around the superior incisors and the 
animal suspended vertically on the corkboard in the supine position. To aid visualisation of 
the vocal chords, the tongue was retracted to the side of the mouth, any mucous cleared 
from the oral cavity and a fibre optic light (Schott, USA) was illuminated over the neck. A 
guide wire (Figure 2-1A) was inserted through the intubation catheter (MillPledge 
Veterinary, UK) (Figure 2-1B) and advanced into the trachea. After, the guide wire was 
quickly removed and intubation confirmed by verifying breathing condensation. The 
ventilator was then connected to the intubation catheter, delivering ~2.5% isoflurane 
mixture at a 2.5-3 mL stroke volume and 61 strokes per minute frequency. To secure the 
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intubation tube in place, a stitch using a 4-0 silk suture (SofsilkTM, Covidien Ltd, UK) was 
performed around the breathing cannula and upper lip. 
 
Figure 2-1 Endotracheal oral intubation kit. A) Guide wire consisting of a blunt malleable wire 
used to guide the intubation tube towards the trachea. B) Intubation catheter introduced in the 
animal’ airways consisting of a 45 mm in length guide wire. 
 
2.6 Vessel cannulation 
During non-recovery experiments, MABP and blood gases [pH, partial pressure of oxygen 
(PaO2) & PaCO2] were monitored via the femoral artery. For studies where IV drug 
administration was carried out, the femoral vein was cannulated. Rats were placed in a 
supine position and the inner thigh shaved and disinfected with chlorhexidine gluconate. A 
surgical incision (~1.5 cm) was performed in the inguinal area to expose the femoral artery 
and vein.  Blunt dissection was carried out to clear the connective tissue surrounding the 
vessels for cannulation. Care was taken to ensure the saphenous nerve that runs along the 
femoral artery was carefully separated from the vessel.   
For each vessel, a folded 4-0 silk thread (SofsilkTM, Covidien Ltd, UK) was placed under 
the vessel and cut at the folded region to create two threads. One of the sutures was placed 
at the distal end near the abductor leg muscle and a tight knot performed. The other suture 
was placed at the proximal end towards the heart and a loose knot done. Both suture ends 
were used to apply tension in the vessels by taping them to the corkboard, preventing 
bleeding at time of cannula insertion. A small incision was made in the vessel with 
microscissors at the distal end and fine tipped right angled forceps (Braun Medical Ltd, 
UK) were inserted into the hole to open the vessel and allow insertion of a polythene 
catheter (external diameter 0.96 mm; internal diameter 0.58 mm) (Smiths Medical 
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International Ltd, UK) filled with 1% heparinised saline (1000 units/mL) (Wockhardt UK 
Ltd, UK) and attached to a 1 mL syringe (BD PlastipakTM, UK).  The polythene catheter 
was advanced 1-2 cm into the vessel with the aid of curved micro dissecting watchmaker 
forceps (Braun Medical Ltd, UK) before obstruction was felt. Blood was withdrawn into 
the cannula to confirm correct cannula placement before the tension on both proximal and 
distal ties was removed. The cannula was secured in place by tying each thread around the 
cannula. Ties were cut short and the incision area sutured using 4-0 sutures. MABP was 
recorded by connecting the catheter to a pressure transducer, previously flushed with 
heparinised salineand connected to a monitoring system (Biopac, Acknowledge Software, 
Biopac Systems, UK). 
2.7 Osmotic Pumps 
2.7.1 Principle and preparation 
In this thesis, ALZET® osmotic pumps (ALZET®, Cupertino, USA) were used as a means 
for drug delivery in Chapters 3, 4 and 5. ALZET pumps are composed of an impermeable 
reservoir, osmotic layer, semipermeable membrane and a flow moderator (Figure 2-2). The 
principle of drug delivery is dependable on pump implantation in the animal. The tissue 
environment where the pump is implanted will create an osmotic reaction towards the 
osmotic layer, meaning that the H2O present in the tissue will flow into the osmotic layer 
through the semipermeable membrane, causing a compression of the impermeable 
reservoir. The compression of the reservoir containing the drug will cause drug solution 
release from the pump to tissue through the flow moderator. ALZET® pumps deliver 
drugs at different volumes and rates, which are predefined by the manufacturer and 
dependent upon the permeability of the semipermeable membrane (Theeuwes and Yum, 
1976). In this thesis, two different models of osmotic pumps were used. 
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Figure 2-2 Osmotic pump drug delivery mechanism. Drug to be delivered is injected into the 
impermeable reservoir, which is surrounded by an osmotic layer. H2O present in the tissue will 
cross into the pump through the semi-permeable membrane creating pressure within the reservoir 
and causing the release of the drug. Adapted from Theeuwes & Yum, 1976. 
 
In Chapter 3, ALZET® pump Model 2ML1 was used for SC delivery (infusion rate: 10 L 
per hour for 7 days, reservoir capacity of 2000 L) (Figure 2-3A). In Chapters 4 & 5, 
Model 2001 was used for intracerebroventricular (ICV) delivery (infusion rate: 1.0 L per 
hour for 7 days, reservoir volume of 200 L; Figure 2-3B). For Model 2001, vinyl tubing 
connected to a magnetic resonance compatible ICV cannula (PlasticsOne®, Virginia, 
USA) was attached to the flow moderator.   
 
Figure 2-3 Osmotic pumps used in experiments. A) Subcutaneous delivery - Model 2ML1: 10 
L per hour for 7 days, with a reservoir capacity of 2000 L, length of 5.1 cm and diameter of 1.4 
cm B) Intracerebroventricular delivery – Model 2001: 1.0 L per hour for 7 days with a reservoir 
volume of 200 L, length of 3.0 cm and diameter of 0.7 cm. 
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Prior to osmotic pump preparation, the mass of drug infusion was calculated in order to 
determine drug dilutions to completely fill the pump. The following equation was used: 
 
 k0: mass delivery rate (g/hr) 
 Q: drug volume delivery rate (L/hr) 
 Cd: concentration of the drug in vehicle solution (g/L) 
Osmotic pumps were filled with a blunt tipped needle to prevent air bubbles and the flow 
moderator fully inserted in the pump. All osmotic pumps were prepared 24 hrs prior to 
usage and left in a water bath at 37ºC overnight to prime them for immediate drug delivery. 
To confirm drug delivery, all pumps were weighed before insertion and again at the end of 
the experiment after pump removal. 
2.7.2 Implantation 
2.7.2.1 Subcutaneous  
Anaesthesia was induced with 5% isoflurane and rats were then placed on a facemask (2.5- 
3% isoflurane mixture) for surgical implantation. The fur was shaved in the back area 
posterior to scapulae and cleaned with chlorehexidine gluconate. A horizontal incision was 
performed in the mid-scapular area exposing the underlying fat and connective tissue. 
Blunt dissection was performed in the incision in order to create a SC pocket to place the 
pump. Once the pocket was of adequate size, the osmotic pump (Model 2ML1) was 
inserted and lesions sutured with 4-0 silk sutures. The animal was allowed to recover from 
anaesthesia and returned to its’ home cage. 
2.7.2.2 Intracerebroventricular 
Anaesthesia was induced with 5% isoflurane and rats orally intubated as described in 
section 1.5.2. Rats were then placed in a stereotaxic frame (Kopft Instruments, CA, USA) 
and the head was secured in place using ear and tooth bars to prevent movement. After 
local anaesthetic administration, a midline incision was made on the scalp with a scalpel 
blade (Swann Morton®, UK) and the underlying fascia cleared to visualise the coronal and 
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sagittal sutures on the skull surface. Bregma was identified and a stereotaxic needle 
(Hamilton Company, Nevada, USA) aligned at its level. The right lateral ventricle 
coordinates for the ICV cannula were 1.6 mm lateral and 0.9 mm posterior according to the 
Atlas of Paxinos& Watson (Paxinos and Watson, 1997). This position was identified and 
marked with a pen, this way serving as a guideline to drill the skull in the right lateral 
ventricle area. 
A burr hole was drilled on the skull using a dental drill (NSK Volvere max, Nakanshishi 
Inc., Japan) until the pial vessels were observed. The stereotaxic needle was used to 
correctly identify the right lateral ventricle in the brain surface. At this point, a SC pocket 
was created posteriorly to the scapulae with blunt scissors. The osmotic pump and part of 
the connecting tubing attached to the ICV cannula were inserted into the SC pocket. After, 
gel superglue (Superglue power flex gel, Henkel Limited, UK) was placed around the burr 
hole and with the use of straight forceps, the ICV cannula was inserted into the lateral 
ventricle and gentle pressure was applied for 3 min to allow the glue to set (Figure 2-4). To 
prevent cannula displacement during animal movement, the holding top piece of the 
cannula was removed with the aid of a heated scalpel blade.  The incision on the head was 
then sutured with 4-0 thread and the animal removed from the stereotaxic frame and 
transferred to the operating board for further procedures. 
 
Figure 2-4 Intracerebroventricular cannula implantation. Rats were placed in a Koft Stereotaxic 
frame and the head secured with ear and tooth bars. An incision was performed on the scalp to 
expose the skull and connective tissue cleared. Bregma was identified and used as a guide to 
define the right lateral ventricle with the coordinates 1.6 mm lateral and 0.9 mm posterior. A burr 
hole was performed in the right lateral ventricle area, the osmotic pump and vinyl tubing placed in 
the SC pocket posteriorly to the scapulae and the ICV cannula glued onto the right cerebral 
ventricle. 
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2.8 Middle Cerebral Artery Occlusion 
The intraluminal filament model was used to induce left MCAO as firstly outlined by 
Koizumi and colleagues (Koizumi et al., 1986), modified by Longa et al. (Longa et al., 
1989) and further altered in-house to minimise vessel damage. Microsurgery was carried 
out with the aid of a light operating microscope (Zeiss, Germany). A midline incision was 
performed with sharp scissors between the jaw and the manubrium and the submandibular 
glands identified. Blunt dissection was carried out in the middle of the glands to expose the 
sternohyoid muscle overlying the trachea. Blunt dissection was then performed in the 
intersection between the sternohyoid and sternocleidomastoid muscles to expose the 
omohyoid muscle overlying the carotid sheath, which was gently dissected. Retractors 
were placed at the level of the omohyoid and sternohyoid muscles as well as the 
sternocleidomastoid muscle to clearly visualise the common carotid artery (CCA). The fat 
and connective tissue surrounding the CCA was carefully dissected with the use of curved 
and straight forceps to isolate the vessel. The CCA was gently separated from the adjacent 
vagus nerve through blunt dissection and a folded 4-0 thread placed under it. The thread 
was cut at the folded zone to originate two different threads, one placed distally and the 
other proximally towards the heart. After, the vessel was tied off at the proximal side and a 
loose knot performed at the distal end. Curved and straight forceps were used to carry on 
with blunt dissection to expose the external carotid artery (ECA), occipital artery (OA), 
ICA and pterygopalatine artery (PA). A 4-0 thread was placed under the ECA and OA and 
tension applied by taping the threads to the corkboard. Two 4-0 threads were placed under 
the ICA in which one was used to tie a loose knot and apply tension at the ICA level and 
the other advanced to reach the PA/ICA bifurcation. The latter was pulled between the 
PA/ICA bifurcation and placed around the PA to exert tension, preventing the intraluminal 
filament from going towards the PA (Figure 2-5A). 
Once all the vessels were carefully isolated, an arteriotomy was performed at the CCA 
level with microscissors, just before the ECA & ICA bifurcation. A Doccol intraluminal 
filament of 0.39 mm or 0.41 mm tip diameter (403934PK10 or 404134PK10; Doccol 
Corporation, MA, USA) bent at 22 mm length was inserted through the ICA until it 
reached the origin of the MCA (Figure 2-5B). The filament was advanced approximately 2 
cm and MCAO confirmed once resistance was felt. After the filament was correctly 
placed, the loose ties around the ICA and CCA were tightly tied to secure the filament in 
place and the tension applied in the vessels released. To prevent the tissues from drying 
out, sterile saline was applied in the neck area. 
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Figure 2-5 Intraluminal filament MCAO model. A) Vessel isolation during surgery; B) 
Intraluminal filament occlusion of the MCA. During surgery 4-0 sutures were placed around the 
common carotid artery (CCA), external carotid artery (ECA), occipital artery (OA) and internal 
carotid artery (ICA). Vessels were isolated to facilitate filament insertion. A Doccol filament was 
inserted through the CCA passing the ICA, the origin of the posterior cerebral artery (PCA) and the 
PA until it reached the origin of the MCA just before the anterior cerebral artery (ACA). This method 
of MCAO can be transient or permanent by either removing or leaving the filament in place, 
respectively. Figure B was adapted from Rami et al. 2008. 
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2.8.1 Reperfusion 
Following 90 min MCAO, tension was applied to the ECA, ICA, OA and PA. The knots 
performed at the CCA and ICA were untied with the use of thin tipped forceps. The 
filament was gently pulled back to allow MCA reperfusion and the wound at the CCA 
sealed with curved diathermy forceps (Eschmann Equipment, Lancing, UK). At this step, 
care was taken to guarantee that the forceps were moist during electrocoagulation to 
prevent vessel rupture. After the vessel was adequately sealed, all ties were removed and 
the thread occluding the CCA at the proximal end untied to allow full reperfusion. The 
neck area was cleaned with sterile saline, isoflurane levels decreased to 1% and the midline 
incision sutured with 4-0 sutures. 
2.8.2 Post-operative care 
Once all incisions were sutured, approximately 1-5 mL of sterile saline were administered 
SC to aid recovery and prevent dehydration. Buprenorphine, a partial opioid agonist, was 
also injected SC at a dose of 0.03 mg/kg to alleviate post-operative pain. Isoflurane and 
NO2 were switched off and O2 increased to 100% to maximise recovery from anaesthesia. 
Once the animals started showing signs of withdrawal reflex, the intubation tube was 
removed and the rats placed on a face mask at 100% O2 until fully conscious. Rats were 
single housed in the recovery room in individual cages lined with absorbent pads until 
sacrificed. During the recovery period animals were fed food pellets, which were softened 
in water and supplemented with Complan (Nutricia, UK). Furthermore, water and dry 
pellets were provided ad libitum. Rats were weighed every day and carefully monitored by 
technical staff and the Named Veterinary Officer (NVO). If the animal’s weight dropped 
below 25% of initial body weight or showed any other issues of concern, the Named 
Animal Care and Welfare Officer and/or NVO were informed to assess the animal’s 
condition and to make a decision regarding its continuation in the study. 
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2.9 Magnetic Resonance Imaging 
All imaging was performed in a Bruker Pharmascan 7T/30 cm magnet system (Bruker, 
Ettlingen, Germany) with a gradient coil of 121 mm internal diameter, 400 mT/m and a 
birdcage resonator of 72 mm. Prior to all imaging sequences, a pilot scan sequence was 
performed to ensure correct geometry and brain location. MRI scans were conducted at 
GEMRIC facilities and MRI scans carried out by trained staff: Mr James Mullin, Mrs 
Lindsay Gallagher, Dr Christopher McCabe and Dr Lisa Roy.  
Rats were transferred to the MRI scanner and placed in the prone position in a specialised 
rat Perspex cradle where the head was restrained by ear and tooth bars and a phased array 
rat brain surface coil placed above the head. Animals scanned during MCAO were 
ventilated via oral intubation whereas rats scanned during recovery were ventilated with a 
face mask during MRI scanning. A rectal probe was inserted and a temperature regulated 
jacket placed around the animal to maintain and regulate body temperature at a 
physiological range of 37 ± 0.5ºC.  
2.9.1 Diffusion-Weighted Imaging  
2.9.1.1 Technical parameters 
In Chapter 4, early ischaemic lesion was assessed at 30 and 60 min MCAO by DWI. A 4-
shot Spin-Echo planar imaging DWI scan was conducted to generate images across 8 
coronal slices with a thickness of 1.5 mm and a resolution of 260 m. For all DWI scans, 
the sequence was performed for approximately 3 min under the following parameters: 
effective echo time (TE) = 22.9 ms, repetition time (TR) = 4,000 ms, matrix size = 96 × 96 
and field of view (FOV) = 25 × 25 mm. The gradient strengths, B values, were obtained in 
three directions of x, y, z and the B values were between 0 and 1,000 sec/mm2. For all 8 
coronal brain sections, ADC maps (mm2/sec) were generated in Paravision v5 software 
(Bruker, Ettlingen, Germany). ADC maps were then analysed by following an established 
imaging protocol with Image J software (https://imagej.nih.gov/ij/). 
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2.9.1.2 Threshold assessment and analysis 
For each ADC map generated, histograms were obtained for all slices in both ipsilateral 
and contralateral hemispheres. After, the number of pixels for each ADC value ranging 
from 0 to 2×10-3mm2/sec at 30 min and 60 min ischaemia following MCAO surgery were 
calculated. It was previously established in our group that abnormal ADC values following 
MCAO range between 0.01-0.58×10-3mm2/sec (Baskerville et al., 2016; Reid et al., 2012) 
with the reported threshold being used to outline early ischaemic lesion. The number of 
pixels per ADC value for 30 min and 60 min MCAO data were plotted, confirming that 
abnormal ADC values in the ipsilateral hemisphere are within 0.01-0.58×10-3mm2/sec 
(Figure 2-6A&B). Once the reported threshold was validated, it was used for all ADC 
maps in this thesis. Figure 2-7 displays a processed ADC map prior to the application of 
the selected threshold (Figure 2-7A) and after the application of the threshold (Figure 2-
7B). The brain areas highlighted by the ADC threshold were obtained for each coronal 
slice, summed and multiplied by slice thickness of 1.5 mm to obtain an early lesion volume 
for each animal. 
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Figure 2-6 ADC value profile at 30 min and 60 min MCAO. A) ADC profile at 30 min MCAO; B) 
ADC profile at 60 min MCAO. The mean number of image pixels, within a range of ADC values, is 
expressed as ×10-3mm2/sec for 48 rats. The vertical line depicted in each graph is set at the ADC 
value of 0.58×10-3mm2/sec, the suggested threshold to detect abnormal ADC values in the 
ipsilateral hemisphere. In both 30 min and 60 min MCAO, there is an increase in ADC values in the 
ipsilateral hemisphere compared to the contralateral hemisphere below and at the threshold 
defined. Therefore, confirming that to detect ischaemic lesion in ADC maps, a threshold of 0.01 to 
0.58 mm-3mm2/sec should be used. 
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Figure 2-7 ADC map prior to and post threshold processing. A) ADC maps at 60 min MCAO across 8 coronal levels prior to threshold processing. ADC 
values ranging between 0.0-2.0×10-3 mm2/sec as set by the scale. B) Respective ADC maps across 8 coronal levels following threshold processing. Threshold 
was set at ADC values of 0.01-0.58×10-3 mm2/sec, highlighing early ischaemia lesion depicted in white. ADC values are expressed as ×10-3 mm2/sec. 
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2.9.2 RARE T2 weighted Imaging 
In Chapters 3, 4 and 5 infarct volume was assessed using a rapid acquisition with refocused 
echoes (RARE) T2 weighted sequence at either 24 hrs; 72 hrs or 7 days post MCAO.  
2.9.2.1 Technical parameters 
T2- weighted imaging was carried out using a RARE sequence with the following 
paramaters: 16 contiguous coronal slices, slice thickness of 0.75 mm and an in-plane 
resolution of 98 m, effective TE:  100 ms, TR: 6,000 ms, matrix size: 256× 256 and FOV:  
25 × 25 mm. 
2.9.2.2 Image processing and analysis 
T2 weighted images were analysed using ImageJ software. Hyperintense regions, excluding 
cerebral ventricles, were manually delineated across the 16 slices in mm2 to define the 
infarct (Figure 2-8). The infarct areas were summed and multiplied by the slice thickness, 
0.75 mm, to obtain the final volume. The ipsilateral and contralateral hemispheres were 
also delineated and hemipshere volumes calculated. Final infarct volume was corrected to 
oedema and compression of the contralateral hemisphere using the Gerriets equation 
(Gerriets et al. 2004) defined by the following formulas:  
 Infarct volume corrected to oedema 
 
 Compression factor  
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 Final infarct volume 
 
 
Figure 2-8 Representative RARE T2 weighted images depicting final infarct volume. Infarct 
was identified as hyperintense regions across the 16 coronal slices in the ipsilateral hemisphere. 
Image J was used to delineate the hemisphere volumes and the infarcted tissue, the latter 
delineated in white. After, infarct volume was corrected for both oedema and contralateral 
compression using Gerriets equation (Gerriets et al. 2004). The animal represented was subjected 
to 90 min MCAO and 72 hrs reperfusion at time of assessment. 
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2.9.3 Magnetic Resonance Angiography  
2.9.3.1 Technical parameters 
Magnetic resonance angiography (MRA) weighted sequences were carried out to confirm 
MCAO and/or successful reperfusion. The MRA sequence was a FLASH based sequence 
with the following parameters: 50 contiguous coronal slices, slice thickness of 0.4 mm, 
effective TE: 3.8 ms, TR: 15 ms, matrix size: 256×256, FOV: 4×4 mm  and a spatial 
resolution of 156 m. 
2.9.3.2 MCAO and reperfusion assessment 
MRA was used as a tool to assess left MCA occlusion and/or reperfusion during and 
following MCAO. The left and right MCAs were identified as the hyperintense regions 
running along the coronal sections as indicated in orange (Figure 2-9). Following MCAO, 
the left MCA was missing due to vessel occlusion whereas flow could clearly be visualised 
in the right MCA (Figure 2-9A). Upon reperfusion, a clear hyperintense signal can be seen 
on both MCAs (Figure 2-9B).  
 
Figure 2-9 MRA across the MCA territory during and post MCAO. A) MRA at 60 min MCAO; 
B) MRA at 7 days reperfusion. During MCAO, the left MCA is occluded with the intraluminal 
filament, thus, it is not visualised along the coronal sections on the left side. Conversely, the right 
MCA is clearly detected and displayed as hyperintense regions in white along the coronal sections. 
These images indicate successful MCAO. During reperfusion, both left and right MCAs are clearly 
visualised along the coronal sections, indicating successful reperfusion. Orange arrows outline the 
location of left and right MCAs depicted in white. 
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2.10 Plethysmography blood pressure measurement 
Conscious tail-cuff BP measurements were carried out in recovery studies (Chapters 3 and 
4) to determine the effect of therapy on systolic BP. The method used is a non-invasive 
technique that enables BP measurement without anaesthetising the animals (Evans et al., 
1994).  
A week prior to BP measurements, animals were handled and acclimatised to the set up to 
prevent stress during measurements. On the day of BP assessment, an insulated heat box 
(dimensions 37 × 35 × 40 cm) was heated with the use of a lamp and a hairdryer (Boots, 
UK) to 38°C. The animal was then placed in the previously warmed box for a period of 10 
min to induce maximal vasodilation of tail arteries and aid BP value detection. Once the 
animals exhibited little movement and a strong pink colour in their ears, they were deemed 
sufficiently warm and ready for BP determination. Rats were placed on the bench top and 
wrapped in a cloth towel, except the tail, and gently held. A tail cuff made of inflatable 
latex tube was tightly placed at the proximal end of the rat’s tail and the piezoceramic 
transducer introduced on the distal end (Figure 2-10). A few measurements were 
performed to familiarise the animal with the procedure and once the rat was stable, the 
latex within the cuff was inflated with an air cylinder until the pressure applied matched 
the pressure in the tail artery. The signal obtained was recorded by the piezoceramic 
transducer and converted in the monitoring system, connected to a laptop (Dell, UK), into 
systolic BP in mmHg. Once the value was obtained, the cuff was deflated to release 
pressure and the procedure repeated until 10 individual BP measurements were acquired.  
After, animals were returned to their cages and rewarded with Cheerios (Nestlé®, UK). 
The mean and standard deviation (S.D.) of the 10 individual values were calculated for 
each animal and shown as systolic BP. 
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Figure 2-10 Plethysmography systolic BP measurement. A tail cuff containing inflatable latex 
tubing and a piezoceramic transducer were placed around the rat’s tail. The latex within the tail cuff 
was inflated until the pressure exerted matched the pressure within the tail vessels. This was then 
detected by the transducer and translated via a monitoring system into systolic BP. The procedure 
was repeated until 10 individual BP values were obtained for each animal. 
 
 
2.11 Neurological Score 
A neurological score was performed on all animals prior and post-MCAO using an 18 
point neurological score as previously described (Garcia et al., 1995). This score has been 
widely used and shown to successfully correlate with the volume and size of the infarct 
(Garcia et al., 1995, 2013). The test assesses the rats’ performance in 6 distinct and 
individual assessments with a maximum score of 3 each adding up to 18 points and a total 
minimum score of 3. The assessments evaluate and score spontaneous activity, symmetry 
of movement, forelimb symmetry, body proprioception, response to vibrissae touch and 
climbing. Table 2-1 outlines the protocol followed to evaluate neurological score. The left 
MCA was occluded in all studies in this thesis and therefore the right side is considered 
impaired.  
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Table 2-1 The 18 point neurological Score. The Garcia neurological score is comprised of 6 distinct tests, scored to a maximum of 3 points. The higher the functional 
outcome, the closer the value is to 18 and vice versa. The table was adapted from Garcia et al., 1995. 
 
 
Test Score 
0 1 2 3 
Spontaneous activity 
(in cage for 5 min) 
No movement Barely moves Moves but does not 
approach at least three 
sides of the cage 
Moves and 
approaches at least 
three sides of cage 
Symmetry of 
movements (four 
limbs) 
Contralateral side:  
No movement 
Contralateral side: 
Slight movement 
Contralateral side: 
Moves slower; general 
movement still forward 
Symmetrical outreach 
Symmetry of 
forelimbs 
(outstretching while 
held by tail) 
Contralateral side:  
No outreach 
Contralateral side: 
Attempts to outreach 
but unsuccessfully 
Contralateral side: 
Moves and outreaches 
less than left side 
Symmetrical outreach 
 
Reaction to touch on 
either side of trunk 
N/A Contralateral side:  
No response 
Contralateral side: 
Weak response 
Symmetrical 
response 
Reaction to vibrissae 
touch 
N/A Contralateral side:  
No response 
Contralateral side: 
Weak response 
Symmetrical 
response 
Climbing wall of wire 
cage 
N/A Fails to climb Contralateral side: 
Displays weak grip 
Normal climbing 
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2.11.1 Spontaneous activity 
Each animal was moved into a clean cage and its behaviour observed for 5 min. A healthy 
animal will quickly explore the cage and approach all four walls of the cage as well as try 
to explore beyond the cage walls. Therefore, animals that exhibited this behaviour were 
given a score of 3. A score of 2 was attributed to animals that were moving in the cage but 
did not approach at least 3 cage walls. A score of 1 was given to animals that moved in the 
cage but did not approach any walls nor explored the environment. A score of 0 was 
attributed to rats that did not move at all during the 5 min inside the cage. 
2.11.2 Symmetry of movement in the four limbs 
Symmetry of the limbs was evaluated by placing the rat on a bench top or on the floor and 
observing the animal while walking. Animals showing complete symmetry of the four 
limbs were given a score of 3. Rats showing that the right limbs were splaying towards the 
side or moving slower than the left limb, yet exhibiting relatively forward movement, were 
scored 2. A score of 1 was given to animals that showed slight right limb movement and 
sideways movement towards the left. A score of 0 was given to animals that showed no 
right limb movement leading to circling behaviour. 
2.11.3 Forelimb symmetry 
Rats were held by the tail and placed near the bench top edge. The animals’ ability to 
outreach to the bench top was assessed whilst the hindlimbs were kept in the air. A score of 
3 was attributed to rats that showed no preference of the right or left limb to outreach to the 
edge of the bench, this way, displaying full forelimb symmetry. A score of 2 was attributed 
to animals showing that the right limb outreached to the bench edge fewer times than the 
left limb and it often missed touching the bench top when compared to the left side. A 
score of 1 was given to animals that still attempted to outreach to the bench top with the 
right limb; however, it was often left hanging. A score of 0 was attributed to rats that 
showed no movement in the right limb, which assumed a retracted position when 
compared to the left limb. 
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2.11.4 Body proprioception 
This test was performed once the animals were not moving or exploring and distracted to 
movement. Without the rat seeing, a pen or pencil was used to touch either side of the 
trunk and the reaction assessed. A score of 3 was attributed to animals that showed a 
symmetrical response to trunk touch on either side by turning their heads and showing a 
startled response upon stimulus. A score of 2 was given to rats exhibiting a weaker 
response on the right side and a score of 1 if the animal did not respond to stimuli at all. 
2.11.5 Response to vibrissae touch 
A pencil or pen was used to brush against the rat’s vibrissae on both the left and right 
sides. In healthy animals, brushing a pen on both sides of vibrissae will elicit the animal to 
turn its head towards the stimuli or try to avoid the pencil, leading to a score of 3. 
However, animals with neurological deficit will show a weaker reaction to vibrissae touch 
on the right side and thus, will fall within a score of 2, or not show any response to 
vibrissae touch at all, which leads to a score of 1. 
2.11.6 Climbing 
Animals were gripped from the base of the tail and placed onto a wire grid. Animals were 
given a score of 3 if they successfully climbed to the top of the grid - displaying similar 
forelimb symmetry and a relatively forward movement. A score of 2 was attributed to 
animals that attempted to climb but showed a weaker grip of the right side, displaying a 
sideward movement. A score of 1 was attributed to animals that failed to climb or tried to 
climb but did not reach halfway of the wire grid. 
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2.12 Brain tissue processing 
2.12.1 Snap freezing 
At the end of the experiment, animals were anaesthetised with 5% isoflurane in a 30:70% 
O2-NO2 mixture. Once the animal was deemed as deeply anaesthetised, it was killed by 
Schedule 1 procedures and the brain carefully removed. The cerebellum and 
bulbusolfactorus were discarded followed by brain tissue sectioning where the contralateral 
and ipsilateral hemispheres were separated and further sectioned into core and peri-infarct 
regions with the aid of RARE T2 imaging. The tissue sectioned was placed in an individual 
Eppendorf tubes and quickly snap frozen in liquid nitrogen, to maintain integrity of RNA, 
and stored at -80oC until further use. 
2.12.2 Perfusion fixation 
To assess protein levels with immunohistochemistry and perform histological 
examinations, animals were subjected to transcardial perfusion fixation with 4% 
paraformaldehyde [(PAM; 4% in 50 mM phosphate buffer; 500 mL), Sigma Aldrich, UK]. 
Rats were deeply anaesthetised with 5% isoflurane and transferred to a tray containing 
absorbent pads and anaesthesia continued on a facemask delivering 3% isoflurane. An 
incision was made in the abdominal wall just underneath the rib cage with the use of large 
blunt scissors followed by a cut in the diaphragm and rib cage, exposing the pleural cavity. 
The heart was cleared from connective tissue and the sternum retracted with the aid of a 
hemostatforcep to clearly visualise the chest cavity. The heart was gripped with hemostat 
forceps a blunt ended 16-gauge needle, directly connected to a perfusion fixation set up, 
was inserted at the base of the heart through the left ventricle into the aorta. Once the 
needle was correctly placed, the needle was clamped to secure in aorta and the right atrium 
cut with sharp scissors to allow blood drainage. The animal was perfused with 1% heparin 
(1000 units/mL heparin; 0.9% saline, 1L) dissolved in 250 mL saline at a pressure of ~120 
mmHg. Once the blood was completely cleared from the circulation, animals were 
perfused with 250 mL of 4% PAM at the same pressure as saline infusion. Correct PAM 
perfusion was confirmed by spontaneous fixation tremors and body stiffness. After, rats 
were decapitated and the heads immersed in 4% PAM for 24 hrs. Brains were removed 
from the skull and left in 4% PAM for another 24 hrs and then in 70% ethanol until 
paraffin embedding processes were performed. 
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2.12.2.1 Paraffin embedding and sectioning 
Tissue was transferred to an automatic processor (Tissue-Tek VIP, Miles Scientific) and 
subjected to a series of washes in ethanol to dehydrate the tissue and xylene, which acts as 
a clearing reagent. Brains were placed in paraffin wax for a total of 6 hrs at 60°C to create 
a paraffin block. The whole process takes 15 hrs to be completed and is described in Table 
2-2. For sectioning, paraffin embedded brains were placed on a wooden block and cut at 5 
m sections with the use of a microtome across 8 cerebral coronal levels (Figure 2-11). 
Two to three 5 m sections were mounted onto poly-l-lysine coated glass slides, three 
slides per coronal level. Sections were allowed to dry and stored in a slide storage box until 
use.  
Table 2-2 Paraffin embedding tissue processing. Brains were dehydrated with alcohol for a 
period of 6 hrs followed by xylene clearing reagent immersion for 3 hrs to then be placed in paraffin 
for 6 hrs. 
 
Stage Reagent Immersion period 
1 70% Alcohol 1 hour 
2 95% Alcohol 1 hour 
3 95% Alcohol 1 hour 
4 100% Alcohol 1 hour 
5 100% Alcohol 1 hour 
6 100% Alcohol 1 hour 
7 Xylene 1 hour 
8 Xylene 1 hour 
9 Xylene 1 hour 
10 Paraffin 2 hours 
11 Paraffin 2 hours 
12 Paraffin 2 hours 
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Figure 2-11 The eight coronal levels covering the territory of the MCA. The diagram shows the 8 pre-defined coronal levels and respective distance from bregma, 
where positive values represent anterior and negative values posterior to bregma. Brain tissue was collected at these levels for histological assessments. The figures 
were obtained from the stereotaxic atlas of Paxinos & Watson (Paxinos and Watson, 1997). 
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2.13 Histological analysis 
2.13.1 Haematoxylin and Eosin histological staining 
Haematoxylin and eosin (H&E) staining technique was used to identify the infarct core and 
peri-infarct areas to then outline where immunohistochemistry analysis would be 
performed. Plus, it was used to confirm the quality of the paraffin embedding and 
sectioning processes. 
Brain sections from coronal levels 3 to 5 were selected as these represent the infarct extent 
across all animals. The sections were stained with H&E (Sugipath, UK) and used to outline 
infarct core and peri-infarct regions (Table 2-3). Slides were placed in a metal rack and 
submerged in 100% Histoclear (National Diagnostics, USA, Atlanta) for a period of 15 
min with regular agitation. Sections were then rehydrated through a sequence of alcohols: 
100% for 6 min, 90% for 3 min and 70% alcohol for 3 min (Sigma Aldrich, UK). After, 
slides were placed in running water for a period of 4 min and subsequently stained with 
haematoxylin for 2 min. To remove excess staining and differentiate the slides, sections 
were submerged in acid alcohol for a few seconds (2-3 dips) and returned to running water 
for 5 min before being transferred to Scott’s Tap Water Substitute (Sigma Aldrich, UK) for 
2 min (blueing). Sections were returned to running water for 2 min and dehydrated by 
being immersed in 70% alcohol for 2 min and 90% alcohol for 2 min. Thereafter, slides 
were stained with alcoholic eosin (95%) for 2 min. The final steps included three washes in 
absolute alcohol for 4 min each to then be placed in 100% Histoclear three times for 4 min 
each. Coverslips were then mounted on the sections with the use of DPX mounting 
medium (Sigma Aldrich, UK). 
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Table 2-3 H&E staining procedure for paraffin embedded sections. 
Stage Solution Time (min) 
1 Histoclear 1 5 
2 Histoclear 2 5 
3 Histoclear 3 5 
4 Absolute Alcohol 1 3 
5 Absolute Alcohol 2 3 
6 90% Alcohol 3 
7 70% Alcohol 3 
8 Wash in running water 4 
9 Haematoxylin  2 
10 Wash in running water 5 
11 Differentiate in Acid Alcohol A few dips only 
12 Wash in running water 5 
13 Scott’s Tap Water Substitute 2 
14 Wash in running water 2 
15 70% Alcohol 2 
16 90% Alcohol 2 
17 Alcoholic Eosin (95%) 2 
18 Absolute Alcohol 1 4 
19 Absolute Alcohol 2 4 
20 Absolute Alcohol 3 4 
21 Histoclear 1 4 
22 Histoclear 2 4 
23 Histoclear 3 4 
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2.13.1.1 Identification of the peri-infarct border 
H&E sections were analysed under a light microscope at 20x and 40x magnification to 
outline the core and peri-infarct ipsilateral regions at coronal levels 3, 4 and 5. Once the 
infarct area was outlined with the help of T2-weighted imaging, 3 distinct regions of 
interest (ROIs) were established in the peri-infarct area per coronal level to serve as 
guidance for immunohistochemical analysis (Figure 2-12). 
 
Figure 2-12 Region of interest determination in coronal levels 3, 4 and 5. H&E was used as a 
tool to identify the infarct (black) across animals in coronal levels 3, 4 and 5 with the help of T2-
wheighed imaging (displayed on the right in white). Once the infarct was identified, the peri-infarct 
zone and corresponding contralateral areas were evaluated and three independent ROIs (red) 
determined in each hemisphere to serve as guidance for immunohistochemical analysis. 
 
To accurately determine the peri-infarct region, morphological characteristics of cells were 
compared. Healthy cells were identified due to the presence of well-defined cytoplasmic 
structures and large round nuclei (Figure 2-13A). Ischaemic neurons were identified due to 
the presence of shrunken pyknotic nuclei, an eosinophilic cytoplasm and triangular shape. 
Moreover, in these cells, surrounding neuropil was disrupted and shown to be unstained 
(Figure 2-13B). On the other hand, the peri-infarct zone was outlined by identifying 
regions that showed both cell phenotypes (Figure 2-13C). 
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Figure 2-13 H&E peri-infarct region determination. A) Healthy tissue. Cells presenting well-
defined cytoplasmic structures and large round nuclei. B) Ischaemic tissue. Cells displaying dark 
stained triangular neurons and pale stained neuropil. C) Peri-infarct region. Cells displaying 
normal morphology characterised by well-defined round nuclei (highlighted in black) as well as 
ischaemic cells as observed in Figure B. Scale bar represents 50M. 
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2.13.2 IBA1 immunohistochemistry labelling 
Adjacent sections used for H&E staining were selected to perform immunostaining for 
ionized calcium-binding adapter molecule 1 (IBA1) positive microglia labelling. To dewax 
and rehydrate, sections were submerged in 100% histoclear for 15 min and then washed in 
100% ethanol for 10 min, 90% ethanol for 5 min, 70% ethanol for 5 min and finally rinsed 
in cold running tap water for ~5 min. Extreme care was taken to not allow the sections to 
dry out between washes to prevent non-specific antibody binding. Heat induced antigen 
retrieval was achieved by placing the sections into a pressure cooker containing an antigen 
retrieval solution (sodium citrate buffer (pH 6.0)) for 4 min after which slides were left in 
running cold water for 10 min. After, sections were washed twice in Tris Buffered Saline-T 
(TBS dissolved in 0.025% Triton x-100; Sigma-Aldrich, UK) for 5 min each. A 
hydrophobic pen (Dako pen; Agilent, UK) was used to draw a ring around each section on 
the slide and blocking solution [TBS containing 10% normal goat serum (Vector 
Laboratories Ltd, UK) and 1% bovine serum albumin (BSA) (Vector Laboratories Ltd, 
UK)] applied for 2 hrs at room temperature in a humidified chamber. Blocking buffer was 
then removed and IBA1 primary antibody (Catalog #: ab139590, Abcam, UK) diluted in 
1:250 TBS with 1% BSA was applied to the sections and incubated overnight at 4°C. The 
following day, samples were rinsed in TBS-T twice for 5 min each and the secondary 
antibody [goat anti-chicken IgY (Catalog #: A-11039; ThermoFisher, UK)] diluted in 
1:500 TBS with 1% BSA was added to the sections and incubated at room temperature for 
1 hr in a dark room. Slides were rinsed in TBS three times for 5 min each time and 
mounted using Vectashield medium containing 4’,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories Ltd, UK). The coverslips were applied and secured in place with 
varnish to seal the slides, which were allowed to dry and stored at 4°C until image 
analysis. 
2.13.2.1 Microglia quantification 
The three ROIs previously outlined with H&E in the peri-infarct tissue and corresponding 
contralateral areas were used as guidance for IBA1+ microglia assessment. Within each 
coronal section, ROIs were imaged at 40x using a light microscope (Leica Biosystems, 
UK), attached to a charge-coupled device (CCD) camera and a laptop, and captured using 
QCapture Pro 6 (QImaging, Surrey, Canada). A negative control (without primary 
antibody) was run to verify nonspecific secondary antibody binding, confirming specificity 
(Figure 14A). IBA1+ microglia were then manually counted and summed to provide total 
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microglia count across each coronal level in the peri-infarct and corresponding 
contralateral region using Image J Software. In addition, cells in the peri-infarct were 
classified into resting or activated through morphological assessment. Resting microglia 
are small cells with little perinuclear cytoplasm and multiple thin ramifying processes 
branched in various directions. Activated microglia present large soma and thickened and 
retracted processes (Kettenmann et al., 2011) (Figure 2-14B). In addition, activated 
microglia can be identified by a giant, amoeboid shape and proposed to be in a phagocytic 
state (Kettenmann et al., 2011) (Figure 2-15C). Data were expressed as cell number per 
mm2 tissue across the 3 coronal levels and activated microglia phenotype expressed as % 
of total microglia number. Figure 2-15 shows representative images of IBA1 microglia 
staining in peri-infarct, contralateral and infarct areas. 
 
Figure 2-14 Secondary antibody specificity and microglia phenotype. A) Negative control 
(without primary antibody). Image shows that secondary antibody selected did not induce non-
specific binding. B) Microglia phenotype. Image shows an example of activated microglia (larger 
cell body and shorter, thicker processes) and resting microglia (smaller cell bodies and longer, 
thinner, ramifying processes). Scale bar is set as 50m. 
 
 
Figure 2-15 Immunohistochemical IBA1+ microglia staining. Representative images of IBA1 
microglia staining (red) at 7 days post 90 min MCAO in the contralateral region (A), peri-infarct 
regions (B) and the infarct core (C). Scale bar is set in white and = 50m. 
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2.14 RNA extraction 
Total RNA was extracted using miRNeasy Mini-kit as outlined by manufacturer (Qiagen, 
Hilden, Germany). For disruption and homogenisation, 50 mg of brain tissue was placed in 
sterile polystyrene bijoux (ThermoFisher, UK) and 700 L of Qiazol (Qiagen, Hilden, 
Germany) quickly added. The sample was lysed using a tissue homogenizer (Qiagen, UK) 
programmed at 5000 rpm for 20 secs. Each homogenate was individually transferred to an 
RNAse free tube and 140 L of chloroform added to divide the sample into aqueous and 
organic phases. Samples were left to settle for 5 min at room temperature and centrifuged 
for a period of 15 min at 12000g at 4°C. The aqueous upper phase containing RNA was 
carefully collected, this way preventing the pipetting of organic phases, and transferred to 
new collection tubes where 525 μL of anhydrous ethanol (Sigma-Aldrich, UK) was added 
and thoroughly mixed. Each sample was transferred into an RNeasy Mini spin column and 
centrifuged at 8000g at room temperature to bind the RNA to the column membrane. In 
order to wash away phenol and other contaminants, 350 L Buffer RWT was added to the 
column and centrifuged for 15 sec at 8000g, this step was performed twice. Columns were 
transferred to a new collection tube and then washed with 500 L of Buffer RPE for 15 sec 
at 8000g in the first wash and for 2 min at 8000g for the second wash. Before eluting the 
purified RNA, columns were again transferred to a new collection tube and the samples 
centrifuged at full speed for 1 min to ensure that the mini column membrane was 
completely dry. Finally, the columns were transferred to an RNAse free tube and 50 L of 
RNase-free H2O was added to the column and centrifuged at 8000g for 1min to elute the 
purified RNA. 
2.14.1 DNAse I treatment 
All samples were subjected to DNAse I treatment to efficiently digest genomic DNA 
during RNA purification as suggested by the manufacturer (Qiagen, Hilden, Germany). 
Briefly, between the 350 L Buffer RWT washes, 80 L of DNase I (10 L) dissolved in 
Buffer RDD (70 L) was pipetted into the RNeasy Mini column membrane and left to act 
for 15 min. After this step, 350 L of Buffer RWT was again added to the column and the 
protocol proceeded as described above.  
80 
 
2.14.2 RNA purity determination 
RNA concentrations [ng/L] were measured using a NanodropTM ND-1000 
Spectrophotometer and v3.1.0 NanoDrop-1000 software (ThermoScientific, 
Loughborough, UK). The instrument works by applying a light source through a pulsed 
xenon flash lamp to the sample. The light generated is detected and measured with a 
spectrometer, which utilises a linear CCD array to analyse the sample. To quantify nucleic 
acids, the instrument uses a modified Beer-Lambert equation taking into account extinction 
coefficients with the following calculation: 
 
 c: Nucleic acid [ ] (ng/mL) 
 A: absorbance (A) 
 : wavelength dependent extinction coefficient (ng-cm/mL) 
 b: path length (cm) 
 
The accepted extinction coefficients were as follows: 
 Double stranded DNA: 50 ng-cm//L 
 Single stranded DNA: 33 ng-cm//L 
 RNA: 40 ng-cm//L 
 
To assess purity, absorbance ratios at 260/280 nm and 260/30 nm were evaluated. Samples 
with a 260/280 nm ratio ranging between 1.8 and 2.0 were considered pure. Samples with a 
ratio lower than 1.8 were considered contaminated as it indicates the presence of phenol, 
protein or genomic DNA. Samples with a 230/260 nm ratio ranging between 1.0 and 2.0 
were considered pure. RNA concentrations were obtained as duplicates and averaged for 
each sample. Purified RNA was stored at -80°C until complementary DNA (cDNA) 
synthesis. 
81 
 
2.15 Complementary deoxyribonucleic acid synthesis 
cDNA was generated from total tissue extracted mRNA by reverse transcription 
polymerase chain reaction (RT-PCR) using TaqMan® Reverse Transcription Kit as 
suggested by the manufacturer (Applied Biosystems, UK). This procedure was 
performedto allow gene expression assessment via qRT-PCR. All procedures were 
performed on ice and a negative control reaction containing RNAse-free H2O prepared.   
For each sample, 16 L Mastermix solution was made up containing 1x PCR buffer, 5. 
mM MgCl2, 2 mM deoxyribonucleotide triphosphate (dNTP) mix (0.5 mM each), 2.5 M 
random hexamers, 0.4 U/L RNAse inhibitor, 1.25 U/L Multiscribe reverse transcriptase 
and RNAse-free H2O (3.7 L). The Mastermix was added to a 96 well plate (Applied 
Biosystems, UK) placed on ice. Stock RNA was defrosted and diluted in RNAse-free H2O 
to yield 1 g of RNA in 4 L. The RNA was then added to the Mastermix to generate a 
total volume of 20 L per sample. The 96 well plate was quickly vortexed and centrifuged 
at 300g for 30 sec before being placed in the PCR block to start RT-PCR under the cycling 
conditions described in Table 2-4. Once RT-PCR was completed, the cDNA was left in the 
PCR block at 4°C for up to 60 min and stored at -20°C until use.  
Table 2-4 RT-PCR cycling conditions. 
Temperature (°C) Duration (min) Outcome 
25 10 Annealing 
48 30 Reverse transcription 
95 5 Reverse transcriptase 
inactivation 
4 60 Storage 
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2.16 Taqman® quantitative real-time polymerase chain 
reaction  
Quantitative real-time polymerase chain reaction (qRT-PCR) is a sensitive technique that 
allows the amplification and quantification of a specific DNA sequence by using the PCR 
principle and a thermocycler that captures fluorescence. In qRT-PCR, the 5’-3’ 
exonuclease properties of DNA polymerase are used to cleave target probes and detect the 
amplification of the gene of interest (Arya et al., 2005). The technique is based on the 
fluorescence resonance energy transfer (FRET) principle and uses TaqMan probes, non-
extendable fluorogenic target sequences, containing a fluorescent reporter dye at the 5’end 
and a quencher dye at the 3’end. Once the cDNA is denatured, the primer and TaqMan 
probe anneal to the sequence. During elongation, the probe is cleaved by the DNA 
polymerase leading to FRET and the fluorescence emitted absorbed by the quenching dye 
(Figure 2-16A). During amplification processes, dye molecules are further cleaved, 
increasing fluorescence intensity, which is detected by a thermocycler (Arya et al., 2005) 
(Figure 2-16B). Gene expression is quantified by assessing the cyclic threshold (Ct) value 
defined as the fractional PCR cycle number at which the fluorescence is greater than the 
established threshold defined by the instrument; the greater the Ct value, the lower the 
gene expression. 
 
Figure 2-16 The qPCR principle. A) TaqMan probe and primer annealing; B) Elongation and 
fluorescence detection. Following cDNA denaturation, the primer and TaqMan probe will anneal 
to the sequence. During elongation, the TaqMan probe is cleaved by DNA polymerase leading to 
the release of a reporter fluorophore, which is absorbed by the quencher dye and detected by the 
thermocycler. Image adapted from Arya et al., 2005. 
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2.16.1 Gene expression reaction 
Procedures were performed on ice and the reactions carried out according to the 
manufacturer’s instructions in a 384 well plate and in technical duplicates for each gene of 
interest. qRT-PCR was performed using inventoried FAM labelled fluorescent Taqman® 
assay probes, which span an exon junction (m1 type) or lie within a single exon (s1 and g1 
types) and are described in Table 2-5 and 2-6. Unless otherwise stated, all materials were 
obtained from ThermoFisher Scientific, UK.   
A reaction mixture of 10 L was prepared for each sample containing 5 L of Taqman® 
Universal MasterMix II, 0.5 L of Taqman probe 20x, 3 L of RNAse-free H2O and 1.5 
L of cDNA. For each probe a negative water control was tested. Once the reaction 
volumes were prepared, samples were centrifuged at maximum speed for 2 min to 
guarantee that there were no air bubbles that could interfere with qRT-PCR procedures. 
The 384 well plates were placed in a QuantStudio 12K Flex PCR System and samples 
incubated in the following cyclic conditions: 95ºC for 10 min to allow enzyme activation, 
40 cycles at 95ºC for 15 sec to denature cDNA and 60ºC for 1 min for primer and probe 
annealing as well as primer extension.  
In this thesis, a panel of genes of reference were run for each experiment to assess which 
gene was most stable between experimental conditions and thus, suitable to use as an 
internal control (Table 2-5). For mechanistic studies, Taqman® probes were run for Sham 
and transient MCAO peri-infarct brain samples and tested for RAS components, 
inflammatory and oxidative stress mediators’ gene expression (Table 2-6).   
Table 2-5 List of genes of reference examined. FAM labelled Taqman® probe assays used in 
experimental procedures. 
Gene name Gene symbol Assay ID Refseq Gene 
Beta-Actin Actb Rn00667869_m1 NM_031144.3 
Beta-2-microglobulin B2m Rn00560865_m1 NM_012512.2 
Glyceraldehyde 3-
phosphate dehydrogenase 
 
Gapdh Rn01775763_g1 NM_017008.4 
Hypoxanyhine-guanine 
phosphoribosyltransferase 
 
Hprt1 
Rn01527840_m1 NM_0012583.2 
Ubiquitin C Ubc Rn01789812_g1 NM_017314.1 
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Table 2-6 List of genes of interest examined. FAM labelled Taqman® probe assays used in 
experimental procedures. 
Gene name Gene symbol Assay ID Refseq Gene 
Angiotensin converting enzyme Ace Rn00561094_m1 NM_012544.1 
Angiotensin converting enzyme 
2 
Ace2 Rn01416293_m1 NM_001012006.1 
Arginase 1 Arg1 Rn00691090_m1 NM_017134.3 
Angiotensin II receptor type 1a Atgr1a Rn02758772_s1 NM_030985.4 
Angiotensin II receptor type 2 Atgr2r Rn00560677_s1 NM_012494.3 
C-C motif chemokine 22 Ccl22 Rn01536591_m1 NM_057203.1 
C-C motif chemokine receptor 2 Ccr2 Rn01637698_s1 NM_021866.1 
C-C motif chemokine receptor 5 Ccr5 Rn00588629_m1 NM_053960.3 
C-C motif chemokine receptor 7 Ccr7 Rn01465443_m1 NM_199489.4 
Cluster differentiation 11b or 
integrin subunit alpha M 
Itgam Rn00709342_m1 NM_012711.1 
Cluster differentiation 163 CD163 Rn01492519_m1 NM_01107887.1 
Cluster differentiation 86 CD86 Rn00571654_m1 NM_020081.1 
Cyclooxygenase-2 or 
prostaglandin-endoperoxide 
synthase 2 
 Ptgs2 Rn01483828_m1 NM_017232.3 
Interleukin 10 Il10 Rn99999012_m1 NM_012854.2 
Interleukin 1 Il1b Rn00580432_m1 NM_031512.2 
Interleukin 6 Il6 Rn01410330_m1 NM_012589.2 
Nitric oxide synthase 2 Nos2 Rn00561646_m1 NM_012611.3 
Mas receptor Mas1 Rn00562673_s1 NM_012757.2 
Metallopeptidase inhibitor 1 Timp1 Rn00587558_m1 NM_053819.1 
Matrix metalloproteinase 9 Mmp9 Rn00579162_m1 NM_031055.1 
Nuclear factor B p105 subunit Nfkb1 Rn01399572_m1 NM_001276711.1 
NADPH oxidase I Nox1 Rn00586652_m1 NM_053683.1 
NADPH oxidase 2 Nox2 Rn00576710_m1 NM_023965.1 
Transforming growth factor 1 Tgfb1 Rn00572010_m1 NM_021578.2 
Vascular endothelial growth 
factor A 
Vegfa Rn01511602_m1 NM_001110333.2 
Vascular endothelial growth 
factor receptor 2 or kinase insert 
domain receptor 
Kdr Rn00564986_m1 NM_013062.1 
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2.16.2 Gene of reference optimisation 
To guarantee the quality and reliability of the experiments, the expression of a gene of 
interest is compared to the expression of a gene of reference. The choice of gene of 
reference is usually based on a gene that is expressed at a constant level in all experimental 
conditions (Arya et al., 2005). All cDNA samples were run to determine adequate internal 
control, this way allowing correcting for variability related to starting RNA quantity and 
quality, cDNA efficiency and PCR amplification. Ct values for hypoxanyhine-guanine 
phosphoribosyltransferase (Hrpt1), glyceraldehyde 3-phosphate dehydrogenase (Gapdh), 
beta-actin (Actb), beta-2-microglobulin (B2m) and ubiquitin C (Ubc) genes were compared 
between groups. In Chapter 4 the gene of reference Ubc was selected whereas in Chapter 5 
Hrpt1 was deemed as suitable. 
2.16.2.1 Peri-infarct tissue obtained 7 days post 90 min MCAO 
In Chapter 4, Ubc was deemed the most suitable reference gene due to comparable Ct 
values amongst groups and the lowest S.D. [Sham: 27.2±0.59; MCAO-Vehicle (artificial 
cerebrospinal fluid (aCSF)): 26.55±0.52; MCAO-Ang-(1-7): 26.92±0.49, P>0.05] (Figure 
2-17A). There were no differences between groups for Hrpt1; Gapdh and Actb; however, 
these displayed higher S.D. amongst groups compared to Ubc (Figure 2-17B:D). B2m 
showed statistically significant Ct values between groups and excluded as a potential 
internal control (Figure 2-17E). 
 
2.16.2.2 Peri-infarct tissue obtained 24 hrs post 90 min MCAO 
In Chapter 5, Hrpt1 was deemed as the most suitable reference gene due to no significant 
differences and comparable S.D. between groups [Sham: 27.22 ± 0.3; MCAO-Vehicle 
(aCSF):26.91 ± 0.47; MCAO-Ang-(1-7): 26.71 ± 0.32; P>0.05] (Figure 2-18A). ANOVA’s 
Bartlett’s test indicated that S.D. was statistically different between groups for Gapdh 
(P=0.02) and therefore, its use was overruled (Figure 2-18B). Actb, B2m and Ubc showed 
statistical differences amongst groups and were deemed as inadequate reference genes 
(Figures 2-18C:E). 
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Figure 2-17 Reference gene candidates assessed in peri-infarct regions at 7 days post 
MCAO. A) Ubc; B) Hrpt1; C) Gapdh; D) Actb and E) B2m. Data from individual animals are 
presented as cyclic threshold (Ct) values. Horizontal bar represents mean. Data were analysed 
using one-way ANOVA with Tukey’s post-hoc test, P<0.05 was deemed as significant. *P<0.05 
compared to Sham. 
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Figure 2-18 Reference gene candidates assessed in peri-infarct regions at 24 hrs post 
MCAO. A) Hrpt1; B) Gapdh; C) Actb; D) B2m and E) Ubc. Data from individual animals are 
presented as cyclic threshold (Ct) values. Horizontal bar represents mean. Data were analysed 
using one-way ANOVA with Tukey’s post-hoc test, P<0.05 was deemed as significant. *P<0.05 
compared to Sham. 
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2.16.3 qRT-PCR analysis 
There are two methods to investigate qRT-PCR data, the absolute quantification method 
and the relative quantification method. The former is a useful analytical method when 
wanting to determine the starting copy number whereas the latter method is used to 
compare expression levels to a control sample. The relative quantification method does not 
require standard curves from serial dilutions of template in each experiment and the most 
common form of analysis follows the Livak method (Livak and Schmittgen, 2001). The 
Livak method presents the data in 2-Ct where Ct is the difference between gene of 
interest and gene of reference and Ct the difference between the average Ct of a 
treatment group and the average Ct for the healthy tissue group, the latter conventionally 
set as 0 (Schmittgen & Livak, 2008). When expressing the data as 2-Ct, Ct values 
obtained from the exponential curve are being converted to the linear form. Although there 
are some reports that indicate the data is normally distributed in the linear form (Livak and 
Schmittgen, 2001; Schmittgen and Livak, 2008), Ct values measure the number of cycles 
required to detect the gene of interest. Therefore, the first assumption is that Ct values are 
normally distributed. In addition, when converting data to the linear form, the results are 
often skewed presenting exaggerated error bars – an indication of non-normality. All 
statistics were performed in Ct format throughout our studies and presented as such. 
Data were presented as a scatter plot in the Ct format. Since Ct values indicate opposite 
expression directions, meaning that the higher the Ct the lower the expression of the gene 
and vice-versa, data was calculated in -Ct so that the values show the correct trend of 
expression using the following formula: 
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2.17 Data presentation and statistical analysis 
Data are shown as mean ± S.D. or median ± interquartile range (IQR) where applicable. 
Infarct volume (mm3), % infarct volume change, systolic BP (mmHg), IBA1+ microglia 
number/phenotype and qRT-PCR data were compared using unpaired Student’s t-test (2 
groups). If normality failed, data were compared using non-parametric Mann-Whitney (2 
groups) or Kruskal-Wallis (more than 2 groups) test. Data compared within groups were 
analysed using paired Student’s t test. Neurological score was compared using non-
parametric Kruskal-Wallis or Mann-Whitney test. Correlations were performed using 
Pearson correlation coefficient (r) or Spearman correlation where normality failed. For data 
acquired over time, the summary measure of area under the curve (AUC) was determined 
for each animal and group means compared with unpaired Student’s t-test. It is described 
by Matthews et al. (1990) that the summary measures of repeated data measurements is an 
adequate method to statistically analyse serially acquired data as it uses the entire data time 
to summarise an individual response (Matthews et al., 1990).  
In Chapters 4, 5 and 6 a power calculation was performed to determine the minimum 
required group size for in vivo experiments. For all power calculations, a power of 80% 
and significance level of 5% was used. The means and S.D. selected were based on 
previous studies. All data was presented as a scatter-plot and analysed using Graphpad 
Prism 5 software (GraphPad Software, California, UK). P<0.05 was deemed as significant.
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Chapter 3: Experimental model 
optimisation and exploratory therapeutic 
studies with an ACE2 activator following 
transient MCAO 
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Chapter 3  
3.1 Introduction 
In this Chapter, experiments were conducted to optimise the performance of permanent 
and transient MCAO in rats. The objective was to tackle experimental challenges observed 
in animal models of stroke as well as optimise drug delivery methods. A first study was 
performed to assess the most suitable rat strain to use in future therapeutic studies. In 
addition, a second study was conducted to determine whether systemic therapy delivery is 
suitable to target the brain RAS following transient MCAO. Simultaneously, Laser 
Doppler Flowmetry (LDF) was examined as a potential infarct outcome prediction tool to 
use in subsequent studies.  
In humans, 70% of all infarcts occur  in the territory of the MCA and its branches 
(Bogousslavsky et al., 1988). For this reason, MCAO models are widely used to study 
ischaemic stroke in the preclinical setting. The intraluminal filament model is suitable to 
performed mechanistic studies and is widely  used to assess therapeutic effects on final 
infarct volume outcome (Macrae, 1992). One of the advantages of this model is that it 
induces a focal infarction within the MCA territory in rats, mimicking human ischaemic 
stroke (Garcia et al., 1995). Another advantage is that it allows the studying of permanent 
MCAO and transient MCAO as the filament may be left in place in the MCA or removed, 
respectively. In particular, transient MCAO is of clinical relevance since the primary 
objective of stroke treatment is to recanalise the occluded vessel by administering alteplase 
or through endovascular thrombectomy procedures. The latter is becoming a widely used 
method due to its extended therapeutic window and effectiveness in treating proximal 
occlusions (Tawil and Muir, 2017). Similar to endovascular thrombectomy, the 
intraluminal filament transient MCAO model induces sudden reperfusion and therefore is a 
suitable model to investigate adjuvant neuroprotective agents (Sutherland et al., 2016).  
Nonetheless, the intraluminal filament model presents some challenges. MCAO leads to 
high lesion volume variability, which tends to present a bimodal form where animals 
exhibit either striatal or striato-cortical lesions. This influences how data are interpreted, 
especially when analysis requires a normal data distribution to test the effect of a 
neuroprotective agent. This variability accounts for the unsuccessful rates in 
neuroprotective strategy development. Therefore, contributing factors must be taken into 
account before conducting neuroprotective studies as outlined by the STAIR guidelines 
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((STAIR), 1999; Howells et al., 2010). One of the contributing variables is the rat strain 
selected. There are several rat strains used in experimental stroke with the Sprague-Dawley 
strain being the most used (Spratt et al., 2006). Sprague-Dawley rats are reported to induce 
the most variable results as these animals have differing MCA anatomy whereas Wistar 
rats are suggested to lead to lower variability as a result of smaller vessel diameter (Fox et 
al., 1993; Kim et al., 2009; Spratt et al., 2006; Ström et al., 2013). Yet, these reports are 
controversial since other studies suggest the opposite trend (Markgraf et al., 1993; 
Walberer et al., 2006), thus, further clarification is required. 
Infarct volume outcome prediction tools are one way to tackle model derived infarct 
variability. LDF is extensively used in preclinical stroke to confirm MCAO and ensure 
adequate reperfusion following filament retrieval (Ansari et al., 2011; Reith et al., 1994). 
Due to inter- and intra-vascular variability amongst rats and the filament displacement 
probability during MCAO, LDF use is highly recommended by the STAIR guidelines 
((STAIR), 1999). LDF works by measuring the microvascular blood perfusion and 
determining red blood cell movement within an area of interest (Fredriksson et al., 2007). 
A single frequency of infrared light is applied over the cortical surface with the use of a 
probe. The light is scattered by moving cells, resulting in a frequency shift proportional to 
red cell velocity, providing an arbitrary perfusion unit (AU) of relative cerebral blood flow 
(rCBF) (Dirnagl et al., 1989; Fredriksson et al., 2007). LDF is also reported to successfully 
predict final infarct volume when measuring CBF within the MCAO territory (Riva et al., 
2012; Soriano et al., 1997). For this reason, LDF will be evaluated as a potential tool to 
predict final infarct outcome and accurately assess the impact of therapy. 
The main outcome of this thesis is to study the therapeutic potential of the counter 
regulatory RAS axis following ischaemic stroke. MasR, AT2R agonists and ACE2 
activators are suggested to induce a therapeutic effect in animal models of stroke when 
administered ICV (Joseph et al., 2014; Mecca et al., 2011). Still, ICV administration is 
highly invasive, may increase the risk of local or systemic infections as well as enhance 
ICP (Kateb and Heiss, 2013). The brain RAS is separated from the circulating RAS 
through the BBB, which restricts peripherally derived RAS circulation within the brain 
(Schelling et al., 1976). Consequently, the brain depends on locally produced RAS 
mediators to exert its physiological and pharmacological properties. Nonetheless, the 
existence of CVOs, brain regions lacking BBB, sparked debates on a peripheral RAS 
interaction with the brain (Deschepper et al., 1986; van Thiel et al., 2017) and the 
possibility to therapeutically target the brain systemically.  
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DIZE is a drug safely and widely used to treat animal trypanosomiasis (Kuriakose and 
Uzonna, 2014). In addition to treating trypanosomiasis, DIZE has ACE2 activating 
properties, stimulating the conversion of Ang II into counter-regulatory peptide Ang-(1-7) 
(Gjymishka et al., 2010). DIZE is most effective when administrated SC and shown to be 
safe at doses of 50 mg/kg/day (Raether et al., 1974). Accordingly, its cytoprotective 
properties have been tested and confirmed in animal models of cardiac ischaemia, 
pulmonary hypertension, subtotal nephrectomy and abdominal aortic aneurysms when 
administered SC at 15 mg/kg/day or 30 mg/kg/day doses (Qi et al., 2013; Rigatto et al., 
2013; Thatcher et al., 2014; Velkoska et al., 2015). In an ischaemic stroke model, DIZE 
ICV therapy starting 4 days prior to ET-1 induced MCAO significantly decreased infarcted 
grey area and improved neurological outcome at 3 days post injury (Mecca et al., 2011); 
however, its systemically induced neuroprotection has not yet been tested. On the contrary 
to Ang-(1-7), which has a half-life of approximately 10 sec, DIZE has a half-life of 
approximately 5 hrs (Miller et al., 2005; Yamada et al., 1998). Moreover, there is extensive 
toxicology knowledge regarding DIZE and high SC doses have been shown to be effective 
and safe in rats. Therefore, this drug was selected to test systemic brain RAS targeting by 
examining its effects on infarct volume following stroke. 
3.1.1 Aims 
Study 1: To determine variability in infarct volume following permanent MCAO in 
different rat strains. 
Study 2: To determine the effect of systemic administration of the ACE2 activator (DIZE) 
on infarct volume following transient MCAO. 
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3.2 Materials and methods 
Study 1: To determine variability in infarct volume 
following permanent MCAO in different strains of rat. 
3.2.1 Randomisation, blinding and exclusion 
A total of 20 adult male rats weighing between 315-395g were used, 10 Wistar and 10 
Sprague Dawley. Animals were randomly assigned to surgery day using an online 
randomisation generator (www.random.org). Animals that failed to show visual indications 
of infarct on 2,3,5-Triphenyl-2H-tetrazolium chloride (TTC) stained sections or that died 
during surgery were excluded. An independent researcher was responsible for collecting 
the rats on day of surgery and the surgeon was blinded to strain. 
3.2.2 Animal preparation and surgical procedures 
Wistar (n=9) and Sprague-Dawley (n=8) rats obtained from Charles River were 
anaesthetised and surgically intubated (Chapter 2.5.2). Throughout the experiment, 
isoflurane levels were maintained at 2.5% in a 30:70% O2-N2O mixture. The femoral 
artery was cannulated (Chapter 2.6) to record MABP and measure PaO2, PaCO2 and pH 
prior to and 1, 2, 3 and 4 hrs post-permanent MCAO. Temperature was monitored through 
a rectal probe and maintained at 37±0.5ºC. Permanent MCAO was induced as previously 
described (Chapter 2.8). A silicone coated Doccol filament was advanced along the 
internal carotid artery until the MCA was blocked. The filament was secured in place and 
MCAO was carried out for a period of 4 hrs. Animals were then deeply anaesthetised with 
5% isoflurane, killed by Schedule 1 procedure and decapitated for whole brain removal.  
3.2.3 Infarct volume determination 
Whole brain tissue was quickly placed in a container at -20ºC for a period of 20 min prior 
to coronal section slicing. Brains were then placed in a rat brain matrix (World Precision 
Instruments, UK) and microtome blades (Feather, Japan) used to obtain 6 sections of 2 mm 
thickness. TTC was used to stain viable brain tissue and determine the infarct. TTC is a 
colourless and water-soluble salt that in the presence of functioning mitochondria is 
oxidised to a lipid soluble bright red formazan by dehydrogenases (Zille et al., 2012). In 
undamaged tissue, TTC stains a deep red whereas infarcted tissueareas display a white 
colour (Figure 3-1). TTC (Sigma-Aldrich, Switzerland) was made up to a 2% (w/v) 
95 
 
solution dissolved in phosphate buffered saline pre-warmed to 37ºC. Coronal sections were 
placed in the 2% TTC solution and left to stain for 15 min until formazan products were 
visually formed. Fully stained sections were then removed from 2% TTC and placed in 4% 
PAM to be fixed overnight prior to imaging.  
 
Figure 3-1 Representative image of TTC staining following 4 hrs of permanent MCAO. Image 
depicts coronal level three with red areas representing viable cerebral tissue and the areas 
delineated in white depicting the infarcted tissue. 
 
 
TTC stained sections were imaged with the use of a digital camera (Canon, UK) and a 
graticule (Imaging Research Inc., Canada) for calibration. Total infarct volume was 
determined by manually delineating the infarct present on all coronal slices, on both sides, 
using Image J software. For each coronal slice, the infarct area was measured on both faces 
of the slice, averaged and summed. Infarct volume was determined by summing the infarct 
areas and then multiplying by the slice thickness, 2 mm. Infarct volume was not corrected 
for hemisphere oedema since at the particular time point chosen (4 hrs post  permanent 
MCAO) there was no significant brain oedema present as previously reported (Slivka et 
al., 1995). 
3.2.4 Statistical analysis 
Physiological parameters were compared between rat strains using AUC and the means 
analysed with unpaired Student’s t-test or Mann-Whitney test where normality failed. 
Infarct volume was compared using unpaired Student’s t-test. Data were expressed as 
mean ± S.D. and considered statistically significant when P<0.05. Infarct volume data were 
shown as a scatterplot with the mean indicated in a horizontal bar. All brain images show 
the median animal for each group. 
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Study 2: To determine the effect of systemic 
administration of the ACE2 activator (DIZE) on infarct 
volume following transient MCAO 
3.2.5 Blinding, randomisation and exclusions 
Animals were assigned to treatment using a random list generator (www.random.org). Rats 
were given a number and randomly allocated to receive either Vehicle [distilled water 
(dH2O)]; DIZE (15 mg/kg/day) or DIZE (30 mg/kg/day). The randomisation schedule was 
kept with 2 colleagues not involved with the study. Four days prior to MCAO, drug was 
prepared by an independent investigator. Thoroughout the experiment, surgeon (MA) was 
blinded to treatment allocation, with treatment schedule being disclosed following infarct 
volume analysis. Rats that died before the end of experimental protocol or showed no signs 
of infarction on MRI-T2 images were excluded from analysis.  
3.2.6 Animals and surgical procedures 
A total of 24 male Wistar rats weighing between 295-345g and purchased from Charles 
River were used in this study; Vehicle (dH2O) n=9;  DIZE (15 mg/kg/day) n=7; or DIZE 
(30  mg/kg/day) n=8. All animals were subjected to MCAO for a period of 90 min 
followed by 3 days reperfusion. Rats were treated SC with distilled water (dH2O) or DIZE 
(15 mg/kg/day or 30 mg/kg/day) via osmotic pump infusion for a period of 7 days starting 
4 days prior to MCAO. Osmotic pumps (ALZET, Model 2ML1) were implanted as 
described in Chapter 2.7.2. All animals underwent conscious systolic BP measurement and 
Garcia neurological score prior to therapy and MCAO and at 3 days post MCAO (Chapter 
2.7 & Chapter 2.8, respectively). On day of surgery, rats were anaesthetised with 5% 
isoflurane and orally intubated (Chapter 2.5.2). Once the animal was stable, isoflurane 
levels were maintained at 2.5% delivering a continuous dose of 30:70% O2-N2O mixtures. 
MCAO was induced for a period of 90 min, as previously described in detail (Chapter 2.8). 
After 90 min ischaemia, the filament was slowly removed for initiation of reperfusion and 
rats were recovered for a period of 3 days (Chapter 2.8.1 and Chapter 2.8.2). 
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3.2.7 Laser Doppler Flowmetry  
Laser Doppler Flowmetry (LDF) was used to confirm successful MCAO/reperfusion and 
investigated as a prediction tool to evaluate final infarct volume. A multi-channel 
microvascular perfusion monitor OxyFlo 2000TM (Oxford Optronix, Oxford, UK) 
connected to an OxyFlo probe (needle shaped, 10 mm length and 1 mm diameter) (Figure 
3-2A) was used to measure rCBF during MCAO and post reperfusion. 
The scalp was shaved using electric hair clippers and the animal quickly placed in the 
stereotaxic frame to place the LDF probe over the appropriate region of the skull. The rat’s 
head was secured with tooth and ear bars and viscotears applied in the animal’s eyes to 
prevent drying. An incision was performed in the skin overlying the skull with the use of a 
scalpel and the underlying fascia gently cleared to expose the skull surface and the left 
ridge. To prevent skull bleeding, pressure was applied with the use of a cotton bud. If 
excessive bleeding from the scalp continued persistently, 10% perchloric acid dissolved in 
dH2O (Sigma Aldrich, UK) was applied with a cotton bud to stop the bleeding and then 
cleared with sterile saline. CBF was measured within the MCA territory at 1.3 mm 
posterior and 4.0 mm lateral from bregma (Soriano et al., 1997). Bregma was identified 
and served as a guide to position the stereotaxic needle over the area of interest, outlined 
with a marker pen. Next, a burr hole was drilled through the skull to reduce the bone 
thickness in the area of interest, to maximise the LDF signal. A probe holder of 10 mm 
diameter (Oxford Optronix Ltd, Oxford, UK) (Figure 3-2B) was glued around the area of 
interest with extreme care. Conductive electrode gel (Electrode gel, Biopac Systems, UK) 
was applied with a syringe in the measurement area to aid signal detection. The animal was 
then removed from the stereotaxic frame and placed on a modified corkboard, with the 
LDF probe inserted through the corkboard and placed in the probe holder glued to the 
skull. The laser was then turned on to start measuring CBF in the MCA territory. 
Following 90 min of MCAO, the filament was removed and successful reperfusion 
confirmed by an increase in LDF signal for a period of 5 min. The laser was then turned 
off and the probe and probe holder removed. Figure 3-2C shows a representative image of 
an animal subjected to LDF imaging. 
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Figure 3-2 The Laser Doppler Flowmetry set up. A) LDF probe needle (10 mm length and 1 
mm diameter); B) LDF probe connected to the probe holder used to measure CBF in the MCA 
territory. C) Representative image of an animal subjected to LDF imaging. 
 
3.2.7.1 LDF analysis 
Data were analysed using Acknowledge Biopac software (Biopac Systems Inc, USA). LDF 
values were obtained for a period of 100 min (6000 sec) and presented as raw data to 
examine the real time changes in LDF for each individual animal.  
To assess mean LDF signal across the treatment groups, data were presented as mean 
percentage (%) change in LDF compared to the 2 min baseline prior to MCAO. To 
compare % rCBF decrease at MCAO between groups, data were presented as % signal 
change at MCAO (filament insertion) - from 1 min baseline to 1 min MCAO - for each 
individual animal. Similarly, % rCBF change at reperfusion (upon filament removal) - 
from 90 min MCAO to 1 min reperfusion - was shown for all animals and compared 
between groups. Changes in rCBF during MCAO were calculated as % signal change from 
1 min to 90 min MCAO. 
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3.2.8 Magnetic Resonance Imaging  
Three days post reperfusion, rats were anaesthetised, transferred to the MRI scanner and 
placed in a rat cradle where the head was restrained with ear and tooth bars. Once a pilot 
sequence had been obtained to ensure correct geometry, a RARE T2 weighted sequence 
was performedas outlined in Chapter 2.9.2. Following MRI scanning, animals were 
anaesthetised with 5% isoflurane and Schedule 1 procedures performed. Final infarct size 
was calculated by manually delineating hyperintense regions on T2-weighted images as 
described in Chapter 2.9.2 and data corrected for hemispheric swelling.  
3.2.9 Statistical analysis 
Infarct volume and systolic BP were compared between groups using one-way ANOVA. 
Neurological score was analysed using Kruskal-Wallis test and presented as median ± 
IQR. % rCBF change at the time of MCAO and reperfusion as well as during MCAO were 
analysed between groups using one-way ANOVA or Kruskal-Wallis test where normality 
failed. Correlations between LDF data and final infarct volume were analysed using 
Pearson correlation or Spearman non-parametric correlation where normality failed. Data 
were expressed as mean ± S.D. and considered statistically significant when P<0.05. 
Graphs are presented as a scatterplot with the mean or median indicated as a horizontal bar. 
All brain images show the median animal for each group. 
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3.3 Results 
Study 1: To determine variability in infarct volume 
following permanent MCAO in different strains of rat. 
3.3.1 Mortality and exclusions 
There was no mortality in this experiment. In terms of exclusions, two Sprague-Dawley 
rats and one Wistar rat were excluded due to lack of infarct on TTC stained sections at 4 
hrs post-permanent MCAO. 
3.3.2 Wistar rats exhibited significantly larger ischaemic lesions 
than Sprague-Dawley animals 
Wistar rats showed significantly larger lesions when compared to Sprague-Dawley animals 
[215.9±84.5mm3 vs 107.9±107.9mm3 (P=0.04)], (Figure 3-3A). In both groups, infarct 
volume displayed high variability ranging between 115.4 - 397.9mm3 in Wistar and 26.7- 
299.2mm3 in Sprague-Dawley rats. However, Sprague-Dawley rats exhibited a tendency to 
generate smaller infarcts as three animals had small subcortical infarcts of 32.5mm3, 
32.7mm3 and 26.7mm3. Figure 3-3B illustrates infarct volume spatial distribution in the 
representative median animal for each group. 
3.3.3 No differences in physiological parameters between strains 
Physiological parameters were measured and maintained within physiological range across 
groups (Figure 3-4). There were no differences in MABP between groups during the 
course of the experiment with a trend for MABP to decrease from 2 hrs post-MCAO until 
the end of the experiment (P>0.05) (Figure 3-4A). Temperature, pH and PaCO2 were 
maintained within range for all rats without differences between groups (P>0.05) (Figures 
3-4B:D). For all animals, PaO2 was higher than reference ranges (80-100mmHg), 
explained by the continuous administration of 30:70 ratio of O2 and N2O.  Sprague-Dawley 
animals exhibited slightly higher values than Wistar; however, Mann Whitney analysis of 
AUC means showed no differences between groups (P>0.05), highlighted by a substantial 
variability particularly observed in the Sprague-Dawley group (Figure 3-4E).  
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Figure 3-3 Infarct volume data at 4 hrs permanent MCAO. A) Infarct lesion comparison 
between Sprague-Dawley (n=8) and Wistar rats (n=9). Lesions were significantly smaller in 
Sprague-Dawley animals when compared to Wistar rats (P=0.04). B) Spatial distribution of 
infarct size between groups. Images depict the median animal in the Sprague-Dawley and Wistar 
strain groups across 6 coronal sections. For each animal, the infarct is highlighted in white. Data 
were analysed using unpaired Student’s t test, P<0.05 was considered statistically significant. 
Horizontal bar represents the mean. 
A) 
B) 
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Figure 3-4 Physiological variables during 4 hrs permanent MCAO. A) MABP (mmHg); B) 
Temperature (ºC); C) pH; D) PaCO2 (mmHg); E) PaO2 (mmHg). There were no differences 
between groups for all physiological parameters. Data depict values for Sprague Dawley (n=8) and 
Wistar rats (n=9). Data were analysed using AUC and means compared using unpaired Student’s t 
test for Figures A-D and non parametric Mann-Whitney test for Figure E, P<0.05 was considered 
statistically significant. Data are expressed as mean ± S.D. Reference values for each 
physiological parameter are shown in the figure. 
 
 
103 
 
Study 2: To determine the effect of systemic 
administration of the ACE2 activator (DIZE) on infarct 
volume following transient MCAO 
3.3.4 Mortality and exclusions 
A total of 24 animals were used in this study of which 4 died during recovery: one DIZE 
(30 mg/kg/day), one DIZE (15 mg/kg/day) and two Vehicle (dH2O) treated rats, leading to 
a 16.6% study mortality. In addition, one animal in DIZE (15 mg/kg/day) died during 
surgery. A total of 19 animals were included in this study: 7 Vehicle (dH2O), 5 DIZE (15 
mg/kg/day) and 7 DIZE (30 mg/kg/day). 
3.3.5 DIZE treatment does not influence systolic BP 
There were no differences in conscious systolic BP measurements before and after 90 min 
MCAO between groups (P>0.05) (Figure 3-5A&B). Prior to MCAO and therapy, systolic 
BP values ranged between 81 mmHg and 194 mmHg, thus, some animals had substantially 
higher BP than what is expected in normotensive rats (80-120 mmHg). In the Vehicle 
(dH2O) group, two animals had a BP of 149 mmHg & 178 mmHg. Similarly, in DIZE (15 
mg/kg/day) group, one rat had 160 mmHg while in DIZE (30 mg/kg/day) one animal had a 
BP of 143 mmHg and another 194 mmHg (Figure 3-5A). At day 3 post transient MCAO, 
systolic BP was not different between treatment groups (P>0.05) with BP values ranging 
between 92 mmHg to 197 mmHg (Figure 3-5B). The animals exhibiting high BP were 
visibly stressed during measurements, indicating the need to acclimatise rats to the set up 
for longer periods of time. In addition, systolic BP change from pre to post MCAO showed 
that therapy did not influence BP (P>0.05) (Figure 3-5C). 
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Figure 3-5 Systolic BP. A) 4 days prior to 90 min MCAO and treatment; B) 3 days post 90 min 
MCAO and 7 days of treatment; C) Systolic BP change between pre to post 90 min MCAO 
(absolute values). No differences in systolic BP between groups prior to and post 90 min MCAO 
with therapy (P>0.05). Therapy did not influence systolic BP between pre and post MCAO 
(P>0.05). Data depicts values for Vehicle (dH2O; n=7), DIZE (15 mg/kg/day; n=5) and DIZE (30 
mg/kg/day; n=7). Data were analysed using one-way ANOVA, P<0.05 was considered statistically 
significant. Horizontal bar represents the mean. 
 
3.3.6 DIZE treatment does not impact neurological score 
An 18-point neurological score was performed 4 days prior to and 3 days post transient 
MCAO. Before MCAO, all animals scored a maximum 18 points (Figure 3-6A). As 
expected, MCAO induced a decrease in neurological score in all groups, confirming 
neurological deficit in all animals included (Figure 3-6B). DIZE treatment did not 
influence neurological deficit between groups (P>0.05). However, compared to vehicle 
animals, DIZE treated rats showed a trend to display enhanced neurological deficit.  
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Figure 3-6 Neurological score. A) 4 days prior to 90 min MCAO and treatment; B) 3 days 
post 90 min MCAO and 7 days of treatment. There were no differences in neurological score 
between groups prior to and post 90 min MCAO with therapy. Data depict values for Vehicle 
(dH2O; n=7), DIZE (15 mg/kg/day; n=5) and DIZE (30 mg/kg/day; n=7). Data were analysed using 
Kruskal-Wallis test, P<0.05 was considered statistically significant. Horizontal bar represents the 
median. 
 
3.3.7 DIZE treatment has no effect on infarct volume 
DIZE SC infusion at 15 mg/kg/day and 30 mg/kg/day doses had not effect on final infarct 
volume at 3 days post MCAO compared to control animals (P>0.05) (Figure 3-7). MCAO 
induced small lesions particularly in three animals in the Vehicle (dH2O) group, suggesting 
that these animals had partial MCA occlusions. Similarly, there was high variability in 
lesion sizes observed in DIZE treated groups; however, these groups showed a trend to 
increase final infarct compared to control. Figure 3-8 shows the spatial distribution of final 
infarct for the median animal in each treatment group. 
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Figure 3-7 Final infarct volume 72 hrs post 90 min MCAO. Infarct lesions at 72 hrs post 90 min 
MCAO were comparable between groups (P>0.05). Data depict values for Vehicle (dH2O; n=7), 
DIZE (15 mg/kg/day; n=5) and DIZE (30 mg/kg/day; n=7). Data were analysed using one-way 
ANOVA, P<0.05 was considered statistically significant. Horizontal bar represents the mean. 
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Figure 3-8 Spatial distribution of infarct tissue for Vehicle (dH2O), DIZE (15 mg/kg/day) and DIZE (30 mg/kg/day) treated animals at 72 hrs post 90 min 
MCAO. Coronal sections represent the median animal for each treatment group. Infarct is highlighted in white, blue and purple for Vehicle (dH2O), DIZE (15 mg/kg/day) 
and DIZE (30 mg/kg/day), respectively. 
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3.3.8 Laser Doppler Flowmetry 
As a result of a technical error, LDF data were not obtained for 3 animals in this study, one 
in Vehicle (dH2O) and two in DIZE (30 mg/kg/day) groups. At MCAO, rCBF decreased in 
all animals, which indicates successful MCAO. Following filament removal (reperfusion), 
mean rCBF increased for all groups, suggesting successful CBF re-establishment (Figure 
3-9). Interestingly, during the course of LDF monitoring, DIZE treated animals showed a 
slight trend to present exacerbated % rCBF deficit during MCAO when compared to the 
vehicle group. There was high variability in LDF readings throughout experiments and the 
extent of rCBF change at time of MCAO and reperfusion amongst animals. Figure 3-10 
shows a representative image of successful LDF measurements for Vehicle (dH2O), DIZE 
(15 mg/kg/day) and DIZE (30 mg/kg/day) treatment groups.  
 
Figure 3-9 % rCBF change during LDF assessments per treatment group. MCAO successfully 
decreased mean rCBF for all groups and reperfusion increased mean rCBF after filament removal. 
Data are presented as mean LDF values normalised to 2 min baseline (prior to MCAO, 100%) for 
Vehicle (dH2O; n=6), DIZE (15 mg/kg/day; n=5) and DIZE (30 mg/kg/day; n=5). Data are expressed 
as mean ± S.D. over the course of 100 min. 
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Figure 3-10 Representative image of successful LDF traces. A) Vehicle (dH2O); B) DIZE (15 
mg/kg/day) and C) DIZE (30 mg/kg/day) treated groups. Data are expressed as arbitrary units 
(AU) over 100 min expressed in seconds (sec). The horizontal dotted line represents 90 min 
MCAO. 
 
3.3.8.1 LDF reliably detects MCAO but not reperfusion extent 
LDF successfully detected a drop in % rCBF at the time of MCAO for all rats included in 
the study, with no statistical differences amongst groups; Vehicle (dH2O): -60.9±13.4%, 
DIZE (15 mg/kg/day): -40.1±18.3%, DIZE (30 mg/kg/day): -56.2±15.5% (Figure 3-11A).  
Overall, reperfusion increased mean % rCBF for all groups, Vehicle (dH2O): 
185.2±113.3%, DIZE (15 mg/kg/day): 76.5±45.7%, DIZE (30 mg/kg/day): 191.9±225.0%. 
However, in some animals, rCBF change at reperfusion was relatively small (25.0% in 
DIZE 15 mg/kg/day or 26.9% in DIZE 30 mg/kg/day groups) (Figure 3-11B). Plus, in the 
DIZE (30 mg/kg/day) group, one animal displayed a decrease of 14.9% rCBF at time of 
reperfusion; yet, this rat had a subcortical lesion of 82.2mm3 and survived the whole 
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experiment, suggesting successful reperfusion (Figure 3-12). Therefore, these results 
indicate that LDF does not reliably detect reperfusion extent.  
 
Figure 3-11 % rCBF change at MCAO and at reperfusion.A) % rCBF change at time of MCAO 
compared to baseline. B) % rCBF change at time of reperfusion compared to 90 min MCAO. 
LDF successfully detected a decrease in rCBF at time of MCAO for all animals but not at 
reperfusion. There were no differences between groups in the extent of % rCBF at MCAO and/or 
reperfusion for Vehicle (dH2O; n=6), DIZE (15 mg/kg/day; n=5) and DIZE (30 mg/kg/day; n=5). 
Data were analysed using one-way ANOVA for Figure A and Kruskal-Wallis test for Figure B, 
P<0.05 was considered statistically different. Horizontal bar represents the mean. 
 
 
Figure 3-12 Representative LDF trace that detected afailure of reperfusion onset. LDF failed 
to detect reperfusion onset, exhibiting a 14.9% decrease in rCBF after filament removal in the 
animal presented. The rat survived the experiment and displayed a final infarct volume of 82.2mm3. 
MRI-T2 image shows a representative figure of the final infarct in coronal level 4 at 3 days post 90 
min MCAO. Data are expressed in arbitrary units (AU) over time in seconds (sec). The horizontal 
dotted line represents 90 min MCAO. 
111 
 
3.3.8.2 % rCBF change at MCAO or at reperfusion does not predict final 
infarct volume  
To study whether the level of ischaemia or reperfusion detected by LDF could predict final 
infarct outcome, the % change in CBF at MCAO and at reperfusion were correlated with 
final infarct for each treatment group. LDF change at MCAO did not correlate with final 
infarct; Vehicle (dH2O): r=-0.24 (P=0.65), DIZE (15 mg/kg/day): r=-0.63 (P=0.25), DIZE 
(30 mg/kg/day): r=-0.31 (P=0.61) (Figure 3-13A). Similarly, at reperfusion, the extent of 
% rCBF increase did not correlate with final infarct volume; Vehicle (dH2O): r=0.49 
(P=0.36), DIZE (15 mg/kg/day): r=0.7 (P=0.23), DIZE (30 mg/kg/day): r=-0.4 (P=0.5), 
(Figure 3-13B).  
 
Figure 3-13 Correlation between % rCBF change at MCAO/reperfusion and final infarct 
volume. A) % rCBF decrease at MCAO vs infarct volume (mm3) LDF data did not correlate with 
final infarct for each group (P>0.05). B) % rCBF change at reperfusion vs infarct volume (mm3). 
LDF data did not correlate with final infarct for each group (P>0.05). Graphs show values for 
Vehicle (dH2O; n=6), DIZE (15 mg/kg/day; n=5) and DIZE (30 mg/kg/day; n=5) treatment groups. 
The vertical dotted line marks 0% rCBF change. Data were analysing using Pearson parametric 
correlation for Figure A and Spearman non-parametric correlation for Figure B, P<0.05 was 
considered statistically significant. 
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3.3.8.3 % rCBF change during MCAO does not predict infarct volume 
Throughout the experiments, it was noticed that there was a recovery in perfusion signal 
during MCAO for all groups; Vehicle (dH2O): 147.4±180.4%, DIZE (15 mg/kg/day): 
38.2±25.3%, DIZE (30 mg/kg/day): 83.1±76.5% (Figure 3-14A). An increase in rCBF 
over time could be an indication of early reperfusion or collateral supply recruitment and 
therefore, smaller lesions. When correlating % rCBF change during MCAO with final 
infarct volume, improving flow during MCAO did not predict smaller lesions; Vehicle 
(dH2O): r=-0.2 (P=0.71), DIZE (15 mg/kg/day): r=-0.4 (P=0.52), DIZE (30 mg/kg/day): 
r=-0.5 (P=0.45), (Figure 3-14B). Figure 3-15C illustrates the LDF traces for the median 
animals in the Vehicle (dH2O), DIZE (15 mg/kg/day) and DIZE (30 mg/kg/day) groups. 
The animals displayed ischaemic lesions of 20.2mm3, 122.9mm3and 132.3mm3, 
respectively. 
 
Figure 3-14 % rCBF change during MCAO and correlation with final infarct volume. A) % 
rCBF change during MCAO; B) Correlation between % rCBF change during MCAO and 
infarct volume (mm3). % rCBF increase during MCAO did not differ amongst groups (P>0.05). 
Additionally, data did not correlate with final infarct for each group (P>0.05). Graphs show values 
for Vehicle (dH2O; n=6), DIZE (15 mg/kg/day; n=5) and DIZE (30 mg/kg/day; n=5) treatment 
groups. The vertical dotted line marks 0% rCBF change. Data were analysed using Kruskal-Wallis 
non-parametric test for Figure A and non-parametric Spearman correlation for Figure B, P<0.05 
was considered statistically significant. 
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Figure 3-15 Representative LDF traces displaying % rCBF changes during MCAO. A) Vehicle 
(dH2O); B) DIZE (15 mg/kg/day) and C) DIZE (30 mg/kg/day). Corresponding MRI-T2 image 
represents infarct volume in coronal level 4 for each animal. Data are expressed as arbitrary units 
(AU) over time in seconds (sec). LDF traces correspond to the median animal in each group. The 
horizontal dotted line represents 90 min MCAO. 
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3.3.8.4 LDF predicts haemorrhage following MCAO 
In the present study, 3 rats died overnight due to SAH. In these animals, it was noticed that 
following filament removal to induce reperfusion, there was an abrupt decrease in LDF 
signal (Figure 3-16). For all animals, the filament was readjusted during MCAO. In two 
out of the three animals, the filament was readjusted following a steep increase in rCBF 
during MCAO, a possible indication of partial occlusion (Figure 16A & C). In another rat, 
the filament was readjusted to ensure correct positioning (Figure 16B), which may have led 
to accidentally induced SAH. These data show that LDF predicts haemorrhage. 
 
Figure 3-16 Representative LDF traces for SAH mortality cohort. A) Vehicle (dH2O); B) DIZE 
(15 mg/kg/day) and C) DIZE (30 mg/kg/day). In all SAH mortality animals, the filament was 
adjusted during MCAO (highlighted in red) and at time of reperfusion, LDF traces steeply 
decreased without recovery, an indication of haemorrhage. Data are expressed in arbitrary units 
(AU) over time in seconds (sec). The horizontal dotted line represents 90 min MCAO. 
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3.4 Discussion 
Infarct size variability is a problem that burdens the entire experimental stroke field as it 
leads to a higher number of animals needed to obtain a suitable statistical power. The 
intraluminal filament MCAO is the most widely used animal model. Despite being 
considered less invasive than other models as it does not require craniotomy, it leads to 
variable ischaemic lesions. Several factors account for the variability of ischaemic lesions 
such as rat strain. In our study, lesion volume outcome was compared between Wistar and 
Sprague-Dawley rats where it was observed that Wistar rats displayed significantly larger 
and less variable lesions than Sprague-Dawley rats following 4 hrs permanent MCAO. In 
this thesis, the main outcome is to study the potential of RAS counter-regulatory axis 
enhancement as an adjuvant therapy along with reperfusion in ischaemic stroke. Following 
the determination of the most suitable rat strain to be used, Study 2 had the objective to 
optimise the performance of transient MCAO. Moreover, it investigated the potential of 
systemic drug delivery to target the brain RAS and the use of LDF as a possible infarct 
volume prediction method for future experiments. Systemic administration of the ACE2 
activator, DIZE, did not significantly alter infarct volume, neurological outcome or systolic 
BP. In addition, it was determined that LDF is an unreliable and challenging technique 
unable to predict infarct volume from the severity of the initial ischaemic insult.  
3.4.1 Wistar rats showed significantly larger lesions following 4 
hrs permanent MCAO than Sprague-Dawley animals 
Wistar rats subjected to 4 hrs permanent MCAO displayed significantly larger ischaemic 
lesions than Sprague-Dawley animals. To guarantee that the infarct volumes obtained were 
due to MCA occlusion only, MABP and blood gases were assessed prior to and during 
MCAO as these factors may impact collateral blood vessel vasodilation or constriction 
(Anderson and Meyer, 2002; Browning et al., 1997; Shin et al., 2008). Temperature was 
also monitored and maintained to prevent hypothermia, which is neuroprotective in 
ischaemic stroke (van der Worp et al., 2007). Isoflurane delivered by mechanical 
ventilation allows the adjustment of anaesthetic levels, providing some control over 
physiological parameters that could interfere with infarct development (Zausinger et al., 
2002). Consequently, MABP, pH, PaCO2 and temperature were maintained stably amongst 
groups with no significant differences between strains over the course of the experiment. 
Conversely, for all animals, PaO2 levels remained higher than the normal range (100 
mmHg) due to the continuous administration of 70:30% N2O-O2 mixtures. Sprague-
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Dawley animals showed a trend to exhibit higher PaO2 values than Wistar rats; however, 
there were no significant differences between groups.  
Wistar rats are reported to offer larger and less variable ischaemic lesions compared to 
Sprague-Dawley rats  (Kim et al., 2009; Ström et al., 2013). Wistar rats have thinner and 
underdeveloped posterior communicating arteries when compared to Sprague-Dawley rats, 
thus, Wistar animals may be more susceptible to injury (Kim et al., 2009). Moreover, 
Sprague-Dawley rats display at least 6 distinct MCA branching patterns. From a total of 
263 Sprague-Dawley rats obtained from the same supplier, 17% presented atypical MCA 
branching (Fox et al., 1993). This suggests that MCAO extent may be diminished due to 
atypical provision of CBF to the injured site, justifying enhanced infarct variability in this 
strain (Fox et al., 1993). One could argue that the choice of animal model may have 
influenced the results obtained. The permanent model was selected in this study as it does 
not add an extra variable in terms of reperfusion, which could impact result interpretation. 
Plus, it was a means to demonstrate that successful MCAO was induced in my hands. 
Nonetheless, the observations in the study are supported by experiments conducted in 
transient MCAO. Following 90 min, 2 hrs or 4 hrs MCAO with 24 hrs reperfusion, Wistar 
rats present greater and less variable cerebral damage as well as lower mortality rates 
compared to Sprague-Dawley rats (Aspey et al., 2000; Walberer et al., 2006).   
Conversely, Walberer and colleagues identified that following 24 hrs permanent MCAO, 
Sprague-Dawley rats developed significantly larger ischaemic lesion volumes compared to 
Wistar animals (Walberer et al., 2006). Several factors could be implicated in the 
differences observed such as stroke severity and infarct volume measurement method. 
However, the choice of rat vendor is the most likely contributing factor for the discrepancy 
observed. Animal supplier is a known contributing factor for infarct volume variability 
amongst strains (Oliff et al., 1995). In our study, animals were obtained from Charles River 
whereas in Walberer’s study rats were purchased from Harlan. When comparing Sprague-
Dawley ischaemic injury susceptibility in animals obtained from Harlan or Charles River 
Laboratories, Harlan animals presented significantly greater CBF reduction and functional 
deficit following permanent MCAO compared to Charles River rats (Nikolova et al., 
2014). Therefore, supporting the decreased severity observed in Sprague-Dawleys in our 
study. Despite a possible vendor related genetic variability, interstrain differences are 
equally seen when purchasing rats from the same supplier. Following global cerebral 
ischaemia in rats obtained from Charles River, Wistar animals were highly predisposed to 
117 
 
severe neuronal damage whereas Sprague-Dawleys exhibited partial damage only (Fuzik et 
al., 2013), further supporting the findings in our study. 
The debate around rat strains led to a meta-analysis conducted in 2013 with the aim to 
investigate the factors influencing infarct outcome variability. There, 346 articles were 
examined and it was concluded that the Wistar rat strain and silicone coated intraluminal 
filament induce the lowest infarct volume variability and mortality (Ström et al., 2013). 
Most recently, Rewell & Howells concluded that when compared to Wistar Kyoto rats, 
sample size calculations using Sprague-Dawleys lead to extensively higher cohort numbers 
due to lesion variability (Rewell and Howells, 2017). Therefore, the authors deemed the 
Sprague-Dawley rat strain suboptimum for intraluminal filament MCAO model 
experiments.  
3.4.2 DIZE treatment does not influence infarct volume, 
neurological score or systolic BP following transient MCAO 
DIZE administered SC for a period of 7 days, starting 4 days prior to MCAO, had no 
significant impact on ischaemic lesion volume, neurological score or systolic BP compared 
to Vehicle (dH2O). This suggests that systemic administration may not be sufficient to 
target the brain RAS and induce a neuroprotective effect following MCAO and therefore 
implies that ICV administration may be the most adequate delivery method as previously 
observed (Mecca et al., 2011). Our study had various protocol differences compared to 
Mecca’s study. First, the rat strain selected was Wistar opposed to Sprague-Dawley. 
Second, the animal model used was the intraluminal filament method instead of ET-1-
induced MCAO. The pathological mechanisms could differ between models. For instance, 
the filament model is suitable to replicate thrombectomy strategies whereas the ET-1 
induced MCAO may replicate alteplase treatment due to progressive reperfusion induction 
rather than an abrupt CBF reestablishment (Sutherland et al., 2016). Third, in Mecca’s 
study, final infarct was examined with TTC staining whereas in our studies, MRI-T2 was 
selected as the method of infarct determination at 72 hrs. TTC reliably detects infarct areas 
at 24 hrs post MCAO. After this point, inflammatory cells begin to infiltrate the damaged 
area with their mitochondria being also stained with TTC (Liszczak et al., 1984). 
Consequently, aside from differences in the route of administration between the studies, 
factors such as rat strain and stroke model could be implicated in the discrepancies 
observed. 
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DIZE induces a hypotensive effect following systemic and ICV administration in 
hypertension and ischaemic stroke studies (Gjymishka et al., 2010; Mecca et al., 2011). 
This outcome is attributed to an increase in ACE2 activity and subsequent Ang-(1-7) 
generation (Gjymishka et al., 2010; Mecca et al., 2011).  However, in our study, treatment 
did not alter systolic BP compared to control animals. Several animals exhibited a systolic 
BP above the normal range (80-120 mmHg) before and after MCAO and were visibly 
stressed during measurements. Concomitantly, a possible hypotensive effect might have 
been masked, indicating that the acclimatisation period should be extended in future.  
DIZE SC therapy at 15 mg/kg/day and 30 mg/kg/day doses for a period of 7 days were 
selected in these studies. Previously, 15 mg/kg/day SC DIZE attenuated inflammatory 
responses in rat models of myocardial infarction, subtotal nephrectomy and pulmonary 
hypertension (Qi et al., 2013; Rigatto et al., 2013; Velkoska et al., 2015). Simultaneously, 
30 mg/kg/day dose was safely administered in a Ang II induced mice model of abdominal 
aortic aneurysms (Thatcher et al., 2014). To examine a dose response effect and to 
guarantee delivery across the CVOs, higher doses of 15 mg/kg/day and 30 mg/kg/day 
DIZE were selected. Interestingly, DIZE treatment showed a trend to worsen infarct 
volume and neurological outcome when compared to control rats. In fact, treated animals 
were visibly worse during post-operative recovery, exhibiting higher levels of porphyrin 
and less movement. In female rats, DIZE therapy exerts a negative impact on reproductive 
performance, possibly inducing a toxic effect (Oguejiofor et al., 2010). Therefore, it is 
plausible that DIZE might have caused off target effects in our experiments. Nevertheless, 
the results obtained suggest that systemic brain RAS targeting may not be sufficient to 
induce drug circulation in the brain and mediate a neuroprotective effect. In addition, DIZE 
was shown to be unsuitable due to its negative impact in animal wellbeing. In future 
experiments, the therapeutic potential of the counter-regulatory RAS axis will be studied 
via an ICV delivery route using a RAS receptor agonist treatment. 
Most recently, DIZE was tested as a post stroke therapy administered IP at 4 hrs, 1 day and 
2 days after ET-1 induced MCAO in a series of daily doses ranging from 0.75 to 15 mg/kg. 
Infarct volume was determined 3 days post MCAO and it was concluded that 0.75, 2.5 and 
7.5 mg/kg DIZE significantly attenuated infarct volume whereas 15 mg/kg had no effect 
(Bennion et al., 2015). This follow up experiment emphasises that the dose selected was 
suboptimal to induce an effect in the brain whilst highlighting that according to the results 
obtained in this Chapter, ICV administration was a suitable method to be selected. 
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3.4.3 LDF reliably detects MCAO only but not reperfusion extent 
LDF is a reference tool in experimental stroke to confirm proper filament placement. 
During MCAO, there is no visual control of occlusion, thus, partial occlusions, SAH or the 
displacement of the filament are often undetected, with the latter leading to early 
reperfusion (Schmid-Elsaesser et al., 1998). Accordingly, LDF has been indicated as a 
reliable technique when conducted continuously to confirm occlusion and is recommended 
by the STAIR guidelines ((STAIR), 1999; Dirnagl et al., 1989). 
In our study, LDF successfully detected perfusion deficit in the MCA territory upon 
filament insertion in all included animals. Although LDF does not allow discernment 
between full and partial MCAO, it was shown to reliably confirm a reduction in perfusion 
deficit at MCAO start. A recent study investigated LDF as a standardising method to be 
conducted during the intraluminal filament model in rats. There, 4 different surgeons with 
various levels of experience conducted MCAO surgery with or without LDF aid. LDF use 
decreased the coefficient of variance in terms of infarct size by helping identify the 
presence or absence of an occlusion (Taninishi et al., 2015), and thus validating the 
accuracy in MCAO detection at the time of filament placement. In contrast, LDF did not 
reliably detect reperfusion extent. At time of filament removal, LDF detected a small CBF 
increase or reperfusion failure in some animals. Yet, these rats presented mid-sized infarcts 
opposed to large lesions, an indication of successful reperfusion. This could be a reflection 
of probe movement during the experiment or the presence of a haematoma in the area 
assessed; possibly caused by the probe tip. Moreover, it could be an indication that 
reperfusion occurred in brain areas that could not be detected by the LDF probe. Also, 
these animals could have had a surge in reperfusion during anaesthetic recovery and 
subsequent increase in BP. Similarly to our study, an experiment conductedin embolic 
stroke models showed that LDF successfully detected MCAO; however, it did not reliably 
detect reperfusion following tPA treatment (Henninger et al., 2009). There, it was observed 
that LDF failed to detect reperfusion in some animals, which developed small infarcts; 
therefore, supporting our conclusions.   
3.4.4 LDF predicts haemorrhage 
In our study, 3 animals died overnight due to SAH. It was noticed that in these rats, the 
filament had been readjusted during MCAO due to CBF increase or to guarantee the 
filament was adequately secured. SAH occurrence was characterised by a sudden decrease 
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in rCBF following filament retrieval as previously identified (Hungerhuber et al., 2006; 
Woitzik and Schilling, 2002). In the MCA filament model, silicone coated filaments cause 
SAH in 8% of all animals opposed to 30% induced by non-coated filaments (Schmid-
Elsaesser et al., 1998). Although Doccol filaments are less likely to induce SAH than non-
coated filaments, it was noticed that when adjusting the filament, the likelihood of 
haemorrhage increases. This shows that following first time insertion, the vessels become 
sensitive to rupture and one must carefully evaluate whether to readjust the filament or not 
under the circumstances described above. 
3.4.5 LDF does not predict final infarct following transient MCAO 
To examine whether LDF changes could predict final infarct volume, rCBF change at 
MCAO and at reperfusion were correlated with MRI-T2 data. LDF was shown to be an 
unsuitable tool to predict final infarct outcome and tackle the lesion variability observed in 
this animal model. Yet, previous studies contradict our findings where LDF at time of 
MCAO, successfully predicted infarct volume (Riva et al., 2012; Soriano et al., 1997). In 
Soriano et al’s study, the 3-vessel model was used, which is substantially more severe than 
the one used in our experiment. By occluding 3 vessels or more, collateral blood supply 
recruitment becomes impaired, diminishing cortical CBF during ischaemia and offering an 
enhanced and less variable assessment of perfusion deficit (Soriano et al., 1997). 
Accordingly, we show that quickly after filament positioning, there was a recovery in CBF 
during MCAO of various extents amongst animals (Figure 3-14). This gradual increase 
could signify that the filament was not occluding the vessel completely causing early 
reperfusion. However, when correlating the extent of rCBF increase during MCAO with 
final infarct outcome, LDF did not predict smaller lesions. The increase in rCBF is likely 
due to the recruitment of MCA collaterals through the anterior cerebral artery (ACA) and 
the leptomeningeal anastomoses (Liebeskind, 2003; Riva et al., 2012; Woitzik and 
Schilling, 2002).  
Collateral vessel recruitment and grade differs amongst individuals in spatial and temporal 
terms (Liebeskind, 2005). This cannot be reliably detected by LDF as the technique 
provides a single point measurement only; therefore, collateral recruitment and LDF probe 
location may have interfered with result interpretation. Moreover, Riva and colleagues 
showed that following 60 min MCAO in Wistar rats, CBF deficit within the penumbra 
correlates with final infarct (Riva et al. 2012). There, LDF values were obtained at 2 mm 
anterior and 2 mm lateral coordinates from bregma (Riva et al., 2012) whereas the 
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coordinates used in our study were 1.3 mm posterior and 4.0 mm lateral from bregma. It 
could also be argued that the probe position was not optimal, as it could have been placed 
within penumbral tissue in some animals yet within the core in others using the same 
stereotaxic coordinates. 
The extent of % rCBF change during MCAO and reperfusion was highly variable amongst 
animals and technically challenging to perform. For instance, rats have a cortical thickness 
of approximately 2 mm whilst LDF has a sample volume of approximately 1 mm3 and 1 
mm depth only (Zilles 1985). To ensure adequate signal in this LDF set up, the rats’ skull 
has to be drilled until the pial vessels are visualised; thus, drilling differences amongst 
animals has the potential to impact LDF signal and result reliability. In addition, absolute 
flow values are dependent on probe placement and position, with minor changes resulting 
in significant alterations in CBF recording (Dirnagl et al., 1989). As a result, slight changes 
in probe holder positioning due to poor probe holder attachment might have influenced the 
extent of perfusion detection. These variables reflect the technical issues that arise when 
performing LDF in this set up. Therefore, MRI will be used in future to reliably detect 
early ischaemic lesion and final infarct volume using DWI and a MRI-T2 sequence, 
respectively, and MRA will be used to confirm successful MCAO and MCA reperfusion. 
3.4.6 Summary 
In this Chapter, Wistar rats were selected as the most suitable strain for the performance of 
in vivo studies due to the generation of mid-large lesions with lower variability compared 
to Sprague-Dawley rats following permanent MCAO. DIZE SC administration as a pre and 
post-MCAO therapy failed to induce a neuroprotective effect following transient MCAO. 
Instead, DIZE treatment showed a trend to exacerbate ischaemic lesion when compared to 
Vehicle (dH2O) following 7 days of treatment. The results indicate that systemic DIZE 
treatment are not optimal to study the therapeutic potential of the counter-regulatory RAS 
axis following MCAO. LDF successfully detected rCBF reduction at MCAO and predicted 
haemorrhage; however, it failed to detect reperfusion extent and it did not predict final 
infarct outcome. LDF proved to be an unreliable method to tackle infarct variability in this 
animal model. Accordingly, the next Chapters will evaluate the therapeutic potential of the 
counter-regulatory RAS axis in ischaemic stroke as an ICV therapy with RAS receptor 
agonists. To tackle infarct volume variability derived from the intraluminal filament 
model, MRI scanning will be performed to confirm MCAO/reperfusion as well as 
determine initial and final infarct lesion to study the extent of treatment effects. 
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Chapter 4: The effects of Ang-(1-7) and/or 
C21 on the extent of tissue salvage 
following transient MCAO 
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Chapter 4  
4.1 Introduction 
The experiments in this Chapter were designed to assess the therapeutic potential of Ang-
(1-7) (MasR agonist) and C21 (AT2R agonist), either alone or in combination as a potential 
synergistic therapy following transient MCAO. The primary outcome of this study was to 
assess the impact of treatment on the extent of cerebral tissue salvage following 
reperfusion. 
Acute ischaemic stroke is a highly disabling condition resulting from the abrupt loss of 
CBF, leading to neuronal cell death and consequent physical disability (Dirnagl et al., 
1999). Currently, the only non-surgical treatment available is alteplase, which acts to lyse 
the clot/thrombus obstructing the vessel, inducing a transitory reperfusion (Tawil and 
Muir, 2017). However, alteplase has various limitations, for instance, the efficacy and 
safety of treatment is restricted to patients within 4.5 hours of symptom onset and it may 
lead to intracranial haemorrhage (Tawil and Muir, 2017). In addition, it often fails to 
effectively recanalise large vessel occlusions (Tawil and Muir, 2017). In recent years, 
mechanical thrombectomy has been shown to be an effective strategy in ischaemic stroke, 
particularly in large vessel occlusion patients, and with an extended therapeutic window of 
6 hrs from symptom onset (Mayank Goyal et al., 2015). This strategy works by 
mechanically retrieving the obstructing clot/thrombus, inducing an abrupt cerebral 
reperfusion as opposed to the slower restoration of cerebral perfusion achieved by the 
thrombolytic action of alteplase. Although reperfusion reestablishment to the occluded 
vessel is the first line of treatment, it may also exacerbate injury by stimulating leukocyte 
recruitment, inflammation, oxidative stress and BBB breakdown (Horsch et al., 2015; Pan 
et al., 2007; Warach and Latour, 2004). Thus, this new line of therapy has reinvigorated the 
development of neuroprotective adjuvant therapies that could reduce infarct volume 
progression after reperfusion injury.  
The RAS, an endocrine system involved in homeostatic control of blood pressure is linked 
to the pathology of cardiovascular conditions (e.g. hypertension and myocardial infarction) 
through an over activation of the ACE/Ang II/AT1R axis(Dzau, 2001). In ischaemic stroke, 
the ACE/Ang II/AT1R is also suggested to be over-activated in the brain and thought to 
exacerbate cerebral injury by promoting vasoconstriction, oxidative stress and 
inflammation (Walther et al., 2002). Accordingly, several experiments have tested the 
neuroprotective properties of ARBs in experimental stroke where these were shown to 
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reduce the extent of tissue damage and degree of behavioural impairment (Krikov et al., 
2008; Liu et al., 2008; Lou et al., 2004), confirming the involvement of the RAS in 
cerebral pathology. Interestingly, the neuroprotective effects induced by ARBs are 
proposed to be due to an enhancement of the counter-regulatory RAS axis, ACE2/Ang-(1-
7)/MasR, as well as a preferred activation of the Ang II alternative receptor, AT2R. In the 
brain, the AT2R is mainly expressed in foetal tissues; however, following cerebral 
ischaemia it is upregulated in penumbral regions (Iwai et al., 2004). Similarly, MasR, is 
upregulated in the brain and serum following MCAO, peaking at 24 hrs post injury and 
remaining highly expressed at 3 and 7 days post MCAO in rats (Lu et al., 2013). These 
findings have placed the counter-regulatory axis and the AT2R as possible therapeutic 
strategies in cerebral injury. 
AT2R activation in experimental stroke has been shown to reduce infarct volume following 
transient MCAO in both normotensive and SHRs (Joseph et al., 2014; McCarthy et al., 
2009, 2012). In normotensive animals, C21, a highly selective non-peptide AT2R agonist, 
reduced infarct volume when administered as a post IP therapy following intraluminal 
filament transient MCAO. The underlying effect was attributed to an enhanced expression 
of anti-inflammatory cytokine IL-10 and decreased protein levels of iNOS (Alhusban et al. 
2015). The proposed anti-inflammatory effect was further observed in an ET-1 induced 
MCAO model where C21 administered via ICV infusion as a pre- and post-therapy 
decreased infarct volume compared to controls at 72 hrs post injury (Joseph et al., 2014). 
The outcome was attributed to a reduction in cerebral pro-inflammatory markers iNOS and 
CCR2, a macrophage chemotaxic receptor (Joseph et al., 2014). 
Similarly, Ang-(1-7) induced MasR activation counteracts the ACE/Ang II/AT1R axis by 
promoting an anti-inflammatory effect (Jiang et al., 2012; Liu et al., 2016; Mecca et al., 
2011; Regenhardt et al., 2013). When administering Ang-(1-7) ICV 3 days prior to and 4 
days post ET-1 induced MCAO, Ang-(1-7) attenuated infarct size and neurological deficit, 
a result suggested to be due to a reduction in iNOS (Mecca et al., 2011). Furthermore, in 
permanent MCAO models, Ang-(1-7) treatment reduced infarct volume due to a NF-B 
suppression and subsequent inhibition of pro-inflammatory markers IL-1β, IL-6 and COX-
2, therefore, exerting an anti-inflammatory effect (Jiang et al. 2012). It is further 
hypothesised that Ang-(1-7) exerts its effects by directly acting on MasR present on 
microglia and modulating microglia/macrophage cytokine profile from an M1 
(inflammatory) to an M2 (anti-inflammatory) type (Liu et al., 2016; Regenhardt et al., 
2013). For instance, in in vitro experiments, Ang-(1-7) treatment on cultured microglia 
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attenuated NF-B activation, IL-1β and proliferating microglia/macrophage marker CD11b 
expression at basal levels whilst enhancing IL-10 (Liu et al., 2016). In in vivo studies, Ang-
(1-7) pre- and post-treatment in ET-1 induced MCAO, downregulated the gene expression 
of pro-inflammatory M1 markers IL-6 and CD11b in the ipsilateral cortex 24 hrs post 
injury (Regenhardt et al., 2013), emphasising its potential anti-inflammatory actions.  
Given the similarity of activation outcome, increasing evidence postulates that MasR and 
AT2R receptors may dimerise and act synergistically. For instance, in ischaemic stroke, 
PD123319, a AT2R antagonist, blocked the cerebroprotective effects induced by Ang-(1-7) 
following transient MCAO whereas C21-induced neuroprotection was reversed when 
administered in combination with MasR antagonist, A779 (Joseph et al., 2014; Mecca et 
al., 2011). On the contrary, experiments postulate that MasR and AT2R could act as two 
independent protective pathways. In permanent MCAO, Ang-(1-7)-induced infarct size 
decrease was overturned by MasR antagonist, A779, but not when administered in 
combination with AT2R antagonist, PD123319 (Jiang et al., 2012). Additionally, in KO 
mice, AT2R agonism generates a vasodilatory effect in aortic rings in MasR-KO (Lemos et 
al., 2005) whereas in AT2R-KO mice, Ang-(1-7) exerted an hypotensive effect (Gembardt 
et al., 2012). Therefore, there is a need to further elucidate the functional implications of 
simultaneous MasR and AT2R agonism in the context of ischaemic stroke. 
The majority of studies testing the neuroprotective potential of Ang-(1-7) and C21 in 
transient MCAO have been performed by using the ET-1 induced MCAO model, which 
induces a gradual reperfusion as opposed to the abrupt reperfusion observed following 
mechanical thrombectomy procedures (Sutherland et al., 2016). In addition, therapy effects 
on infarct volume have been primarily assessed as a pre and post stroke treatment, 
particularly for Ang-(1-7). In the clinic, it is challenging to anticipate when a patient will 
suffer a stroke. Therefore, there is a need to study the neuroprotective potential of these 
therapies in models that replicate thrombectomy procedures and as a post-injury therapy 
administered during subacute/chronic stages of cerebral injury. Importantly, the synergistic 
neuroprotective potential of MasR and AT2R agonism as a single or combination therapy 
following focal cerebral ischaemia in subacute/chronic stages of injury is yet to be 
determined. Consequently, this study aims to assess the neuroprotective potential of Ang-
(1-7) and/or C21 as a post-stroke therapy for a period of 7 days following transient MCAO.  
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4.1.1 Study Aims 
 Primary outcome: To determine the effect of post-stroke central administration of 
Ang-(1-7) and/or C21 on the extent of tissue salvage following 90 min MCAO with 
7 days reperfusion. 
 To determine the effects of Ang-(1-7) and/or C21 on blood pressure and functional 
outcome following 90 min MCAO. 
 To dissect potential underlying mechanisms via gene expression assessment of 
RAS components, leukocyte chemokine receptors, microglia/macrophage 
phenotype and oxidative stress marker gene expression in ipsilateral peri-infarct 
regions.  
 To qualitatively evaluate microglia total cell count and activated cells in the peri-
infarct regions following treatment. 
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4.2 Methods 
4.2.1 Sample size calculation 
Sample size was assessed using power analysis programme G*Power (version 4.1, 
Germany). An “a priori” power analysis was performed for F test ANOVA, fixed effects, 
one-way. Using data from previous in house studies assessing final infarct volume 
following 90 min MCAO with 7 days reperfusion (mean infarct volume of 170mm3 and a 
S.D. of 67mm3). Ang-(1-7) administered as an ICV infusion was previously demonstrated 
to induce a 50% reduction in % compared to control (Mecca et al., 2011). Similarly, ICV 
C21 infusion leads to approximately 50% reduction infarct size compared to vehicle 
groups (Joseph et al., 2014). Therefore in order to detect an effect size of 50% reduction in 
infarct volume, a minimum n number of 11 for each group with a type I error rate () of 
0.05 and power of 0.80 was demonstrated to be necessary.  
4.2.2 Drug treatment dosage 
Ang-(1-7) ICV infusion dose of 1.1 nmol per 1L/hr dissolved inartificial cerebrospinal 
fluid(aCSF) was selected based on permanent MCAO and ET-1 induced MCAO studies 
(Mecca et al., 2011; Jiang et al., 2012; Jiang et al., 2014; Regendhardt et al., 2013). C21 
was shown to successfully decrease infarct volume in ET-1 induced MCAO models at a 
dose of 7.5 ng/hr in normotensive rats (Joseph et al., 2014) and at 50 ng/hr in hypertensive 
animals (McCarthy et al., 2014). Since higher doses of C21 are suggested to interact with 
AT1R; a 7.5 ng/hr dose was selected as recommended by Vicore Pharma®.  
All animals were treated ICV for a period of 7 days with treatment starting immediately 
following reperfusion with the use of ALZET osmotic pumps delivering treatment at a rate 
of 1L/hr (ALZET®, Model 2001), dissolved in aCSF (ALZET®, CA, USA). Treatment 
groups were as follows: Vehicle [(aCSF); L/hr; n=13)], Ang-(1–7) (1.1 nmol; L/hr; 
n=13), C21 (0.0075 g/hr; L/hr; n=12), Ang-(1-7) + C21 (1.1 nmol Ang-(1-7) + 0.0075 
g/hr of C21; L/hr; n=11). Ang-(1-7) was purchased from Bachem® (Bachem, 
Bubendorf, Switzerland) and C21 was kindly supplied by Vicore Pharma®. One day prior 
to the experiment, osmotic pumps containing allocated treatment were made up and left in 
a water bath at 37ºC until surgery, in order to prime for drug delivery. 
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4.2.3 Randomisation and blinding 
Rats were assigned a number and randomly allocated to treatment groups through a list 
randomiser (www.random.org) and prior to study commencement. Investigators, including 
MA, were blinded to treatment group throughout the experimental study. Treatment 
schedule was kept by a colleague within the department who was responsible for drug 
preparation. Systolic BP and neurological score were performed by a blinded independent 
investigator prior to and post MCAO. Data analysis was performed under a blind fashion 
by two independent investigators. Once all analysis and assessments were conducted, 
treatment codes were revealed.  
4.2.4 Animals, surgical procedures and recovery 
Male Wistar rats (n=102; 300-380g) obtained from Charles River Laboratories were 
subjected to 90 min MCAO followed by 7 days reperfusion using the intraluminal filament 
model. One day prior to MCAO, conscious systolic BP was measured (following 7 days 
acclimatisation period) and neurological score carried out for each rat as previously 
described (Chapter 2.10 - 11). Neurological score was carried out again at day 3 and 7 
reperfusion whereas systolic BP was measured at day 7. On day of surgery, rats were 
anaesthetised with 5% isoflurane and orally intubated for anaesthesia maintenance at 2-
2.5% isoflurane in a 30:70% O2-NO2 mixture (Chapter 2.5). Local anaesthetic (Norapin®; 
1mg/kg) was administered SC in all incision sites. After, animals were placed in a Kopf 
stereotaxic frame for ICV osmotic pump cannula implantation in the right cerebral lateral 
ventricle (Chapter 2.7.2). The animals were then moved to a corkboard and MCAO 
surgerycarried out (Chapter 2.8). The filament size selected was based on individual 
animal weight and according to Doccol Corporation guidelines. Following 90 min MCAO, 
the filament was removed, all the incisions sutured and the animal allowed recovering for a 
period of 7 days. Recovery and post-operative procedures were carried out as defined in 
Chapter 2.8.1 and 2.8.2, respectively.  
4.2.4.1 Sham procedures 
Sham treated animals were anaesthesised as outlined above. A burr hole was drilled in the 
skull and the cannula inserted into the cerebral ventricle and then quickly removed. MCAO 
surgery was performed; however, the Doccol filament was introduced into the vessel 
without occluding the MCA. Anaesthesia was maintained for the same period of time as 
MCAO animals. Recovery protocol procedeed as described for a period of 7 days.  
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4.2.5 MRI scanning protocol 
At the start of MCAO rats were immediately transferred to the MRI scanner and placed in 
a rat cradle where the head was restrained with tooth and ear bars and the surface coil 
placed above the head. The intubation tube was reconnected and a rectal probe along with 
a homeothermic blanket placed on the animal to maintain anaesthesia and regulate body 
temperature. Three distinct scans were performed during MCAO: DWI, MRA and RARE 
T2 weighted MRI (Chapter 2.9). DWI was performed at 30 and 60 min MCAO and ADC 
maps generated to detect initial MCAO lesion prior to therapy. MRA was conducted to 
confirm successful MCAO and correct ICV cannula placement confirmed using RARE T2 
weighted MRI.  
The imaging protocol was then repeated following 7 days of reperfusion and recovery. 
Rats were initially anaesthesised, placed in the scanner and anaesthesia maintained using a 
facemask. Final infarct volume was determined by a RARE T2 weighted MRI. MRA was 
performed to confirm reperfusion of the left MCA. At the end of the MRI scanning, rats 
were killed and brains removed for either molecular or immunohistochemical assessments 
(Chapter 2.12:16). Figure 4-1 provides an overview of the experimental protocol 
conducted. 
4.2.5.1 MRI data analysis 
Data analysis for DWI and T2 MRI scanning was performed as described in detail in 
Chapter 2. Initial ischaemic lesion at 30 and 60 min MCAO was assessed by generating 
ADC maps (using Paravision v5 software) for each of the 8 coronal slices images obtained 
following DWI scanning. ADC maps were processed using ImageJ and initial lesion 
volume was calculated by applying a threshold between 0.01 and 0.58×10-3mm2/sec 
(Chapter 2.9.1). RARE T2 scans were used to determine final infarct volume at 7 days post 
90 min MCAO. Image J was used to delineate hypertintense regions across the 16 coronal 
sections in order to calculate infarct area on each slice. Contralateral and ipsilateral 
hemisphere volumes were also calculated across the 16 coronal slices (Chapter 2.9.2).  
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4.2.6 Post-mortem assessments 
Total RNA was extracted from peri-infarct ipsilateral brain regions for sham (n=7), 
MCAO-aCSF (n=9) and MCAO-Ang-(1-7) (n=9) treated animals (Chapter 2.14) and 
cDNA generated from the total extracted RNA by RT-PCR (Chapter 2.15). qRT-PCR was 
performed and the genes outlined in Chapter 2.16.1 assessed. Results were analysed by 
taking the means of the technical duplicates and then normalising to theinternal control 
selected, UBC. Data analysis was conducted as described in Chapter 2.16.3. 
Vehicle (aCSF) (n=2), Ang-(1-7) (n=2), C21 (n=2) and Ang-(1-7) + C21 (n=2) treated 
animals were subjected to perfusion fixation and paraffin embedding/sectioning (Chapter 
2.12.2). To identify the peri-infarct, core and contralateral regions, histological analysis 
was carried out (Chapter 2.13.1). Briefly, brain sections from coronal levels 3 to 5, which 
correspond to the core of the MCA territory, were selected and stained with H&E and 
analysed under light microscopy at 40x. Adjacent sections were then selected and 
immunohistochemistry for microglia marker IBA1 was conducted (Chapter 2.13.2). Three 
distinct ROIs were defined within the peri-infarct area on each level and a homotopic ROI 
within the contralateral hemispherewas chosen as a control non-ischaemic area. Sections 
were imaged at 40x under fluorescent microscopy. IBA1+ microglia werecounted using 
Image J and expressed as number/mm2 in peri-infarct and contralateral regions across the 3 
coronal levels selected. In addition, cells were differentiated into activated and resting, % 
activated microglia were presented as % from total cell count for each animal.  
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4.2.7 Exclusion criteria 
The exclusion criteria were applied at the end of the study by three independent researchers 
that were blind to treatment allocation. Before the start of the study exclusion criteria was 
established and animals excluded if presenting the following characteristics:  
 Left MCA not fully occluded at 60 min MCAO or not fully reperfused at day 7 as 
identified by MRA.  
 Cannula for drug delivery not within the cerebral ventricle at day 7 as shown by 
MRI-T2. 
  ICH of the MCA at day 7 reperfusion as shown by MRI-T2.  
 Animals that died or were sacrificed prior to 7 days recovery. 
4.2.8 Statistical analysis 
Ischaemic lesion at 30 min, 60 min MCAO and final infarct at 7 days post MCAO were 
compared between treatment groups using one-way ANOVA. To determine treatment 
effects, percentage (%) and absolute change in ischaemic lesion from 60 min MCAO and 7 
days post MCAO were calculated and compared between groups using one-way ANOVA 
with Tukey’s posthoc test. Systolic BP data were compared using one-way ANOVA. 
Neurological score data were compared between groups using the non-parametric Kruskal-
Wallis test. Absolute ischaemic lesion change from 60 min MCAO to 7 days reperfusion 
within groups was analysing using paired Student’s t test.  
Gene expression data were compared between Sham, MCAO-Vehicle (aCSF) and MCAO-
Ang-(1-7) groups using one-way ANOVA and shown as -Ct normalised to Ubc. For 
immunohistochemistry data, total IBA1+ microglia number and % activated cells were 
presented for peri-infarct ipsilateral and homotopic contralateral hemisphere regions. 
Statistical tests were not performed for IBA1 immunohistochemitry data, representing 
qualitative data.  
Data were presented as mean ± S.D or median ± IQR. Data were shown as a scatterplot 
and a p value of <0.05 was deemed statistically significant.  
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Figure 4-1 Diagram detailing experimental protocol. Prior to MCAO, systolic BP and neurological score were carried out. On day of surgery, MCAO was induced 
and ICV cannula implanted into the right lateral ventricle. Animal was then placed in the MRI scanner and DWI, MRA and T2 weighted scans conducted. After 90 min 
MCAO, reperfusion and treatment started for a period of 7 days. Animals were allowed to recover for 7 days and neurological score and systolic BP assessed. MRI-T2 
weighted and MRA scans were performed at day 7 and brain samples collected for post mortem analysis. 
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4.3 Results 
4.3.1 Mortality and surgical death 
Out of 102 animals used in this study, a total of 22 rats died or were euthanised during 7 
days of recovery (Table 4-1). From these animals, 15 rats died spontaneously: 2 Vehicle 
(aCSF), 4 Ang-(1-7), 7 C21 and 2 Ang-(1-7) + C21 treated rats. Plus, 7 animals were 
euthanised due to breathing difficulties or weight loss below 25% of initial body weight: 4 
Vehicle (aCSF), 1 C21 and 2 Ang-(1-7) + C21 treated animals (Table 4-1). Overall, this 
study had a mortality rate of 21.5%, with the C21 group presenting highest mortality 
within groups (Table 4-1). During surgical procedures, 12 animals died due to 
experimental error and were not included in mortality rates: 2 Vehicle (aCSF), 3 Ang-(1-
7), 2 C21 and 5 Ang-(1-7) + C21 treated rats (Table 4-1). 
Table 4-1 Study mortality and surgical death per treatment group. 
 Vehicle  
N=25 
 
Ang-(1-7) 
N=26 
C21 
N=26 
C21 + Ang-(1-7) 
N=24 
Total N 
 
 Total animals 
per group 
25 26 27 24 102 
Spontaneous 
death  
2 4 7 2 15 
Euthanised 4 0 1 2 7 
Mortality 6 4 8 4 22 
Surgical 
death   
2 3 2 5 12 
% mortality 
per group 
24% 15% 30% 17%  
 
4.3.2 Exclusions 
In this study, 68 rats survived the experiment of which 49 were included for analysis: 13 
Vehicle (aCSF); 13 Ang-(1-7); 12 C21 and 11 Ang-(1-7) + C21 treated animals. Following 
inspection of the MRI-T2 scan, 8 rats did not have the ICV cannula placed in the cerebral 
ventricle and were excluded: 3 Vehicle (aCSF), 3 Ang-(1-7), 1 C21 and 1 combination 
treated rats (Table 4-2), (Figure 4-2A). In total, 7 rats demonstrated partial MCAO at 60 
min MCAO following inspection of the MRA scan: 1 Vehicle (aCSF), 2 Ang-(1-7), 3 C21 
and 2 Ang-(1-7) + C21 rats (Table 4-2), (Figure 4-2B). MRA performed at day 7 
reperfusion indicated that all animals were reperfused adequately. Moreover, MRI-T2 
revealed that 2 animals had ICH and one animal showed signs of ventricular enlargement 
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at day 7 reperfusion, indicating infection caused by the presence of the cannula (Table 4-
2), (Figure 4-2C). 
Table 4-2 Exclusion criteria and excluded animals per treatment group. 
 Vehicle  Ang-(1-7) C21 C21 + Ang-(1-7) Total N 
 
Surviving 
animals 
17 19 17 15 68 
Cannula not in 
place 
3 3 1 1 8 
Partial MCAO 1 2 3 2 7 
MCA not 
reperfused at day 
7 
0 0 0 0 0 
Haemorrhage 
present at day 7 
0 1 0 1 2 
Signs of infection 
at day 7 
0 0 1 0 1 
Total exclusions 4 6 5 4 19 
 
 
Figure 4-2 Representative images of excluded animals per treatment group. A) Cannula 
displacement. MRI-T2 at 7 days post MCAO displaying cannula displacement in the rightlateral 
cerebral ventricle. B) Partial occlusions. MRA at 60 min MCAO showing indications of partial 
occlusion of the left MCA. C) ICH and infection. MRI-T2 at 7 days post MCAO indicating ICH of the 
MCA outlined in green and animal with ventricular infection. 
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4.3.3 Ischaemic lesion evolution during MCAO 
4.3.3.1 Variability in baseline lesion volume prior to treatment 
MCAO was induced for 90 min and DWI scanning performed at 30 min and 60 min 
MCAO to examine ischaemic lesion volume evolution prior to treatment. At 30 min 
MCAO (prior to therapy), all animals exhibited an ischaemic lesion comparable between 
treatment destined groups; Vehicle (aCSF): 141.8±55.3mm3; Ang-(1-7): 145.9±57.4mm3; 
C21: 106±36.3mm3 and Ang-(1-7) + C21: 104.3±45.6mm3 (P>0.05), (Figure 4-3A).  
At 60 min MCAO (prior to therapy), lesion volumes were not significantly different 
between treatment destined groups; however, there was a trend for C21 destined rats to 
start with smaller lesions compared to the Ang-(1-7) group (P=0.07). Lesion volumes were 
as follows; Vehicle (aCSF): 171.8±50.8mm3; Ang-(1-7): 187.1±67.7mm3; C21: 
131.1±41.5mm3 and Ang-(1-7) + C21: 133.9±63.2mm3 (P>0.05), (Figure 4-3B). Data 
indicate that prior to therapy; ADC ischaemic lesions at 30 min and 60 min MCAO are 
variable within and between groups as indicated by high S.D.  
4.3.3.2 MCAO duration increases lesion size  
MCAO duration prior to therapy increased ischaemic lesion volume within treatment 
destined groups for Vehicle (aCSF) (141.8±55.3mm3 vs 171.8±50.8mm3); Ang-(1-7) 
(145.9±57.4mm3 vs 187.1±67.7mm3); C21 (106.0±36.3mm3 vs 131.1±41.5mm3); Ang-(1-
7) + C21 (104.3±45.6mm3 vs 133.9±63.2mm3), (Figure 4-4). Figure 4-4 emphasises the 
variability in ischaemic lesion evolution amongst and between groups prior to therapy.  
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Figure 4-3 Ischaemic lesion during MCAO and prior to therapy. A) 30 min MCAO; B) 60 min MCAO. Lesion volume did not differ between groups at 30 min or 60 
min MCAO. Data depicts ADC lesion volume (mm3) for Vehicle (aCSF) (n=13), Ang-(1-7) (n=13), C21 (n=12) and Ang-(1-7) + C21 (n=11) treatment destined animals. 
Data were analysed using one-way ANOVA, P<0.05 was considered statistically significant. Horizontal bars represent the mean. 
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Figure 4-4 Ischaemic lesion evolution within treatment destined groups during MCAO. Data 
indicate that during ischaemia, ADC lesion increased from 30 min to 60 min MCAO for Vehicle 
(aCSF) (n=13), Ang-(1-7) (n=13), C21 (n=12) and Ang-(1-7) + C21 (n=11) destined rats. Figure 
depicts lesion (mm3) evolution for each individual animal per group, highlighting lesion variability 
prior to therapy. Data are presented as ADC lesion volume (mm3) for each individual animal. 
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4.3.4 Final infarct volume 7 days post MCAO 
4.3.4.1 Inter-rater assessment of reproducibility 
MRI-T2 weighted imaging was performed at day 7 to assess final infarct volume and 
analysed by delineating hyperintense infarct areas. Assessment of reproducibility in 
delineating infarct volume was carried out by two independent investigators and analysed 
using parametric Pearson correlation and Bland-Altman plot (Figure 4-5). Data showed 
that Subject 1 (most experienced) and Subject 2 (least experienced) analyses significantly 
correlated (r=0.98, P<0.0001), (Figure 4-5A). Moreover, Bland-Altman analysis indicated 
an acceptable final infarct volume analysis agreement with a bias of 8.3mm3 (Subject 1 
scored a higher infarct volume on an average of 8.3mm3 than Subject 2) and limits of 
agreement between -12.3 and 29.0mm3. Subject 1 consistently scored higher volumes in 
comparison to Subject 2 as demonstrated by increased values falling on the positive axis 
(Figure 4-5B). The average of the two analyses was used to determine final infarct volume 
for each animal. 
 
Figure 4-5 Inter-rater variability in infarct volume measurement 7 days post 90 min MCAO. 
A) Correlation between Subject 1 and Subject 2 analysis. Infarct volume measurements from 
both Subjects 1 and 2 significantly correlated (r=0.98; P<0.0001). B) Bland-Altman analysis 
displaying difference and average in infarct analysis between Subjects. Analysis agreement 
had a bias of 8.3mm3 and limits of agreement were between -12.3 and 29.0mm3, marked in the 
figure. Data were analysed using Peason parametric correlation coefficient, P<0.05 was 
considered statistically significant. 
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4.3.4.2 Treatment does not impact final infarct volume at 7 days post MCAO 
There were no significant differences in final infarct volume at day 7 between treatment 
groups; Vehicle (aCSF): 130.6±50.7mm3, Ang-(1-7): 111.3±47.4mm3; C21: 
91.7±40.6mm3 and Ang-(1-7) + C21: 85.9±48.4mm3 (P>0.05), (Figure 4-6). 
  
 
 
Figure 4-6 Final infarct volume at 7 days post 90 min MCAO. Final infarct was comparable 
amongst groups following 7 days reperfusion with therapy (P>0.05). Data indicates final infarct 
(mm3) for Vehicle (aCSF; n=13), Ang-(1-7) (n=13), C21 (n=12) and Ang-(1-7) + C21 (n=11) treated 
animals. Data were analysed using one-way ANOVA, P<0.05 was considered statistically 
significant. Horizontal bars represent the mean. 
 
4.3.5 Impact of treatment on the extent of tissue salvage following 
reperfusion 
4.3.5.1 Reperfusion with and without therapy significantly decreases lesion 
volume  
Reperfusion resulted in a significant decrease in lesion size from 60 min MCAO to 7 days 
post MCAO with or without therapy in all groups. Vehicle (aCSF): 171.8±50.8mm3 to 
130.6±50.7mm3 (P<0.0001), (Figure 4-7A); Ang-(1-7): 187.1±67.7mm3 to 111.3±47.4mm3 
(P<0.0001), (Figure 4-7B); C21: 131.1±41.5mm3 to 91.7±40.6mm3 (P<0.0001), (Figure 4-
7C), and Ang-(1-7) + C21: 133.9±63.2mm3 to 85.9±48.4mm3 (P<0.0001), (Figure 4-7D). 
To determine therapy effects and account for variability in baseline lesion volume (60 min) 
prior to treatment, the change in lesion volume was assessed for each individual animal. 
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Figure 4-7 Ischaemic lesion evolution from 60 min MCAO to 7 days post 90 min MCAO 
within treatment groups. A) Vehicle (aCSF); B) Ang-(1-7); C) C21 and D) Ang-(1-7) + C21. 
Reperfusion with and without treatment significantly attenuated ischaemic lesion volume from 60 
min MCAO to 7 days post MCAO for all groups (P<0.0001). Data indicates ischaemic lesion (mm3) 
evolution for Vehicle (aCSF; n=13), Ang-(1-7) (n=13), C21 (n=12) and Ang-(1-7) + C21 (n=11) 
treated animals. Data were analysed using paired Student’s t test. ***P<0.0001. 
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4.3.5.2 Ang-(1-7) with reperfusion increases tissue salvage 7 days post 
MCAO 
When normalising data to lesion size at 60 min MCAO for each animal, Ang-(1-7) 
infusion with reperfusion for 7 days significantly decreased ischaemic lesion volume to a 
greater extent than aCSF alone [41.2±10.2% vs 24.5±14.1% reduction, (P=0.01)], (Figure 
4-8A). Likewise, Ang-(1-7) + C21 showed a trend to attenuate lesion volume when 
compared to aCSF alone, however, it did not reach significance [38.5±12.9% vs 
24.5±14.1%, (P=0.052)]. On the other hand, C21 showed no difference in ischaemic lesion 
progression compared to Vehicle (aCSF) [32.6±15.2% vs 24.5±14.1% reduction, 
(P=0.368)], (Figure 4-8A).  
Data were also presented as absolute change in ischaemic lesion from 60 min MCAO to 7 
days reperfusion (Figure 4-8B). Results show that Ang-(1-7) infusion with reperfusion 
significantly decreased absolute ischaemic lesion volume compared to aCSF 
[41.2±23.6mm3 vs 75.8±28.4mm3 reduction, (P=0.0023)], C21 [39.4±16.3mm3 vs 
75.8±28.4mm3reduction, (P=0.0016)] and Ang-(1-7) + C21 [48.0±22.1mm3 vs 
75.8±28.4mm3reduction, (P=0.0016)] treated groups. C21 treatment did not differ from 
combination group (P>0.05). Additionally, C21 and combination groups did not differ 
from Vehicle (aCSF) group (P>0.05), (Figure 4-8B). 
Figures 4-9 to 12 show ADC map at 60 min and corresponding MRI-T2 scan at 7 days for 
the median animal in the Vehicle (aCSF), Ang-(1-7), C21 and Ang-(1-7) + C21 treatment 
groups determined from Figure 4-8A, respectively.  
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Figure 4-8 Ischaemic lesion evolution from 60 min MCAO to 7 days post 90 min MCAO following therapy. A) % ischaemic lesion change; B) Absolute 
ischaemic lesion change. Ang-(1-7) treatment along with reperfusion significantly decreased % lesion volume from 60 min MCAO compared to Vehicle (aCSF). In 
addition, Ang-(1-7) treatment significantly decreased absolute lesion volume (mm3) from 60 min MCAO compared to Vehicle (aCSF) (P<0.01), C21 (P<0.01) and Ang-
(1-7) + C21 (P<0.05). Data depicts % or absolute (mm3) lesion volume change for Vehicle (aCSF) (n=13), Ang-(1-7) (n=13), C21 (n=12) and Ang-(1-7) + C21 (n=11) 
treated animals. Data were analysed using one-way ANOVA with Tukey’s post hoc analysis, P<0.05 was considered statistically significant. Horizontal bars represent 
the mean. *P<0.05; **P<0.01. 
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Figure 4-9 Representative image of ischaemic lesion evolution between 60 min MCAO to 7 days post 90 min MCAO for Vehicle (aCSF) treated median 
animal. Top images depict the ADC ischaemic lesion, highlighted in white, at 60 min MCAO prior to therapy across 8 coronal levels on the top. The bottom images 
show the corresponding MRI-T2 final infarct at 7 days post 90 min MCAO, highlighted in white. 
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Figure 4-10 Representative image of ischaemic lesion evolution between 60 min MCAO to 7 days post 90 min MCAO for Ang-(1-7) treated median animal.  
Images show ADC ischaemic lesion, highlighted in white, at 60 min MCAO prior to therapy across 8 coronal levels on the top. The bottom images show the 
corresponding MRI-T2 final infarct at 7 days post 90 min MCAO, highlighted in red. 
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Figure 4-11 Representative image of ischaemic lesion evolution between 60 min MCAO to 7 days post 90 min MCAO for C21 treated median animal.  
Images show ADC ischaemic lesion, highlighted in white, at 60 min MCAO prior to therapy across 8 coronal levels on the top. The bottom images show the 
corresponding MRI-T2 final infarct at 7 days post 90 min MCAO, highlighted in blue. 
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Figure 4-12 Representative image of ischaemic lesion evolution between 60 min MCAO to 7 days post 90 min MCAO for Ang-(1-7) + C21 treated median 
animal. Images show ADC ischaemic lesion, highlighted in white, at 60 min MCAO prior to therapy across 8 coronal levels on the top. The bottom images show the 
corresponding MRI-T2 final infarct at 7 days post 90 min MCAO, highlighted in green. 
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4.3.6 Treatment does not have any effect on systolic blood 
pressure. 
Prior to MCAO and treatment, systolic BP was comparable amongst groups (P>0.05), 
(Figure 4-13A). Similarly, at day 7 post MCAO with treatment, BP was not significantly 
different between groups; Vehicle (aCSF): 129±23mmHg; Ang-(1-7): 118±21mmHg, C21: 
114±27mmHg, Ang-(1-7) + C21: 125±27mmHg (P>0.05), (Figure 4-13B). BP change 
from pre to post MCAO did not differ amongst groups; Vehicle (aCSF): 15.20±25mmHg, 
Ang-(1-7): 15.58±25mmHg, C21: 8.427±22mmHg, Ang-(1-7) + C21: 12.13±33mmHg 
(P>0.05), Figure 4-13C). At day 7, BP could not be obtained for two animals, one in 
Vehicle (aCSF) and one in C21 treated groups due to the rats being highly stressed during 
measurements.  
4.3.7 Treatment does not improve neurological function 
Neurological score was assessed prior to MCAO and at 3 and 7 days post-MCAO. Prior to 
MCAO, all animals scored a maximum of 18 points and were therefore, included in the 
study (Figure 4-14A). Day 3 post MCAO, neurological score decreased for all rats, 
indicating a neurological deficit induced by MCAO; however, data were not significantly 
different between groups: Vehicle (aCSF), 11.0 (IQR: 10.0; 12.5); Ang-(1-7), 12.0 (IQR: 
10.5; 12.5); C21, 11.0 (IQR: 10.3; 12.0); Ang-(1-7) + C21, 11.0 (IQR: 10.0; 11.0); 
(P>0.05), (Figure 4-14B). At day 7 post MCAO, there was an improvement in neurological 
score for all groups but no statistically differences observed between groups: Vehicle 
(aCSF), 14.00 (IQR: 11; 15); Ang-(1-7), 15 (IQR: 14; 15); C21, 14 (IQR: 12.3; 15.8); Ang-
(1-7) + C21, 14 (IQR: 12; 15); (P>0.05), (Figure 4-14C).  
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Figure 4-13 Systolic BP. A) Systolic BP prior to MCAO and therapy; B) Systolic BP 7 days 
post MCAO with therapy; C) Systolic BP absolute change from pre MCAO to 7 days post 
MCAO with therapy. There were no differences in systolic BP prior to MCAO or post MCAO with 
therapy between groups (P>0.05). In addition, BP change over time was comparable amongst 
treatment groups (P>0.05). Data depicts BP values for Vehicle (aCSF; n=13-12), Ang-(1-7) (n=13), 
C21 (n=12-11) and Ang-(1-7) + C21 (n=11) treated animals. Data were analysed using one-way 
ANOVA, P<0.05 was considered statistically significant. Horizontal bars represent the mean. 
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Figure 4-14 Neurological score. A) Prior to MCAO and therapy; B) 3 days post MCAO with 
therapy; C) 7 days post MCAO with therapy. All animals scored a maximum of 18 prior to MCAO 
and therapy. There were no significant differences in neurological between groups at 3 and 7 days 
post MCAO with therapy (P>0.05). Data depicts values forVehicle (aCSF; n=13), Ang-(1-7) (n=13), 
C21 (n=12) and Ang-(1-7) + C21 (n=11) treated animals. Data were analysed using non-parametric 
Kruskal-Wallis test, P<0.05 was considered statistically significant. Horizontal bars represent the 
mean. 
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4.4 Quantitative Real Time PCR 
At day 7 following 90 min MCAO brain tissue from the peri-infarct region from Sham 
(n=7), MCAO-aCSF (n=9) and MCAO-Ang-(1-7) (n=9) treated animals were analysed for 
gene expression. Ubc was the most stable reference gene and selected for data 
normalisation (Chapter 2.16.2).  
4.4.1 MCAO significantly decreases Mas1 expression at 7 days 
reperfusion 
To investigate potential alterations in classical and counter-regulatory axis components, 
gene expression for RAS receptors AT1A (Agtr1a), AT2R (Atgr2) MasR (Mas1) and 
enzymes ACE (Ace) and ACE2 (Ace2) were assessed. Moreover, B2R (Bdkrb2) gene 
expression was evaluated due to reports that Ang-(1-7)’s effects may be partly mediated by 
B2R signalling (Lu et al., 2008). 
Following 90 min MCAO and 7 days reperfusion, the expression of Atgr1a was 
comparable to sham treatment and not significantly different between vehicle and Ang-(1-
7) treated rats (Figure 4-15A), (P>0.05). Conversely, Atgr2 levels were significantly 
increased in control treated rats following MCAO when compared to Sham [-4.5±1.6 vs -
8.0±1.4 (P=0.002)], (Figure 4-15B) while Ang-(1-7) showed a trend to attenuate this 
increase (-6.4±2.1), (Figure 4-15B).  Interestingly, Mas1 significantly decreased following 
MCAO in both Vehicle (aCSF) and Ang-(1-7) treated groups compared to Sham [-4.4±1.0 
vs -2.7±0.8 (P=0.02); -4.2±1.5 vs -2.7±0.8 (P=0.046); respectively], (Figure 4-15C). 
Ace and Ace2 expression was similar to Sham levels following MCAO in both Vehicle and 
Ang-(1-7) treated groups (P>0.05), (Figure 4-15D&E). Similarly, Bdkrb2 expression was 
comparable to Sham animals following MCAO (P>0.05), (Figure 4-15F). 
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Figure 4-15 RAS components and B2R gene expression 7 days post 90 min MCAO. A) 
Atgr1a; B) Atgr2r; C) Mas1; D) Ace; E) Ace2 and F) Bdkrb2. MCAO significantly upregulates 
Atgr2r in Vehicle (aCSF) treated animals only compared to Sham (P>0.05). Mas1 is significantly 
downregulated following MCAO in both Vehicle (aCSF) and Ang-(1-7) treated animals compared to 
Sham (P>0.05). There were no differences between groups for Atgr1a, Ace, Ace2 and 
Bdkrb2levels. Data were presented as -Ct normalised to Ubc for Sham (n=7); Vehicle (aCSF) 
(n=9) and Ang-(1-7) (n=9) treated animals in peri-infarct regions. Data were analysed using one-
way ANOVA with Tukey’s post-hoc test, P<0.05 was considered statistically significant. Horizontal 
bars represent the mean. *P<0.05; **P<0.01 compared to Sham. 
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4.4.2 Ptgs2 and Nfkb1 levels are unchanged following treatment 
COX-2 (Ptgs2) was comparable to Sham levels following MCAO (P>0.05), (Figure 4-
16A). Moreover, there were no differences between treatment groups for NF-B 
(Nfkbfollowing MCAO (P>0.05), (Figure 4-16B). 
 
Figure 4-16 COX-2 and NF-B gene expression 7 days post 90 min MCAO. A) Ptgs2; B) 
Nfkb1. MCAO does not impact Ptgs2 or Nfkb1 expression at 7 days post MCAO in peri-infarct 
regions compared to Sham. Data were presented as -Ct normalised to Ubc for Sham (n=7); 
Vehicle (aCSF) (n=9) and Ang-(1-7) (n=9) treated animals in peri-infarct regions. Data were 
analysed using one-way ANOVA, P<0.05 was considered statistically significant. Horizontal bars 
represent the mean. 
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4.4.3 Ang-(1-7) significantly attenuates Nox1 expression when 
compared to Vehicle (aCSF) treated animals 
Nox1 expression was significantly decreased in Vehicle (aCSF) treated animals following 
MCAO when compared to Sham group [-7.8±1.0 vs -6.5±0.6 (P=0.04)]. In contrast, Ang-
(1-7) treatment attenuated this decrease with levels similar to that observed in sham rats [-
6.6±1.2 vs -7.8±1.0 (P=0.04)], (Figure 4-17A). Nox2 levels were unchanged between 
groups (P>0.05), (Figure 4-17B). 
 
Figure 4-17 NOX type 1 and 2 gene expression 7 days post 90 min MCAO. A) Nox1; B) Nox2. 
MCAO-Vehicle (aCSF) significantly downregulated Nox1 expression compared Sham (P<0.05) 
whereas MCAO-Ang-(1-7) treatment significantly upregulated Nox1 expression compared to 
MCAO-Vehicle therapy (P<0.05). MCAO did not alter Nox2 expression compared to Sham 
(P>0.05). Data were presented as -Ct normalised to Ubc for Sham (n=7); Vehicle (aCSF; n=9) 
and Ang-(1-7) (n=9) treated animals in peri-infarct regions. Data were analysed using one-way 
ANOVA with Tukey’s post-hoc test, P<0.05 was considered statistically significant. Horizontal bars 
represent the mean. *P<0.05 compared to Sham; #P<0.05 compared to MCAO-Vehicle (aCSF). 
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4.4.4 Ccr5 expression is increased following transient MCAO 
The expression of Cxcr2 and Ccr2 were unchanged in both vehicle and Ang-(1-7) treated 
rats following transient MCAO when compared to sham rats (P>0.05), (Figures 4-
18A&B). In contrast, Ccr5, was shown to be significantly increased following MCAO in 
both Vehicle (aCSF) and Ang-(1-7) treatment groups when compared to Sham [-0.6±0.9 vs 
-2.3±0.8 (P=0.0009); -0.7±0.7 vs -2.3±0.8 (P=0.001), respectively], (Figure 4-18C). 
 
 
Figure 4-18 Chemokine receptor gene expression 7 days post 90 min MCAO. A) Cxcr2; B) 
Ccr2; C) Ccr5. MCAO did not alter Cxcr2 or Ccr2 expression compared to Sham animals (P>0.05). 
On the other hand, MCAO significantly upregulated Ccr5 in both Vehicle (aCSF) and Ang-(1-7) 
treated animals compared to Sham (P<0.01). Data were presented as -Ct normalised to Ubc for 
Sham (n=7); Vehicle (aCSF; n=9) and Ang-(1-7) (n=9) treated animals in peri-infarct regions. Data 
were analysed using one-way ANOVA with Tukey’s post-hoc test, P<0.05 was considered 
statistically significant. Horizontal bars represent the mean.  **P<0.01, ***P<0.001 compared to 
Sham. 
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4.4.5 Treatment does not impact M1 type profile marker mRNA 
expression 
Gene expression for M1 type markers CD86 (CD86), CD11b (Itgam), IL-1(Il1b), IL-6 
(Il6), CCR7 (Ccr7) and iNOS (Nos2) were examined in peri-infarct regions in all samples. 
CD86 levels was significantly increased following 90 min MCAO in both vehicle and 
Ang-(1-7) treated rats compared to Sham animals [-1.7±1.2 vs -5.1±1.1 (P<0.001); -
2.1±1.4 vs -5.1±1.1 (P<0.001); respectively] (Figure 1-19A). Similarly, Itgam was 
upregulated following MCAO in both vehicle and Ang-(1-7) treated groups when 
compared to Sham rats [-0.6±1.3 vs -4.1±0.8 (P<0.01); -1.3±1.3 vs -4.1±0.8 (P<0.01); 
respectively], (Figure 4-19B). Ccr7, Il6 and Il1b were unchanged following MCAO and 
Ang-(1-7) treatment had no effect (P>0.05), (Figure 4-19C, D, E). In contrast, Nos2 
expression was undetected in both Sham and MCAO peri-infarct brain tissue. 
4.4.6 Treatment does not impact M2 type profile marker mRNA 
expression 
Gene expression for M2 type markers Arg1 (Arg1), CD163 (CD163), CCL22 (Ccl22), 
TGF-1 (Tgfb1) and IL-10 (Il10) were examined in peri-infarct regions in all samples. 
Arg1, CD163 and Ccl22 levels were unchanged following MCAO in both vehicle and 
Ang-(1-7) treated rats when compared to sham treated rats (P>0.05), (Figure 4-20A, B, C) 
whereas Il10 was not detected in peri-infarct regions in all rats. Tgfbexpression was 
significantly increased in Vehicle (aCSF) treated rats following 90 min MCAO compared 
to Sham [1.7±1.3 vs -0.3±0.6 (P<0.05)], (Figure 4-20D). In contrast, there was a trend for 
Ang-(1-7) treated group to attenuate Tgfblevels (Figure 4-20D). 
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Figure 4-19 M1 type microglia/macrophage markers 7 days post 90 min MCAO. A) CD86; B) 
Itgam; B) Ccr7; C) Il6 and D) Il1b MCAO significantly upregulates CD86 and Itgam compared to 
Sham treated animals (P<0.01). MCAO does not alter Ccr7, Il6 or Il1b compared to Sham animals. 
Data were presented as -Ct normalised to Ubc for Sham (n=7); Vehicle (aCSF; n=9) and Ang-(1-
7) (n=9) treated animals in peri-infarct regions. Data were analysed using one-way ANOVA with 
Tukey’s post-hoc test, P<0.05 was considered statistically significant. Horizontal bars represent the 
mean. **P<0.01 compared to Sham. 
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Figure 4-20 M2 type microglia/macrophage markers 7 days post 90 min MCAO. A) Arg1; B) 
CD163; C) Ccl22 and D) Tgfb1MCAO-Vehicle (aCSF) group significantly upregulated Tgfb1 
compared to Sham treated animals (P<0.01). MCAO did not alter Arg1, CD163 or Ccl22 compared 
to Sham animals. Data were presented as -Ct normalised to Ubc for Sham (n=7); Vehicle (aCSF; 
n=9) and Ang-(1-7) (n=9) treated animals in peri-infarct regions. Data were analysed using one-
way ANOVA with Tukey’s post-hoc test, P<0.05 was considered statistically significant. Horizontal 
bars represent the mean. *P<0.05 compared to Sham. 
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4.4.7 Assessment of IBA1+ microglia 
Immunohistochemistry was performed across coronal levels 3, 4 and 5 for Vehicle (aCSF) 
n=2), Ang-(1-7) (n=2), C21 (n=2) and Ang-(1-7) + C21 (n=2) treated groups. This data set 
provides a qualitative assessment of total IBA1+ microglia per group. 
Mean total IBA1+ microglia number did not show an indication of Ang-(1-7) induced 
effects compared to other groups; Vehicle (aCSF): 259.0±1.5 n/mm2, Ang-(1-7): 
260.0±79.4 n/mm2, C21: 260.0±79.4 n/mm2and Ang-(1-7) + C21: 225.7±33.8 n/mm2 
treated animals (Figure 4-21A). Similarly, mean total IBA1+ microglia number in the 
homotopic region of the contralateral hemisphere did not indicate a trend for an Ang-(1-7) 
induced effect compared to other groups; Vehicle (aCSF): 141.4±29.4 n/mm2, Ang-(1-7): 
163.3±4.4 n/mm2, C21: 132.1±7.4 n/mm2, Ang-(1-7) + C21: 151.8±64.7 n/mm2 (Figure 
4-21B). Results indicate higher numbers of total stained cells in the peri-infarct area 
compared to the homotopic contralateral region. 
When assessing % activated IBA1+ microglia from total numbers, values were comparable 
amongst groups in the peri-infarct area; Vehicle (aCSF): 95.2±1.1%, Ang-(1-7): 
96.5±2.2%, C21: 99.2±0.4%, Ang-(1-7) + C21: 99.2±1.2% (Figure 4-22A). Similarly, % 
activated IBA1+ in the homotopic contralateral region did not suggest an Ang-(1-7) 
induced effect compared to other groups; Vehicle (aCSF): 82.4±6.8%, Ang-(1-7): 
77.2±8.4%, C21: 85.4±11.4%, Ang-(1-7) + C21: 78.3±5.4% (Figure 4-22B). Moreover, 
immunohistochemistry showed that at 7 days reperfusion, IBA1+ microglia are mainly 
present within the ischaemic core and exhibiting an amoeboid/active phenotype (Figures 4-
23 to 24). 
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Figure 4-21 Total IBA1+ microglia number in peri-infarct and contralateral regions 7 days 
post 90 min MCAO. A) Peri-infarct region; B) Homotopic contralateral region. Data shows 
total microglia number per mm2 brain area for Vehicle (aCSF; n=2), Ang-(1-7) (n=2), C21 (n=2) and 
Ang-(1-7) + C21 (n=2) treated animals. Horizontal bar represents the mean. 
 
 
Figure 4-22 % activated microglia in peri-infarct and contralateral regions 7 days post 90 
min MCAO. A) Peri-infarct region; B) Homotopic contralateral regions. % activated cells from 
total number for Vehicle (aCSF; n=2), Ang-(1-7) (n=2), C21 (n=2), Ang-(1-7) (n=2) treated animals. 
Horizontal bar represents the mean. 
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Figure 4-23 IBA1+ microglia staining in peri-infarct, contralateral and infarct regions for Vehicle (aCSF) treated animal. Peri-infarct regions were defined with 
the aid of histology analysis as defined in Paxinos and Watson coronal levels. Infarct was outlined (grey) and three ROIs were defined for imaging and IBA1+ cell count 
in peri-infarct and homotopic contralateral areas (red squares). IBA1+ microglia staining (highlighed in red) across coronal levels 3, 4 and 5 indicate that active microglia 
are mainly concentrated in infarct areas. Scale is set at 50M per white bar. 
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Figure 4-24 IBA1+ microglia staining in peri-infarct, contralateral and infarct regions for Ang-(1-7) treated animal. Peri-infarct regions were defined with the aid 
of histology analysis as defined in Paxinos and Watson coronal levels. Infarct was outlined (higlighted in pink) and three ROIs were defined for imaging and IBA1+ cell 
count in peri-infarct and homotopic contralateral areas (red squares). IBA1+ microglia staining (highlighed in red) across coronal levels 3, 4 and 5 indicate that active 
microglia are mainly concentrated in infarct areas. Scale is set at 50M per white bar. 
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Figure 4-25 IBA1+ microglia staining in peri-infarct, contralateral and infarct regions for C21 treated animal. Peri-infarct regions were defined with the aid of 
histology analysis as defined in Paxinos and Watson coronal levels. Infarct was outlined (higlighted in blue) and three ROIs were defined for imaging and IBA1+cell 
count in peri-infarct and homotopic contralateral areas (red squares). IBA1+ microglia staining (highlighed in red) across coronal levels 3, 4 and 5 indicate that active 
microglia are mainly concentrated in infarct areas. Scale is set at 50M per white bar. 
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Figure 4-26 IBA1+ microglia staining in peri-infarct, contralateral and infarct regions for Ang-(1-7) + C21 treated animal. Peri-infarct regions were defined with 
the aid of histology analysis as defined in Paxinos and Watson coronal levels. Infarct was outlined (higlighted in green) and three ROIs were defined for imaging and 
IBA1+cell count in peri-infarct and homotopic contralateral areas (red squares). IBA1+ microglia staining (highlighed in red) across coronal levels 3, 4 and 5 indicate that 
active microglia are mainly concentrated in infarct areas. Scale is set at 50M per white bar. 
164 
 
4.5 Discussion 
This is the first study to investigate the impact of Ang-(1-7) and/or C21 on the extent of 
tissue salvage following 90 min MCAO and 7 days reperfusion with treatment. We have 
demonstrated that Ang-(1-7) treatment increases tissue salvage following transient MCAO 
when compared to vehicle treatment; however, C21 or combination therapy had no effect.  
This effect was not a result of changes in BP over the time course. These experiments had 
strict exclusion criteria and with the help of MRI, it was possible to confirm that all 
animals had correct ICV cannula placement and that the MCA was successfully occluded 
during ischaemia with complete MCA reperfusion following filament removal. 
4.5.1 Ischaemic lesions are variable during MCAO and prior to 
therapy 
The use of DWI-MRI immediately following MCAO allowed us to determine the initial 
ischaemic lesion during MCAO and prior to reperfusion and treatment in all groups. As 
expected, the acute ADC lesion volume increased between 30 and 60 min MCAO prior to 
reperfusion and treatment. Although MRA confirmed successful MCAO, considerable 
variability in the baseline lesion volume prior to reperfusion and treatment was observed, 
an outcome widely detected within experimental stroke. This variability is likely due to 
inter-animal variability in collateral vessel supply. Specifically, leptomeningeal 
anastomoses variances between MCA and ACA or posterior cerebral artery collateral 
anastomoses may lead to enhanced or diminished collateral blood supply to the ischaemic 
brain by providing retrograde blood flow to the MCA territory – distal from occlusion 
(Cuccione et al. 2016). In support of this, differences in the extent of collateral supply in 
humans have been shown to influence ischaemic stroke outcome (Liebeskind, 2014). For 
instance, poor collateral grade leads to exacerbated stroke severity at 3 to 5 days post 
recanalization in stroke patients (Bang et al., 2007). In addition, in the Solitaire flow 
restoration device versus the Merci Retriever (SWIFT) trial, patients with enhanced 
collateral supply were associated with reduced ischaemic damage prior to therapy (Saver et 
al., 2012).  
In our study, anaesthetic levels and ventilator stroke volume and rate were the same for all 
animals during MCAO. However, for the purpose of animal welfare during recovery, the 
femoral artery was not cannulated, which meant that MABP, PaCO2, PaO2 and pH levels 
were not monitored during MCAO surgery. This is relevant since mild rises in BP enhance 
cerebral tissue oxygenation and collateral blood flow in the core and penumbral areas 
165 
 
during MCAO whereas low PaCO2 levels and pH promote infarction (Anderson and 
Meyer, 2002; Browning et al., 1997; Shin et al., 2008). Importantly, in the present study, 
animals were moved between the MRI scanner and surgical bench, and vice versa, which 
altered body temperature. Animals were maintained within the 37±0.5ºC range by 
performing the transfer as quickly as possible; however, cooling in small animals is 
neuroprotective and this may have been a contributing factor to lesion variability (van der 
Worp et al., 2007). By carrying out acute imaging during MCAO, it allowed us to 
overcome this variability and to assess the change in lesion volume following reperfusion 
with or without treatment in individual animals. 
4.5.2 Reperfusion results in tissue salvage 
MRI-T2 analysis of infarct requires manual delineation of the hyperintense signal, thus, 
introducing an element of variability due to the subjective nature of delineating the infarct. 
As a result, two blinded independent investigators assessed final infarct volume. Inter-rater 
assessments showed successful reproducibility and the mean infarct volume for the two 
analyses was used for study outcome evaluation.  
For all groups, reperfusion with and without treatment significantly decreased lesion 
volume by day 7 compared to 60 min MCAO. These findings are in agreement with 
thrombectomy trials in which, early initiation of reperfusion alone or in combination with 
IV alteplase improves functional outcome in ischaemic stroke patients (Berkhemer et al., 
2015; Campbell et al., 2015; M Goyal et al., 2015; Jovin et al., 2015; Saver et al., 2015). 
One of the concerns of abrupt reperfusion restoration is that a rise in ipsilateral CBF above 
metabolic demand might lead to reperfusion injury or “cerebral hyperperfusion syndrome”. 
This syndrome is characterised by exacerbated brain injury caused by BBB breakdown, 
impaired autoregulation and enhanced inflammatory responses (Ogasawara et al., 2003). 
One other concern is the development of HT, which is thought to be caused by enhanced 
reperfusion in areas of pronounced perfusion deficit (Fiehler et al., 2005). Our data, 
however, depicts that following transient MCAO in Wistar rats; reperfusion alone does not 
exacerbate injury or cerebral haemorrhage at 7 days post MCAO, since from all surviving 
animals; ICH was only present in two animals, confirming the protective nature of 
reperfusion alone.  
The extent of tissue salvage following reperfusion differed amongst animals. In vehicle 
treated animals, lesion volume decrease ranged from 42% to 1% from initial lesion and, as 
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mentioned above, differences in collateral grade amongst animals are a probable 
contributing factor. In the clinic, robust collateral supply is associated with successful 
recanalization, greater reperfusion and better clinical outcome (Liebeskind et al., 2014; 
Saver et al., 2012). Therefore, the extent of collateral grade is likely to influence the degree 
of reperfusion and subsequent infarct volume outcome. In addition, secondary injury 
mechanisms are another possible contributor. Rats subjected to 90 min MCAO display 
maximal injury from 48 to 72 hrs reperfusion that then reduces at 7 and 14 days post stroke 
onset (Neumann-Haefelin et al., 2000; Rewell et al., 2017). These findings are further 
confirmed with our neurological score data, which show that at 3 days post MCAO rats 
had substantial neurological impairment that then improved at 7 days post MCAO for all 
groups. Although reperfusion is beneficial in the longer term, secondary injury 
mechanisms such as BBB disruption may impact infarct outcome amongst animals (Pillai 
et al., 2013).  
Interestingly, when comparing data at day 7 only, there were no differences in final infarct 
volume between treatment groups. Previous studies in the ET-1 induced MCAO model 
showed that Ang-(1-7) and C21 administered ICV as a pre and post stroke onset therapy 
led to a 50% reduction in final infarct when assessed at end-points (Joseph et al., 2014; 
Mecca et al., 2011; Regenhardt et al., 2013). Our experiment; however, suggests that any 
potential action induced by drug therapy is of mild to moderate effect and likely masked by 
the variability in initial lesion sizes. In turn, this may lead to false positive results by an 
overestimation of effect sizes or treatment effects could also be undetected (Leithner et al., 
2015). Therefore, early ADC imaging has been considered a crucial tool to avoid type I 
and type II errors in neuroprotective studies and experimental stroke study quality 
(Leithner et al., 2015). Accordingly, the treatment effects on final infarct volume were 
examined by normalising the data to each animals own respective baseline lesion volume 
at 60 min MCAO.   
4.5.3 Ang-(1-7) treatment with reperfusion increases tissue 
salvage possibly through NOX1 expression 
When normalising data to initial lesion, Ang-(1-7) treatment along with reperfusion 
significantly attenuated lesion progression at day 7 when compared to Vehicle (aCSF). 
Similarly, absolute change in infarct volume between 60 min MCAO and 7 days recovery 
showed that Ang-(1-7) treatment alone significantly decreased ischaemic lesion compared 
to all other groups. This study shows for the first time that Ang-(1-7) treatment for a period 
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of 7 days during reperfusion has the potential to attenuate ischaemic lesion progression 
without impacting systolic BP. These results go in accordance with ET-1 induced MCAO 
studies where Ang-(1-7) treatment as a pre and/or post therapy was shown to be 
neuroprotective (Regenhardt et al. 2013; Mecca et al. 2011). One of the objectives of this 
study was to assess potential mechanistic effects underlying the outcome observed. In 
particular, this study focused on the Ang-(1-7) induced anti-inflammatory/anti-oxidative 
mechanism hypothesis which is widely reported in the literature (Jiang et al., 2012, 2013; 
Mecca et al., 2011; Regenhardt et al., 2013). Our study indicates that COX-2 or NF-B 
mRNA levels were not significantly altered by Ang-(1-7) as previously reported (Jiang et 
al., 2012; Liu et al., 2016). Similarly, when assessing leukocyte chemokine receptors and 
microglia/macrophage markers, Ang-(1-7) did not significantly affect gene expression 
levels at day 7 compared to Vehicle (aCSF).  
In the brain, the RAS classical axis activates NOX1 and NOX2 isoforms, which are 
involved in the pathology of cerebral ischaemia (Garrido and Griendling, 2009; Zhang et 
al., 2016). Specifically, Ang II induces an inward Ca2+ current in neurons due to NOX2-
derived ROS and stimulates superoxide in cerebral arteries through NOX1 (Wang et al. 
2006; Sun et al. 2005; Jackman et al. 2009; Kahles et al. 2010). Our data shows that 
phagocytic NOX2, the main mediator in neuroinflammation-derived superoxide production 
(Girouard et al. 2009), was expressed at Sham levels without Ang-(1-7) treatment effects 
observed. Interestingly, gene expression results indicate that Ang-(1-7) treatment might 
exert its mechanisms by targeting NOX1. In peri-infarct brain regions, NOX1 mRNA 
levels were decreased in Vehicle (aCSF) treated rats when compared to sham brain tissue; 
however, this decrease was significantly attenuated in Ang-(1-7) treated rats. NOXs are the 
major source of ROS and important mediators in oxidative stress, a known mechanism of 
injury following stroke (Lipton 1999; Gursoy-Ozdemir et al. 2004). Yet, aside from its 
involvement in cellular injury, reports suggest that ROS might have a role in CNS cellular 
maintenance, particularly in cellular growth and neurological synaptic plasticity (Knapp 
and Klann, 2002; Suzukawa et al., 2000; Tsatmali et al., 2005). Therefore, by preventing 
NOX downregulation post-stroke, Ang-(1-7) could mediate therapeutic effects. Still, the 
cellular locus at which Ang-(1-7) may be acting is yet to be defined. 
KO studies have investigated the impact of NOX1 following MCAO, in which it was 
observed that NOX1-KO mice have larger infarcts compared to wild type (WT) animals 
(Choi et al., 2015). Additionally, NOX1-KO mice subjected to MCAO and treated with 
Ang II, displayed lower levels of ROS yet extensively larger infarct volumes when 
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compared to WT mice (Jackman et al., 2009). As a result, NOX1 might be neuroprotective 
in the context of cerebral injury. The mechanism behind this protective effect is not well 
understood; however, research indicates that it may be a ROS derived neurogenesis effect. 
In embryonic rat cortical cells, ROS intracellular accumulation is associated with cellular 
differentiation into neurons (Tsatmali et al., 2005) whereas in PC12, an immortalised 
neuronal cell line, neuronal differentiation through nerve growth factor is dependent on 
ROS concentration (Suzukawa et al., 2000). One could postulate that Ang-(1-7) enhances 
neurogenesis and homeostatic maintenance through NOX1 derived ROS and thus, 
improved ischaemic lesion by day 7.  
A caveat in the present study is the lack of protein assessments and the small number of 
samples collected for immunohistochemical analysis. Therefore, it is not possible to 
conclude whether Ang-(1-7) might be promoting neurogenesis by targeting NOX1. 
Immunohistochemical co-localisation analysis of NOX1 and proliferating cell nuclear 
antigen antibodies in the peri-infarct region would have been a suitable approach to test the 
neurogenesis hypothesis (Sierra et al., 2011). 
4.5.3.1 Central Ang-(1-7) infusion does not modify brain RAS components  
AT1A receptor mRNA expression was not altered at day 7 following MCAO in peri-infarct 
brain tissue. The same outcome was verified in ET-1 induced MCAO, where AT1R gene 
expression was comparable to Sham rats following 72 hrs reperfusion (Mecca et al., 2011). 
Similarly, ACE gene expression did not change following MCAO in peri-infarct regions. 
These results propose that at day 7 following 90 min MCAO, the classical axis within the 
brain is not altered and that its detrimental effects might be temporally dependent. For 
instance, a recent study showed that following permanent MCAO, AT1A gene expression 
was upregulated at 24 hrs injury only (Wakayama et al., 2017). Therefore, it is plausible 
that in normotensive animals, Ang II and AT1R may exert its detrimental effects in MCAO 
injury at an earlier stage (e.g. 24 hrs) rather than at subacute/chronic phases. However, to 
confirm ACE/Ang II/AT1R over activation at the time point evaluated, brain Ang II and 
AT1R protein levels would have to be assessed following MCAO and compared to Sham in 
the model used.  
AT2R mRNA levels were significantly increased following MCAO in the present study. 
Previous reports have shown that following MCAO, AT2R mRNA levels increase at 24 hrs 
and 72 hrs with our data indicating that at day 7 this upregulation persists (Kagiyama et al., 
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2003; Makino et al., 1996; Zhu et al., 2000). Interestingly, ACE2 was compared to Sham as 
reported in ET-1 induced MCAO models at 72 hrs post stroke onset (Mecca et al. 2011) 
whereas MCAO significantly decreased MasR expression in peri-infarct regions. It has 
been previously suggested that both ACE2 and MasR (mRNA and protein levels) are 
upregulated following 120 min MCAO at day 7 in the RVLM (Chang et al. 2014). In our 
studies, brain tissue obtained for mRNA analysis was excised from the cortical region 
corresponding to the peri-infarct; thus, counter-regulatory RAS expression in other CNS 
areas such as the medulla was not assessed. Nonetheless, our results indicate that in the 
model used, AT2R and MasR have a time-dependent role following cerebral ischaemia 
within the peri-infarct areas. Therefore, MasR agonism possibly exerts its maximal 
cytoprotective effects at acute/subacute whilst AT2R agonism may provide neuroprotection 
at a subacute/chronic phase of injury. This could justify why neuroprotection was observed 
for MasR agonism but not with AT2R agonism in our study.  
In addition, a preceding study postulated that Ang-(1-7)’s protective effects may be partly 
mediated by B2R signalling, thereby enhancing a vasodilatory effect (Lu et al., 2008). 
Following transient MCAO, Ang-(1-7) ICV post treatment enhances the expression of B2R 
and up to 72 hrs post stroke onset (Lu et al., 2008). However, in the present study, B2R 
mRNA levels were expressed to Sham levels without Ang-(1-7) treatment effects, thus, the 
effect observed is unlikely due to bradykinin signalling exacerbation.   
4.5.3.2 Ang-(1-7) does not alter microglia/macrophage and leukocyte 
infiltration markers following MCAO 
Following 7 days reperfusion with treatment, Ang-(1-7) did not alter pro-inflammatory 
mediators or microglia/macrophage M1/M2 mRNA profile. The brain tissue samples used 
to examine gene expression do not discern cell specific cytokine profile; still, these results 
provide an indication that at this time point, Ang-(1-7) does not exert a 
microglia/macrophage induced anti-inflammatory effect. Ang-(1-7) reaches its maximum 
cerebral tissue concentration at 24 hrs post-transient MCAO (Lu et al. 2013), thus, possibly 
exerting a microglia-derived anti-inflammatory effect at an earlier time point in injury as 
previously reported (Regenhardt et al., 2013). Simultaneously, inflammatory gene 
expression for COX-2, NF-B, NOX2, IL-6, IL-1 were expressed at Sham levels in 
MCAO groups while IL-10 and iNOS were undetected in all samples.  
The balance between M1/M2 microglia/macrophage phenotype is dynamic after ischaemic 
stroke and the underlying mechanisms are not well understood (Cotrina et al., 2017; Ritzel 
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et al., 2015). It is proposed that following transient MCAO and at day 7, these cells express 
a M1 phenotype (Hu et al., 2012). Our data supports this hypothesis since M1 type markers 
CD86 and CD11b were upregulated following MCAO. This indicates that in the peri-
infarct, microglia/macrophages are active and involved in antigen presenting to T cells as 
suggested by CD11b and CD86, respectively (Taylor and Sansing, 2013). M2 phenotype is 
reported to occur up to 5 days post MCAO and then shift towards a M1 phenotype (Hu et 
al., 2012). From all the M2 markers studied, TGF- only was upregulated 7 days 
following MCAO, without Ang-(1-7) induced effects. Microglia are major sources of 
TGF- in the brain (Welser-Alves and Milner, 2013) and once released it will contribute 
towards tissue regeneration as well as T regulatory (Treg) cell development, hence cellular 
repair (Iadecola and Anrather, 2011; Liesz et al., 2009). Together, the data obtained 
indicates that Ang-(1-7) therapy did not influence microglia/macrophage cytokine profile. 
To obtain a qualitative assessment of treatment effects on microglia numbers and 
phenotype within the peri-infarct, IBA1+ microglia were evaluated. Following 90 min 
MCAO with 7 days reperfusion, AT1R blockers decrease infarct volume due to a decrease 
in microglia activation in the ipsilateral hemisphere (Lou et al., 2004). In the present study, 
IBA1+ immunostaining indicated that MasR agonism through Ang-(1-7) therapy did not 
influence microglia activation or total number in the peri-infarct region. This emphasises 
that Ang-(1-7) does not act at the microglia level at this time point. It was also observed 
that IBA1+ cells numbers were enhanced in ipsilateral peri-infarct regions compared to the 
contralateral side and mostly concentrated within the infarct core for all groups. In the 
infarct region, all IBA1+ cells exhibited an amoeboid/active form; suggesting that repair 
mechanisms are taking place by clearing cellular debris (Denes et al., 2007).  
Ang-(1-7) does not mediate its effects via leukocyte recruitment at day 7. Neutrophils peak 
between 1 and 3 days post MCAO with numbers subsequently declining by day 7, whereas 
macrophages levels peak between day 3 and 7 (Grønberg et al., 2013). Our data shows that 
CXCR2 and CCR2, neutrophil and macrophage chemokine receptors, were unchanged 
following MCAO when compared to Sham without treatment effects. Conversely, CCR5 
was significantly upregulated following MCAO without Ang-(1-7) induced effects. CCR5 
is expressed in T cells, astrocytes, microglia and neurons (Westmoreland et al., 2002). T 
cells are reported to infiltrate infarcted brain 3 to 7 days post injury and peak no earlier 
than 5 days post MCAO (Grønberg et al., 2013), which justifies the increase in CCR5 gene 
expression. The role of this receptor in ischaemic stroke is not well understood; however, 
KO studies indicate that 7 days following MCAO, CCR5-KO mice have larger infarcts 
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than WT mice (Sorce et al., 2010), proposing a role in cellular repair possibly through Treg 
cell recruitment and activation (Li et al., 2017).  
4.5.4 AT2R receptor agonism and combined AT2R/MasR agonism 
has no effect on tissue salvage 
AT2R agonism did not attenuate ischaemic lesion progression following 7 days MCAO. 
One possibility for the effect observed is that the dose selected might not have been at a 
therapeutic level. C21 elicits AT1R specific effects at higher doses (Gao, Zhang et al. 
2011), thus, the dose used in our study, 7.5 ng/hr, was selected as recommended by Vicore 
Pharma®. Supportively, Joseph et al. used the same C21 dose as this study; yet, in their 
experiment, the effects on infarct volume were assessed in a single 2 mm coronal brain 
section from each rat by TTC staining whereas in the present study we assessed the entire 
rostral-caudal extent of damage. Conversely, McCarthy et al., observed a neuroprotective 
effect when testing 50 ng/hr C21 dose ICV in SHRs following MCAO but not at lower 
doses (McCarthy et al., 2014), highlighting that higher doses might be needed in future 
studies. 
Similarly to our study, C21 treatment for 4 days post-MCAO did not impact infarct volume 
when compared to control groups (Schwengel et al., 2016). Instead, C21 treatment 
decreased mortality between groups (Schwengel et al., 2016) whereas in the present study, 
C21 treated rats exhibited the highest mortality out of all groups. Furthermore, in 
Schwengel’s experiment, neurological score was significantly improved at 1, 2 and 4 days 
post transient MCAO, an effect not observed in our experiment. The improvement in NS 
was associated with an upregulation of BDNF gene and protein expression within the 
ipsilateral hemisphere, which possibly led to an anti-apoptotic effect in penumbral regions 
(Schwengel et al., 2016). The authors did not perform acute MRI to assess the baseline 
lesion volume; therefore, it could be possible that in the model used, C21 might have 
induced a mild effect on infarct progression at 4 days reperfusion. It is important to note 
that in Schwengel’s experiment, studies were conducted in mice and C21 administered IP 
(Schwengel et al., 2016); therefore, this method of administration may be more suitable 
and effective than the one used in our study.    
AT2R activation could have a neuroprotective effect at later stages of injury as evidenced 
by an upregulation of AT2R gene expression in peri-infarct regions following 7 days 
reperfusion. A recent study examined the neuroprotective potential of C21 treatment 
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following transient MCAO for a period of 3 weeks (Bennion et al., 2017). There, it was 
shown that C21 therapy attenuated infarct volume when compared to control animals 
(Bennion et al., 2017), thus, confirming this hypothesis. It is suggested that C21 post stroke 
treatment IP might impact infarct volume by enhancing angiogenesis via the eNOS/NO 
pathway following 90 min MCAO (Alhusban et al., 2015). The angiogenic hypothesis was 
further examined in a chronic intraluminal permanent MCAO model in which C21 was 
administered as a post therapy for 21 days and shown to improve neurological function, an 
outcome associated with an upregulation of VEGF protein and gene expression levels in 
the ipsilateral hemisphere (Mateos et al., 2016).  
Interestingly, a combination of C21 and Ang-(1-7) had no effect on tissue salvage or 
neurological outcome in the present study. When examining % ischaemic lesion change 
between 60 min MCAO and 7 days recovery, the combination group showed a trend to 
improve infarct evolution; however, absolute lesion change suggested that combination 
therapy did not impact infarct progression. This indicates that at 7 days post 90 min 
MCAO, simultaneous AT2R and MasR receptor agonism does not act synergistically to 
enhance neuroprotection as initially hypothesised. One of the limitations of Ang-(1-7) 
treatment is that it is a short 7 amino acid peptide and once in circulation it has a half-life 
of  approximately 10 sec (Yamada et al., 1998). Although Ang-(1-7) has high selectivity 
for MasR (Santos et al., 2003), its short half-life impacts its actions, which might justify 
why only a mild to moderate effect was observed. Conversely, C21 has a K(i) value of 0.4 
nmol/L for the AT2R, displaying high selectivity, and an estimated half-life of 4 hrs in rats 
(Wan et al., 2004), therefore, suggesting that its actions were prolonged in the combination 
group compared to Ang-(1-7). MasR agonists are being developed and these include AVE 
0991, a non-peptide compound, high selective for the MasR and orally active(Santos and 
Ferreira, 2006). AVE 0991 is thought to have higher efficacy and a longer half-life than 
Ang-(1-7) (Santos and Ferreira, 2006); nevertheless, its effects only recently started being 
tested in the context of ischaemic stroke and so far were unsuccessful (Lee et al., 2015). 
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4.5.4.1 Treatment did not impact neurological score 
In this study, there were no differences in neurological score at 3 and 7 days post 90 min 
MCAO between groups. Ang-(1-7) induced a mild effect on tissue salvage at day 7, which 
was detected when normalising data to initial lesion at 60 min MCAO. When assessing 
infarct volume at day 7, treatment effects were not detected due to infarct volume 
variability, therefore, it would be unlikely to see any functional improvement between 
groups. At the same time, the Garcia score might have not been a sensitive test to detect 
subtle changes induced by therapy. The 18 point score is an easy and simple test to detect 
function but is of a highly subjective nature (Schaar et al., 2010). Instead, behavioural 
assessments could have been a better approach.  
Sensorimotor tests such as the adhesive removal test are reported to detect functional 
impairments up to 11 weeks following cerebral ischaemia, displaying high sensitivity to 
sensory neglect in small cerebral lesions (Zarruk et al., 2011). Other tests include the 
passive avoidance test which is a highly sensitive cognitive test, detecting impairment up 
to 7 weeks following MCAO by examining avoidance learning and shown to successfully 
correlate with size of lesion. Moreover, the beam walking test, which assesses motor 
coordination provides good sensitivity after MCAO (Zarruk et al., 2011). In future, these 
tests could be selected to study functional outcome. 
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4.5.5 Summary 
Ang-(1-7) ICV treatment along with reperfusion for 7 days post MCAO significantly 
increased tissue salvage when normalising data to initial lesion without impacting BP. 
Ang-(1-7) has a short half-life which might have contributed to a mild to moderate effect 
that was not detected when assessing data at day 7. The results obtained suggest that 
selective MasR agonists may provide neuroprotection along with reperfusion following 
thrombectomy. On the other hand, C21 alone and in combination with Ang-(1-7) did not 
show a significant impact in lesion growth at 7 days reperfusion.  
Following MCAO, neurological score was shown to decrease for all animals at day 3 and 
subsequently improve by day 7. As predicted, and as a result of comparable infarct lesions 
at day 7, there were no differences in neurological score between groups. However, it must 
be noted that the score used for functional assessment was not sensitive enough to detect 
potential Ang-(1-7)-induced alterations. Instead, it provided an overall indication of animal 
condition. In future, behavioural examinations such as the adhesive removal test should be 
used as these provide a more sensitive evaluation of deficit.  
The mechanism of action underlying the actions of Ang-(1-7) was assessed via gene 
expression assays. Although a conclusion could not be drawn from mRNA level only, 
Ang-(1-7) may have a role in oxidative stress by attenuating the decrease in NOX1 levels 
seen with vehicle treatment and possibly impacting neurogenesis. In normotensive rats, 
MCAO does not induce an imbalance in AT1A gene expression; however, AT2R was 
upregulated and MasR gene expression significantly decreased following injury. MasR 
activation possibly exerts its neuroprotective effects at an earlier stage in injury whereas 
AT2R agonism might act at a subacute/chronic level. In terms of treatment effects induced 
by Ang-(1-7) in gene expression, there were no differences in RAS components, 
chemokine leukocyte receptors, pro-inflammatory and anti-inflammatory markers 
compared to Vehicle (aCSF).  
In conclusion, Ang-(1-7) treatment along with reperfusion following MCAO for a period 
of 7 days attenuates cerebral infarct progression possibly by acting on oxidative stress 
levels or inflammatory responses at an earlier time point. To elucidate potential underlying 
mechanisms that could explain the neuroprotection observed, Ang-(1-7) treatment will be 
examined at an acute stage of injury in the subsequent study. 
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Chapter 5: The effects of Ang-(1-7) on BBB 
breakdown and microglia activation 
following transient MCAO 
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Chapter 5  
In Chapter 4, Ang-(1-7) significantly increased tissue salvage following reperfusion, a 
mechanism independent of inflammatory responses. Literature reports often attribute Ang-
(1-7)’s neuroprotective effect to a direct anti-inflammatory mechanism on 
microglia/macrophages (Liu et al., 2016; Regenhardt et al., 2013). In turn, microglia 
activation is implicated in BBB disruption by generating ROS and pro-inflammatory 
cytokine release (Yenari et al., 2006). Therefore, Ang-(1-7) may act to maintain integrity 
of the BBB via an inhibition of microglia activation. This study was designed to determine 
the effects of Ang-(1-7) post stroke therapy on BBB breakdown, infarct volume, 
microglia/macrophage activation and pro- and anti-inflammatory gene expression 
following 90 min MCAO and 24 hrs reperfusion.  
5.1 Introduction 
The BBB is a specialised structurethat separates the CNS from the periphery and consists 
of endothelial cells anastomosed to one another through TJPs. The endothelial cells in the 
BBB are surrounded by astrocytes, pericytes, neurons and basement membranes, 
ultimately forming the NVU, and providing functional and structural support to the BBB 
(Yang & Rosenberg 2011; Zlokovic 2008). After ischaemic stroke, the BBB becomes 
disrupted, allowing intravascular proteins to enter the brain parenchyma as well as 
inflammatory cells. In turn, this causes brain vasogenic oedema, increases the risk of HT 
and contributes towards morbidity and mortality (Chapouly et al., 2015; Haley and 
Lawrence, 2017).  
In the clinic, many patients exhibit a phenomenon termed HARM, characterised by blood 
vessel permeability in the meninges over the area of the stroke and associated with worse 
clinical outcome (Kohrmann et al. 2012). This is of extreme importance as thrombolysis 
treatment is reported to induce BBB breakdown and lead towards the development of 
HARM and HT (Kassner et al., 2009; Kidwell et al., 2008; Lakhan et al., 2013). Likewise, 
patients subjected to thrombectomy and presenting signs of BBB leakage, are equally 
associated with poorer clinical outcomeand HT (Renú et al., 2015). Since alteplase 
administration is the treatment of choice and endovascular therapy is becoming 
increasingly used, it is crucial to identify a potential adjuvant therapy with the capacity to 
limit BBB breakdown injury.  
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In rodents, BBB breakdown is proposed to occur in a biphasic manner following 
reperfusion onset; yet, there is no agreement on when the BBB opens and closes. Evidence 
from experimental studies suggests that the early opening of the BBB occurs between 3 to 
6 hrs following reperfusion. Following this, the barrier closes again at approximately 15 to 
24 hrs post reperfusion and by 48 to 72 hrs post reperfusion BBB breakdown is maximal 
(Belayev et al., 1996; Pillai et al., 2009; Rosenberg et al., 1998; Veltkamp et al., 2005). 
Nevertheless, the biphasic pattern of BBB opening is controversial as MRI studies indicate 
that BBB breakdown is a continuous, long-lasting mechanism and evident for at least 5 
weeks post injury (Strbian et al. 2008; Nagel et al. 2008; Lin et al. 2008). For this reason, 
the dynamics of BBB breakdown require further understanding as it could help determine 
optimal time points for neuroprotective therapy administration. 
BBB breakdown derives from an interplay of mechanisms such as inflammation, oxidative 
stress and angiogenesis within the NVU (Sandoval and Witt, 2008). In particular, 
metalloproteinases (MMPs) are widely implicated in BBB breakdown by degrading 
components of the extracellular matrix and TJPs. For instance, metalloproteinase 2 
(MMP2) is involved in the initial disruption at 3 hrs post MCAO whereas MMP9 promotes 
BBB breakdown between 24-72 hrs post stroke onset (Rosell et al., 2006; Rosenberg et al., 
1998; Sandoval and Witt, 2008; Yang et al., 2007). At later stages, BBB disruption is also 
mediated by ROS, leukocyte extravasation and pro-inflammatory mediators including 
COX-2 and iNOS(da Fonseca et al., 2014). In addition, at this stage, the angiogenic 
mediator, vascular endothelial growth factor A (VEGFA) is thought to enhance BBB 
leakage by activating vascular endothelial growth factor receptor 2 (VEGFR-2) present on 
endothelial cells (Valable et al., 2005; Zhang et al., 2000). Together, these reports highlight 
the complexity of the mechanisms underlying BBB breakdown following stroke. 
In recent years, the role of microglia in contributing towards the integrity of the NVU has 
received particular focus. Following stroke onset, these cells are quickly activated, 
recruited into the injured site and thought to exacerbate injury (da Fonseca et al., 2014). 
Supporting evidence suggest that following LPS-induced rat microglia activation, activated 
cells disrupt TJPs by stimulating NOX and subsequently ROS in a BBB disruption model 
(Sumi et al., 2010). Similarly, in vitro, studies have shown that microglia enhance barrier 
leakage by producing pro-inflammatory cytokines and ROS, an outcome reversed by 
minocycline and apocycin therapy (Yenari et al., 2006). In in vivo models, rats subjected to 
MCAO and minocycline treatment showed reduced BBB breakdown, a result suggested to 
be due to microglia phenotype modulation, promoting M2 profile (Yang et al., 2015). 
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Conversely, a recent study demonstrated that microglial cells rapidly aggregate around 
injured capillaries and mediate prompt resealing of the leaked barrier (Lou et al., 2016), 
proposing a protective role. 
Ang-(1-7) is widely reported to modulate microglia/macrophage phenotype at 24 hrs and 
72 hrs post stroke onset in normotensive rats as well as in in vitro models (Liu et al., 2016; 
Mecca et al., 2011; Regenhardt et al., 2013). In microglial cell cultures, Ang-(1-7) 
treatment prevented the upregulation of IL-6, IL-1 and NF-B activation whilst 
stimulating the generation of anti-inflammatory cytokine, IL-10 (Liu et al., 2016). 
Furthermore, Ang-(1-7) treatment attenuated iNOS and CD11b gene expression in 
normotensive rats following stroke, indicating that treatment inhibits 
microglia/macrophage activation and modulates M1/M2 phenotype (Regenhardt et al., 
2013). Accordingly, these reports place Ang-(1-7) as a possible neuroprotective drug by 
potentially modulating microglia phenotype and indirectly targeting the BBB. 
In experimental stroke, literature points towards a detrimental role of the classical RAS in 
BBB breakdown. In rat brain capillary endothelial cells subjected to 6 hrs oxygen glucose 
deprivation and 24 hrs reoxygenation, candesartan therapy reversed BBB disruption 
without impacting TJP expression or oxidative stress (So et al., 2015). The pre-treatment 
effects of candesartan were then tested in normotensive rats subjected to 60 min MCAO 
followed by 24 hrs reperfusion. The authors showed that at this time point, MCAO led to 
an exacerbated BBB breakdown with candesartan preventing disruption (Panahpour, 
Nekooeian, et al., 2014). A follow up experiment was then conducted testing the ACE 
inhibitor, enalapril as a post-stroke therapy. There, enalapril decreased BBB permeability 
due to an antioxidant effectin the same MCAO protocol (Panahpour, Dehghani, et al., 
2014). Moreover, in embolic MCAO, Wistar rats subjected to candesartan and t-PA 
combination therapy displayed reduced HT, an outcome associated to decreased NF-B 
activity (Ishrat et al., 2013). These findings implicate the classical axis in BBB injury; 
highlighting a potential therapeutic effect of the counter-regulatory axis.  
Recently, the effect of Ang-(1-7) on BBB breakdown was tested in an animal model of 
stroke. A dose response curve for Ang-(1-7) was carried out in rats at 24 hrs following 
transient MCAO and the authors demonstrated a reduction in BBB breakdown at a dose of 
0.5 pmol/hr and 5 pmol/hr (Wu et al., 2015). The outcome observed was attributed to drug 
induced TJP preservation through MMP9 expression downregulation and enhancement of 
metallopeptidase inhibitor 1 (TIMP1) levels (Wu et al., 2015). In neuroprotective studies, 
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Ang-(1-7) has been shown to attenuate infarct progression when administered ICV at a 
dose of 1.1 nmol/hr following 24 hrs, 48 hrs, 72 hrs post MCAO onset as well as 7 days as 
seen in Chapter 4 (Jiang et al., 2012, 2014; Mecca et al., 2011; Regenhardt et al., 2013). 
One could hypothesise that the underlying mechanism involves BBB preservation. Yet, the 
effect of Ang-(1-7) in BBB disruption at a dose of 1.1 nmol/hr has not been tested as a 
post-stroke therapy following 90 min MCAO and examined with MRI.  
In Chapter 4, Ang-(1-7) along with reperfusion increased tissue salvage compared to 
vehicle treated rats. Mechanistic data showed that Ang-(1-7) did not influence RAS, pro- 
and anti-inflammatory or microglia/macrophage M1/M2 phenotype marker gene 
expression and qualitative IBA1 positive microglia cell count at day 7 post reperfusion. 
Currently, there is evidence that implicates the involvement of the RAS in BBB damage, 
inflammation and microglia/macrophage activation at acute stages of cerebral injury. As a 
result, this study hypothesised that Ang-(1-7) exerts its neuroprotective effects by 
attenuating BBB disruption at 24 hrs post MCAO via a direct anti-inflammatory effect on 
microglia in the peri-infarct.  
5.1.1 Study aims: 
- Primary outcome: To evaluate the effects of post stroke Ang-(1-7) treatment on 
BBB breakdown following transient focal cerebral ischaemia. 
- To investigate the effects of Ang-(1-7) on infarct volume following transient focal 
cerebral ischaemia. 
- To determine the impact of Ang-(1-7) treatment on inflammatory gene expression 
and microglia activation in peri-infarct regions.  
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5.2 Methods 
5.2.1 Sample size calculation 
Sample size was assessed using power analysis programme G*Power (version 4.1, 
Germany). An “a priori” power analysis was performed for a t test between two 
independent means. Using data from the previous study, MCAO with reperfusion induces 
an infarct volume of 130.6mm3 with a S.D. ( of 50.7mm3. Ang-(1-7) administered as an 
ICV infusion was reported to induce approximately 50% reduction in infarcted tissue at 24 
hrs post stroke onset (Regenhardt et al., 2013). To detect an effect size of 50% reduction in 
infarct volume, a minimum n number of 9 for each group with a type I error rate () of 
0.05 and power of 0.80 was obtained.  
5.2.2 Randomisation and blinding 
Prior to study commencement, rats were assigned a number and randomly allocated to 
either Vehicle (aCSF; L/hr) or Ang-(1-7) (1.1 nmol; L/hr) treatment groups via a list 
randomiser (www.random.org). Investigators were blinded to treatment group throughout 
the experimental study. Treatment schedule was kept by a colleague within the department 
who was responsible for drug preparation one day prior to the experiment. One day prior to 
90 min MCAO and at 24 hrs post MCAO, an 18 point neurological score was performed 
for each rat as previously described (Chapter 2.11). Data analysis was performed by the 
investigator blinded to treatment group. Once all analysis and assessments were performed, 
the treatment codes were revealed.  
5.2.3 Animals and surgical procedures 
Male Wistar rats (n=33; 311-342g) were subjected to 90 min cerebral ischaemia and ICV 
treatment via osmotic pump (ALZET®, Model 2001) of Vehicle (aCSF) or Ang-(1-7) at 
start of reperfusion for 24 hrs. Experimental procedures and recovery were carried out as 
outlined in Chapter 2 and 4. In this study, 4-0 nylon silicone coated tip monofilament 
(403934PK10 or 404134PK10; Doccol Corporation, MA, USA) were used to occlude the 
MCA. For sham animals, surgery was performed as outlined; however, the filament was 
not introduced into the vessel to occlude the MCA.  
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5.2.3.1 Tail vein cannulation  
After 24 hrs reperfusion, rats were subjected to MRI imaging and gadolinium-
diethylenetriamine penta-acetic acid (Gd-DTPA, Magnevist®, Bayer, UK) contrast agent 
IV injection for BBB breakdown assessment. Animals were anaesthetised in an induction 
chamber with 5% isoflurane and then placed on a facemask at 3% isoflurane in a 70:30% 
N2O/O2 mixture. The tail vein was heated with a heating lamp to vasodilate the vessels, 
this way aiding vessel visualisation. Once the veins were easily identified, a 26 gauge × 19 
mm cannula (MillPledge Veterinary, UK) was used to cannulate the dorsal vein starting at 
the distal end. Successful cannulation was confirmed by blood sample withdrawal through 
the cannula. The cannula was then secured in place using super glue to prevent cannula 
displacement when transferring to the MRI scanner. The cannula was attached to an MR 
compatible syringe connected to tubing to allow contrast agent administration to be carried 
out while the rat is in the MRI scanner and during scanning. 
5.2.4 MRI scanning protocol 
The rat was placed in the cradle and the head restrained with ear and tooth bars and the 
surface coil placed above the head. Anaesthesia set at 3% isoflurane mixture was 
administered via facemask. Temperature was monitored with a rectal probe and controlled 
with an homeothermic blanket.  
MRA was carried out to confirm left MCA reperfusion and MRI-T2 performed to then 
assess infarct outcome. For these two scans, data was analysed and corrected to oedema 
and hemispheric compression as described in detail in Chapter 2. To quantify BBB 
breakdown, MRI-T1 weighted imaging was carried out prior to and post Gd-DTPA tail vein 
injection at 5, 10, 15, 20, 25 and 30 min from injection start. The sequence used was a 
RARE T1 with the following parameters: 8 coronal slices with a slice thickness of 1.5 mm, 
effective TE=13.5 ms, TR=800 ms and matrix size=256 × 256 with a FOV= 30 × 30 mm 
resulting in a plane resolution of 117M.  
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5.2.4.1 MRI-T1 image analysis  
RARE-T1 imaging analysis was conducted using Matlab (MathWorks Ltd, UK). MRI data 
was exported in DICOM format to be processed by an in-house developed Matlab code 
written by Dr Antoine Vallatos.  
Gd-DTPA uptake was determined in % signal change contrast-enhanced images for each 
time point post Gd-DTPA injection. % signal change maps were generated by subtracting 
MRI-T1 images before and after Gd-DTPA injection and normalising to pre-contrast MRI-
T1 scan. The following equation was carried out, where M represents image: 
 
To calculate Gd-DTPA brain volume uptake in signal change maps, a series of ROIs were 
manually selected on the dataset to generate a range of masks: 
1. A “noise” region situated outside the animal position was selected to calculate 
signal-to-noise ratio (SNR), therefore, removing variability that may have been 
caused by movement or scanning conditions (Figure 5-1A). 
2. The “whole brain” region was outlined on the MRI-T1 data prior to Gd-DTPA 
injection to remove background noise (Figure 5-1B). 
3. To avoid false positives from Gd-DTPA leakage outside the brain or in the surgery 
site where the ICV cannula was inserted, a “half brain/ipsilateral” region of interest 
was also selected on the T1 data prior to Gd-DTPA injection. In this experiment, a 
MRI phantom scan was not applied, thus, when selecting the half brain region, 
extreme care was taken to not include the base of the brain regions, which are 
usually detected in signal change maps caused by signal decay (Figure 5-1C). 
4. Cerebral ventricles were outlined with the guidance of MRI-T2 images (Figure 5-
1D) and excluded from analysis. 
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Figure 5-1 MRI-T1 image analysis protocol. A) Noise mask outline B) Whole brain ROI C) Half 
brain/ipsilateral ROI. Images A, B, C were performed on MRI-T1 data prior to Gd-DTPA injection. 
D) Cerebral ventricle ROI. MRI-T2 scans were used to outline the cerebral ventricles. 
Once all the ROIs had been performed, the “half brain/ipsilateral” masks were applied on 
the post Gd-DTPA scans and pixels intercepting the cerebral ventricles removed from the 
image. The SNR and % noise were calculated by carrying out the following formulas, 
where M is defined as noise standard deviation of the magnitude image as previously 
described (Gudbjartsson and Patz, 1995): 
 
After, % noise to signal change maps were generated and investigated to identify noise 
contribution within all images. It was observed that for all rats, noise contribution was 
approximately above 2% and below 5% for all image pixels within the brain (Figure 5-
2A). As a result, % signal change maps were generated for each time point post Gd-DTPA 
injection (Figure 5-2B) and a 25% threshold, five times higher than noise contribution 
(<5%), was arbitrarily set to quantify Gd-DPTA volume uptake in all post injection scans.  
To determine Gd-DTPA uptake volume (mm3) within the ipsilateral hemisphere, a binary 
mask was generated. Values below the established threshold were set as 0 and values 
above the threshold set as 1 (Figure 5-2C). The voxels defined as 1 were counted and 
multiplied by the voxel dimensions to obtain the overall Gd-DTPA uptake brain volume 
(mm3) for each of the 6-time point scans. After, a final Gd-DTPA uptake volume was 
obtained by averaging the volumes determined in each 6-time point % signal change map. 
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Figure 5-2 MRI-T1 % signal change map assessment. A) % noise to signal change map. 
Image shows the noise contribution in signal change in a representative brain scan slice. It was 
observed that for all scanning images, noise was above 2% and below 5% for the majority of 
pixels. A threshold of 25%, five times higher the noise contribution (<5%) was defined to determine 
Gd-DTPA uptake in ipsilateral hemisphere across. B) % Signal change map prior to threshold 
assessment. Gd-DTPA uptake in the ipsilateral hemisphere at 5 min, 10 min, 15 min, 20 min, 25 
min and 30 min post Gd-DTPA injection across 8 coronal levels. C) % Signal change map at 25% 
threshold. Representative image of Gd-DTPA uptake signal change in ipsilateral hemisphere 
defined at 25% threshold and at 20 min post Gd-DTPA injection across 8 coronal levels. Scale is 
defined from 0 to 1, where 0 represents voxels below threshold and 1 represents voxel values 
above the threshold (identified in white) and used to calculate Gd-DTPA uptake brain volume 
(mm3). 
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5.2.5 Brain tissue processing 
At the end of the MRI scanning, animals were removed from the MRI cradle and deeply 
anaesthetised for brain removal. For 14 rats (7 animals in each group), cerebral tissue was 
quickly sectioned into contralateral and ipsilateral sides and further divided into core and 
penumbra, snap frozen in liquid nitrogen and placed in -80oC for gene expression. The 
remaining 10 animals (5 in each group) were perfusion fixed for histological assessment 
and IBA1+ microglia analysis carried out as defined in Chapter 2.  
5.2.6 Exclusion criteria 
The exclusion criteria were applied at the end of the study by two independent researchers 
that were blind to treatment allocation. Animals were excluded if presenting the following 
characteristics: 
 Cannula not adequately placed in the cerebral ventricle at 24 hrs reperfusion as 
identified by MRI-T2. 
 MCA not adequately reperfused at 24 hrs reperfusion as shown by MRA 
 ICH at the MCA origin at 24 hrs reperfusion as shown by MRI-T2. 
 Animals that died or were sacrificed prior to study completion. 
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5.2.7 Statistical analysis 
Hemisphere volumes were compared within groups using paired Student’s t-test. Infarct 
volume and Gd-DTPA uptake were compared across treatment groups using unpaired 
Student’s t-test. Infarct volume intra-rater variability was assessed using parametric 
Pearson correlation and Bland-Altman analysis. Neurological score was compared using 
non parametric Mann-Whitney test. 
Gene expression data were compared between Sham, MCAO-Vehicle(aCSF) and MCAO-
Ang-(1-7) groups using one-way ANOVA with Tukey’s post hoc test andshown as -Ct 
normalised to Hrpt1.  
Total IBA1+ microglia expressed as n°/mm2 and % activated microglia from total cell 
number were compared between MCAO-Vehicle(aCSF) and MCAO-Ang-(1-7) treated 
groups in peri-infarct and homotopic contralateral regions using unpaired Student’s t-test. 
Total microglia count and % activated microglia were compared within groups using 
paired Student’s t-test.  
Data are presented as mean ± S.D or median ± IQR. A p value of <0.05 was deemed 
statistically significant. 
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5.3 Results 
5.3.1 Mortality and exclusions 
A total of 33 animals were used in these experiments, where two in the Vehicle (aCSF) 
group died overnight, leading to a study mortality of 6.1%.  
MRI-T2 showed that 3 animals did not have the ICV cannula correctly placed [1 in the 
Vehicle (aCSF) and 2 in the Ang-(1-7) treated groups] and were therefore, excluded from 
this study. All animals demonstrated reperfusion of the MCA at 24 hrs post 90 min MCAO 
as determined by MRA and a total of 28 animals were included for infarct volume and 
neurological score analysis, 13 in the Vehicle (aCSF) and 15 in the Ang-(1-7) treated 
groups. For BBB breakdown assessment, 5 animals were excluded from analysis, 1 in the 
Vehicle (aCSF) and 4 in the Ang-(1-7) treated groups, as contrast agent injection was 
unsuccessful during tail vein injections. As a result, Gd-DTPA uptake was assessed in 12 
rats in the Vehicle (aCSF) and 11 in the Ang-(1-7) groups.  
5.3.2 Neurological Score 
In this study, DWI or MRA were not conducted during MCAO. Consequently, 
investigators were blinded to initial lesion size and whether MCA was fully occluded. All 
animals with indications of neurological deficit at 24 hrs were included in this study. 
Garcia score shows that all animals had neurological impairment in both Vehicle (aCSF) 
and Ang-(1-7) treatment groups (Figure 5-3).  
5.3.2.1 Ang-(1-7) does not affect neurological score 
Data did not statistically differ between treatment groups, with Ang-(1-7) not influencing 
neurological outcome when compared to Vehicle (aCSF) treated animals (P>0.05). The 
median score for the Ang-(1-7) treated group was 11 (IQR: 10.0; 15.0). Similarly, Vehicle 
(aCSF) animals scored a median value of 13 (IQR: 10.50; 14.50), (Figure 5-3).  
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Figure 5-3 Neurological Score 24 hrs post 90 min MCAO. Neurological score at 24 hrs for 
Vehicle (aCSF) (n=13) and Ang-(1-7) (n=15) treated animals. There were no significant differences 
in neurological score between groups (P>0.05). Data were analysed with non-parametric Mann-
Whitney test; P<0.05 was deemed as significant. Horizontal bar represents the median. 
 
5.3.3 Hemisphere swelling 
MRI-T2 image analysis indicated that at 24 hrs post MCAO, ipsilateral hemisphere volume 
was significantly larger than contralateral hemisphere for both Vehicle (aCSF) 
[720.4±40.6mm3 vs 653.7±35.8mm3 (P<0.001)] and Ang-(1-7) [745.3±54.9mm3 vs 
665.4±39.1mm3 (P<0.001)] treated groups (Figure 5-4A&B). These results indicate 
significant brain oedema at this time point following transient MCAO.   
5.3.3.1 Ang-(1-7) does not affect % hemispheric swelling 
The % of ipsilateral hemisphere swelling was calculated as a measure of vasogenic 
oedema. When assessing % hemisphere swelling between groups, Ang-(1-7) treatment did 
not impact % hemisphere swelling with values being comparable to Vehicle (aCSF) group 
[12.2±7.7% vs 10.6±10.1% (P>0.05)], (Figure 5-4C).  
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Figure 5-4 Hemispheric swelling 24 hrs post 90 min MCAO. A) Hemispheric volume for Vehicle (aCSF) treated animals; B) Hemispheric volume for Ang-(1-7) 
treated animals and C) % hemispheric swelling between groups. At 24 hrs post MCAO, ipsilateral hemisphere was significantly larger than the contralateral 
hemisphere for both Vehicle (aCSF) (P=0.002) and Ang-(1-7) (P<0.001) treated animals. Data indicates that there were no differences between Vehicle (aCSF) and 
Ang-(1-7) treated animals regarding % hemisphere swelling at 24 hrs post MCAO (P>0.05). Data depicts values for Vehicle (aCSF) (n=13) and Ang-(1-7) (n=15) 
treated animals. Figures A & B were analysed using paired Student’s t test and Figure C analysed with unpaired Student’s t test; *P<0.05 was deemed as significant. 
Horizontal bar represents the mean. **P<0.01; ***P<0.001. 
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5.3.4 Infarct volume 
5.3.4.1 Ang-(1-7) does not change infarct outcome at 24 hrs reperfusion 
Infarct volume was analysed blind to treatment groups and independently analysed on two 
separate occasions to assess intra-rater reproducibility (r= 0.99; P<0.0001), (Figure 5-5A). 
Bland-Altman assessments indicated that both analyses had a bias of -2.8mm3 and a S.D of 
15.5mm3 with limits of agreement at -33.1mm3 and 27.6mm3 ranges (Figure 5-5B). The 
average of both analyses was taken as the final volume for each animal and corrected to 
hemisphere volume.  
 
Figure 5-5 Intra-rater variability in infarct volume measurement 24 hrs post 90 min MCAO. A) 
Correlation between infarct volume analyses. Infarct volume was blindly assessed two 
independent times for each animal. Pearson correlation indicates that both analyses significantly 
correlate with a Pearson r of 0.99 (P<0.0001). B) Bland-Altman analysis displaying difference 
and average in infarct analyses. Both infarct volume analyses had a bias of -2.8mm3 and a S.D. 
of 15.5mm3 with limits of agreement at -33.1mm3and 27.6mm3 ranges. Horizontal lines represent 
limits of agreements and the intersection of x and yaxis at 0,0 coordinates. 
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At 24 hrs post 90 min MCAO, Ang-(1-7) treatment did not change infarct volume when 
compared to the control group. Infarct volume was 136.4±91.4mm3 for Vehicle (aCSF) 
and 147.6±92.7mm3 for Ang-(1-7) treated groups (P>0.05), (Figure 5-6). Two animals in 
both groups exhibited extremely small lesions, below 33mm3, and this could be an 
indication that these animals had partial occlusions. Figure 5-7 illustrates the median 
animal for each treatment group. 
 
Figure 5-6 Infarct volume 24 hrs post 90 min MCAO. Infarct volume was not significantly 
different between groups (P>0.05). Data indicates infarct volume (mm3) for Vehicle (aCSF; n=13), 
Ang-(1-7) (n=15) treated animals. Data were analysed using unpaired Student’s t test; *P<0.05 was 
deemed as significant. Horizontal bar represents the mean. 
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Figure 5-7 Infarct volume distribution for Vehicle (aCSF) and Ang-(1-7) treated median animals. Images show MRI-T2 delineated infarct at 24 hrs post 90 min 
MCAO highlighted across 8 coronal levels. The top sequence illustrates the median animal in the Vehicle (aCSF) treated group highlighted in white whereas the bottom 
sequence shows the infarct size in the median animal in the Ang-(1-7) treated group highlighted in red. 
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5.3.5 Blood brain barrier breakdown assessment 
The impact of Ang-(1-7) treatment on the extent of BBB breakdown at 24 hrs post 90 min 
MCAO was assessed by carrying out MRI-T1-weighted sequences prior to and post- Gd-
DTPA contrast agent IV injection at 5, 10, 15, 20, 25 and 30 min from injection start. The 
Gd-DTPA uptake volume determined at the 6 time points post injection was averaged to 
establish final Gd-DTPA cerebral uptake volume within the ipsilateral hemisphere.  
5.3.5.1 Ang-(1-7) does not affect Gd-DTPA enhancement 24 hrs post tMCAO 
Ang-(1-7) did not alter total Gd-DTPA uptake volume in the ipsilateral hemisphere when 
compared to Vehicle (aCSF) [19.7±8.7mm3 vs 19.4±7.7mm3 (P>0.05)], (Figure 5-8A). 
Total Gd-DTPA uptake volume was more variable in the Vehicle group, where 3 rats had 
very little uptake while 1 animal had an uptake of approximately 66mm3, highlighting that 
at 24 hrs reperfusion there is considerable variability in the extent of BBB breakdown. 
The extent of Gd-DTPA uptake was expressed as a % of the respective infarct areas. 
Similarly, Ang-(1-7) treatment did not influence Gd-DTPA enhancement in infarct areas 
compared to Vehicle (aCSF) treatment [16.8±23.0% vs 19.0±22.3% (P>0.05)], (Figure 5-
8B). Together, these results suggest that Ang-(1-7) has no effect on BBB breakdown 24 hrs 
post MCAO. Figure 5-9 and 5-10 show a representative image of Gd-DTPA enhancement 
in infarct areas for the median animal in Vehicle (aCSF) and Ang-(1-7) groups, 
respectively.  
194 
 
 
Figure 5-8 Gd-DTPA enhancement 24 hrs post 90 min MCAO. A) Total ipsilateral hemisphere Gd-DTPA volume uptake (mm3) and B) Gd-DTPA volume 
uptake expressed as % of infarct volume (%). Ang-(1-7) treatment does not influence total Gd-DTPA volume or % uptake in infarct areas at 24 hrs post 90 min 
MCAO (P>0.05). Data depicts values for Vehicle (aCSF) (n=12) and Ang-(1-7) (n=11) treated animals. Data were analysed using unpaired Student’s t test; P<0.05 was 
deemed as significant. Horizontal bar represents the mean. 
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Figure 5-9 Gd-DTPA enhancement in Vehicle (aCSF) treated median animal. A) MRI-T2 delineated infarct at 24 hrs post 90 min MCAO. Images show infarct 
volume across 8 coronal levels, highlighted in white. B) MRI-T1 signal change map. % signal change map from pre to 30 min post Gd-DTPA injection. Images show 
Gd-DTPA enhancement across 8 coronal levels and the scale is set from 0 to 100% of Gd-DTPA enhancement. The Gd-DTPA enhancement observed in the 
contralateral hemisphere is due to ICV cannula placement. C) MRI-T1 signal change map at 25% threshold assessment. Gd-DTPA enhancement at 25% threshold 
within the infarct areas as determined by MRI-T2. Gd-DTPA uptake is highlighted in white and the scale bar defined from 0 to 1, where the voxels defined as 1 were 
counted and multiplied by the voxel dimensions to obtain the overall Gd-DTPA uptake brain volume. 
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Figure 5-10 Gd-DTPA enhancement in Ang-(1-7) treated median animal. A) MRI-T2 delineated infarct at 24 hrs post 90 min MCAO. Images show infarct volume 
across 8 coronal levels, highlighted in red. B) MRI-T1 signal change map. Figures show % signal change map from pre to 30 min post Gd-DTPA injection prior to 
image processing as defined in the methods. Images show Gd-DTPA enhancement across 8 coronal levels andthe scale is set from 0 to 100% Gd-DTPA 
enhancement. The Gd-DTPA enhancement observed in the contralateral hemisphere is due to ICV cannula placement. C) MRI-T1 signal change map at 25% 
threshold assessment. Gd-DTPA enhancement at 25% threshold within the infarct areas as determined by MRI-T2. Gd-DTPA uptake is highlighted in white and scale 
bar is defined from 0 to 1, where the voxels defined as 1 were counted and multiplied by the voxel dimensions to obtain the overall Gd-DTPA uptake brain volume. 
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5.4 IBA1+ microglia assessment 
Immunohistochemistry was performed across coronal levels 3, 4 and 5 for Vehicle (aCSF, 
n=5) and Ang-(1-7) (n=5) treated groups as defined in Chapter 2. Peri-infarct regions and 
ischaemic area were defined with the aid of H&E staining where 3 ROIs were outlined in 
the peri-infarct area in ipsilateral and homotopic contralateral hemispheres. IBA1+ 
microglia were counted in each of the 3 ROIs per coronal section and averaged. Data were 
expressed in n/mm2 taking into account cell count within each coronal level. In addition, 
cells were differentiated into resting or activated (Chapter 2) and presented as % activated 
microglia from total cell count. 
5.4.1 Ang-(1-7) does not influence microglia levels in peri-infarct 
and contralateral regions compared to Vehicle (aCSF) 
Total microglial numbers were similar between Ang-(1-7) and Vehicle (aCSF) treated 
groups in peri infarct regions [106.1±36.3 n/mm2 vs 111.1±45.4 n/mm2 (P>0.05)], 
(Figure 5-11A). Similarly, in the homotopic contralateral region, Ang-(1-7) treatment did 
not influence total microglia count when compared to Vehicle (aCSF) [129.0±20.3 n/mm2 
vs 130.6±29.3 n/mm2 (P>0.05)], (Figure 5-11B).  
Treatment did not alter % activated microglia in the peri-infarct region when compared to 
the Vehicle (aCSF) group [86.2±30.8% vs 93.0±11.7% (P>0.05)], (Figure 5-12A). 
Similarly, % activated microglia was comparable between groups in the homotopic 
contralateral hemisphere [62.2±2.9% vs 68.3±24.1% (P>0.05)], (Figure 5-12B). Together, 
this data suggests that Ang-(1-7) does not alter total microglia count or cell activation at 24 
hrs post MCAO. 
Data also indicates that cell numbers were similar in the peri-infarct and homotopic 
contralateral hemisphere within groups. Although microglia were not counted in the 
infarct, it was observed that IBA1+ cells were rarely observed in this area. Figure 5-13 and 
5-14 show a representative image of IBA1+ microglia staining within the peri-infarct, 
contralateral and ischaemic core. Images represent IBA1+ positive staining across the three 
assessed coronal levels for the median animal in the Vehicle (aCSF) and Ang-(1-7) treated 
group, respectively.  
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Figure 5-11 Total microglia in peri-infarct and contralateral regions 24 hrs post 90 min 
MCAO. A) Peri-infarct region; B) Homotopic contralateral region. Total microglia n/mm2 were 
comparable between Vehicle (aCSF) and Ang-(1-7) treated groups (P>0.05) in both peri-infarct and 
homotopic contralateral regions. Data shows total cell number per mm2 brain area for Vehicle 
(aCSF; n=5) and Ang-(1-7) (n=5) treated animals. Data were analysed with unpaired Student’s t 
test; P<0.05 was deemed as significant. Horizontal bar represents the mean. 
 
 
 
Figure 5-12 % activated microglia in peri-infarct and contralateral regions 24 hrs post 90 min 
MCAO. A) Peri-infarct region; B) Homotopic contralateral region. % activated cells from total 
number were comparable between treatment groups in both peri-infarct and homotopic 
contralateral regions (P>0.05). Data shows % activated microglia from total number for Vehicle 
(aCSF; n=5) and Ang-(1-7) (n=5) treated animals. Data were analysed with unpaired Student’s t 
test; P<0.05 was deemed as significant. Horizontal bar represents the mean. 
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Figure 5-13 IBA1+ microglia staining in peri-infarct, contralateral and infarct regions for Vehicle (aCSF) treated animal. Peri-infarct regions were defined with 
the aid of histology analysis as defined in Paxinos and Watson coronal levels. Infarct was outlined (grey) and three ROIs were defined for imaging and IBA1+ cell count 
in peri-infarct and homotopic contralateral areas (red squares). IBA1+ microglia immunohistochemistry staining (highlighed in red) across coronal levels 3, 4 and 5. 
Scale is set at 50M per white bar. 
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Figure 5-14 IBA1+ microglia staining in peri-infarct, contralateral and infarct regions for Ang-(1-7) treated animal. Peri-infarct regions were defined with the aid 
of histology analysis as defined in Paxinos and Watson coronal levels. Infarct was outlined (pink) and three ROIs were defined for imaging and IBA1+ cell count in peri-
infarct and homotopic contralateral areas (red squares). IBA1+ microglia immunohistochemistry staining (highlighed in red) across coronal levels 3, 4 and 5. Scale is set 
at 50M per white bar. 
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5.4.2 Total microglia count is comparable between peri infarct 
and contralateral regions within groups at 24 hrs 
In the prior section, it was observed that microglia numbers were similar between peri-
infarct and contralateral regions. To confirm that the model successfully increased 
activated microglia within the peri-infarct in comparison to the homotopic contralateral 
region, values were compared within each group.  
In the Vehicle (aCSF) animals, total microglia cell count was comparable between peri-
infarct and homotopic contralateral regions [111.1±45.44 n/mm2 vs 130.6±29.28 n/mm2 
(P>0.05), respectively], (Figure 5-15A). The peri-infarct region exhibited significantly 
higher % of activated microglia [92.97±11.74% vs 62.20±2.89% (P<0.01), respectively] 
(Figure 5-15B). Similarly, in the Ang-(1-7) group, total microglia count were comparable 
between regions [106.1±36.27 n/mm2  vs 129.0±20.27 n/mm2 (P>0.05)], (Figure 5-16A). 
The peri-infarct exhibited significantly higher levels of % activated microglia compared to 
the contralateral region [86.23±30.79% vs 68.28±24.07%; (P<0.01)], (Figure 5-16B). 
These results indicate that although total cell count was comparable within peri-infarct and 
homotopic regions, MCAO successfully led to an increase in % of activated cells within 
the peri-infarct compared to homotopic contralateral regions for both groups.  
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Figure 5-15 IBA1+ microglia assessment within Vehicle (aCSF) treated group. A) Total cell 
count; B) % activated cells. Total microglia n/mm2 was comparable in peri-infarct and 
contralateral regions (P>0.05). % activated cells were significantly higher in the peri-infarct region 
compared to the contralateral side (P<0.01). Data were expressed as total nº/mm2 or % of total cell 
count. Data were analysed with paired Student’s t test; P<0.05 was deemed as significant. 
Horizontal bar represents the mean. 
 
Figure 5-16 IBA1+ microglia assessment within Ang-(1-7) treated group. A) Total cell count; 
B) % activated cells. Total microglia n/mm2 were comparable in peri-infarct and contralateral 
regions (P>0.05). % activated cells were significantly higher in the peri-infarct region compared to 
the contralateral side (P<0.01). Data were expressed as total nº/mm2 or % of total cell count. Data 
were analysed with paired Student’s t test; P<0.05 was deemed as significant. Horizontal bar 
represents the mean. 
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5.5 Quantitative Real Time PCR 
Following 24 hrs reperfusion, peri-infarct ipsilateral brain regions for Sham (n=6), MCAO-
aCSF (n=7) and MCAO-Ang-(1-7) (n=7) treated animals were assessed for gene 
expression. Hrpt1 was selected as internal control for data normalisation as described in 
detail in Chapter 2.  
5.5.1 MCAO did not affect RAS or Bdkrb2 expression 
Following 24 hrs post 90 min MCAO, Atgr1a, Atgr2r, Mas1, Ace, Ace2 and Bdkrb2 levels 
were comparable to Sham tissue, P>0.05 (Figure 6-17A:F).   
5.5.2 MCAO significantly increased Mmp9 and Timp1 expression 
Mmp9 expression was significantly higher in MCAO-aCSF group when compared to Sham 
tissue [-3.1±1.6 vs -5.8±2.0 (P<0.05)], (Figure 5-18A). MCAO-Ang-(1-7) showed a trend 
to significantly upregulate Mmp9 expression when compared to Sham, however, this was 
not statistically significant [-3.3±1.9 vs -5.8±2.0 (P=0.056)], (Figure 5-18A). Treatment 
did not change Mmp9 expression following MCAO.  
Timp1 was significantly upregulated following MCAO in both Vehicle (aCSF) and Ang-
(1-7) treated animals compared to Sham; 2.1±2.5 vs -3.3±0.6 (P<0.001) and 3.1±1.9 vs -
3.3±0.6 (P<0.001), respectively (Figure 5-18B). The relative expression of Timp1 was 
higher than Mmp9 at this time point, perhaps explaining the low levels of brain Gd-DTPA 
uptake after 90 min MCAO. Supportively, the average Ct values for Timp1 were 25.0 and 
23.6 for Vehicle and Ang-(1-7) treated groups whereas Mmp9 Ct values were 30.2 and 
30.0, respectively. 
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Figure 5-17 RAS components and B2R gene expression 24 hrs post 90 min MCAO. A) Atgr1a; 
B) Atgr2; C) Mas1; D) Ace; E) Ace2 and F) Bdkrb2. MCAO did not alter RAS mediators or B2R 
gene expression in both Vehicle (aCSF) and Ang-(1-7) treated animals compared to Sham 
(P>0.05). Data were presented as -Ct normalised to Hrpt1 for Sham (n=6); MCAO-Vehicle 
(aCSF;n=7) and MCAO-Ang-(1-7) (n=7) treated animals in peri-infarct regions. Data were analysed 
with one-way ANOVA; P<0.05 was deemed as significant. Horizontal bar represents the mean. 
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Figure 5-18 MMP9 and TIMP1 gene expression 24 hrs post 90 min MCAO. A) Mmp9 and B) Timp1. MCAO significantly upregulated Mmp9 in MCAO-aCSF group 
compared to Sham (P<0.01). MCAO-Ang-(1-7) animals showed a trend to significantly upregulate Mmp9 compared to Sham (P=0.056). There were no statistical 
differences between MCAO-Vehicle and MCAO-Ang-(1-7) groups. MCAO significantly upregulated Timp1 expression compared to Sham in both Vehicle (aCSF) 
(P<0.001) and Ang-(1-7) (P<0.001) treated groups. Data were presented as -Ct normalised to Hrpt1 for Sham (n=6); MCAO-Vehicle (aCSF;n=7) and MCAO-Ang-(1-
7) (n=7) treated animals in peri-infarct regions. Data were analysed with one-way ANOVA with Tukey’s post-hoc test; P<0.05 was deemed as significant. *P<0.05; 
***P<0.001 compared to Sham. Horizontal bar represents the mean. 
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5.5.2.1 Ang-(1-7) treatment did not impact Vegfa or Kdr expression 
VEGFA (Vegfa) and VEGFR-2 (Kdr) levels were comparable between groups, P>0.05 
(Figure 5-19A&B).  
 
Figure 5-19 VEGFA and VEGFR-2 gene expression 24 hrs post 90 min MCAO. A) Vegfa and 
B) Kdr. MCAO did not alter Vegfa or Kdr expression when compared to Sham (P>0.05). Data were 
presented as -Ct normalised to Hrpt1 for Sham (n=6); MCAO-Vehicle (aCSF; n=7) and MCAO-
Ang-(1-7) (n=7) treated animals in peri-infarct regions. Data were analysed with one-way ANOVA; 
P<0.05 was deemed as significant. Horizontal bar represents the mean. 
5.5.3 MCAO significantly increased Ptgs2 but not Nfkb1 
MCAO in Vehicle (aCSF) and Ang-(1-7) treated groups significantly upregulated Ptgs2 
expression compared to Sham tissue; 0.7±1.7 vs -1.8±1.1 (P<0.05) and 1.4±1.8 vs -1.8±1.1 
(P<0.05), respectively (Figure 5-20A). Conversely, Nfkb1 levels ware comparable to Sham 
levels between groups (P>0.05), (Figure 5-20B).  
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Figure 5-20 COX-2 and NF-B gene expression 24 hrs post 90 min MCAO. A) Ptgs2 and B) 
Nfkb1. MCAO significantly upregulated Ptgs2 expression when compared to Sham (P<0.05). 
Conversely, Nfkb1 levels were comparable amongst groups (P>0.05). Data were presented as -
Ct normalised to Hrpt1 for Sham (n=6); MCAO-Vehicle (aCSF; n=7) and MCAO-Ang-(1-7) (n=7) 
treated animals in peri-infarct regions. Data were analysed with one-way ANOVA with Tukey’s 
post-hoc test; P<0.05 was deemed as significant. Horizontal bar represents the mean. *P<0.05; 
**P<0.01 compared to Sham. 
5.5.4 MCAO significantly upregulated Cxcr2, Ccr2 and Ccr5 
Cxcr2 was significantly upregulated in MCAO-Vehicle (aCSF) and MCAO-Ang-(1-7) 
when compared to Sham animals in peri-infarct regions: -5.0±2.3 vs -8.8±1.2 (P=0.002) 
and -6.0±1.6 vs -8.8±1.2 (P=0.02), respectively (Figure 5-21A). Similarly, MCAO 
significantly upregulated Ccr2 in Vehicle and Ang-(1-7) treated groups compared to Sham: 
-3.2±2.2 vs -6.2±0.8 (P=0.01) and -3.0±1.8 vs -6.3±0.8 (P=0.009), respectively (Figure 5-
21B). Ccr5 levels significantly increased following MCAO-Vehicle (aCSF) compared to 
Sham, -1.24±0.50 vs -2.12±0.76 (P=0.04). MCAO-Ang-(1-7) treated rats showed a trend to 
prevent the increase in Ccr5 expression as seen in MCAO-Vehicle animals. MCAO-Ang-
(1-7) Ccr5 values were not significantly different from Sham (P=0.64) or MCAO-Vehicle 
rats (P=0.17), (Figure 5-21C). 
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Figure 5-21 Chemokine receptor expression 24 hrs post 90 min MCAO. A) Cxcr2; B) Ccr2 
and C) Ccr5. MCAO significantly upregulated Cxcr2 and Ccr2 expression compared to Sham 
animals (P<0.05). MCAO significantly upregulated Ccr5 in MCAO-aCSF group compared to sham 
(P<0.05) whereas MCAO-Ang-(1-7) was not significantly different from Sham or MCAO-Vehicle 
(aCSF) (P>0.05). Data were presented as -Ct normalised to Hrpt1 for Sham (n=6); MCAO-Vehicle 
(aCSF; n=7) and MCAO-Ang-(1-7) (n=7) treated animals in peri-infarct regions. Data were 
analysed with one-way ANOVA with Tukey’s post-hoc test; P<0.05 was deemed as significant. 
Horizontal bar represents the mean. *P<0.05 compared to Sham. 
5.5.5 MCAO does not impact Nox1 or Nox2 expression 
Nox1 and Nox2 gene expression were comparable to Sham levels between groups 
(P>0.05), (Figure 5-22A&B). 
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Figure 5-22 NOX type 1 and type 2 gene expression 24 hrs post 90 min MCAO. A) Nox1; B) 
Nox2. Data shows that MCAO did not alter Nox1 or Nox2 compared to Sham (P>0.05). Data were 
presented as -Ct normalised to Hrpt1 for Sham (n=6); MCAO-Vehicle (aCSF; n=7) and MCAO-
Ang-(1-7) (n=7) treated animals in peri-infarct regions. Horizontal bar represents the mean. Data 
were analysed with one-way ANOVA; P<0.05 was deemed as significant. 
 
5.5.6 MCAO increased M1 type microglia/macrophage profile 
expression 
MCAO significantly upregulated CD86 levels compared to Sham; -3.2±1.5 vs -5.6±0.8 and 
-3.3±1.6 vs -5.6±0.8 (P<0.001) in Vehicle and Ang-(1-7) treated rats, respectively (Figure 
5-23A). Similarly, MCAO significantly increased Itgam [-0.3±0.8 vs -3.2±0.7 and -0.8±0.7 
vs -3.2±0.7 (P<0.001)] (Figure 5-23B), Il6 [-3.8±2.6 vs -8.7±0.9 and -3.2±1.7 vs -8.7±0.9 
(P<0.001)] (Figure 5-23C), Il1b-4.89±1.95 vs -7.62±0.60 (P=0.002) and -4.91±1.82 vs -
7.62±0.60 (P<0.001)] (Figure 5-23D), Nos2 [-4.9±2.8 vs -10.4±1.1 and -4.8±1.8 vs -
10.4±1.1 (P<0.001)] (Figure 5-23E), in both vehicle and Ang-(1-7) treated groups 
compared to sham, respectively. Ang-(1-7) did not change the gene expression of M1 type 
markers compared to MCAO-aCSF (Figures 5-23A:E). 
Ccr7 showed a trend to increase following MCAO, however, it was most predominant in 
Ang-(1-7) treated animals being statistically different when compared to Sham [-5.2±1.9 
vs -7.7±1.0 (P<0.05)], (Figure 5-23F). MCAO-Vehicle values did not differ from Sham or 
Ang-(1-7) treated groups (P>0.05).  
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Figure 5-23 M1 type microglia/macrophage markers 24 hrs post 90 min MCAO. A) CD86; B) 
Itgam; C) Il6; D) Il1b E) Nos2 and F) Ccr7. MCAO significantly upregulated the expression of 
CD86, Itgam, Il6, Il1b and Nos2 compared to Sham (P<0.05) with no differences between MCAO 
treatment groups (P>0.05). Ccr7 was significantly upregulated in MCAO-Ang-(1-7) treatment group 
compared to Sham. MCAO-Vehicle (aCSF) Ccr7 values did not significantly differ from Sham or 
MCAO-Ang-(1-7) groups (P>0.05). Data were presented as -Ct normalised to Hrpt1 for Sham 
(n=6); MCAO-Vehicle (aCSF;n=7) and MCAO-Ang-(1-7) (n=7) treated animals in peri-infarct 
regions. Data were analysed with one-way ANOVA with Tukey’s post-hoc test; P<0.05 was 
deemed as significant. Horizontal bar represents the mean. *P<0.05; **P<0.01; ***P<0.001 
compared to Sham. 
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5.5.7 MCAO increased M2 microglia/macrophage markers, Ccl22 
and Tgfb1 but not Arg1 or CD163 
M2 surface markers Arg1 and CD163 were comparable to Sham following MCAO (Figure 
5-24A&B). Conversely, MCAO significantly increased the expression of Ccl22 [-5.3±1.9 
vs -8.3±0.7 and -5.5±2.1 vs -8.3±0.7 (P<0.05)] and Tgfb11.5±1.2 vs -0.2±0.8 (P<0.05) 
and 1.8±1.0 vs -0.2±0.8, (P<0.001)] when compared to Sham animals in control and Ang-
(1-7) animals, respectively (Figure 5-24C&D). Il10 was not detected in peri-infarct 
samples.  
 
Figure 5-24 M2 type microglia/macrophage markers 24 hrs post 90 min MCAO. A) Arg1; B) 
Cd163; C) Ccl22 and D) Tgfb1. MCAO significantly upregulated the expression of Ccl22 and 
Tgfb1 compared to Sham (P<0.05). Conversely, Arg1 and CD163 levels were comparable between 
groups (P>0.05). Data were presented as -Ct normalised to Hrpt1 for Sham (n=6); MCAO-Vehicle 
(aCSF;n=7) and MCAO-Ang-(1-7) (n=7) treated animals in peri-infarct regions. Data were analysed 
with one-way ANOVA with Tukey’s post-hoc test; P<0.05 was deemed as significant. Horizontal 
bar represents the mean. *P<0.05; **P<0.01; ***P<0.001 compared to Sham. 
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5.6 Discussion 
This study was designed to examine the potential impact of Ang-(1-7) on BBB breakdown, 
infarct volume; microglia number/activation and gene expression at 24 hrs post 90 min 
MCAO. The time point selected represents a stage where the BBB is transitioning from a 
closed to open state and the final infarct has not yet matured (Pillai et al. 2013; Neumann-
Haefelin et al. 2000). Results indicate that at 24 hrs post MCAO, Ang-(1-7) treatment does 
not improve BBB breakdown, infarct volume, microglia number, activation or pro and 
anti-inflammatory gene expression markers when compared to Vehicle (aCSF) treated 
animals.  
5.6.1 Ang-(1-7) does not affect BBB breakdown and vasogenic 
oedema 24 hrs post MCAO 
 
For the first time, the effects of Ang-(1-7) on BBB breakdown at 24 hrs post MCAO were 
evaluated with contrast enhanced MRI. Moreover, MRI-T2 and MRA were used to confirm 
that the ICV cannula was adequately placed in the ventricle and that all animals were 
reperfused at 24 hrs. Results show that at 24 hrs following transient focal cerebral 
ischaemia, central Ang-(1-7) treatment does not influence total Gd-DTPA enhancement 
volume across the ipsilateral hemisphere. Similarly, % Gd-DTPA extravasation per infarct 
volume was comparable to the Vehicle (aCSF) group, indicating that treatment had no 
effect on BBB breakdown at this time point. MRI-T2 analysis successfully identified that at 
the time point assessed; vasogenic oedema is present within the ipsilateral hemisphere as 
hemispheric volume was significantly higher when compared to contralateral side. Still, 
when comparing hemispheric swelling between groups, data showed no differences 
induced by therapy. These results highlight that Ang-(1-7) does not act by preventing BBB 
disruption or vasogenic oedema in our hands.  
The “classical axis” of the RAS has been implicated in BBB disruption pathology 
following stroke in in vitro models as well as in vivo assessments following MCAO in 
normotensive rats (Panahpour, Nekooeian, et al. 2014; So et al. 2015; Panahpour, 
Dehghani, et al. 2014); therefore, setting the premise that the counter-regulatory axis might 
offer a protective effect. Ang-(1-7) was previously tested in a normotensive MCAO rat 
model where it was shown that treatment decreased Evans Blue (EB) extravasation 24 hrs 
post 90 min MCAO. The outcome observed was attributed to a reduction of MMP9 and 
enhancement of TIMP1 gene and protein expression, which promoted claudin-5 and ZO-1 
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preservation (Wu et al., 2015). In Wu’s study, Ang-(1-7) was tested at 5 different doses 
(0.005 pmol/hr; 0.005 pmol/hr; 0.05 pmol/hr; 0.5 pmol/hr; 5 pmol/hr) with the authors 
identifying that Ang-(1-7) prevented BBB disruption at higher doses only (0.5 pmol/hr and 
5 pmol/hr) and subsequently proposing a dose dependent effect on BBB preservation (Wu 
et al., 2015). In our study, Ang-(1-7) was administered at a dose of 1.1 nmol/hr, which is 
substantially higher than the doses used beforehand. Therefore, in future, lower doses 
might be more effective. Additionally, Wu’s study did not evaluate the extent of infarct 
volume damage; thus, the results obtained could not be associated with a treatment-
induced effect in the ischaemic damage, contrarily to our experiment. 
MRI was chosen as the method of assessing BBB breakdown as it is the most commonly 
used technique to study BBB disruption in both preclinical and clinical studies (Wunder et 
al., 2012). Alternatively, Wu et al. selected EB extravasation as a method of assessing 
integrity of the BBB (Wu et al., 2015). Although EB extravasation is a simple and widely 
used method, it has the disadvantage of potentially overestimating BBB breakdown as it 
presents reversible binding kinetics to serum albumin and also binds to other plasma 
proteins and tissues (Connelly et al. 2015). Conversely, Gd-DTPA does not bind to 
albumin and induces a differential extravasation pattern to that observed in EB staining, 
perhaps explaining the contradicting results. Yet, studies using Gadofluorine M, a new 
contrast agent formulation with strong binding properties to albumin, identified that 
following stroke; Gadofluorine M leads to highly sensitive signal enhancement within 24 
hrs and an extravasation pattern similar to that observed in EB assessment (Stoll et al., 
2009). One could postulate that the absence of Gd-DTPA signal enhancement does not 
necessarily mean that BBB breakdown is not occurring but rather that Gd-DTPA might not 
be sensitive enough to detect subtle changes.  
Gd-DTPA contrast enhancement technique was shown to be quite challenging as contrast 
administration failed in 5 rats, which meant that more animals were required to have a 
sufficient sample size. Furthermore, several factors influence Gd-DTPA distribution 
amongst rats including vessel permeability, surface area, blood flow as well as 
intravascular and extracellular-extravascular volume fractions (Kassner and Merali, 2015). 
Physiological parameters were not assessed during imaging or included in BBB breakdown 
analysis; therefore, one could assume that these variables might have influenced Gd-DTPA 
extravasation amongst rats. Alternatively, dynamic contrast enhanced MRI (DCE-MRI) 
takes into account these factors and provides a sensitive method to detect subtle MRI-T1 
contrast enhancement changes when compared to contrast-enhanced T1 alone (Heye et al., 
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2014). In DCE-MRI, multiple sampling times are obtained characterising the enhancement 
over time, this way, allowing mapping of spatial BBB breakdown throughout the brain. To 
do so, compartmental models are used to define the contrast exchange between blood 
plasma and tissue extracellular compartment (Heye et al., 2014; Kassner and Merali, 
2015). This type of assessment has been shown to consistently detect BBB breakdown in a 
sensitive manner in both preclinical and clinical studies 24 hrs post MCAO (Lin et al., 
2002; Merali et al., 2017), providing a suitable alternative method to use in future.  
It is important to note that this proof of principle study was conducted in young, healthy 
male rats. As mRNA data indicates, RAS components were expressed to Sham levels, 
suggesting that the RAS may not be implicated in cerebral injury at 24 hrs and justifying 
the results obtained. It is possible, however, that in co-morbidity animal models, counter-
regulatory axis targeting may be beneficial in preventing BBB injury. For instance, 
SHRSPs subjected to salt loading or Ang II with candesartan treatment, showed that 
treatment prevented BBB impairment and superoxide generation (Kim-Mitsuyama et al., 
2005). Additionally, in Dahl salt-sensitive rats, olmesartan therapy reduced BBB 
breakdown in the hippocampus by attenuating Ang II levels and preserving TJPs (Pelisch 
et al., 2011). As a result, in comorbid models, counter-regulatory targeting therapies may 
provide an enhanced benefit rather than what is seen in normotensive models. 
5.6.1.1 BBB breakdown displays a variable pattern at 24 hrs reperfusion  
Gd-DTPA uptake at 24 hrs displayed a variable pattern amongst animals. In some rats, 
contrast enhancement was remotely present in areas of infarct whereas in others, it was 
identified in over 70% of the ischaemic area. These results imply that at this time point, the 
BBB is at a transient point of disruption. This suggests a biphasic BBB pattern rather than 
a continuous disruption as previously hypothesised (Belayev et al., 1996; Pillai et al., 2009; 
Rosenberg et al., 1998; Veltkamp et al., 2005). The transient pattern of BBB disruption at 
24 hrs post stroke is not well characterised. However, it is postulated that this mechanism 
is an outcome of claudin-5 and occludin protein expression decrease in the endothelial 
cells yet present in astrocytes surrounding the vasculature, justifying this temporary closure 
(Yang et al., 2007). In addition, TJPs are suggested to reassemble due to a reversal in ROS 
mediated injury (Meyer et al., 2001). Supportively, qPCR results showed that in peri-
infarct regions, NOX1 and NOX2 mRNA levels were comparable to Sham levels. There is 
no consensus regarding the time point at which the BBB is at its maximum disruption, with 
literature proposing that it might occur between 48 hrs and 72 hrs reperfusion (Belayev et 
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al., 1996; Pillai et al., 2009; Rosenberg et al., 1998; Veltkamp et al., 2005). Since at 24 hrs 
BBB opening was shown to vary amongst animals, the time point selected may not have 
been optimal to examine the treatment effect of Ang-(1-7) on BBB breakdown. 
Longitudinal experiments investigating the impact of Ang-(1-7) on BBB disruption should 
be performed to identify the appropriate time at which maximal barrier disruption occurs 
and whether this is influenced by treatment. 
Although our findings indicate that BBB disruption is variable at the point assessed, 
vasogenic oedema was present and detected by differences in hemispheric volumes. It 
could be argued that oedema is the outcome of the first phase of BBB opening (Rosenberg 
et al., 1998). At the same time, following 90 min MCAO, the expression of TJPs in 
Fluorescein Isothiocyanate (FITC)-albumin leakage regions are unaltered at 24 hrs 
reperfusion, yet, structural alterations take place in the vascular endothelium causing 
swelling and oedema (Krueger et al., 2017). Therefore, in some animals, it is likely that 
structural endothelial cell changes are occurring and allowing free flow of water molecules 
into the brain; however, the TJP integrity might not allow the extravasation of Gd-DTPA.  
5.6.1.2 MCAO upregulates MMP9 and TIMP1 gene expression with no Ang-
(1-7) induced effects 
To dissect potential undetected effects, the expression for markers involved in BBB 
disruption were assessed with qPCR. MMP9 mRNA levels were upregulated following 
MCAO compared to Sham whereas MCAO-Ang-(1-7) rats indicated a trend to increase 
MMP9, nearly reaching significance. In turn, MMP9 may be acting to disrupt the BBB, 
explaining why disruption was observed in all animals even if at low levels in some. 
Indeed, MMP9 is of special relevance in BBB disruption since stroke patients with 
increased serum MMP9 levels demonstrate exacerbated DWI lesion growth and higher risk 
of developing HT (Inzitari et al., 2013; Rosell et al., 2005), highlighting its involvement in 
BBB breakdown in preclinical and clinical studies. Ang-(1-7) was previously suggested to 
decrease MMP9 mRNA and protein expression following 90 min MCAO with 24 hrs 
reperfusion (Wu et al., 2015). Our data, however, contradicts previous findings and further 
emphasises that therapy does not alter BBB breakdown at the time point examined. 
MMP9 is regulated by TIMP1 by non-covalent binding in the MMP catalytic domains 
(Turner and Sharp, 2016). In our study, TIMP1 mRNA expression was significantly 
increased following MCAO and contrarily to Wu’s study (Wu et al., 2015); we 
demonstrate no Ang-(1-7) therapy induced effects. Interestingly, the relative expression of 
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TIMP1 was substantially higher than MMP9 in brain samples, perhaps explaining the 
decrease in BBB breakdown at this time point. In fact, MMP9/TIMP1 ratio, favouring 
MMP9 expression, positively correlates with brain damage following cerebral ischaemia in 
preclinical and clinical assessments (Li et al., 2013; Piccardi et al., 2015), thus, increases in 
TIMP1 could protect MMP9-derived ECM and TJP degradation. The protective role of 
TIMP1 in BBB breakdown has been extensively studied. TIMP1-KO mice display 
enhanced MMP9 protein expression compared to WT, which was associated with BBB 
disruption (Fujimoto et al., 2008). On the contrary, mice overexpressing TIMP1 had 
reduced MMP9 levels, an effect linked to attenuated infarct volume and ameliorated BBB 
leakage (Tejima et al., 2009). These results place MMP9 as a main mediator in barrier 
disruption that is possibly being reversed by TIMP1. To confirm these effects, MMP9 and 
TIMP1 protein levels through Western Blot or immunohistochemistry should be assessed 
within the peri-infarct regions as well as TJP protein levels to confirm 
preservation/degradation. At the same time, complementary experiments such as 
gelatinzymography could be performed to study MMP9/TIMP1 induced ECM and TJP 
degrading activity in cultured brain cells (Toth et al., 2012). 
Other BBB breakdown markers studied were VEGFA and VEGFR-2. VEGFA is a potent 
growth factor involved in BBB breakdown in the early phases of injury through VEGFR-2 
activation (Bates et al., 2002). The role of VEGFA in mediating stroke injury is well 
described, with its inhibition at 24 hrs reperfusion attenuating BBB disruption following 
stroke (Zhang et al., 2017). In permanent MCAO, Ang-(1-7) therapy was shown to alter 
VEGF expression at 24 hrs post stroke onset (Jiang et al., 2014); however, in the present 
study, VEGFA and VEGFR-2 mRNA expression levels were comparable to Sham animals 
in MCAO groups. VEGFA and VEGFR-2 proteins are highly present 3 days post injury in 
the lesion site (Lennmyr et al., 1998),  thus, VEGFA could be mainly involved in the 
subsequent BBB opening between 48-72 hrs, where there is a dramatic increase in 
permeability (Pillai et al., 2013).  
5.6.1.3 Ang-(1-7) does not alter inflammation, oxidative stress or leukocyte 
infiltration markers 
In ET-induced MCAO models, Ang-(1-7) therapy is suggested to induce an anti-
inflammatory effect at 24 hrs and 72 hrs post stroke onset by attenuating iNOS mRNA and 
protein expression in the ipsilateral hemisphere (Mecca et al., 2011; Regenhardt et al., 
2013). In addition, in permanent MCAO, Ang-(1-7) treatment decreased COX-2 protein 
levels in peri-infarct tissue at 24 hrs post injury start (Jiang et al., 2012). iNOS and COX-2 
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enzymes are thought to interact with one another as COX-2-positive neurons are present in 
close proximity to iNOS positive neutrophils (Nogawa et al., 1998). This in turn, 
stimulates an increase in ROS and toxic prostanoids promoting BBB breakdown (Nogawa 
et al., 1998). The mRNA levels for both these mediators were upregulated following 
MCAO in peri-infarct regions, highlighting its involvement in injury. However, compared 
to vehicle treated group, Ang-(1-7) treatment did not change iNOS and COX-2 gene 
expression at 24 hrs post stroke onset. 
Ang-(1-7) is also suggested to decrease phosphorylated IB- and NF-B p65 protein 
levels as well as attenuate NF-B mRNA and protein levels in microglia cultures (Jiang et 
al., 2012; Liu et al., 2016). Following MCAO, NF-B mRNA levels were comparable to 
Sham animals. Yet, the expression of iNOS, COX-2, IL-6, and MMP9 were upregulated 
following MCAO and these are dependent on NF-B activation (Harari and Liao, 2010). 
Ang-(1-7) did not alter NF-B, IL-6, MMP9, COX-2 or iNOS; therefore, suggesting that 
Ang-(1-7) does not induce an anti-inflammatory effect in the animal model used and as a 
post-stroke onset therapy. Simultaneously, the method used to study therapy effects on NF-
B levels may not have been appropriate. In future studies, Western Blot or 
immunohistochemistry analysis of NF-B components such as p50, p52 and RelB subunits 
should be assessed as well as protein signalling pathway components.  
We then assessed NOX1 and NOX2 mRNA levels since Ang II is suggested to enhance 
oxidative stress in the brain through these mediators (Wang et al. 2006; Sun et al. 2005; 
Jackman et al. 2009; Kahles et al. 2010). NOX1 and NOX2 enzymes are main mediators of 
vascular damage and shown to contribute towards BBB breakdown (Chen et al., 2011; 
Gray and Jandeleit-Dahm, 2015). Specifically, when inhibiting NOX with apocynin or by 
genetic ablation, the severity of BBB disruption is reduced (Chen et al., 2009). In the 
present study, NOX1 and NOX2 were expressed at Sham levels at 24 hrs following 
transient MCAO, possibly an indication of reduced oxidative stress and thereby explaining 
the biphasic BBB pattern at 24 hrs (Meyer et al., 2001). Interestingly, Ang-(1-7) did not 
change NOX1 or NOX2 mRNA expression, contrarily to what was observed at day 7 post 
transient MCAO in Chapter 4. These results further emphasise that at 24 hrs reperfusion, 
Ang-(1-7) post stroke therapy does not alter inflammatory or oxidative stress markers.  
The effects of Ang-(1-7) on leukocyte chemokine receptors CXCR2, CCR2 and CCR5 
were also studied. CXCR2 mediates neutrophil extravasation and is implicated in BBB 
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breakdown by increasing the permeability of endothelial cell monolayers cells 
(Gelderblom et al., 2012). CCR2 regulates the mobilisation of monocytes from bone 
marrow to inflammatory sites and its expression in astrocytes and endothelial cells is 
directly implicated in BBB breakdown by inducing TJP phosphorylation (Chu et al., 2014; 
Dimitrijevic et al., 2006). Moreover, CCR5 was recently suggested to stimulate Treg cell 
chemotaxis following stroke leading to Treg-induced BBB preservation (Li et al., 2017). In 
the present study, MCAO significantly increased the expression of CCR2, CXCR2 and 
CCR5 at 24 hrs post injury. Ang-(1-7) treatment did not significantly alter leukocyte 
chemokine receptor mRNA expression compared to vehicle treated animals; however, it 
showed a trend to prevent the increase in CCR5 expression as seen in the control group. 
The role of CCR5 in BBB breakdown is currently not well understood and a potential Ang-
(1-7) effect on this receptor should be studied. Nonetheless, these results postulate that 
Ang-(1-7) does not influence leukocyte infiltration. 
5.6.2 Ang-(1-7) does not impact infarct volume, neurological 
score or RAS mediators 
In normotensive rats, the ischaemic lesion following reperfusion has been shown to peak at 
2 days and subsequently decrease by day 7 (Neumann-Haefelin et al., 2000); therefore, at 
24 hrs post MCAO, the infarct volume may not have fully matured. Ang-(1-7) is proposed 
to act at this stage of injury by decreasing infarct volume following ET-1 induced MCAO 
(Regenhardt et al., 2013). Our results, however, contradict previous findings as infarct 
volume and neurological score were comparable to Vehicle (aCSF). DWI-MRI was not 
performed during MCAO; thus, it was not possible to normalise final ischaemic lesion to 
initial lesion as we did in the previous Chapter. Ang-(1-7) could be exerting a mild 
neuroprotective effect that is not detected due to lesion variability during MCAO, similar 
to what was seen in Chapter 4. Furthermore, MRA was not performed during MCAO and 
therefore variability due to partial occlusions may play a role in the present study. 
Neurological score was used as a tool to examine whether rats should be included in this 
experiment and indeed, all animals exhibited neurological deficit at 24 hrs. However, Ang-
(1-7) failed to induce a therapeutic effect in neurological score similar to what was 
observed in Chapter 4.  
Interestingly, at 24 hrs post injury onset, MCAO alone did not induce any alterations in 
RAS components’ gene expression, emphasising that the RAS may not be implicated in 
cerebral injury at this time point. Consequently, it is plausible that the RAS might be 
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implicated in injury at 48-72 hrs post stroke onset once injury reaches its hiatus. Contrary 
to our findings, MasR and ACE2 mRNA levels were previously shown to be upregulated 
24 hrs following stroke onset in a permanent MCAO model (Lu et al., 2013). One could 
postulate that MasR and ACE2 are implicated in models of persistent hypoxia at 24 hrs but 
not in reperfusion injury. In addition, B2R mRNA levels were similar to Sham, indicating 
that at 24 hrs post MCAO, Ang-(1-7) does not stimulate B2R expression and subsequent 
vasodilation, as previously suggested (Lu et al., 2008).  
5.6.3 Ang-(1-7) does not affect IBA1+ microglia or M1/M2 
microglia/macrophage mRNA profile 
Ang-(1-7) is reported to act on microglia/macrophages in experimental stroke models (Liu 
et al., 2016; Mecca et al., 2011; Regenhardt et al., 2013, 2014). Firstly, MasR is expressed 
in microglia and secondly, Ang-(1-7) treatment is thought to modulate 
microglia/macrophage inflammatory gene and protein expression (Liu et al. 2016; 
Regenhardt et al. 2013). Equally, Ang-(1-7) therapy prevented LPS-induced NO induction 
in primary glial cultures (Regenhardt et al., 2013), supporting this hypothesis. In the 
present study, IBA1+ microglia total numbers did not differ between Ang-(1-7) and 
Vehicle (aCSF) treatment in peri-infarct and the homotopic contralateral regions. 
Similarly, the % of activated microglia in both peri-infarct and contralateral regions were 
comparable between groups.  
To confirm the validity of the model used, IBA1+ microglia numbers/activation were 
compared within groups. Total IBA1+ cell numbers were similar in peri-infarct and 
contralateral regions in both groups; however, MCAO increased % activated microglia in 
the peri-infarct region compared to the homotopic contralateral side. Therefore, confirming 
that transient focal cerebral ischaemia alone resulted in a significant activation of microglia 
within the peri-infarct region. Previous studies have shown that following 90 min MCAO, 
IBA1+ microglia appear in the peri-infarct regions as early as 3.5 hrs hours post-
reperfusion and peak at 7 days (Ito et al., 2001). Thus, indicating that microglia numbers 
are not maximal at 24 hrs. In addition, in the ischaemic core, IBA1+ microglia were 
scarcely present. Microglia degenerate 12 hrs after reperfusion with active IBA1+ cells 
then infiltrating the core after 24 hrs and peaking at 4 and 7 days post-reperfusion (Ito et 
al., 2001). We show that at early stages of microglia infiltration Ang-(1-7) does not alter 
IBA1+ cell number or activation. Similarly, at day 7 when microglia levels reach its hiatus, 
there were no indications of Ang-(1-7) induced effects (Chapter 4).  
220 
 
Microglia/macrophage M1 and M2 type mRNA markers were similar between MCAO 
groups. Previous findings demonstrated that Ang-(1-7) attenuated CD11b and iNOS 
mRNA at 24 hrs following ET-1 induced MCAO (Regenhardt et al., 2013). Our results 
show that all M1 type markers CD11b, CD86, IL-1, IL-6, CCR7 and iNOS mRNA levels 
were upregulated following MCAO with Ang-(1-7) having no effect on expression. In 
Regenhardt’s study, Ang-(1-7) was administered as a pre and post therapy for a total of 7 
days in the ET-1 induced MCAO model, whereas in our protocol, Ang-(1-7) was 
administered for 24 hrs only and tested in the intraluminal filament MCAO model. Once 
could postulate that due to its short half-life, Ang-(1-7) might act in a cumulative manner 
at the MasR level and that 24 hr treatment duration might not have been sufficient to 
observe an effect in our model. Furthermore, in in vitro assessments, Ang-(1-7) 
administration on microglia cultures for either 6 or 12 hrs at 100 nM decreased microglial 
expression of IL-1 and TNF- whilst upregulating IL-10 levels (Liu et al., 2016). 
However, in our study, IL-10 mRNA expression was undetected in all groups whereas IL-
1 and IL-6 were upregulated in both Vehicle and Ang-(1-7) treated rats following MCAO.  
M2 specific cell surface markers, Arg1 and CD163 (Cherry et al., 2014), were comparable 
to Sham levels following MCAO with no Ang-(1-7) induced effects. Interestingly, M2 
markers TGF- and CCL22 were upregulated following MCAO in the peri-infarct regions 
and again with Ang-(1-7) treatment having no effect on mRNA levels. The TGF- 
signalling pathway is implicated in the regulation of BBB functional integrity and TJP 
expression by decreasing endothelial cell permeability (Dohgu et al., 2004; Ronaldson et 
al., 2009). Conversely, the role of CCL22 in BBB disruption and ischaemic injury is not 
well understood; however, it might be involved in repair. For instance, in human ischaemic 
brains, CCL22 protein levels were shown to be decreased in the infarcted tissue 
vasculature and this reduction was associated with enhanced neurological severity (García-
Berrocoso et al., 2014). Together these results strongly suggest that Ang-(1-7) post stroke 
therapy for 24 hrs does not interfere with microglia number, phenotype or inflammatory 
profile whilst highlighting a complex interplay of injury/repair mechanisms.  
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5.7 Summary 
This study shows for the first time that Ang-(1-7) treatment as a post stroke therapy for 24 
hrs does not influence BBB breakdown, final infarct volume, microglia number and 
activation and pro- or anti-inflammatory mRNA gene expression. BBB breakdown was 
quantified following Gd-DTPA contrast agent administration with MRI-T1. Here, some 
animals presented high levels of Gd-DTPA enhancement within the infarct regions 
whereas others showed scarce Gd-DTPA leakage. These findings suggest that at 24 hrs, the 
BBB is in a transient phase of opening, implying that BBB breakdown follows a biphasic 
pattern in rats. Ang-(1-7) did not alter BBB breakdown following 24 hrs reperfusion or the 
expression of BBB breakdown markers MMP9, TIMP1, VEGFA or VEGFR-2. Moreover, 
infarct volume was comparable between Ang-(1-7) and Vehicle (aCSF) treated groups, an 
outcome further evidenced by neurological score. Ang-(1-7) did not alter gene expression 
for leukocyte extravasation or pro-inflammatory mechanisms, although these were 
upregulated following injury. Ang-(1-7) did not influence IBA1+ microglia total cell count 
or influence cellular phenotype in peri-infarct and contralateral regions. Interestingly, RAS 
mediator mRNA levels were comparable to Sham, indicating that RAS may not be 
implicated in injury at this stage in normotensive rats and possibly explaining the results 
obtained. 
In conclusion, this study provides robust evidence that Ang-(1-7) does not attenuate BBB 
breakdown, infarct volume, and microglia phenotype nor pro- anti-inflammatory gene 
expression at 24 hrs in normotensive rats. At the same time, our results highlight a 
complex interplay of mediators potentially acting to simultaneously promote and reverse 
injury following stroke and at the time point selected.  
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Chapter 6: The effects of Ang-(1-7) on 
cortical CBF following transient MCAO 
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Chapter 6  
6.1 Introduction 
In Chapter 4, Ang-(1-7) significantly increased tissue salvage following reperfusion when 
compared to vehicle treatment. In Chapter 5, Ang-(1-7) had noeffect on BBB breakdown, 
infarct volume or microglia number/activation at 24hrs post stroke onset. To further 
elucidate a possible underlying mechanism, this study was designed to determine whether 
Ang-(1-7) treatment has any direct effect on the cerebrovasculature following transient 
MCAO.  
The CNS is dependent on appropriate delivery of glucose and oxygen, which relies on 
CBF being maintained at critical levels, approximately 55-60 mL/100g/min in healthy 
humans (Ellenbogen et al., 2012). Following MCAO, cerebral perfusion is severely 
reduced within the ischaemic core resulting in irreversible cell death within minutes. The 
ischaemic core is surrounded by the ischaemic penumbra, a region of reduced blood flow 
where electrical activity is impaired yet ion homeostasis and metabolic activity 
maintaineddue to collateral vessel supply (Heiss, 2000). In humans, it was determined that 
the CBF threshold for the ischaemic penumbra is between 12-22 mL/100g/min whereas 
values below represent the ischaemic core. On the other hand, when CBF is above 22 
mL/100g/min but less than 55-60 mL/100g/min the brain is placed in a state of benign 
oligaemia, which is in a less severe hypoperfused state and not at risk of infarction (Heiss, 
2000). 
Once reperfusion is established after cerebral ischaemia, damaged tissue undergoes post-
ischaemic hyperperfusion which is then quickly followed by post-ischaemic 
hypoperfusion, possibly due to capillary narrowing, plugging and loss of arteriolar 
reactivity (Attwell et al., 2010; Hauck et al., 2004; Leffler et al., 1989). Therapeutic 
strategies with the ability to reverse ongoing hypoperfusion following reperfusion therefore 
have the potential to be protective in stroke (Sutherland et al., 2011). This assumption is 
further supported by clinical studies where better functioning collaterals are associated 
with greater reperfusion following thrombectomy and subsequent reduction in ischaemic 
lesions (Liebeskind, 2014).  
One other important mechanism thought to be implicated in ischaemic injury is CSD 
(Hartings et al., 2003; Mies et al., 1993). This phenomenon is associated with a loss of 
224 
 
electrical and ionic homeostasis in neurons and astrocytes, resulting in cortical excitatory 
mechanisms (Kramer et al., 2016). In healthy tissue, CSD is compensated by a neuronal 
hyperaemic response; however, following focal cerebral ischaemia this effect cannot be 
achieved promoting further ischaemia, a phenomenon termed PID (Lauritzen et al., 1990; 
Windmuller et al., 2005). PIDs have been mostly studied during MCAO; with frequency 
and duration within peri-infarct areas being associated with exacerbated infarct size 
(Hartings et al., 2003; Mies et al., 1993). Similarly, following reperfusion, PIDs have been 
shown to occur particularly after 2 hrs of reperfusion onset, potentiating injury (Hartings et 
al., 2006).  
Vasodilation is one of the most widely reported effects induced by Ang-(1-7) in the 
vasculature and has been observed in canine coronary arteries (Brosnihan et al., 1996; 
Feterik et al., 2000), porcine coronary endothelium (Gorelik et al., 1998), rabbit arterioles 
(Ren et al., 2002), rat MCAs (Durand et al., 2010) and vascular coronary beds (Moraes et 
al., 2017). In addition, Ang-(1-7) is suggested to modulate systemic and regional blood 
flow in rats, improving regional haemodynamics within the brain (Sampaio et al., 2003). 
Following ischaemic stroke, there are few studies assessing the direct cerebrovascular 
effects of Ang-(1-7) and these contain contradicting results. A study conducted in 2011 
showed that in ET-1-induced MCAO, Ang-(1-7) ICV administration as a pre and post 
treatment did not improve cerebral perfusion during MCAO when compared to Vehicle 
treated rats (Mecca et al., 2011). Conversely, in Wistar rats, 4 weeks of Ang-(1-7) ICV pre-
treatment followed by permanent MCAO improved perfusion in peri-infarct regions 1 hr 
and 24 hrs post stroke onset (Jiang et al., 2014). Accordingly, there is a need to evaluate 
the acute impact of Ang-(1-7) administration on cerebral perfusion. 
Laser Speckle Contrast Imaging (LSCI) has become a widely used tool to study cortical 
CBF after focal cerebral ischaemia (Armitage et al., 2010; Liu et al., 2017; Strong et al., 
2006; Winship et al., 2014). LSCI is used to monitor perfusion within the cortical surface 
and with a high temporal and spatial resolution (Dunn, 2012). The technique uses the 
speckle phenomenon, consisting of an interference pattern generated by light 
scattered/reflected from an area of interest. In this method, a laser is applied onto the 
cerebral cortex and as it comes into contact with moving particles such as red blood cells, 
the speckle pattern becomes blurred (Dunn, 2012; Wood et al., 2016). The patterns within 
each image pixel are detected by a CCD camera attached to the laser, allowing to map 
temporal and spatial cortical CBF alterations (Dunn, 2012; Dunn et al., 2001; Strong et al., 
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2006). Due to its ability to detect CBF alteration in near-real time, LSCI is also a useful 
method to reliably study PIDs during and following MCAO (Paul et al., 2005). 
Reports have emphasised the need to assess the effects of potential neuroprotective 
strategies on CBF within the preclinical setting before proceeding to clinical trials 
(Sutherland et al., 2011). Accordingly, this study aims to examine the impact of acute 
administration of Ang-(1-7) on the dynamic changes in cortical perfusion following 
reperfusion after MCAO.  
6.1.1 Aims: 
 To determine the effect of acute systemic infusion of Ang-(1-7)/Vehicle on cortical 
perfusion immediately following initiation of reperfusion after MCAO.  
 To determine whether Ang-(1-7) treatment influences the occurrence of PIDs 
during reperfusion. 
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6.2 Methods and materials 
6.2.1 Sample size calculation 
Power calculations were performed using the power analysis programme G*Power 
(version 4.1, Germany). An “a priori” power analysis was performed for t test: difference 
between two independent means (unpaired Student’s t test) to assess Ang-(1-7) treatment 
impact and Vehicle (dH2O) on cortical perfusion. Ang-(1-7) ICV infusion was shown to 
induce a 10% improvement in perfusion when compared to Vehicle treated animals in the 
peri-infarct region 1 hr after MCAO (Jiang et al., 2014). We have conducted pilot 
experiments using LSCI where we have analysed the perfusion in different ROIs.  Within 
the hypoperfused territory (CBF between 43-75% of normal) at 1 hr following MCAO, 
perfusion mean values were 68.6 and S.D. was 4 in perfusion units (PU). Using these data, 
a p value of 0.05 and setting power at 80%, a total sample size of 10 was determined (n of 
5 per group) to detect changes in perfusion of at least 10% between groups. 
6.2.2 Animals and surgical procedures 
In this study, 18 male Wistar rats (310-353g) were used and subjected to 90 min MCAO 
and 90 min reperfusion. Rats were initially anaesthetised with 5% isoflurane delivered in a 
30:70% O2-NO2 mixture ratio as described in Chapter 2.5.1 and aseptic technique carried 
out as outlined in Chapter 2.3. Rats were then orally intubated and mechanically ventilated 
at 3-4 mL stroke volume and 56-58 strokes per min delivering 2.5% isoflurane. To reduce 
tracheal secretions that could obstruct the intubation tube during the experiment, atropine 
sulphatewas administered SC (0.05 mg/kg; Martindale Pharmaceuticals, UK) prior to 
surgery and local anaesthetic, ropivacaine (Norapin®), administered SC at incision sites. 
6.2.2.1 Physiological monitoring and drug delivery  
All animals were subjected to physiological monitoring of MABP and blood gases (pH, 
PaO2 and PaCO2) through a cannula inserted in the left femoral artery. Drug delivery and 
-chloralose administration were performed in the left and right femoral veins, 
respectively. The left femoral artery, left femoral vein and right femoral vein were 
cannulated as described in Chapter 2.6. Rectal temperature was monitored and regulated 
with the aid of an electric blanket. 
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6.2.2.2 Skull Thinning                                                                                                                                             
Following blood vessel cannulation, rats were transferred to a stereotaxic frame for skull 
thinning procedures. The head was secured in place with the use of ear and tooth bars 
tightly adjusted to prevent movement. A midline incision was performed in the skull with a 
scalpel and the underlying connective tissue cleared to visualise the skull surface. To 
enhance the FOV and prevent drilling obstruction, four 4.0 threads were sutured onto each 
side of the incision and tension applied to prevent the skin from interfering with the 
drilling. A dental drill (NSK Volvere max, Nakanshishi Inc., Japan) was then used to thin 
the skull surface by applying continuous vertical strokes across the scalp surface. The 
procedure was carried out until the pial vessels were visualised and the skull surface 
uniformly thinned. Throughout the procedure, dH2O was regularly used to regulate the 
skull temperature, preventing vessel damage due to heat, and to clean the bone dust 
produced. Scalp and muscle bleeding was ceased by applying pressure with a sterilised 
cotton bud. In cases where bleeding was persistent, 10% perchloric acid (Sigma Aldrich, 
UK) was applied to the scalp with a cotton bud and then thoroughly cleaned with dH2O. 
6.2.2.3 MCAO and reperfusion 
Following skull thinning procedures, rats were removed from the stereotaxic frame and 
placed onto the corkboard for MCAO procedures as described in Chapter 2.8. A modified 
4-0 nylon silicone coated tip monofilament (404134PK10; Doccol Corporation, MA, USA) 
was used to occlude the MCA for a period of 90 min. To allow reperfusion to be induced 
whilst the animal was subjected to LSCI, a small 5.0 suture was tied and glued at the end 
of the Doccol filament and gently placed outside the incision site just before the forelimbs. 
After 90 min MCAO, the 5.0 suture attached to the monofilament occluding the MCA, was 
gently pulled back with the aid of clamping forceps. Animals were allowed to reperfuse for 
90 min and then sacrificed via Schedule 1 procedures.   
6.2.3 -chloralose 
Isoflurane was selected as the anaesthetic of choice to perform surgical procedures as it 
provides adequate anaesthetic levels, which are easily controllable. Although isoflurane 
has been deemed by some researchers as a suitable anaesthetic to be used in 
cerebrovascular studies (Franceschini et al., 2010; Masamoto et al., 2006), it is suggested 
to dose dependently induce cerebral vasodilation, enhance vascular reactivity and alter 
autoregulation (Iida et al., 1998; Sicard et al., 2003). On the other hand,  -chloralose is 
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not a suitable anaesthetic to induce anaesthesia; however, it has been found to preserve 
cerebral autoregulation and decrease arterial CO2 sensitivity and is, therefore, the 
anaesthetic of choice to study CBF dynamics (Masamoto and Kanno, 2012; Ueki et al., 
1992). Accordingly, at MCAO start and prior to LSCI, anaesthesia was switched from 
isoflurane to -chloralose and animals allowed to stabilise prior to imaging. -chloralose 
was prepared fresh by dissolving 250 mg of -chloralose (Sigma-Aldrich, UK) in 25 mL 
of dH2O. The solution was stirred and heated to 75ºC to dissolve. Once fully dissolved, the 
solution was kept at 58ºC in a water bath until administration.  
-chloralose dose was selected based on previous reports (Haensel et al., 2015). An initial 
IV -chloralose bolus of 80 mg/kg at near body temperature was administered with the use 
of a 5 mL syringe (2.8 mL in a 350g rat) and slowly injected into the right femoral vein to 
prevent a steep drop in MABP. Once MABP started decreasing, isoflurane concentration 
levels were reduced to 1.5%. Immediately after the IV bolus, -chloralose was 
administered as a 40 mg/kg/hr infusion (1.4 mL/hr in a 350g rat). MABP was closely 
monitored as well as the response to hindlimb pinch to ensure adequate anaesthesia and to 
determine at what point isoflurane levels should be turned off. Once MABP started to 
decrease, isoflurane was gradually switched off. Animals were allowed to stabilise for a 
period of 60 min prior to CBF assessments. During the full duration of the LSCI protocol, 
animals were ventilated with 30:70% an O2-NO2 mixture and anaesthesia maintained at a 
continuous infusion of 40 mg/kg/hr -chloralose. 
6.2.4 Ang-(1-7) dose selection 
In this experiment, treatment could not be infused ICV as it would compromise LSCI. For 
this reason, IV administration was selected as the treatment method. Ang-(1-7) has a short 
half-life and to guarantee treatment delivery in cerebral vessels, a dose 5 times higher than 
the one used in ICV studies was selected: 5 nmol/hr Ang-(1-7) infusion dissolved in dH2O. 
Treatment was administered IV as a continuous infusion at near body temperature in the 
left femoral vein for 90 min beginning immediately following reperfusion. The Ang-(1-
7)/Vehicle IV delivery rate was the same as the infusion rate set for -chloralose IV 
infusion according to animal weight (1.4 mL/hr in a 350g rat). Control animals were 
subjected to dH2O infusion only.  
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6.2.5 Laser speckle contrast imaging 
6.2.5.1 System 
LSCI was carried out using a PeriCam PSI System (Perimed, Sweden) with a solid-state 
laser diode of 785 nm for blood perfusion measurements and at a FOV of 1.4 cm width and 
1.4 cm height. The laser beam was spread over a rectangular surface by a diffuser and 
placed 10 cm distance from the skull surface providing a measurement area of 5.9 × 5.9 cm 
(Figure 6-1A).  Speckle patterns were generated from the backscattered light from the laser 
beam illumination and recorded through a 1388 × 1038 pixel CCD camera inside the 
PeriCam PSI head at a frame rate of 10 images per second (50 Hz mains frequency). 
Dynamic changes in CBF speckle patterns were acquired at 1 image per 5 seconds 
(average of 50 images) at a spatial resolution of 0.02 mm (Figure 6-1B). In addition, a 
monochrome intensity image was generated from the total amount of reflected light 
(Figure 6-1C).  
 
Figure 6-1 The LSCI system. A) Animal subjected to LSCI. Rats were placed in a stereotaxic 
frame and head secured with tooth and ear bars. The skull previously thinned is exposed by 
retracting overlying skin with the aid of 4.0 sutures sutured onto incision edges and taped onto the 
frame. The LSCI camera was placed 10 cm from the skull surface, Johnson & Johnson oil applied 
on the brain surface and imaging started. B) Representative image of dynamic change in CBF 
speckle patterns. Cortical perfusion map prior to MCAO displaying the superior sagittal sinus. 
Colour scale is set from 0 to 300 PU, where red represents increased perfusion. C) Monochrome 
intensity image. Cortical surface image displaying the amount of reflected light in the scalp. 
 
 
230 
 
6.2.5.2 Imaging protocol  
Following skull thinning and MCAO onset, animals were placed on a stereotaxic frame 
and the head secured in place with the use of ear and tooth bars. The skull was exposed 
with the aid of four separate 4-0 threads sutured onto the edges of the skin incision and 
taped onto the stereotaxic frame to enhance FOV. To prevent skull drying, which could 
impact reliability of results, Johnson & Johnson oil (Johnson & Johnson, USA) was 
applied on the skull surface and left in place during the whole experiment. Imaging started 
at 60 min MCAO and was carried out for 2 hrs. Following 90 min MCAO, the filament 
was retracted in order to induce reperfusion of the MCA and IV Ang-(1-7)/Vehicle 
treatment started for a period of 90 min.  
6.2.5.3 Imaging analysis 
Once the imaging protocol was completed, raw speckle images were obtained for each rat 
and processed in PU using PIMSoft, a PeriCam PSI dedicated Software (Perimed, 
Sweden). In this study, we were interested in assessing the impact of Ang-(1-7) on 
perfusion in the contralateral hemisphere as well as the ischaemic core, ischaemic 
penumbra and oligaemic/perfused areas in the ipsilateral hemisphere during reperfusion. 
The first step in image analysis consisted in the determination of the ipsilateral ROIs and to 
do so, thresholds were establishedon mean perfusion values within the contralateral 
hemisphereduring MCAO. A ROI was outlined on the contralateral hemisphere and a 
mean perfusion value (PU) was calculated from the images recorded during MCAO for a 
period of 15 min. From this mean perfusion value, a set of thresholds were applied to 
define the ischaemic core (<43% of contralateral perfusion), ischaemic penumbra (43-75% 
of contralateral perfusion) and oligaemic/perfused tissue (76%-100%) during MCAO 
(McLeod et al., 2015; Shen et al., 2003). These ROIs were then used to assess changes in 
perfusion over time. Figure 6-2 shows a representative image of the ROIs outlined in each 
rat. The superior sagittal sinus was excluded from analysis. 
The second step in image analysis consisted in the determination of a baseline mean 
perfusion value for each individual ROI by averaging the images recorded during MCAO 
for a period of 15 min. The perfusion signal was then normalised to the mean signal during 
MCAO within the respective ROI’s allowing us to calculate the % change in perfusion 
following reperfusion with or without treatment. 
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To identify PID occurrence during reperfusion for each animal, the cerebral perfusion 
videos obtained during LSCI were analysed and fast hyperaemic responses in the peri-
infarct region were counted. 
 
Figure 6-2 Determination of ROIs for cortical perfusion analysis. Mean PU values obtained in 
the contralateral hemisphere between 75-90 min MCAOwere used to apply thresholds across the 
ipsilateral hemisphere. Ischaemic core was set as 0-43% of mean PU in contralateral hemisphere 
during MCAO. Ischaemic penumbra was set as 44-75% of mean PU in contralateral hemisphere 
during MCAO. Oligaemic/perfused region was set as 76-100% of mean PU in contralateral 
hemisphere during MCAO. Colour scale is set as 0 to 300 PU for the top image. 
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6.2.6 Randomisation, blinding and exclusions 
Animals were randomly assigned to surgery day using an online randomisation plan 
generator (www.random.org). Surgeon (MA) was not blinded to treatment assignment.  
Rats displaying the following characteristics were excluded:  
 Failure to completely reperfuse the entire cortical surfaceupon filament retrieval.  
 SAH 
 Animals that did not exhibit evidence of cortical perfusion deficit.  
 Persistent muscle, skin and scalp bleeding impairing cortical cerebral perfusion 
measurement. 
6.2.7 Statistics 
Physiological parameters pH, PaO2, PaCO2, temperature were analysed using repeated 
measures two-way ANOVA followed by Sidak’s test to correct for multiple comparisons 
with time and treatment as factors.  
MABP and cerebral perfusion within the contralateral hemisphere, ischaemic core, 
ischaemic penumbra and oligaemic/perfused areas in the ipsilateral hemisphere were 
presented as a time course, starting at baseline (MCAO) and finishing at 90 min 
reperfusion. Differences between treatment groups in MABP and perfusion dynamics were 
analysed by assessing the summary measure of AUC during reperfusion and the means 
compared using unpaired Student t-test. PIDs were counted during the reperfusion period 
and analysed between groups using unpaired Student t-test. Data were presented as mean ± 
S.D. and p<0.05 deemed as statistically significant. 
Descriptive perfusion alterations for all ROIs within groups were shown as mean PU ± 
S.D. Statistics were not conducted for this data set. 
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6.3 Results 
6.3.1 Exclusions 
A total of 18 male Wistar rats were used in this study and 7 were excluded: 4 in Vehicle 
(dH2O) and 3 in the Ang-(1-7) treatment groups. Two animals in the Ang-(1-7) and three 
in the Vehicle (dH2O) treatment groups failed to completely reperfuse the entire cortical 
surface upon filament removal. From these animals, one in each group showed signs of 
haemorrhage seen as darker patches in the perfusion map within the ipsilateral hemisphere. 
In addition, one rat in Ang-(1-7) group showed signs of partial occlusion due to lack of 
cortical perfusion deficit during MCAO. One Vehicle (dH2O) treated rat had to be 
excluded due to excessive bleeding originating from the skull and adjacent muscles/skin, 
which caused frequent imaging obstruction and influenced the reliability of the values 
obtained.  Overall, 11 animals were included, 5 in Vehicle (dH2O) and 6 in Ang-(1-7). 
Figure 6-3 shows all excluded animals in Vehicle (dH2O) and Ang-(1-7) treated groups.  
6.3.2 Physiological parameters 
Physiological parameters pH, PaCO2, PaO2 were measured and recorded during isoflurane 
and α-chloralose anaesthesia. Parameteres were maintained within physiological range 
with the exception of PaO2, which was higher throughout experimental procedures due to 
mechanical ventilation with 30% O2. Prior to stroke surgery, all physiological parameters 
were maintained stable between groups with no statistical differences at this time point 
(P>0.05), (Table 6-1).   
At MCAO baseline and just prior to reperfusion, blood pH and arterial PaCO2 were 
maintained within range. Rectal temperature was slightly lower for both treatment groups 
and the most challenging parameter to maintain stable as rats had to be frequently moved 
between surgical corkboard and stereotaxic frame for surgical procedures. There were no 
statistical differences between physiological parameters between groups during MCAO 
(P>0.05), (Table 6-1). During reperfusion, all physiological values were set within range 
between groups, to the exception of PaO2, with no statistical differences (P>0.05), (Table 
6-1).  
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A)  
 
Vehicle(dH2O) 
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Figure 6-3 Excluded animals. A) Vehicle (dH2O) group. Three animals failed to complelety reperfuse the entire cortical surface upon filament retrieval. One other rat 
was excluded due to persistent bleeding originating from the skull and adjacent muscles and skin, often interfering with imaging particularly in the contralateral 
hemisphere. B) Ang-(1-7) group. Two animals failed to completely reperfuse the entire cortical surface upon filament retrieval. One other rat was excluded due to 
partial MCAO, indicated by lack of perfusion deficit in the ipsilateral hemisphere during MCAO. Arrows indicate haemorrhage in animals within Vehicle (dH2O) and Ang-
(1-7) treated groups. Colour scale is set from 0 to 300 PU. A representative image of cerebral perfusion dynamics at baseline, reperfusion and every 30 min post 
reperfusion is shown for each animal. 
B)  
 
Ang-(1-7) 
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Table 6-1 Physiological parameteres: pH, PaO2, PaCO2 and temperature prior to MCAO, at 
baseline and 1 hr reperfusion. Blood pH and PaCO2 were maintained within the normal 
physiological range for Vehicle (dH2O) and Ang-(1-7) treated groups thoroughout the experiment. 
PaO2 was above range in all experiments due to mechanical ventilation. Temperature was slightly 
below range 36.5°C for both groups at baseline due to animal movement between frames. There 
were no statistical differences between groups at all-time points. Data were analysed using 
repeated measures two-way ANOVA; P<0.05 was deemed as significant. Data are expressed as 
mean ± S.D. 
 
 
 Vehicle (dH2O) Ang-(1-7) 
 
 
 
 
Prior to MCAO 
surgery 
 
Blood pH 
7.4±0.1 7.4±0.03 
 
Arterial PaO2 
(mmHg) 136.8±36.5 120.0±19.0 
 
Arterial PaCO2 
(mmHg) 
 
 
 
43.5±7.2 
 
 
41.8±2.9 
 
Temperature 
(°C) 36.6±0.6 36.7±0.4 
 
 
 
MCAO  
(Baseline prior 
to therapy) 
 
Blood pH 
 
 
7.4±0.1 
 
 
7.4±0.1 
 
Arterial PaO2 
(mmHg) 
 
147.1±17.6 
 
169.3±36.2 
 
Arterial PaCO2 
(mmHg) 
 
36.6±6.0 42.3±5.5 
Temperature 
(°C) 36.2±0.6 36.3±1.0 
 
 
 
 
Reperfusion 
(1 hr) 
 
Blood pH 
7.4±0.01 7.4±0.1 
 
Arterial PaO2 
(mmHg) 
 
135.8±29.6 
 
 
151.4±57.8 
 
Arterial PaCO2 
(mmHg) 
 
42.2±3.9 
 
44.4±5.0 
 
Temperature 
(°C) 36.8±0.2 37.1±0.7 
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6.3.2.1 Mean arterial blood pressure 
MABP values (mmHg) during MCAO and following reperfusion with MABP maintained 
within normal levels throughout (80-120mmHg) (Figure 6-4). Prior to reperfusion, MABP 
was 101.2±10.8 mmHg in Vehicle (dH2O) and 100.7±16.9 mmHg in Ang-(1-7) treated 
groups. Comparison of mean group AUC values showed that there were no differences 
between groups in MABP during MCAO (P>0.05) and reperfusion with treatment 
(P>0.05).  
Figure 6-4 Mean arterial blood pressure. During baseline (MCAO), MABP was stable between 
groups with values being maintained within healthy ranges (80-120 mmHg). Following reperfusion 
and treatment, MABP values were maintained within range for all rats with no significant 
differences between treatment groups (P>0.05). Data displays values for Vehicle (dH2O; n=5) and 
Ang-(1-7) (n=6). Data were analysed with mean AUC comparisons followed by unpaired Student’s t 
test; *P<0.05 was deemed as significant. Data are expressed as mean ± S.D. 
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6.3.3 Cerebral perfusion following stroke 
MCAO successfully decreased perfusion in the ipsilateral hemisphere when compared to 
contralateral hemisphere. Results are presented as mean PU obtained for Vehicle (dH2O) 
(Figure 6-5A) and Ang-(1-7) (Figure 6-5B) treated animals for all ROIs.  
Following 90 min MCAO, the filament was removed from the MCA to start reperfusion. In 
Vehicle rats, there was a trend for perfusion to increase in the contralateral hemisphere 
over the course of 90 min reperfusion by 15.3±13.5 PU. Conversely, the Ang-(1-7) treated 
group, perfusion values showed fluctuations, with a small indication to decrease overtime 
by 13.4±14.8 PU. Reperfusion start caused an increase in perfusion in both treatment 
groups in the ipsilateral hemisphere. In Vehicle treated animals, reperfusion induced a 
97.5±25.6 PU increase inperfusion within the ischaemic core, 72.6±34.0 PU increase 
within the ischaemic penumbra and 15.4±34.7 PU rise in oligaemic/perfused ROI. In Ang-
(1-7) treated animals, reperfusion resulted in a 110.2±34.6 PU increase within the 
ischaemic core, 40.9±26.6 PU in the ischaemic penumbra and 4.8±15.9 PU in 
oligaemic/perfused region. Reperfusion resulted in a marked increase in perfusion within 
the ischaemic core, penumbra and oligaemic/perfused ROIs in both groups, particularly 
within the first 15 min after reperfusion. After 20 min of reperfusion there was a general 
trend for perfusion to decrease over time in both groups. Figure 6-6 shows a representative 
image of an animal within each group at baseline, reperfusion and every 30 min post 
reperfusion. Images display the decrease in perfusion in ipsilateral hemisphere compared to 
the contralateral side over time.  
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Figure 6-5 Cerebral perfusion change during the experimental protocol. A) Vehicle (dH2O) treated animals. During baseline (MCAO) perfusion was higher in the 
contralateral hemisphere compared to the ipsilateral hemisphere. Following reperfusion, there was a trend for perfusion to increase over time in the contralateral 
hemisphere. Reperfusion start induced a steep increase in perfusion within the ischaemic core, ischaemic penumbra and oligaemic/perfused region peaking at 15 min 
post reperfusion and subsequently decreasing for the following 75 min of imaging. B) Ang-(1-7) treated animals. During baseline, perfusion values were higher in the 
contralateral hemisphere compared to the ipsilateral hemisphere. Following reperfusion, perfusion valuesfluctuated in the contralateral hemisphere and showed a trend 
to decrease. Reperfusion start induced a steep increase in perfusion within the ischaemic core, hypoperfused area and oligemic region with values peaking at 20 min 
post reperfusion in the ischaemic core and ischaemic penumbra. Perfusion subsequently decreased for the following 70 min of imaging in these two areas. In the 
oligaemic/perfused region, perfusion values peaked at 10 min post reperfusion and thendecreased over time. Data are expressed as mean± S.D.in PU for Vehicle 
(dH2O; n=5) and Ang-(1-7) (n=6) treated rats. 
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Figure 6-6 Representative images of cortical cerebral perfusion dynamics over time per treatment group. Top and bottom figures display cerebral perfusion 
dynamics for Vehicle (dH2O) and Ang-(1-7) treated groups at MCAO, reperfusion and every 30 min post reperfusion start, respectively. For each animal, there was a 
gradual decrease in cortical perfusion within the ipsilateral side when compared to the contralateral hemisphere after reperfusion onset. 
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6.3.4 Ang-(1-7) treatment significantly decreases perfusion in the 
contralateral hemisphere 
Following reperfusion there was a trend for perfusion to increase in the contralateral 
hemisphere over the 90 min time course, whereas Ang-(1-7) treated rats showed a trend to 
decrease contralateral perfusion. In Vehicle treated rats, perfusion increased by 11.7±8.1% 
whereas Ang-(1-7) treatment induced a 4.5±10.4% reduction between 0-90 min 
reperfusion. Comparison of mean group AUC values showed that Ang-(1-7) treatment 
significantly decreased cortical perfusion compared to Vehicle (P=0.02), (Figure 6-7). 
Figure 6-8 displays a representative image of perfusion dynamics in the contralateral 
hemisphere for the median rat in each treatment group. Since data were evaluated as 
perfusion change from baseline for all animals, baseline images were subtracted from the 
whole data set to confirm the trend observed (Figure 6-8). 
Figure 6-7 Contralateral hemisphere perfusion % change from baseline. Following 
reperfusion, Vehicle (dH2O) animals showed a trend to increase perfusion during 90 min 
reperfusion whereas Ang-(1-7) treated animals showed a trend to attenuate it. Ang-(1-7) treatment 
induced a significant change in contralateral hemisphere perfusion compared to Vehicle (dH2O) 
(P=0.02). Data displays values for Vehicle (dH2O; n=5) and Ang-(1-7) (n=6) treated animals. Data 
were analysed with mean AUC comparisons followed by unpaired Student’s t test; *P<0.05 was 
deemed as significant. Data are expressed as mean ± S.D. % from baseline. 
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Figure 6-8 Contralateral hemisphere perfusion dynamics normalised to baseline. Top and bottom figures display contralateral perfusion dynamics for the median 
animals in the Vehicle (dH2O) and Ang-(1-7) treated groups at MCAO, reperfusion and every 30 min post reperfusion start, respectively. Image pixels within baseline 
(MCAO) were subtracted from all images obtained during reperfusion. Vehicle (dH2O) treated rat displays an increase in perfusion in the contralateral hemisphere 
during 90 min reperfusion (contralateral ROI outlined in white). On the other hand, Ang-(1-7) treated animal displays a decrease in perfusion within contralateral 
hemisphere when normalised to MCAO. Colour scale ranges from -300 to 300 PU, where red represents increased perfusion and blue represents decreased perfusion 
from baseline (MCAO). 
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6.3.5 Ang-(1-7) treatment does not influence perfusion in the 
ipsilateral hemisphere 
In the ischaemic core, reperfusion led to a steep increase in perfusion in Vehicle (dH2O) 
and Ang-(1-7) treated groups, 157.2±62.4% and 174.1±62.4% from start to 5 min 
reperfusion, respectively (Figure 6-9). Ang-(1-7) treatment showed a trend to enhance 
perfusion compared to the control group, however, comparison of mean group AUC values 
indicated that differences were not significant when compared to the Vehicle group 
(P>0.05), (Figure 6-9). Both groups displayed high variability in perfusion extent. For the 
Ang-(1-7) group, 3 rats showed higher perfusion changes than the remaining group cohort 
whereas in the Vehicle group, values were fairly consistent with the exception of one 
animal. 
 
Figure 6-9 Ischaemic core perfusion % change from baseline. Following reperfusion, there was 
a steep increase in perfusion within Vehicle (dH2O) and Ang-(1-7) treated animals and followed by 
perfusion attenuation overtime. Ang-(1-7) did not significantly alter perfusion within the ischaemic 
core compared to control group (P>0.05). Data displays values for Vehicle (dH2O; n=5) and Ang-
(1-7) (n=6) treated animals. Data were analysed with mean AUC comparisons followed by unpaired 
Student’s t test; *P<0.05 was deemed as significant. Data are expressed as mean ± S.D. % from 
baseline. 
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In the ischaemic penumbra, reperfusion led to a cerebral perfusion increase in Vehicle and 
Ang-(1-7) treated groups, 87.8±47.7% and 62.5±17.5% from start to 5 min reperfusion, 
respectively (Figure 6-10). During the course of reperfusion, Ang-(1-7) did not influence 
perfusion when compared to Vehicle as determined by comparison of mean group AUC 
values (P>0.05), (Figure 6-10).  
 
Figure 6-10 Ischaemic penumbra perfusion % change from baseline. Following reperfusion, 
there was an increase in perfusion within Vehicle (dH2O) and Ang-(1-7) treated animals and 
followed by perfusion attenuation over time. Treatment had no impact in perfusion within the 
ischaemic penumbra compared to control animals (P>0.05). Data displays values for Vehicle 
(dH2O; n=5) and Ang-(1-7) (n=6) treated animals. Data were analysed with mean AUC 
comparisons followed by unpaired Student’s t test; *P<0.05 was deemed as significant. Data are 
expressed as mean ± S.D. % from baseline. 
 
In the oligaemic/perfused region, reperfusion led to a slight increase in perfusion in 
Vehicle (dH2O) and Ang-(1-7) treated groups, 19.9±19.9% and 15.0±8.4% from start to 5 
min reperfusion, respectively (Figure 6-11). Comparison of mean group AUC values 
showed that Ang-(1-7) treatment did not differ from vehicle treated animals over 90 min 
reperfusion (P>0.05), (Figure 6-11), further confirming that Ang-(1-7) does not enhance 
perfusion within the ipsilateral hemisphere. 
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Figure 6-11 Oligaemic/perfused area perfusion % change from baseline. Following 
reperfusion, there was a slight increase in perfusion within Vehicle (dH2O) and Ang-(1-7) treated 
animals, peaking at 15 min and 10 min, respectively. Treatment did not influence cerebral perfusion 
within the oligaemic/perfused area during reperfusion (P>0.05). Data displays values for Vehicle 
(dH2O; n=5) and Ang-(1-7) (n=6) treated animals. Data were analysed with mean AUC 
comparisons followed by unpaired Student’s t test; *P<0.05 was deemed as significant. Data are 
expressed as mean ± S.D. % from baseline. 
 
6.3.6 Peri-infarct depolarisations 
PIDs were quantified across ipsilateral and contralateral hemispheres. PIDs were detected 
in 1 out of 5 rats for Vehicle group and 3 out of 6 rats for Ang-1-7. There were no 
significant differences in the frequency of PIDs between groups [0.5±0.55 vs 0.2±0.5 
(P>0.05)], (Figure 6-12). PIDs occurred a few seconds after reperfusion onset and were not 
evident afterwards. 
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Figure 6-12 Peri-infarct depolarisation frequency during reperfusion. PIDs were detected in 
four animals just after reperfusion onset, one in control group and three in Ang-(1-7) treated rats. 
Treatment did not influence PIDs occurrence during reperfusion (P>0.05). Data were analysed 
using unpaired Student t test; *P<0.05 was deemed as significant. Horizontal bar represents the 
mean. 
 
6.4 Discussion 
This study was designed to examine the potential impact of Ang-(1-7) in improving 
cortical perfusion in ipsilateral and contralateral hemispheres during 90 min reperfusion 
following MCAO. Ang-(1-7) therapy at 5 nmol/hr IV infusion had no significant effect on 
cerebral perfusion within the ischaemic core, ischaemic penumbra and oligaemic/perfused 
tissue. In contrast, within the contralateral hemisphere, there was a significant decrease in 
cerebral perfusion in Ang-(1-7) treated animals. Moreover, treatment did not diminish PID 
frequency during reperfusion or impact MABP during the course of the experiment. To our 
knowledge, this experiment shows for the first time cortical surface perfusion dynamics 
during MCAO and following reperfusion with LSCI technique whilst testing Ang-(1-7) 
therapy.  
For several years MRI and CT have been conducted aiming to identify thresholds to 
successfully defined core from penumbra in both clinical and preclinical settings (Albers et 
al., 2006; An et al., 2015; Davis et al., 2008; Reid et al., 2012). However, these have 
proven to be a challenge due to inconsistencies regarding choice of imaging techniques and 
selection of perfusion and mismatch parameters (Davis et al., 2008). In MRI-DWI 
assessments, ADC abnormal thresholds comprising the ischaemic core represent ADC 
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pixels <43% of mean contralateral CBF at 1 hr, 3 hrs and 4 hrs MCAO (Meng et al., 2004; 
Robertson et al., 2015; Shen et al., 2003). On the other hand, following MCAO in male 
Wistar rats, perfusion CT performed at 90 min ischaemia identified that the ischaemic core 
represented <55% of mean contralateral CBF whereas the penumbra was accurately 
predicted at a <75% threshold (McLeod et al., 2015). To study the impact of Ang-(1-7) in 
ischaemic core, penumbra and oligaemic/perfused regions, the ischaemic core threshold 
<43% of contralateral CBF was selected as it was consistently observed in 3 studies. The 
penumbra was defined between 44-75% of perfusion as defined by McLeod et al whereas 
oligaemic/perfused areas were arbitrarily set as 76-100%. 
In this study, 5 out of 7 rats were excluded due to incomplete cortical surface reperfusion 
upon filament retrieval. Several factors could be implicated in this event such as poor 
collateral blood supply or “no-reflow” mechanisms, the latter characterised by 
inflammatory cell recruitment and microvessel lumen obstruction (Burrows et al., 2015; 
Liebeskind et al., 2014; Saver et al., 2012). In turn, delays in cortical perfusion lead to 
prolonged ischaemia and likely contribute towards lesion evolution. This observation 
supports Chapter 4 findings, where it was seen that reperfusion alone exerts differential 
levels on infarct volume progression. Furthermore, it explains why LDF could not detect 
reperfusion in all animals in Chapter 3. Although inhomogeneous reperfusion is an 
interesting phenomenon in itself, reperfusion onset took place at different rates in these 
animals and to account for this variability, animals were excluded from analysis.  
For all included animals, cortical cerebral perfusion was successfully measured with no 
significant alterations in pH, PaCO2, PaO2 or temperature between treatment groups with 
changes in physiological parameters being quickly corrected to the advised range. Body 
temperature was difficult to maintain stably amongst animals due to frequent movement 
between corkboard and stereotaxic frame to perform surgical procedures and imaging. A 
drop in temperature is suggested to decrease perfusion in pigs (Ehrlich et al., 2002) and it 
is possible that temperature alterations might have affected cerebral perfusion 
measurements in our study.  
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6.4.1 Ang-(1-7) does not alter MABP 
MABP was continuously measured and maintained at stable levels throughout imaging, 
without treatment effects. Moreover, MABP fluctuations did not influence cerebral 
haemodynamics during reperfusion, thereby indicating that -chloralose was an adequate 
anaesthetic for CBF experiments, as previously indicated (Haensel, 2015). A caveat with 
the use of -chloralose is that this compound cannot be dissolved in small volumes 
otherwise it precipitates; therefore, larger volumes had to be administered in the animals. 
The recommended IV volumes to be administered in rats are typically 5 mL/kg bolus (1.75 
mL in a 350g rat) and 4 mL/kg/hr infusion (1.4 mL/hr in a 350g rat) (Diehl et al., 2001). 
However, in our study, an IV bolus of 2.8 mL and infusion volume of 2.8 mL/hr (-
chloralose and therapy) was administered to a 350g rat. Nonetheless, animal welfare 
guidelines also suggest that a 12 mL/hr IV infusion is well tolerated in rats, consisting of a 
substantially larger volume than the one administered in our studies (Workman et al., 
2010). Plus, in the present study, the animals were continuously monitored during the 
experiment and at no point were there indications of negative physiological consequences 
as highlighted by the stable MABP values.    
In this study, Ang-(1-7) IV infusion therapy did not influence MABP. Yet, Ang-(1-7) 
might have vasodepressor or vasoconstrictive properties depending on the animal model 
and dose studied. For example, Ang-(1-7) infusion increased MABP when administered 
SC at a dose of 24 g/kg/hr in a model of subtotal nephrectomy (Velkoska et al., 2015) 
whereas Ang-(1-7) IV infusion at 0.3 nmol/hr did not influence MABP in conscious rats 
(Walters et al., 2005). Similarly, direct Ang-(1-7) stimulation in the dorsal medulla caused 
a hypotensive response (Campagnole-Santos et al., 1989), a mechanism further supported 
in Mas-KO mouse studies, which exhibited elevated BP when compared to WT animals 
(Xu et al., 2008). However, in a more recent study, Mas-KO mice showed comparable 
MABP to WT (Botelho-Santos et al., 2012).  
It is fair to deduct that the effect of Ang-(1-7) on MABP is controversial and possibly due 
to the use of different anaesthetics between studies. The majority of anaesthetics induce 
MABP fluctuations that could influence result interpretation with isoflurane and 
chloralose-urethane being considered the most suitable anaesthetics for cardiovascular 
studies (Bencze et al., 2013; Fitzner Toft et al., 2006). Moreover, to account for the short 
half-life and the differing route of administration from previous Chapters, the Ang-(1-7) 
dose used in the present study: 5 nmol/hr, was arbitrarily selected as 5 times higher than 
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the one used in ICV experiments. Therefore, Ang-(1-7) may modulate MABP at higher 
doses as seen in Velkoska’s experiment (Velkoska et al., 2015) but not at smaller doses as 
observed in our study. This goes in agreement with the results observed in conscious 
systolic BP measurements in Chapter 4 and previous reports in stroke studies in both 
normotensive and SHR animals (Jiang et al., 2013; Mecca et al., 2011; Regenhardt et al., 
2013). 
6.4.2 Contralateral hemisphere perfusion is significantly lower in 
Ang-(1-7) treated animals 
A surprising feature in the results was that contralateral perfusion increased over time in 
the Vehicle (dH2O) group and showed a slight trend to decrease in Ang-(1-7) treated 
animals, displaying a statistical difference between groups. In the contralateral hemisphere 
one would expect perfusion values to remain fairly stable over time following stroke 
(Harston et al., 2017; Hartmann, 2010). Therefore, the possibility that the effect observed 
might be a false positive or a reflection of alterations in PaCO2 over time that failed to be 
detected, cannot be excluded.  
Increasing reports claim and demonstrate that the vast majority of conclusions within 
biomedical research are false, likely due to the small n numbers used (Button et al., 2013; 
Ioannidis, 2005). Although both groups met the n number criteria set in the power 
calculation; the lower the power in a study, the less likely a statistical effect actually 
reflects a real effect (Ioannidis, 2005). Conversely, when an experiment with small n 
numbers identifies a true effect, it is probable that the effect provided is exaggerated, an 
effect inflation referred to as “winner’s curse” (Ioannidis, 2008; Ioannidis et al., 2011). The 
statistical observation must be examined with caution and follow up studies should be 
performed to confirm the reproducibility of these results.  
If the effect is indeed physiological, it could be the outcome of “steal phenomena” reversal. 
The “steal phenomena” is characterised by a shift in blood flow to non-ischaemic areas and 
is associated with worsened neurological outcome in patients (Alexandrov et al., 2007). A 
CBF shift towards the contralateral hemisphere via the anterior communicating artery 
could diminish perfusion within the ipsilateral hemisphere and promote injury. 
Concomitantly, revascularisation in cervical carotid stenosis patients leads to perfusion 
enhancement in the contralateral hemisphere with the degree of perfusion correlating with 
the grade of stenosis (Sadato et al., 2017). As a result, Ang-(1-7) could be acting to prevent 
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contralateral CBF shifting and, as a consequence, ipsilateral injury in the longer term. To 
confirm this hypothesis, further studies need to be performed to understand the 
physiological impact and underlying mechanisms. 
6.4.3 Ang-(1-7) does not alter ipsilateral hemisphere perfusion 
Throughout the imaging period, Ang-(1-7) did not improve perfusion within the ischaemic 
core, ischaemic penumbra or oligaemic/perfused area. The role of Ang-(1-7) in improving 
ipsilateral cerebral perfusion is somewhat controversial with these results strengthening the 
hypothesis that at lower doses, Ang-(1-7) has no effect. In stroke, Ang-(1-7)’s effects have 
been studied as an ICV delivery and with the use of LDF techniques; which allow a 
measure of perfusion in a limited area within the MCA territory (Jiang et al., 2014; Mecca 
et al., 2011). In our study, LSCI provided a sensitive near real-time mapping of cortical 
surface vasculature during reperfusion and was therefore, a reliable semi-quantitative 
measure of cerebral perfusion across the cortical surface. Importantly, the animal models, 
drug administration method and time of CBF dynamics assessment used in previous 
studies were substantially different from the methodology used in our study (Jiang et al., 
2014; Mecca et al., 2011). For instance, in Mecca’s study, Ang-(1-7) was administered as a 
3 day pre-therapy in the ET-1 induced MCAO model and the impact of treatment on CBF 
was evaluated prior to and 1 hr post ET-1 injection (Mecca et al. 2011). In Jiang’s study, 
studies were performed in the permanent MCAO model, Ang-(1-7) therapy administered 
for 4 weeks prior to injury and CBF dynamics were studied at MCAO onset as well as 1 hr 
and 24 hrs post stroke onset (Jiang et al. 2014). Consequently, the present study is the first 
experiment to evaluate the effects of Ang-(1-7) on CBF as a post stroke therapy, in a 
transient MCAO model, at reperfusion and with LSCI. 
In the ischaemic core there was a trend for Ang-(1-7) to improve perfusion in comparison 
to Vehicle (dH2O); however, the differences were not statistically different. Out of 6 
animals in the Ang-(1-7) group, 3 showed higher levels of perfusion upon filament 
retrieval whereas in the control group, only 1 animal displayed perfusion increase to a 
similar extent. This variability in perfusion within the ischaemic core might reflect 
differences in reperfusion alone, possibly due to larger ischaemic lesions. For instance, 
patients that develop post-ischaemic hyperperfusion in infarcted areas display increased 
bioenergetic depletion, confirmed by greater ADC coefficients (Kidwell et al., 2001). 
Accordingly, it is plausible that animals with increased perfusion in this region developed 
exacerbated ischaemic lesions. Contrarily, the results could be an indication that these 
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particular animals had better functioning collateral supply than the remaining cohort as 
seen in the clinic and thus, enhanced tissue salvage (Bhaskar et al., 2017). To confirm this, 
lesion volumes would have to be assessed; however, this was not performed in our study, 
representing a study limitation. 
The impact of Ang-(1-7) in human brain CBF has not yet been evaluated, however, 
experiments conducted in human brain vascular smooth muscle cell cultures suggest that 
0.1 M Ang-(1-7) treatment inhibits cell migration, proliferation and apoptosis (Bihl et al., 
2015). Furthermore, Ang-(1-7) administration in isolated canine MCA and femoral arteries 
induced vascular relaxation in arterial rings with intact endothelium, an outcome observed 
at higher doses only (Feterik et al., 2000). Similarly, topical application of Ang-(1-7) in 
pial arterioles in anaesthetised pigs induced a modest vasodilation at high doses (Meng and 
Busija, 1993). Although the studies described were conducted in normoxic conditions, the 
results set the premise that Ang-(1-7) treatment could have the potential to enhance CBF 
following cerebral injury.  
There are several factors that could have contributed towards the neutral effect seen within 
the ipsilateral hemisphere in the present study. Firstly, the experiments conducted by Meng 
& Busija and Feterik et al suggest that Ang-(1-7) treatment leads to a cerebral vasodilatory 
effect when administered directly and at higher doses only (Feterik et al., 2000; Meng and 
Busija, 1993). Consequently, a 5 nmol/hr IV infusion dose through the femoral vein may 
not have been sufficient to enhance CBF in the compromised ipsilateral hemisphere.  
Secondly, the animal model used and treatment schedule may present contributing factors. 
In in vivo models, Ang-(1-7) pre-treatment for 48 hrs (1.1 nmol/hr ICV) did not influence 
ipsilateral perfusion at MCAO and at 24 hrs permanent MCAO when compared to vehicle 
(Jiang et al., 2012). However, in a follow up study, Ang-(1-7) pre-treatment for 4 weeks 
increased CBF in the peripheral region at 1 hr and 24 hrs permanent MCAO, an effect 
attributed to an improvement in NO production and VEGF protein levels (Jiang et al., 
2014). The results observed suggest that Ang-(1-7) acts in a cumulative manner and longer 
treatment schedules are necessary to observe a cerebrovascular effect in the penumbral 
region. Additionally, Ang-(1-7) possibly enhances perfusion in permanent models; 
however, in transient MCAO models, reperfusion alone may transcend an Ang-(1-7) 
induced vascular outcome. In accordance, following ET-1 induced MCAO, CBF was 
shown to transiently increase over 60 min in the ipsilateral hemisphere; however, Ang-(1-
7) 1.1 nmol/hr ICV treatment did not influence haemodynamics or vessel diameter 
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compared to vehicle therapy in normotensive rats (Mecca et al., 2011), supporting this 
hypothesis. 
Finally, Ang-(1-7) could produce a cerebrovascular effect at later stages of injury. 
Following transient MCAO, Ang-(1-7) ICV post stroke therapy upregulated bradykinin 
expression in ischaemic tissue at 6 hrs and 48 hrs after reperfusion at moderate and higher 
doses (100 pmol/hr and 10 nmol/hr) (Lu et al., 2008). Plus, Ang-(1-7) at 10 nmol/hr  ICV 
treatment stimulated NO levels from 3 to 72 hrs reperfusion (Zhang et al., 2008). Both 
bradykinin and NO are potent vasodilatory mediators; therefore, Ang-(1-7) could incite 
vasodilation from 3 hrs post reperfusion start.  Overall, Ang-(1-7) did not influence cortical 
cerebral perfusion in the ipsilateral hemisphere following 90 min MCAO, yet, it is 
plausible that Ang-(1-7) might enhance ipsilateral CBF when administered locally, at high 
doses and at later stages of injury. It is also important to note that, in the present study, 
perfusion assessments represent an outcome of both arterial and venous flow. Therefore, 
the impact of therapy in influencing cerebral vascular dynamics within individual vessels 
and in the subcortical vasculature was not addressed. In future, myography experiments in 
cerebral vessels (e.g MCA) following MCAO, could be a suitable experiment to confirm 
the results obtained. 
6.4.3.1 Ipsilateral perfusion does not recover to contralateral levels 
Reperfusion following 90 min MCAO resulted in an initial period of hyperperfusion, 
lasting for 15 min in Vehicle and 20 min in Ang-(1-7) treated animals within the ischaemic 
core and the ischaemic penumbra. Conversely, in the oligaemic/perfused region, 
hyperperfusion was evident for 10 min in the Ang-(1-7) group and for 15 min in control 
animals. This initial period of hyperperfusion was then followed by hypoperfusion across 
the ipsilateral hemisphere until the end of the experiment. Perfusion values in the 
ipsilateral side remained below contralateral values during the hypoperfusion phase, 
suggesting that during 90 min reperfusion, the brain is still at risk of further hypoxic injury.  
The underlying mechanism behind hyperperfusion is not well understood; however, 
accumulation of acid metabolites, ROS and CO2 during MCAO are thought to lead to 
abnormal vasodilation in the ischaemic area (Jackman & Iadecola 2015). Although this 
mechanism is a hallmark of efficient reperfusion after MCAO and confirmation that MCA 
reperfusion was successful, it could also be a contributor towards stroke progression (Pan 
et al., 2007; Sage et al., 1984). For example, in rats, post-ischaemic hyperperfusion was 
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associated with larger cortical infarcts and shown to mediate MCA remodelling due to 
vascular oxidative stress and inflammation (Onetti et al., 2015; Pérez-Asensio et al., 2010), 
hence its possible role in infarct progression.  
Similarly, the causes underlying hypoperfusion require further evaluation. One hypothesis 
includes vessel obstruction and increase in vascular resistance mediated by endothelial and 
glial cell swelling (Hossmann and Lechtape-Grüter, 1971). Other studies indicate that 
hypoperfusion is caused by vessel constriction, vasospasm, oedema and the “no reflow” 
phenomena (Kunz & Iadecola 2009; Ames et al. 1968). Other possible causes include 
pericyte constriction during and following MCAO (Hall et al., 2014) as well as MCA 
myogenic tone and reactivity impairment, thus, promoting vessel resistance (Ahnstedt et 
al., 2016; Cipolla et al., 1997, 2014).  
Ang-(1-7) did not influence cerebral perfusion during hyper- or hypoperfusion phases. 
However, the findings in this study highlight the neuroprotective potential of CBF 
enhancing therapies when administered at acute stages of reperfusion onset and during the 
hypoperfusion phase. 
6.4.4 Ang-(1-7) does not interfere with PID frequency 
Until now, the study of therapy impact on PIDs has been compromised by the lack of 
methods that provided sufficient spatial and temporal sampling(Strong et al., 2006). LSCI 
is a suitable technique to tackle these changes and was shown to successfully identify PIDs 
frequency across the cortical surface during MCAO and reperfusion. In this study, Ang-(1-
7) at the dose selected did not interfere with PID number during reperfusion.  
PIDs follow a biphasic pattern and are reported to occur during MCAO and between 2 to 
12 hrs after reperfusion (Hartings et al., 2003). PIDs were shown to initiate no earlier than 
2 hrs after reperfusion and to induce a detrimental effect that correlated with final infarct at 
24 hrs (Hartings et al., 2006). In our study, PIDs occurred in 4 out of 11 animals, 1 in 
control and 3 in Ang-(1-7) treated rats and these took place just after reperfusion 
reestablishment. Our study implies that during 90 min reperfusion, the biphasic pattern of 
PID has not yet started as previously suggested (Hartings et al., 2006). 
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6.4.5 Summary 
This study assessed for the first time the impact of Ang-(1-7) 5 nmol/hr IV infusion in 
cortical perfusion after stroke with LSCI. Ang-(1-7) therapy delivered on reperfusion did 
not improve perfusion within the ischaemic core, ischaemic penumbra and 
oligaemic/perfusion regions across the ipsilateral hemisphere. Treatment did not alter 
MABP, PaCO2, PaO2, pH and temperature compared to control with -chloralose showing 
to be a suitable anaesthetic for CBF imaging. Moreover, Ang-(1-7) did not influence the 
occurrence of PIDs, which tended to occur just after reperfusion onset.   
Interestingly, Ang-(1-7) prevented perfusion increase in the contralateral hemisphere 
compared to control animals. It could be hypothesised that these results are the outcome of 
PaCO2 variations that were not detected at later stages of reperfusion and represent a false 
positive. However, if the mechanism in indeed physiological, it is an indication that Ang-
(1-7) may prevent “steal phenomena” towards the contralateral hemisphere. Conversely, 
Ang-(1-7) did not alter cerebral haemodynamics in the ipsilateral hemisphere. It is possible 
that 90 min treatment at the dose selected was not sufficient to induce an effect, with 
literature suggesting that Ang-(1-7) induces vasodilatory effects when administered 
locally, at high doses, for extensive therapeutic schedules and when studied in permanent 
MCAO models (Jiang et al., 2014; Feterik, 2000).  
In conclusion, this study provides robust evidence that Ang-(1-7) IV treatment at 5 nmol/hr 
dose does not influence ipsilateral cortical cerebral perfusion, PID frequency or MABP at 
the dose selected for 90 min reperfusion following MCAO. At the same time, Ang-(1-7) 
may be acting to prevent “steal phenomena” towards the contralateral hemisphere. Follow 
up studies need to be performed to confirm the reproducibility of the effect observed. 
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Chapter 7  
In this Chapter, an overall summary of study findings will be provided where study 
limitations will be addressed and possible future studies outlined. Firstly, the restraints and 
directions of preclinical neuroprotective studies in normotensive animal models will be 
discussed. 
7.1 Animal models of ischaemic stroke 
In preclinical stroke, over 1000 compounds have been reported to provide neuroprotection 
in animal models; however, apart from alteplase, all the interventions reaching clinical 
trials have failed to be effective (Henninger et al., 2010; O’Collins et al., 2006). The major 
translational roadblocks are attributed to experimental design as well as animal model 
limitations (Macleod et al., 2008; Rewell and Howells, 2017). In an attempt to minimise 
cofounding variables from interfering with study interpretation, we ensured that 
appropriate experimental design was carried out for instance the use of randomisation and 
blinding and acute imaging as recommended within the STAIR guidelines ((STAIR), 
1999). In addition, ensuring good animal welfare during and after stroke surgery was taken 
into account according to the recommendations in the recently published IMPROVE 
(Ischaemia Models: Procedural Refinements of in Vivo Experiments) guidelines (Percie du 
Sert et al., 2017).  
For neuroprotective studies (Chapters 4-6), sample size calculations were performed to 
determine adequate animal numbers to detect a therapeutic effect. Sample size calculations 
were not conducted in Chapter 3 since these experiments consisted of pilot studies to 
assess methodologies to use in subsequent neuroprotective assessments. All studies were 
randomised according to a random list generator (www.random.org) and an independent 
investigator kept the allocation schedule. Blinding was carried out for all drug studies 
where an independent investigator not involved in the study was responsible for preparing 
the appropriate drug or vehicle according to the allocation schedule. Data analysis was also 
conducted in a blinded manner by ensuring that experiments were coded in an unbiased 
manner. In Chapter 6, the author was responsible for drug infusion calculations, which had 
to be corrected for animal weight on day of surgery, and was not blinded to therapy. To 
account to this potential source of bias, treatment was disclosed and prepared at the time of 
reperfusion and administered by an independent investigator. In addition, blood gases were 
closely monitored and data analysed twice by the author and a blinded researcher.  
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It is important to note that experiments carried out in rodents cannot directly replicate 
clinical stroke. Rats have a lissencephalic brain with different neuroanatomical and 
functional structure to that observed in humans, which have a large gyrencephalic brain 
(Figure 7-1) (Sommer, 2017). White matter represents 60% of brain tissue in humans 
whereas in rats only 15% (Krafft et al., 2012). Since white matter damage is an important 
factor implicated in stroke prognosis in all major stroke subtypes; rodents experiments 
pose a challenge in terms of accurate modelling (Ahmad et al., 2015). Additionally, 
rodents have the ability to rapidly recover from ischaemic insult on the contrary to humans, 
limiting behavioural and neurological deficit assessments (Sommer, 2017). Nevertheless, 
rodents present a similar cerebrovascular anatomy to that observed in humans with both 
species having a circle of Willis. In addition, rodents provide a cheap, standardised and 
reproducible approach to study the pathophysiological mechanisms of ischaemic damage 
and the impact of potential therapeutic interventions (Fluri et al., 2015; McCabe et al., 
2017).  
 
Figure 7-1 Structural and anatomical differences between human (A) and rat (B) brains. 3D-
polarised light imaging illustrating connectivity, colour sphere represents the direction of fibers. 
Figure adapted and obtained from Sommers et al, 2017. 
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One important consideration in preclinical stroke is the selection of the most adequate 
model of focal cerebral ischaemia. In this thesis the intraluminal filament model was 
selected as it mimics human stroke localisation and allows to investigate the impact of 
reperfusion on outcome (Garcia et al., 1995; Kumar et al., 2016). In the clinic, spontaneous 
reperfusion occurs up to 17% of stroke patients in the first hours after stroke onset whereas 
the intraluminal filament model induces an abrupt reperfusion (Kassem-Moussa and 
Graffagnino, 2002). Although the animal model selected does not accurately represent the 
entire stroke population, it induces sudden and abrupt reperfusion that closely mimics 
mechanical thrombectomy procedures (Sutherland et al., 2016), which are primarily 
performed in patients with proximal large vessel occlusion of the anterior circulation 
and/or non-responsive to alteplase (Tawil and Muir, 2017). The validity of the model used 
was further confirmed in Chapter 4 where reperfusion alone improved outcome, a result 
equally observed in the clinic in large artery occlusion patients subjected to thrombectomy 
(Dargazanli et al., 2017). 
The studies presented within this dissertation highlight the importance of selecting the 
most adequate rat strain and study methods for neuroprotective studies. A major drawback 
of the intraluminal filament model and the use of normotensive animals is infarct volume 
variability. In Chapter 3 we showed that in comparison to Wistar rats, Sprague-Dawley rats 
exhibited enhanced variability, thereby limiting the validity of using this strain for 
neuroprotective studies (Figure 3-3) (Rewell and Howells, 2017; Ström et al., 2013). 
STAIR guidelines recommend the use of LDF to confirm successful MCAO and suggest a 
minimum of 60% CBF reduction for inclusion criteria ((STAIR), 1999). In addition, 
several groups use LDF as a means to predict infarct volume variability or study CBF 
(Soriano et al. 1997; McCabe et al. 2017). We have demonstrated that LDF is a 
challenging method that does not correlate with final infarct volume nor adequately detect 
the extent of reperfusion (Figure 3-13). The use of LDF provided evidence of accidental 
SAH with the filament model, however; in general, the technique adds an extra variable 
and negatively impacts animal recovery while providing limited information. Instead, MRI 
techniques provided an accurate and reliable tool of outcome assessment and allowed the 
establishment of strict exclusion criteria. DWI during MCAO was useful to determine the 
starting lesion and allowed us to use each animal as its own control in order to examine the 
impact of therapy on infarct volume (McCabe et al., 2017). MRI-T2 allowed us to confirm 
successful ICV placement of cannula and MRA confirmed adequate MCAO and MCA 
reperfusion.  
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Although a strict methodological and design criterion was employed in the studies outlined 
in this thesis, DWI data during MCAO emphasised the variability in ischaemic lesion 
volume in Wistar rats prior to therapy and reperfusion (Figure 4-4). Additionally, LSCI 
showed that several animals exhibited variability in the extent of cortical reperfusion 
following removal of the filament, which improved over time at different rates (Figure 7-
3). This brings attention to the extent of MCAO and subsequent variability in reperfusion 
in normotensive rats and its impact on data interpretation, especially when assessing 
therapeutic interventions. With respect to reperfusion, it is challenging to determine which 
animals display inhomogeneous cortical reperfusion and the reasons for this are still poorly 
understood. This means that these rats are usually included in study cohorts introducing a 
variable that may greatly impact outcome interpretation. Contrary to normotensive 
animals, hypertensive rats exhibit larger infarcts and smaller collaterals with diminished 
vasodilator capacity, which limits infarct variability (McCabe et al. 2009; Reid et al. 2012). 
However, hypertensive rats present significantly less penumbral volumes that influence the 
chance to detect a drug effect (Rewell and Howells, 2017). For this reason, proof of 
principle studies are recommended to be conducted in normotensive rats prior to the 
addition of a co-morbidity such as hypertension ((STAIR), 1999). This thesis demonstrates 
that in order to accurately determine efficacy of therapeutic interventions, the use of acute 
imaging to confirm baseline lesion volume and confirmation of successful MCAO and/or 
MCA reperfusion greatly enhances the statistical power of studies and avoids type II 
errors. In turn, this emphasises the need for robust collaborations amongst the stroke field 
for improved experimental reproducibility. 
7.2 Counter-regulatory axis as an ischaemic stroke target 
This thesis aimed to examine the therapeutic potential of the counter regulatory axis of the 
RAS, ACE2/Ang-(1-7)/MasR, in ischaemic stroke. Due to the reported beneficial effects 
induced by MasR and AT2R agonism following cerebral ischaemia (Chapter 1), this first 
therapeutic study examined the effects of MasR, AT2R and combined MasR and AT2R 
agonism in a model of transient focal cerebral ischaemia. We showed that reperfusion 
along with Ang-(1-7) ICV infusion further prevented lesion growth expansion at 7 days 
when compared to baseline lesion volume (60 min MCAO) whereas C21 (AT2R agonist) 
or combination therapy did not induce any additional therapeutic effects when compared to 
vehicle treatment. In addition, therapy did not influence systolic BP or neurological 
outcome at days 3 and 7 for any group. This study establishes that at day 7 following 
reperfusion, MasR and AT2R agonism do not act synergistically to prevent ischaemic 
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lesion growth at the doses administered; however, MasR agonism alone may confer some 
additional protection in combination with reperfusion. 
Interestingly, the neuroprotective effect of Ang-(1-7) could only be detected when taking 
into account the initial baseline lesion since there were no differences between groups at 
day 7. This suggests that following abrupt reperfusion, central infusion of Ang-(1-7) 
treatment leads to a mild to moderate effect at the dose selected, in contrast to the large 
effect sizes observed in previous published studies at 24 hrs and 72 hrs, albeit using 
different models of focal cerebral ischaemia (Mecca et al., 2011; Regenhardt et al., 2013). 
Our experiments also confirm that the RAS is imbalanced after cerebral injury since AT2R 
mRNA was upregulated and MasR downregulated at 7 days post MCAO. Interestingly, the 
classical RAS axis mediators ACE and AT1R were not altered, confirming that transient 
MCAO enhances AT2R expression only (Kagiyama et al., 2003; Zhu et al., 2000). Whilst 
Ang-(1-7) is reported to act at the microglial level by influencing its phenotype or 
diminishing NF-B and COX-2 activity (Liu et al., 2016; Regenhardt et al., 2013); our 
mRNA data implies that Ang-(1-7) does not induce an anti-inflammatory effect. Instead, 
Ang-(1-7) could exert its effect by promoting neurogenesis through NOX1 expression.  
A drawback in this study was the lack of protein assessment. Brains were collected for 
immunohistochemistry assessment at the end of the study, which meant that n numbers 
were low for a quantitative assessment of protein levels for microglia activation. Plus, 
NOX1 was not examined in terms of protein and for this reason it was not possible to 
conclude whether Ang-(1-7) might be inducing its effects by enhancing NOX1. It is 
common practice to use mRNA levels as a way to correlate with protein levels; however, 
relative abundance of protein may not be proportional to relative mRNA expression. In 
mammals, mRNAs are produced at lower rates than protein with mRNAs displaying a half-
life of up to 7 hrs compared to 46 hrs for proteins (Vogel and Marcotte, 2012). To confirm 
the proposed mechanism, NOX1 protein levels would have to be examined and colocalised 
with a proliferation marker such as proliferating cell nuclear antigen, which is reported to 
label neuroprogenitor cells (Sierra et al., 2011).   
Next, we hypothesised that MasR targeting induces its therapeutic effect in a biphasic 
pattern and at earlier stages of injury. Ang-(1-7) was administered as central infusion 
immediately following stroke for 24 hrs and its effects on BBB breakdown and infarct 
volume evaluated. Although vasogenic oedema was present, an indication of BBB 
breakdown, the BBB at this time point was at a transient state with some animals 
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presenting high Gd-DTPA extravasation and others minimal uptake. Not surprisingly, 
Ang-(1-7) did not alter hemispheric swelling or BBB breakdown. In addition, final infarct 
volume was comparable to vehicle animals and no differences in neurological outcome 
were observed at this time point. This reinforces the suggestion that Ang-(1-7) induces a 
mild effect that cannot be detected when analysing data at end points only. Mechanistic 
data performed at 24 hrs confirmed that Ang-(1-7) does not influence microglia number or 
activation nor affect gene expression levels for the markers assessed. However, an 
interesting finding was that at 24 hrs, RAS mediator gene expression was comparable to 
sham following MCAO, emphasising the biphasic nature of the RAS in cerebral injury and 
implying that the RAS may not be implicated in injury at this time point. 
Overall, Chapters 4 & 5 demonstrate that Ang-(1-7) does not induce an anti-inflammatory 
effects, contrary to previous reports (Jiang et al., 2012; Mecca et al., 2011; Regenhardt et 
al., 2013). In an attempt to study the effects of Ang-(1-7) on microglia/macrophage 
phenotype, M1 and M2 type markers were selected and gene expression examined. The 
presence of multiple activation phenotypes for microglia is a relatively recent concept and 
there is no consensus regarding specific mediators for both M1 and M2 profiling 
(Ransohoff, 2016). Plus, as described above, gene expression may not provide an accurate 
measurement for microglia phenotype. Methods that are more accurate include flow 
cytometry where peri-infarct homogenates are subjected to M1/M2 marker antibody 
staining and protein levels quantified. Furthermore, NF-B mRNA levels in the peri-infarct 
tissue was shown to be comparable to sham in both Chapter 4 & 5; to confirm NF-B 
activation and expression as well as therapy impact, nuclear translocation assays and 
signalling pathway investigation at protein levels would have to be assessed.  
Finally, in Chapter 6, the effects of Ang-(1-7) on CBF at a hyperacute stage of injury were 
assessed with LSCI. The role of Ang-(1-7) on the cerebrovasculature is controversial and 
until now examined with LDF, which provides a limited spatial assessment of CBF (Jiang 
et al., 2014; Mecca et al., 2011). We examined CBF across the entire cortical surface and 
demonstrated that IV infusion of Ang-(1-7) immediately following reperfusion did not 
influence CBF within the ipsilateral hemisphere; however, it prevented CBF enhancement 
in the contralateral hemisphere without influencing MABP or PIDs. This effect could be 
the outcome of “steal phenomena” reversal by Ang-(1-7), thus, preventing CBF shift from 
the ipsilateral side. There was a large variability in the results obtained, particularly in the 
ipsilateral hemisphere. Subsequent power calculations indicate that to detect a drug effect 
of at least 10% in the ischaemic penumbra and in the model used an n=11 per group would 
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be required. Consequently, follow up experiments should be performed to confirm study 
reproducibility. 
One of the major limitations in the studies performed was that drugs had to be 
administered ICV. This method is not a recommended route of administration in the clinic 
as it impairs the ability to administer sustainable long-term therapies. Additionally, central 
treatment was technically challenging and resulted in cannula misplacement in several 
animals, which had to be excluded. C21 is a highly selective AT2R agonist with a 4 hr half-
life and shown to induce therapeutic effects when administered IP (Alhusban et al., 2015; 
Wan et al., 2004). Conversely, Ang-(1-7) has a half-life of 10 sec in the circulation and is 
hydrophilic (Iusuf et al., 2008; Trask and Ferrario, 2007), thus, to maximise Ang-(1-7)’s 
therapeutic potential, drugs were administered centrally. Furthermore, Chapter 3 studies 
provided an indication that RAS targeting via peripheral administration may not be suitable 
to perform proof of principle experiments in ischaemic stroke, hence the method selected. 
It has been reported that RAS mediators do not cross the BBB, thus, the brain relies on 
locally produced peptides (Schelling et al., 1976). Interestingly, recent evidence now 
proposes that the brain RAS does not exist and the presence of RAS peptides is actually the 
outcome of trapped mediators from the circulation (Sigmund et al., 2017), setting the 
premise of new peripheral routes to target the brain RAS after stroke. A study conducted 
this year verified that an Ang II vaccine administered SC, reduced infarct volume after 
permanent MCAO (Wakayama et al., 2017), highlighting the neuroprotective potential of 
systemic RAS targeting. In Chapter 6, Ang-(1-7) was administered as an IV infusion to 
allow successful LSCI whilst maximising the activation of MasR present on cerebral 
endothelial cells (Becker et al., 2007; Kumar et al., 1996). The fact that Ang-(1-7) induced 
an effect on CBF supports the hypothesis that in future, Ang-(1-7) systemic therapy may 
also be adequate in ischaemic stroke. In the clinic, Ang-(1-7) was recently tested SC at 20 
mg/kg/day in phase II metastatic sarcoma trials and proven to be well tolerated (Savage et 
al., 2016). Plus, a phase I clinical trial is being conducted testing the effects of IV Ang-(1-
7) infusion of up to 20 ng/kg/min in human hypertension and expected to be completed in 
2018 (clinicaltrials.gov). These scientific advances may help direct future steps in stroke 
studies; still, the peptide’s short half-life poses a therapeutic challenge that must be taken 
into account. To tackle this limitation, an alternative includes novel cyclic Ang-(1-7) 
analogues, which are resistant to human ACE and consist in a stable, long-lasting and 
possibly suitable approach to use in future (Wester et al., 2017).  
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7.3 Future studies 
Despite the efforts to elucidate the underlying mechanisms responsible for the 
neuroprotection observed in Chapter 4, these remain mostly elusive. Since Ang-(1-7) 
induced a mild to moderate neuroprotective effect in this thesis, it is crucial to perform IV 
dose response experiments to confirm the effect observed and test treatment feasibility in 
the stroke setting. Once the neuroprotective effect has been demonstrated through 
alternative methods of administration and at a more efficient extent, further studies should 
then be conducted. 
In Chapter 4, we showed that Ang-(1-7) alone decreased infarct volume progression from 
60 min MCAO to 7 days reperfusion. However, C21 and combination therapy did not exert 
a neuroprotective effect, suggesting that both MasR and AT2R agonism does not 
synergistically decrease infarct volume. To understand the implications of receptor 
antagonism in infarct volume outcome in the model used, MasR antagonist, A779, and 
AT2R antagonist, PD123319, cohorts should be studied in future.  In addition, to examine 
whether Ang-(1-7)-mediated neuroprotection is dependent on both MasR and AT2R 
activation in the model used, receptor antagonists should be administered along with Ang-
(1-7) in subsequent experiments.  
The experiments in Chapter 6 propose that Ang-(1-7) IV administration influences CBF 
profile to some extent, therefore, it could hypothetically preserve the penumbra. An 
important study to be conducted is the effect of Ang-(1-7) on the extent of penumbra 
salvage using DWI/PWI mismatch. In the clinic, penumbra determination with DWI/PWI 
mismatch has proven to be effective in determining patients who most likely benefit from 
alteplase and thrombectomy procedures (Albers et al., 2006; Wheeler et al., 2013), 
therefore, it is likely that in future, DWI/PWI mismatch will become part of standard 
eligibility criteria. Consequently, mismatch studies are crucial to evaluate the efficacy of a 
neuroprotective agent and its translation from preclinical to clinical studies (Fisher et al., 
2009).  
The results in this thesis emphasise that the effects of Ang-(1-7) may be time dependent 
and of various aetiologies. A logical study to perform would be the effect of Ang-(1-7) on 
BBB breakdown at 72 hrs post stroke when the BBB is maximally permeable and 
inflammatory mechanisms at its hiatus (Sandoval and Witt, 2008). In addition, Ang-(1-7) 
is thought to prevent lesion growth in permanent MCAO by stimulating angiogenesis via 
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the eNOS/NO and VEGF pathways (Jiang et al., 2014), thus, its role in angiogenesis at 
later stages of injury could be assessed in transient models. Interestingly, central treatment 
with C21 failed to induce a neuroprotective effect, yet, this compound is implicated in 
neuroprotection following ischaemic stroke when administered IP (Alhusban et al., 2015; 
Joseph et al., 2014; Lee et al., 2012; Schwengel et al., 2016). Our mRNA data implies that 
the AT2R may be involved in injury at 7 days post reperfusion; therefore, AT2R targeting 
may be potentially beneficial at later stages of injury. Accordingly, in permanent MCAO 
studies, C21 induces an angiogenic effect following 21 days therapy whereas in transient 
MCAO, 3 week C21 treatment diminishes infarct volume (Bennion et al., 2017; Mateos et 
al., 2016), supporting this hypothesis. By performing time course experiments, one would 
be able to evaluate at what time points MasR and/or AT2R targeting following stroke could 
be most beneficial. 
In vivo experiments should be supported with in vitro examinations. As mentioned in 
Chapter 1, AT1R signalling is detrimental through a variety of processes involving the 
activation of G-protein dependent and independent pathways. While these signalling 
pathways are well described in peripheral CVD, there is limited information in neuronal 
cells. Similarly, the signalling pathways underlying AT2R or MasR activation are scarcely 
known in ischaemic stroke. Previous studies conducted by our lab have demonstrated that 
in smooth muscle cells, MasR inhibits ERK1/2 (McKinney et al., 2015); however, it is yet 
to be established whether in neuronal cells, MasR leads to SHP-2 activation and effectively 
inhibits MAPKs or NOX as outlined in Chapter 1. Equally, whether AT2R agonism leads 
to MPK-1, SHP-1 and PP2A activation should be assessed. To do so, primary neuronal 
cells would be subjected to OGD challenge and treatment upon reoxygenation. After, 
signalling pathways would be assessed in cell lysates using protein arrays such as PathScan 
Antibody Array from Cell Signalling Technology, which allows a simultaneously and 
quantitative measurement of at least 30 phosphorylated proteins (Kopf et al., 2005). 
Finally, the use of normotensive young male animals is relevant in the context of proof of 
principle studies; however, these do not reflect the stroke population in clinic, which often 
exhibit a spectrum of co-morbidities (Fisher et al., 2009). The author of this thesis (MA) 
collaborated in a follow up study where Ang-(1-7) and A779 (MasR antagonist) were 
tested in the same experimental protocol in SHRSPs (unpublished data). Ang-(1-7) failed 
to induce a neuroprotective effect; however, MasR antagonism exacerbated injury. This 
further emphasises that Ang-(1-7) at the dose administered may not be optimal whilst 
stressing the therapeutic potential of specific MasR agonists in both normotensive and 
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hypertensive settings. Nonetheless, the effects of Ang-(1-7) in females, diabetic and older 
rats are yet to be studied. In particular, sex is thought to highly influence RAS expression. 
Testosterone is suggested to stimulate the “classical axis” whilst oestrogen promotes AT2R 
expression and counter-regulatory RAS axis activity (Sullivan 2008; Silva-Antonialli et al. 
2004; Sampson et al. 2008; Sullivan et al. 2015). Plus, female rats subjected to 
ovariectomy display enhanced AT1R brain expression and diminished AT2R levels, hence, 
a possible involvement in the elderly population (Rodriguez-Perez et al., 2010). The 
therapeutic potential of the counter-regulatory RAS axis should be evaluated in these 
settings before proceeding to larger animals.  
7.4 Conclusions 
This thesis conducted novel studies examining the therapeutic potential of the counter-
regulatory axis of the RAS following transient MCAO using acute imaging techniques. We 
demonstrated that the RAS is implicated in cerebral injury in a biphasic pattern with MasR 
agonism as a post stroke therapy inducing a mild to moderate neuroprotective effect at 7 
days reperfusion. Our studies indicate that Ang-(1-7) did not exert its effect via an anti-
inflammatory mechanism nor prevented BBB breakdown at 24 hrs reperfusion. Instead, we 
hypothesise that Ang-(1-7) may exert its effects by enhancing neurogenesis through NOX1 
enhancement and/or CBF modulation after stroke onset. Although this thesis provides 
encouraging findings, the underlying mechanism is still elusive and further investigations 
should be conducted. In particular, the therapeutic potential of selective MasR agonists as 
adjuvant systemic therapies should be assessed. This thesis strongly emphasises the 
importance of adequate methodologies when performing neuroprotective studies, which 
should be closely considered in future experiments.  
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